Back Matter (PDF)

Home , Miura 5

Aarsvold,JN, 474, 112P(ab) 124P(ab),158P(ab), Angels,RR, 5P(ab) Azure, MI, 133P(ab), Barker, WC, 61P(ab), Abdel-Dayem,HM, 56P(ab), 162P(ab),163P(ab), Angrist,B, 609,67P(ab), 134P(ab) 124P(ab), 178P(ab) 172P(ab),233P(ab), 169P(ab),181P(ab), 102P(ab) Barlaud,M, 194P(ab) Barnes, DC, 1377 261P(ab) 195P(ab),207P(ab), Ansar@AN, 1990 Babaian,Ri, 115P(ab) Barnes,PD,1045 Abdel-Nabi,H, 213P(ab), 210P(ab),228P(ab), Ansari,MS, 132P(ab), Babchydc B, 177P(ab) 246P(ab),262P(ab) 229P(ab),230P(ab) 158P(ab),202P(ab) Babich,JW, 1282,1529, Barnett, CA, 151P(ab) Abe, M, 2124 Albani,C, 1XP(ab) Antar, MA, 400, 1834(Ie) 1964,1975,2130,2176, Barnhart,c:s, 75P(ab), Abe, Y, 780 Aibro,JE, 1905 Antich,PP, 9P(ab),124P(ab) 2253,15P(ab),51P(ab), 149P(ab) Abi-Dargham,A, 31P(ab), Alderson,P0, 122P(ab) Antico,VP, 1172 69P(ab),73P(ab),88P(ab), Barn,ME, 220P(ab) 108P(ab),109P(ab), Al-Doohan,S, 195P(ab) Antonuk,LE, 100P(ab) 104P(ab),172P(ab), Baron,JC, 241P(ab) 211P(ab) Akxoff@D, 131P(ab) Anzai,Y, 224P(ab) 173P(ab),232P(ab), Baron,ii, 75P(ab),85P(ab) Abitbol,C, 249P(ab) All, A, 151P(ab) Appelbaum,F, 1031 240P(ab) Bane,L,241P(ab) Aboud, A, 117P(ab), All, KSM,66P(ab),67P(ab), Applebaum,JW, 2111 Bach, D, 97P(ab), 107P(ab) Barrett,}IH,474,27P(ab) 137P(ab) 104P(ab) Applebaum,FR, 1839 Bacharach,SI, 311, Barrett, JA, 173P(ab) Abrahamowicz,M, 589 Allababidi,S, 245P(ab) Arai, M, 86P(ab),198P(ab) 27P(ab),60P(ab),61P(ab), Barreft,T, 16P(ab), Abrams, Mi, 1964,104P(ab), Me, K, 140P(ab) Arai, T, 1886 124P(ab),177P(ab), 229P(ab),230P(ab) 172P(ab),173P(ab), Allen,BC, 1239 Arano, Y, 29P(ab),59P(ab) 178P(ab) Barrio, J, 183P(ab), 174P(ab) Allen,DM,255P(ab) Aras, T, 84P(ab),172P(ab) Bachmayr,5, 122P(ab) 202P(ab),238P(ab), Abrams,P0, 908 Allen, EW, 190P(ab), Arata, L, 40P(ab) Bacin,Fi, 1260 239P(ab) Aburano,1, 28P(ab), 257P(ab) Araujo,U, 181P(ab) Badun&iR@182P(ab) Barrio,JR,679 139P(ab),223P(ab) Allen, 0, 37P(ab) Aravund,s, 124P(ab) Beer, L, 47P(ab) Barritault,L,387 Acevedo, ME, 32P(ab) Allen, IE, 234 Archambault,YG, 59P(ab) Bag@R, 172P(ab) Barron, at, 256P(ab), Ackermann,B, 148P(ab) Allen,P, 144P(ab) Archer, CM, 222 Bagni,B, 11OP(ab) 260P(ab) Ackermann,R, 25P(ab), Allen, SB, 161P(ab) Ardalan,B, 214P(ab) Bagni,I, 11OP(ab) Barrow,S,1975,172P(ab) 11OP(ab) Allenberg,JR, 139P(ab) Areeda,J, 1494,64P(ab), Bahnasy,5, 168P(ab) Barrow,SA,1975,2176 Adachi,I, 221P(ab) Al-Mohannadi,S, 172P(ab) 148P(ab),189P(ab) Baidoo,KE, 18P(ab), Bars, DL, 22P(ab),103P(ab) Mam, Mi, 237P(ab), Alonso,c:; 146P(ab) Arena, A!, 117P(ab) 135P(ab) Barsamian,S.190P(ab) 242P(ab) Alpert, N, 879 Aths, JM, 1905 Bailey,DL, 1367,1752, Bar-Shalom,R, 2101 Adams, S, 205P(ab) Alpert, NM, 6, 24P(ab), Aretz, HT, 1282 184P(ab) Bartensteun,P,3P(ab), Addison,Si, 1031 47P(ab),51P(ab),57P(ab), Argenyi,EE, 167P(ab), Baird,I, 78P(ab) 45P(ab),57P(ab) Adeistein,Si, 1175, 71P(ab),73P(ab),88P(ab), 185P(ab) B@, CN, 34P(ab) Bartlett,E,40P(ab) 123P(ab),221P(ab), 196P(ab),203P(ab), Arimizu,N, 211P(ab) Baker,JA, 39 Bartlett,M, 178P(ab) 241P(ab) 260P(ab) Ariyoshi,K, 932 Baker, M, 1031 Baruchin,MA, 193 Adiseshan,P, 90P(ab) Alt, A, 41P(ab) Arka, A, 41P(ab) Baker,RW,78P(ab) Barzilai,D, 141P(ab) Adler, RS, 524(le) Altehoefer, C, 23P(ab), Armour,K, 217P(ab) Bakke,A, 352(le) Baselga,3, 213P(ab) MoLf,J, 112P(ab) 148P(ab) Armstrong,WF, 107P(ab) Baldter,WH@2025,165P(ab) Basheiin,H, 117P(ab) Aerts, R, 222P(ab) Al-Tlkriti,M, 48P(ab), Arndt, J-W, 1052 Balasubraninnian,N, 61 Bases,P,77P(ab) Affieck,D, 218P(ab) 102P(ab),108P(ab), Arochick,J, 230P(ab) Balduni,MT, 219P(ab) Bassevitz,R, 152P(ab) Afi-iyie,M, 1235 201P(ab),243P(ab) Aronen,H, 206P(ab), Baldwin,B, 1595,162P(ab) Basten, A, 153P(ab) Afriyle,M, 166P(ab) Akin, RS, 261P(ab) 208P(ab) Baldwin,RM,31P(ab), Bastidas,DA, 66P(ab), Agarwal,P. 64P(ab), Aitland,B, 54P(ab) Aronovitz,M, 65P(ab) 48P(ab),90P(ab),102P(ab), 104P(ab) 65P(ab),95P(ab),151P(ab) Altmann,A, 220P(ab) Aronson,F, 210P(ab), 108P(ab),109P(ab), Basu, AK, 168P(ab) Agnew,JE, 1859 Amara, SG, 1140 233P(ab) 157P(ab),201P(ab), Bataille,0, 576, 1OP(ab) Agostini,D, 24P(ab) Amarenco,0, 205P(ab) Artze, M, 137P(ab),263P(ab) 211P(ab), 243P(ab) Bateman,TM, 75P(ab), Agrees,H, 1326 Amarenco,P, 205P(ab) Asada,Y, 159P(ab) Ballinger,JR, 242,268,1274, 149P(ab) Ahluwalia,R, 62P(ab), Amato, R, 212P(ab) Asakawa,Y, 161P(ab) 242P(ab) Bates, E, 107P(ab) 71P(ab),196P(ab), Ambrecht,ii, 2038 Ascah, IU, 74P(ab) Ballon,D,1152 Batjer, H, 1239 249P(ab) Ambrose,KR, 946 Ashburn@WL, 122P(ab) Balu, D, 1818 Battles,A,229P(ab) Ahmad,M, 1309,53P(ab), Ambrosia,A, 115P(ab) Ashida,K, 291 Bamrah,VS, 94P(ab) Baudhuin,T, 15P(ab), 54P(ab),94P(ab) Amendola,MA, 263P(ab) Ashok,0, 37P(ab),77P(ab), Banaszczyk,MG, 39P(ab) 44P(ab),86P(ab),121P(ab) Ahn, S, 163P(ab) Ainir,D, 104 139P(ab) Bananas, A, 260P(ab) Baudouy,M, 1472,45P(ab) Ahonen,A, 2068,3P(ab) Amsterdam,JD, 48P(ab) Ashraf,R, 5P(ab) Bangerter,M, 217P(ab) Bauer,A, 15P(ab) Aillet,G, 1267 Amyotte,G, 213P(ab) Askienazy,S, 1243 Banish,M, 176P(ab) Bauer, H, 21P(ab) Aisen, AM, 1190 Anderson,A-L, 1246 Assassa,0, 1990,261P(ab) Banks,W, 8P(ab),218P(ab) Baulieu,i-L, 1217(k), Akabani,G, 1367,1382 Anderson,Ci, 18P(ab), Assassa, GS, 1990 Baranowska-Kortylewicz,J, 194P(ab) Akansel,G, 961 28P(ab),81P(ab),134P(ab), Assies,J, 41P(ab) 1175,123P(ab),221P(ab), Baum,RP, 100P(ab), Akkermans,LMA, 582, 216P(ab) Atitins,FB, 227P(ab) 241P(ab),247P(ab) 126P(ab),205P(ab) 170P(ab) Anderson,CM, 62P(ab), Atkins,H, 43P(ab),222P(ab) Barbarics,E, 242P(ab) Bauman,JM,1995 Aksut, S, 85P(ab),95P(ab) 71P(ab),157P(ab), Atkins,ffl@899,1382 Barber,GO, 74P(ab) Baumann,ML, 134P(ab), @ Aktolun, 2276Qe) 249P(ab) Atkinson,JB, 826 Barbe@i,1267,1662 216P(ab) Akutsu, H, 222P(ab) Anderson,JA, 9P(ab) Atlas, SW, 1447 Barbour,MM, 152P(ab) Baumgarten,D,467 Alagona,P, 155P(ab) Anderson,JR, 200P(ab) Atuk, NO, 162P(ab) Barbour,SI,131P(ab) Baumgartner,0,1039 Alavi,A, 208,506,697, Mderson,1, 250P(ab) Asbin-Brunet, V. SP(ab) Barclay,AB, 179P(ab) Baumgold,3,2169 1009,1109,1119,1214, Andreasen,N@ 68P(ab) Aung,MT, 74P(ab) Barclay,PD, 123P(ab), Bautovich,03, 153P(ab) 1447, 1612, 1681, 1851, A@, 1W, 268 Austin,MC, 666 221P(ab),241P(ab) Bavaria,0,l4OP(ab) 1866,1910,2049,2191, Andrich,MP, 1854 Avril,N, 41P(ab) Barefleld,KP, 1766 Bax, ii, 147P(ab),154P(ab) 12P(ab),16P(ab),17P(ab), Mama, PC, 179P(ab), Awh, ES, 57P(ab) Barentsz,J, 163P(ab) Baxter, KG, 262P(ab) 32P(ab),43P(ab),48P(ab), 227P(ab) AxeloffD,609 Bares, R, 98P(ab),158P(ab), Baxter, L, 70P(ab),183P(ab) 73P(ab),76P(ab),92P(ab), Angelberger,P, 1397 Azuma,M, 111P(ab), 164P(ab),183P(ab), Baxter,LR,1198 116P(ab), 121P(ab), Angelides,5, 153P(ab) 170P(ab) 217P(ab) Ba@, H,889

Mthor Index â€¢1993 2281 B@th

Bayouth,JE, 33P(ab), Berkovic,SF, 666 Blasberg,R, 1152,37P(ab), Bourguignon,M, 14P(ab), Brunt, E, 234 127P(ab),134P(ab), Berlin,JA, 1681 56P(ab) 211P(ab) Bnistesco,C, 124P(ab), 161P(ab),180P(ab), Berman,D, 1485 Blaufcx,MD, 250P(ab) Bourlart-Daneski,V, 211P(ab) 192P(ab),218P(ab) Berman,DS, 1349,1494, Blevins,L, 133P(ab) 194P(ab) Bruyns,J, 99P(ab) Beam,CA, 23P(ab) 1845,34P(ab),64P(ab), Blickman,H, 171 Bousser,MG, 205P(ab) Buchbinder,5, 113P(ab) Beanlands,R, 336,968 130P(ab),148P(ab), Bloch,5, 92 Bowen,WD, 2169,235P(ab) Buchfelder,M, 37P(ab) Beanlands,RSB, 83, 189P(ab),257P(ab), Block,TA, 112P(ab) BoWsher,JE, 19P(ab), BUchier,M, 223P(ab), 35P(ab),50P(ab),107P(ab) 259P(ab) BIOk,D, 1052 20P(ab) 225P(ab) @ Beattie, B, 1152 Berman,ML, 122P(ab) Bio@m,SR, 41P(ab) 242,268,242P(@b) Buchpiguel,CA, 142P(ab) Beaft@r,BO, 1294 &rman, KF, 67P(ab), Bhi@@k, FA, 229P(@b) @Â°Y@'@â€˜1619 Buchsbaum,Di, 29P(ab), BeaU)@,JD, 1294 228P(ab) Blumenthal, RD, 1028(le), B@Y@r,A, 127P(ab), 192P(ab) 100P(ab) @ Beaumier,PL, 908,2111 Berman,RB, 123P(ab) 215P(ni,) AS, 29P(ab) Buck,A, 1XP(ab) Beaure@, OC, 297 BernÃ¡,L, 1503,13P(ab), Bh@h@th,R, 2160, Breams,3W,55P(ab) Buckley,KR, 481 Beazley,RM,2095 145P(ab),146P(ab) 24@ab) Brachman,MB, 18 Buckman,BO, 79P(ab) Beck, H, 172P(ab) Bernard,HF, 165P(ab) @ochert,R, 8P(ab) B@db@fl)@,CW, 48P(ab) Buczala,S, 66P(ab) Beck, RN, 112P(ab) Bernardo,3, 1441 B@kl@ch,A, 1632,1134, Brady, LW, 99, 1574 Budd, P, 231P(ab) Becker, iA, 2044, 27P(ab), Bernardo, M, 77P(ab) 161P(ab) Brady, Ti, 39P(ab), 208P(ab) Budd, SE, 1995 179P(ab),203P(ab), Bernstein,Mi, 131P(ab) @@kerH, 32P(ab) Braegelmann,F, 34P(ab), Budinger,iT, 184P(ab) @ 208P(ab),212P(ab), Berridge,MS,239P(ab) @, 66P(ab) Bud, U, 23P(ab),98P(ab), 259P(ab) Berry,ii, 39 Brandt,J, 5P(ab) 148P(ab),158P(ab), @ Becker, LC, 86P(ab) Bertollo, D, 40P(ab) Beer, GJ, 207P(ab), 225P(ab) @,381 1M@), 183P(ab), Becker,W, 92, 37P(ab), Besnard,i-C, 235P(ab) @Â°@â€œ@â€˜G, 55P(ab) Braun, U, 355 217P(ab),222P(ab) @ 172P(ab) Besozzi,M, 155P(ab), 0, 105P(ab), Braunstein,EM, 381 Bugaj,i, 232P(ab) Beckers, C, 129P(ab) 261P(ab) 247P(ab) Braunstein,P, 1246 Buist,MR,82P(ab) @ Beckurts, KTE, 112P(ab) Besse,T, 129P(ab) AA Jr., 39P(ab) Brawer,MK, 218P(ab) Bullard,0, 17P(ab) Beger, HG, 223P(ab), Better, N, 151P(ab) @8@' @â€˜ @@th) Braziel,R, 352(le) Bulteau,C, 1717 225P(ab) Bettinardi, V. 137 B@k@B, 226P(5b) Brechbiel, MW, 241P(ab) Bump, K, 1811 Begley,MG, 173 Bettman,L, 141P(ab) B@l,A, 15P(ab),44P(ab), Breeman,WAP,2025, Bundesen,PG, 100P(ab), Behta, B, 114P(ab) Beuter, B, 225P(ab) 86P(Sb),121P(@b) 165P(ab) 153P(ab) Beilin,I, 23P(ab) Bevilacqua,G, 1175 @0'@r,B, 11P(ab) Breiter, HCR, 47P(ab) Bunko,H, 1478 Bekdik,CF,84P(ab) Bex,M,576 B01fl@fl@B,6P(ab),55P(ab) Breithardt,G,3P(ab), Buonocore,E, 6P(ab), Belenger,J, 46P(ab) Bhadkamkar,V,33P(ab), Bomanii,J, 119P(ab) 45P(ab) 109P(ab),261P(ab) Belezzueli,EV, 122P(ab) 53P(ab),88P(ab),115P(ab), BOnianji,lB. 845 Breitz, RB, 908,2111 Buraggi,GL, 219P(ab) Bell, RL, 158P(ab) 223P(ab) Bonafous,iF, 1260 Bremner,D, 102P(ab) Burchert,W, 1770 Bellande,E, 18P(ab), Bhargava,DK, 168P(ab) Bonar, DC, 200P(ab) Bremner,JD, 205P(ab) Burger,CW, 82P(ab) 134P(ab) Bhargava, R, 138P(ab) Bonasera, TA, 49P(ab), Brenner, H, 82P(ab) Burger, P, 37P(ab) Bellanger,C, 243P(ab) Bhat, 0, 153P(ab) 56P(ab),69P(ab),160P(ab) Brenner,Ri, 18 Burke, G, 112P(ab) Beller,GA, 96P(ab) Bianchi,R, 2032 Born,0, 2032 Brenot, F, 229P(ab) Burke, Gi, 196P(ab) Belles,B, 249P(ab), Bianco,JA, 866(le) Boniface,G, 213P(ab) Brewster,Li, 1595,162P(ab) Burney, Ri, 56P(ab) 260P(ab), 263P(ab) Biasio, Y, 1485 Boniface, GR, 100P(ab), BrianÃ§on,C, 1565 Burns, Ri, 1692, 1834(le), Bellina,CR, 2032 Bida,GT, 239P(ab) 153P(ab) Briandet,P, 1204 54P(ab),149P(ab) Bello, 5, 131P(ab) Biedermann, M, 148P(ab), Bonnerot, V, 1410 Bnchtswein, K, 77P(ab) Burr, G, 1@2P(ab),103P(ab) Belloy,M, 226P(ab) 158P(ab) Bonnin,F, 226P(ab) Bride, B, 77P(ab),204P(ab) Burrows,P, 21P(ab) Beltrami,CA, 166P(ab) Biedler,JL, 114P(ab) Bonow,RO, 311 Britton,KE, 845,82P(ab), Burt, M, 11P(ab) Ben-Arush,MW,2101 Bier, D, 58P(ab) Bonte, FJ, 1239,115P(ab) 119P(ab) Burton, ML, 236P(ab) Bencomo,J, 88P(ab) Biersack,Hi, 1632,793,946, Booker,FS, 222 Brodie,JD, 18P(ab), Burwinkel,P, 153P(ab) Bender, D, 68P(ab) 77P(ab),187P(ab), Borchert,R, 218P(ab) 40P(ab),63P(ab),67P(ab) Buscombe,JR, 1621, Bendriem, B, 981, 1739, 204P(ab), 243P(ab) Bordewyk, P2, 32P(ab) Broek, W, 163P(ab) 138P(ab) 1899,36P(ab),109P(ab), Bigelow,LB, 228P(ab) Borehert,RD. 469 Broich,K, 77P(ab),204P(ab) Bush, NE, 1839 186P(ab) Biggs,T, 370 Borer, iS, 1321,34P(ab), Brooks,Di, 57P(ab) Busnardo,B, 1626 Benedetto, P, 33P(ab), Bigio, EH, 115P(ab) 66P(ab) Brown, BP, 11P(ab) Bussiere, F, 1260, 1472, 214P(ab) Bihi,H, 97P(ab) Borm,0, 247P(ab) Brown,C, 168P(ab) 5P(ab),45P(ab),194P(ab) Benjamin,C,96P(ab), Billings,J, 132P(ab), Bonnans,0, 4P(ab), Brown,CV,12P(ab), Butchko,GM,53P(ab) 121P(ab) 235P(ab) 11OP(ab),141P(ab) 257P(ab) Butler, @S,20P(ab) Benjamin, R, 33P(ab), Biniakiewicz, D, 120P(ab), Borrel, E, 57 Brown, JW, 1169 Buttram, 5, 66P(ab), 55P(ab) 248P(ab) Borsato, N, 161P(ab) Brown,KA, 1467,2061, 104P(ab) Ben-Shahar,M, 2101 Binns,R, 62P(ab) Bossuyt,A, 152P(ab), 54P(ab),85P(ab),147P(ab) Buxton,DB, 2038,4P(ab), Bentourkia,M, 136P(ab) Bischoff,H, 21P(ab) 211P(ab) Brown,M,37P(ab) 50P(ab),183P(ab) Benzi,R, 46P(ab) Biskupiak,JE, 411,918, Botelho,MFR, 1441 Brown,ML, 2236,2241, Byars, UI, 1367 Berdichevsky,D, 51P(ab), 79P(ab) Bothun,E, 148P(ab) 2247,231P(ab) Byrd, 5, 62P(ab) 71P(ab),88P(ah) Bisson,G, 49P(ab) Bottlaender,M, 102P(ab), Brown,RS, 75 Byrne,H, 26P(ab) Bererhi,L, 128P(ab) Bizais,Y, 1204 211P(ab) Brown,5.1,1574,173P(ab) Byulund,DB, 238P(ab) Beretta, L, 93P(ab) Bjorn,Mi, 908,2111 Botvinick,EH, 303,46P(ab), Brown,T, 243P(ab) Berg,BO, 1922 Black,HR. 1416 64P(ab),65P(ab),95P(ab), Brown,WD, 157P(ab) Cabahug,C, 899 Berger,Hi, 234 Black,PM, 241P(ab) 151P(ab) Brownell,A-L, 25P(ab), CadiIre, GB, 99P(ab) Berger, l(L, 322,56P(ab) Black,PML, 1045 Boubaker,A, 84P(ab) 73P(ab),202P(ab) Cadorette,J, 1O1P(ab), Bergin,M, 1082 Blahd,WI!, 12P(ab), Boudreau,Ri, 29P(ab) BrowneD,G, 73P(ab), 136P(ab) Bergman,J, 1, 1711,2068, 88P(ab),257P(ab) Bougas,C, 199,879, 202P(ab) Caillat-Vigneron,N, 3P(ab),21P(ab),69P(ab), Blair, J, 172P(ab) 1616Qe),2277(le) Brucer,M, 354Qe),1219(le) 128P(ab) 224P(ab) Blake,GM,141P(ab), Bouillon,R,576,11OP(ab) Bruck,B,78P(ab) Cairns,HS,1163 Bergmann,SR, 717,36P(ab), 142P(ab) Boulabdour,H, 2105 Bruder,B, 257P(ab) Calam,J, 41P(ab) 79P(ab),86P(ab),87P(ab), Blanc,CH, 84P(ab) Boulin,R, 234 Bruland,OS, 216P(ab) Caidwell,JH, 918,79P(ab) 154P(ab) Blanc-Feraud,L, 194P(ab) Bourachot,ML, 14P(ab) Bruni,WL, 97P(ab) Callahan,AP, 946,54P(ab), Berk, J, 1152 Blanchard, RA, 2095 Bourgoignie, J, 249P(ab) Brunken, RC, 35P(ab) 236P(ab), 243P(ab) Berk, MR, 1218Qe) BlandO,L, 233P(ab) Bourguet,P. 1204 Brims,C, 80P(ab) Callahan,Ri, 1282,1309,

2282 TheJournalofNuclearMedicine Dahi

1529,39P(ab),69P(ab), Cerqueira,MD, 1441, Cherqui,D, 2105 aarke, SEM, 144P(ab) 142P(ab),150P(ab), 83P(ab),171P(ab), 74P(ab) Cherty, SR, 143,671 aarke, SW, 1859 195P(ab) 172P(ab) CÃ©rulus,0, 1OP(ab) Chetanneau,A, 1662 Cavo,A, 2279(k) Cooper,M,798,112P(ab), Callahan,RL, 15P(ab) aiaar, M, 22P(ab) Cheung,N-K, 106P(ab), Qavo, AC, 414, 773, 239P(ab),243P(ab) Caluser,CI, 145P(ab) Chabriat,H, 205P(ab) 114P(ab) 73P(ab),93P(ab) Coppens,A, 121P(ab) Camera, I, 58P(ab), Chadduck,W, 52P(ab) clevalier, A, 387 aero, J,387,1565 Cop@a,R,235P(ab) 241P(ab) Qiaiken, L, 224P(ab) c:hevres,A, 1574,163P(ab), aiff,RO,2160 Corbelli,C,1166 Camici,P, 867(le) Qiaitman, BR, 85P(ab), 173P(ab) @Iinthorne,NH,9P(ab), Corbett,JR, 84P(ab), Camsonne,R, 241P(ab) 120P(ab) Qua,LG, 167P(ab) 90P(ab),91P(ab),100P(ab), 90P(ab) Caner, B, 162P(ab),230P(ab) c:haiwatanrat,T, 845 Qiianeffi,M, 246P(ab) 113P(ab), 190P(ab) Cordes, M, 31P(ab), Canthn&LR@22 c:hakraborty,P, 13P(ab), Chiao,P, 9P(ab),148P(ab) aorius, JH, 48, 1075, 164P(ab) Cannon, RA, 2120 45P(ab),123P(ab), c:hiariello,M, 1688,147P(ab) 139P(ab) Corley,JH,196P(ab) Cao,72,192P(ab) 236P(ab) aiien, D, 190P(ab) aoutier,Di, 75P(ab), Corlija,M, 248P(ab) Capell@5,205P(ab) aialy, T, 180P(ab),209P(ab) chiesichetti,F, 161P(ab) 85P(ab),152P(ab) Cornelius,E, 255P(ab), Capello,WN, 381 c:hamplin,R, 33P(ab), Chimowitz,MI,207P(ab) Coade, GE, 122P(ab) 262P(ab) Caplin,D, 57P(ab) 161P(ab), 218P(ab) aim, B, 143P(ab) Cochoff,5, 150P(ab) Cornish,KG, 238P(ab) Carabasi,M, 105P(ab) chan,A,165P(ab) Chin,LM, 1811 Cochran,AJ, 54P(ab) Correia,JA, 51P(ab), CaracÃ´,C, 82P(ab),115P(ab) Oian, B, 109P(ab),132P(ab), aim, MC,46P(ab) Coderre, JA, 222P(ab) 69P(ab),73P(ab),88P(ab) Caraher, JM, 440, 123P(ab) 133P(ab), 197P(ab) c:hinn,G, 175P(ab),185P(ab) Cody, RL, 224P(ab) Corrigan,P, 251P(ab) Cardella,Ci,149P(ab) than, BY, 146P(ab) c:hinol,M, 1536,166P(ab), Coenen,MM,107P(ab) Corstens,FHM, 1316,1621, Cardella,IF, 121P(ab) Oian,J,172P(ab) 233P(ab) Cogneau,M, 15P(ab), 62P(ab),105P(ab), Cardenal, C, 1452 Chan, JO, 666 Chiou,PF, 176P(ab) 86P(ab),121P(ab) 112P(ab),163P(ab), Cardillo,A,231P(ab) Gian, KH, 27P(ab) cliron, C, 1717 Cohen,AM, 1656,83P(ab), 247P(ab) Cardiot,G,98P(ab) Chan, Y-W, 18P(ab) Qiiu, KW, 222 214P(ab) Cossermelli,W, 142P(ab) Caretta, RF, 64P(ab) Oiandramouli,B, 6P(ab), Chiu,ML, 140P(ab) Cohen,B,257P(ab) Costa,WI, 258P(ab) Carey, JE, 25P(ab), 7P(ab),21P(ab),47P(ab), Qiiu,5, 1595,162P(ab) Cohen,BM, 1101 Costi,P,121P(ab) 123P(ab),158P(ab) 73P(ab),169P(ab) Chiouverakis,G, 34P(ab) Cohen,D, 263P(ab) Cotton,LA,148P(ab) Caride,Vi,1390Qe) Qianey,RC,9P(ab) c@ho,KS,138P(ab) Cohen,GE, 169P(ab) Counsell,RE, 787 Carison, KE, 18P(ab) c:hang,LS, 138P(ab) Choi,CW, 212P(ab) Cohen, I@,1877 Couto,JC, 53P(ab) Carmant, L@,226P(ab) Oiang@SL,138P(ab) Choi,H, 88P(ab) Cohen,M, 1859 Cowan,DSM,242 Carmichael,N, 83P(ab), c:hang,W, 9P(ab),195P(ab) c:hoi,J, 258P(ab) Colao,A, 42P(ab),219P(ab) Coyle,i, 12P(ab),88P(ab) 106P(ab),114P(ab), Qiao,5,34P(ab) Choi,NC, 1571,73P(ab) Cole, CW, 74P(ab) Coyle,K, 88P(ab) 213P(ab),214P(ab) Oiapman,CR,1839 c:hoi,SS,83P(ab) Coleman,E, 16P(ab), c:raddudÃ§ID,179P(ab), Carnochan,P,243P(ab) c:hapman,JD,405,885 c:hoi,y, 488,2009,2038, 17P(ab) 256P(ab) Caroline,D,169P(ab) c:haralambous,A,8P(ab) 1832(le), 4P(ab), 40P(ab), Coleman,RE, 39,567, Cram, BJ, 23P(ab) Caron, M, 96P(ab) Charalel,J, 76P(ab) 50P(ab),137P(ab), 869(br),1109,1119,1577, Crane, J, 223P(ab) Caron, PC, 105P(ab) Charbonnier,P, 194P(ab) 183P(ab),224P(ab) 1587, 1998, 2269, 7P(ab), Crawford,SM, 93P(ab) Carr,KF,261P(ab) c:harkes,DN, 1OP(ab) Chossat,FM, 1260 1OP(ab),17P(ab),19P(ab), Creasy,JL, 37P(ab) Carrasquillo,JA, 58P(ab), Qiarkes, ND, 576,11P(ab), Christian,BT,1058, 20P(ab), 21P(ab), 23P(ab), Crebs,CK,62P(ab) 124P(ab), 233P(ab), 169P(ab) 184P(ab),248P(ab) 26P(ab),30P(ab),37P(ab), Cromie,Wi, 51P(ab) 241P(ab) Charlotte,F, 2105 Christian,PE, 1905,30P(ab), 79P(ab), 80P(ab), 81P(ab), Cronmiller,JR, 1829(Ie) Carriero, MV, 213P(ab) chamey, DS, 31P(ab), 62P(ab),71P(ab),91P(ab), 1O1P(ab),144P(ab), Croop,JM, 140P(ab) Carrio, I, 171,1503,13P(ab), 48P(ab),102P(ab), 157P(ab),176P(ab), 190P(ab),l9lP(ab), c@rozatler,B, 1899 145P(ab),146P(ab) 108P(ab),109P(ab), 187P(ab),196P(ab) 195P(ab) Crouzel,C, 981,45P(ab), Carson, RE, 311,27P(ab), 205P(ab),211P(ab), Christin,A,1367 Collecchi,P,1175 109P(ab),205P(ab) 155P(ab) 243P(ab) Chu, LS, 143P(ab) Collier,BD, 961,2236,2241, Culbert,P, 237P(ab) Casaer, P, 210P(ab) Chartrand,R, 145P(ab) Chu, TH, 281,29P(ab), 2247,44P(ab),56P(ab), Qillom,Si,96P(ab) Casara, D, 1626,161P(ab) Chatal,i-F, 180,1267,1662 36P(ab),44P(ab),179P(ab) 213P(ab) Qilver,C, 349 Casciari,J,215P(ab) aiatterton, BE, 125P(ab) Chu,YK, 145P(ab) Collins,C,1031,1839 Qilver,CM,1210,158P(ab) Casciai@i,ii,21P(ab) Qiau, P, 465 aiua,T,1349,1485, Collins,DL, 70P(ab) Qimming,P, 31P(ab) Casey, I(L, 56P(ab) Chaudhuri,TR, 238P(ab) 189P(ab) Collins,PJ,125P(ab) c:umnlings,D,156P(ab), Casey, M, 7P(ab),55P(ab) Oiayes, Z, 76P(ab),77P(ab) c:hugo,A,192P(ab) Collorec@R,1204 205P(ab) Cassidy,EH, 239P(ab) Chen, BC, 203P(ab), Chumpradit,5, 89P(ab), Colnaghi,MI, 213P(ab) Oinningham,J, 53P(ab) Castaigne,A, 1899,14P(ab), 251P(ab) 132P(ab),235P(ab) Colombo,F,360 Oiocolo,A,173,1602,1688, 36P(ab) Chen, C, 1854, 40P(ab), Oning, D-G, 204P(ab) Colombo,L,226P(ab) 147P(ab),153P(ab) Castellani,MR. 219P(ab) 109P(ab),132P(ab), Quing, DH, 83P(ab) Colombo,P, 114P(ab) Curtet, C, 1267 Castelli,L, 82P(ab), 197P(ab),198P(ab) Chung,HK, 212P(ab) Comans,EFI, 649,15P(ab) c:urtin,CR,109P(ab) 115P(ab),153P(ab) chen, C-T, 112P(ab), aning, i-K, 1651,212P(ab) Comar,D,1460 Curtis,M,717 Castellino,R, 56P(ab) 186P(ab) clung, T-S, 1987 Comazzi,V, 18P(ab), Cutler, PD, 136P(ab), Castilla,EP, 589 Chen, DCP, 261P(ab) Cicoria,A, 143P(ab) 134P(ab) 176P(ab) Castronovo,FP Jr., Oien,G,94P(ab) Ckslak@RD, 1190 Comtois,R, 1927 Cyr, JE, 18P(ab),146P(ab) 157P(ab),869(br) Oien,LW,127P(ab) Gal, R, 39P(ab) Connett,JM, 28P(ab), c:zernin,3, 488, 1832(le), Catafau, AM, 77P(ab) Chen, J-C, 474 CinOtti,L, 22P(ab),103P(ab) 81P(ab),134P(ab), 35P(ab),165P(ab) Cave,GL,117P(ab) Chen, K, 4P(ab), 40P(ab), Civelek,AC, 143P(ab) 216P(ab) Cavagnaro,F, 117P(ab), 50P(ab) Qaci@,R,80P(ab) Conrad, B, 32P(ab) 137P(ab),249P(ab) Chen, LF, 589 Claessens,RAMJ, 1621, Conte, PJ, 54P(ab),61P(ab) Dadparvar,5, 1574, CavaillolÃ¨s,F, 229P(ab) Chen, M, 149P(ab) 35N(12),62P(ab), Conti,PS,182P(ab) 163P(ab),173P(ab) CaVallini,AR, 11OP(ab) Qien, MN, 245P(ab) 105P(ab),112P(ab), Conway, J, 1029(le) Dae, MW,303,46P(ab), Cave, V, 75P(ab) then, MT, 138P(ab) 247P(ab) Conway,ii,226P(ab) 64P(ab),65P(ab),95P(ab) Cazzuola,F, 2032 Chen, WL, 238P(ab) Oanton, JA, 469 Cook, C, 241P(ab) Daghighian,F,1595, Cecil,MP,1826Qe) Chen, Y, 88P(ab), 188P(ab) aark, J, 185P(ab) Cook,iS,239P(ab) 37P(ab),114P(ab), Cei, A, 1175 Chen, YK, 145P(ab) a@,R,176P(ab) Cook,SA,400,1834(k) 127P(ab),162P(ab), Censi, C, 67P(ab) Qeng, KT, 106P(ab), clarke, G, 138P(ab) Cooke,CD, 1494,96P(ab) 213P(ab),214P(ab) Ceriani,R,1067 179P(ab),245P(ab) Qarke, GA, 1778 Cooke, I, 232P(ab) Dagousset,F,387 Cenani, RL, 53P(ab) Qieng,TP,238P(ab) aarke, MF, 6P(ab) Cooper,JA, 1341,51P(ab), DaM,3, l48P(ab)

Atithor Index â€¢1993 2283 Dahlberg

Dahlberg,ST, 927, 14P(ab), Deiager, R, 214P(ab) Deutsh,0, 92P(ab) Dottorini,ME, 226P(ab) Elder, RC, 38P(ab), 46P(ab),130P(ab) Deiesus, OT, 8P(ab), Devanand,DP,1090 Dougan,H, 235P(ab) 120P(ab),248P(ab) Dahibom, M, 143, 488, 2009, 69P(ab) DeVito,R, 29P(ab) Douglas,MA,311 Eldredge,WJ, 261P(ab) 1832(le),1O1P(ab), de long, M, 2025,165P(ab) Devlin,5, 172P(ab) Doussal,J-ML,1662 Elfner, R, 87P(ab) 137P(ab),184P(ab) deiong, RBJ, 164P(ab) Devous,MD, 1239,23P(ab), Douville,C, 62P(ab) Elgazzar,A@H,52P(ab), D'Alessandro,HA, 258P(ab) de Kerviler,E, 98P(ab) 68P(ab),91P(ab) Dragotakes,SC, 199, 227P(ab),255P(ab), D'Alessandro,MP, 258P(ab) de Kleijn,EMHA,62P(ab) Devous,MD Sr.,754 172P(ab),1616(le),1975, 261P(ab) DallaPozza,L, 1082 de Klerk,JMH,223P(ab) de Vries,Di, 72P(ab) 2176,2277(le) Eli,PJ,169,1621,138P(ab), Daliyrnple,GV, 896, De Kock,M,44P(ab) Dewald,CL, 50P(ab) Draho,JM, 394,35P(ab) 153P(ab) 111P(ab) Delaage,M, 1267,1662 Dewan,N,20P(ab) Drane,WE, 658 Elliott, D, 196P(ab),203P(ab) Daly,ii, 255P(ab) Delak@ye,AB, 84P(ab) Dewanjee,MX, 172P(ab), Drueke,T, 128P(ab) Elliott,DO, 53P(ab) Daly,PA, 149P(ab) Delaloye,B, 84P(ab) 174P(ab),214P(ab), D'Souza, MF, 190P(ab) Ellison,D, 82P(ab) Dam, K, 168P(ab) DeLaPaz,R, 56P(ab) 221P(ab),224P(ab) Duatti,A, 18P(ab),134P(ab) Elmaleh,DR. 1309,1529, Damjanov,I, 260 De La Pena, RC, 22P(ab) Dewey,SL, 246,609,619, Dubey,A,90P(ab) 25P(ab),73P(ab),202P(ab), Damsker,J, 163P(ab) Delbeke,D, 826,2185, 67P(ab),78P(ab),200P(ab) Dubovsky,EV, 249P(ab) 232P(ab),236P(ab) Daniel, G, 1267 86P(ab) DeWit,H, 798 Duchak,3M,94P(ab) Elser, H, 217P(ab) Dannals,RF, 120,25P(ab), deLeon,Mi,2019 Dey, H, 84P(ab),201P(ab), Duckett,JW, 117P(ab) Elsinga,PH,49P(ab), 31P(ab),86P(ab),103P(ab), Delforge,J, 981,45P(ab), 205P(ab) duCret,P2, 29P(ab) 183P(ab) 109P(ab),132P(ab), 102P(ab),lO9P(ab) Dey,HM, 1416 Dudczak,R, 1397 Emmrich,F,92 133P(ab),197P(ab), Dell'Acqua,A, 93P(ab) Dhawan,A, 40P(ab) Dufour,JM, 58P(ab) Emmrich,JG, 99 199P(ab),228P(ab), DellaVittoria,G, 44P(ab) Dhawan,V, 180P(ab), Duncan,i,205P(ab) Emrich,D, 153P(ab) 234P(ab) Delpassand,E, 88P(ab), 209P(ab) Duncan,JR, 1728,59P(ab) Enas, J, 7P(ab) Danos, P, 77P(ab) 119P(ab) Dhumeaux, D, 2105 Duncan,iS, 57P(ab), Endert, E, 225P(ab) Dansereau,RN, 229P(ab) delRosario,RB, 1147, Diamond,GA, 150P(ab) 187P(ab) Endo,K, 815,1745,2085, Darcourt, G, 5P(ab) 135P(ab) Diaz,A, 263P(ab) Duncker,D, 1503,13P(ab) 14P(ab),42P(ab),119P(ab), Darcourt,J, 1472,5P(ab), DelSole,A, 5P(ab) Diaz,M, 212P(ab) Dunigan,K, 218P(ab) 215P(ab) 45P(ab),194P(ab) DelVecchio,A, 94P(ab) DiBella,E, 29P(ab) Dunn,Ti, 135P(ab) Engel,J, Jr., 1892 Das, MK, 239P(ab),243P(ab) DelVecchio,P, 1927 DiCarli,M, 184P(ab) Dunn, WL, 141P(ab), Enright,Di, 142P(ab) DasGupta,P.30 DelVecchio,5, 213P(ab) Di Donna,A, 126P(ab) 142P(ab) Ensing,Gi, 2280(le) DaSilva, JN, 25P(ab) Demacker,PNM, 1316 DiFabrizo,L,172P(ab) Dupont,M, 1642 Enta,A, 1944 Datz, FL, 128,455, 1905, Demmelbauer,K, 212P(ab) Dig@, L, 187,140P(ab), Duranceau,A, 140P(ab) Epelbaum,R, 2101 l389(le), 2135, 30P(ab), Dempke,W, 164P(ab) 144P(ab),231P(ab) Durham,iS, 908 Epperly,M, 231P(ab) 62P(ab),71P(ab),91P(ab), DeNardO,GL, 1020,1067, DiGiorgio,ML, 261P(ab) Duryea,RA,197P(ab), Epstein, AL, 114P(ab) 157P(ab),176P(ab), 53P(ab),93P(ab),128P(ab), Dilsizian,V,178P(ab) 202P(ab) Ercan, MT, 84P(ab) 196P(ab),220P(ab), 189P(ab) Dilts,C, 151P(ab) Dutoit,M, 84P(ab) Erickson, KL, 93P(ab) 249P(ab) DeNardo,Si, 1020,1067, DiLuca,L,1175 Dutschka,K, 58P(ab) Eriksson,L, 1O1P(ab) Daube-Witherspoon,ME, 53P(ab),93P(ab),128P(ab), Dimitrakopoulou,A,12, Duval,D,243P(ab) Erkonen,W, 256P(ab) 60P(ab),177P(ab) 189P(ab) 1075,218P(ab),220P(ab) Duvernoy,C, 155P(ab) Erlandsson,K, 9P(ab) Dauphin,F, 241P(ab), Denays,R, 1223,226P(ab) Dimopoulos,M, 33P(ab), Dworkin,RI, 349,1028(le), Erlichman,C, 242P(ab) 243P(ab) Dence,c:S, 56P(ni,),79P(ab) 161P(ab) 1210,158P(ab) Erwin, WD, 35P(ab), Dauriac,C, 182 Dendale,P, 152P(ab) Ding,Y.S, 246,619,69P(ab), 128P(ab),151P(ab), Davidson,J,30 denHollander,W, 82P(ab) 78P(ab) Eades, CO. 182P(ab) 175P(ab) Davies, R@F,74P(ab) Denton,TA, 150P(ab) Dione,DP, 97P(ab) Eagle,K, 149P(ab) Eshima,D, 129P(ab), Davison,A, 242P(ab) de Paulis,T, 132P(ab), DiPaula,AF Jr., 86P(ab) Eai@r,iF,1031,1839 244P(ab), 246P(ab), Day,P, 151P(ab) 202P(ab), 158P(ab) DiResta,G, 56P(ab) Eber, 0, 2278(le),2280(le), 250P(ab) Daya,SA,614 Dc Pauw, M, 15P(ab), DiRocco,R, 15P(ab), 122P(ab) Esposito,G, 12P(ab), Dayanildi,F, 35P(ab), 86P(ab) 92P(ab) Eberl,5,1752 67P(ab) 36P(ab),l4SP(ab), DePuey,EG, 1871,2006, DiRocco,RI,641 Ebert, A, 107P(ab) Easer, PD, 48P(ab),60P(ab), 155P(ab) 1829(le), 24P(ab), 64P(ab), DiSacco,5,1175 Ebert, D, 47P(ab) 125P(ab) Dayankikli,BF, 958 131P(ab),150P(ab) DiStefano,R,1175 Eckard, DA, 1239 Essiambre,R, 96P(ab) Dean,R, 66P(ab) DePuey,FG, 1871 Divgi,CR, 422,1656, Eckehnan,WC, 641 Esterbrooks,Di, 50P(ab) Dean, RT, 17P(ab),66P(ab), Dequeker,J, 141P(ab) 53P(ab),83P(ab),94P(ab), Edeibmek,MAL, 582 Esteves, MI, 171P(ab) 104P(ab) Derbekyan,V, 853,1992 105P(ab),114P(ab), Edgeworth,J, 90P(ab) Estorch, M, 1503,13P(ab), de Andrea,L, 1503 Derenzo,SE, 1O1P(ab), 127P(ab),213P(ab), Edlin,J,188P(ab) 146P(ab) De Biasi,F, 126P(ab) 184P(ab) 214P(ab) Edwards,B,222 Estrada,WN, 1214 de Bruin,K, 225P(ab) DeRogatis,A, 24P(ab) Do,1,1294 Eenigevan, Mi, 649 Ethier, J, 58P(ab) Debruyne,D, 241P(ab) de Rolan,FS, 92P(ab) Dobbeleir,A, 186P(ab) Efange,SMN, 8P(ab), Eubanks,RSJr., 345 Dc Carli, F, 91P(ab) De Roo, M, 576,4P(ab), Dobko,T, 184P(ab) 90P(ab) Eubig,C, 1XP(ab),255P(ab) Declerck,P, 227P(ab) 1OP(ab),11OP(ab), Dobrinsky,C,1871 Effert,H, 217P(ab) Evans, AC, 57P(ab),70P(ab) deCosta,BR, 235P(ab) 141P(ab),210P(ab), Docter, R, 2025 Effird, J, 206P(ab) Evans, D, 111P(ab) Dedrick,RL, 1552 222P(ab),227P(ab) Doerr,Ri,1818 Eggli,DF, 121P(ab) Evans,ML, 21P(ab) Deeb, M, 43P(ab) Derwanz,R,1632 Dogan,AS, 1607,226P(ab) Ehlers, M, 31P(ab) Evans, NH, 1818 de FatimaPacheco,M, 1441 De Sadeleer,C, 152P(ab) Dokumaci,B,889 Ehrhardt,GJ, 38P(ab), Even-Sapir, E, 458, 1377 Defrise,M, 1367 De Saedeleer,C, 117P(ab) Dole, MG, 51P(ab), 220P(ab) 231P(ab) Evora,PH,8P(ab) DeFulvio,3, 260 Desai, FR, l8OP(ab) Doll,J, 12,21P(ab),218P(ab) Eidelberg,D, 180P(ab), Eysman,L, 230P(ab) De Geeter, F, 1217(le), Desai,SP, 955,1748 Donaldson,G, 1839 209P(ab) Ezuddin,5, 117P(ab), 152P(ab) De Santi, MS. 115P(ab) Donath,A, 1367 Eisen, Hi, 2049 137P(ab),174P(ab), Degomme,P, 1217(k) Desgrez,A, 229P(ab) Dond, M, l29P(ab) Eisenberg, B, 169P(ab) 221P(ab) DeGrado,TR, 1287,45P(ab), DeSombre,ER, 272 Dondi,M,1166 Eisenhut, M, 217P(ab) Ezzedine,B, 8P(ab), 1O1P(ab),107P(ab) Deutsch,E, 1132,38P(ab) Donnerstag,B, 126P(ab) Eisert, D, 206P(ab) 218P(ab) De Groof,M, 154P(ab) Deutsch,EA, 228,120P(ab), Dorflinger,E, 131P(ab) Eisner,RL,281,978, DeHaven-Hudkins,DL, 156P(ab),248P(ab) Dorfman,D, 77P(ab) 29P(ab),36P(ab),44P(ab), Faber, T!@.,96P(ab) 243P(ab) Deutsch,G, 64P(ab) Dorian,SM, 199P(ab) 96P(ab),146P(ab), Fabry,0, 227P(ab) Dehdashti,F, 49P(ab), Deutsch,K, 38P(ab) Dormans,TPJ,1316 179P(ab) Faajia, 0, 114P(ab) 56P(ab) Deutsch,KF, 135P(ab) DOrr,U, 97P(ab) Ejiri,K, 159P(ab) Fagret, D, 57, 1392(le)

2284 TheJournalof NudearMedicine Fahey, FH, 182P(ab) 206P(ab),208P(ab), Frey, KA, 322,22P(ab), Galema, TW, 147P(ab), Germano,0, 1349,1485, Falchook,F, 112P(ab) 232P(ab),236P(ab), 25P(ab),56P(ab),108P(ab), 154P(ab) 1494, 64P(ab), 189P(ab) Falen, SW, 48P(ab) 240P(ab), 260P(ab) 116P(ab),123P(ab), Galetta,SL, 1009,1447 Gerretsen,M, 1953 Fallone, PS, 1656,83P(ab), Fish, DR. 57P(ab) 207P(ab) Gallagher,JO, 75P(ab) Gerson,MC, 1520,120P(ab), 214P(ab) Fisher,DR,908,106P(ab) Frick, OS, 210P(ab) Gallagher,R,193 152P(ab),153P(ab), Fan,SH, 26P(ab) Fisher, IU, 232P(ab) Frick, M, 21P(ab),251P(ab) Gallik,DM, 3P(ab) 156P(ab),248P(ab) Fang, OW, 233P(ab) Fisher, RS, 11P(ab), Frickhofen,N, 217P(ab) Gallinger,5, 99P(ab) Gervais,A, 49P(ab) Fantanas, C, 190P(ab) 169P(ab) Friden,A, 33P(ab) Galloway,5,208 Geusens,P, 11OP(ab), Fanti, 5, 1166,129P(ab) Fisher, Si, 75, 787,104P(ab), Friedman,AR, 23P(ab) Galonska,P, 164P(ab) 14'P(ab) Fantinato, L, 97P(ab), 245P(ab) Friedman,J, 1485,64P(ab), Galvan,0, 122P(ab) Gewirtz,H, 862,24P(ab) 135P(ab) Fishman,5, 353(le) 130P(ab),148P(ab) Galvin,J, 256P(ab),258P(ab) Geworski,L, 58P(ab) Fanwick,PE, 228 Fitchett,DH, 589 Friedman,M, 150P(ab) Gal)@,0, 103P(ab) Ghafouripour, AK, 174P(ab), Faraggi,M, 98P(ab) Flameng,W, 4P(ab) Friedman,P. 193 Gambaro,M, 91P(ab) 221P(ab),224P(ab) Farahi,JB, 12P(ab), Flanagan,R, 58P(ab), Fries, H, 225P(ab) Gandler,WR, 60P(ab) Ghali,5K, 138P(ab) 257P(ab) 119P(ab) Frim, DM, 202P(ab) Gangopadhyay,A, 246P(ab), Ghandour,C, 182 Farde, L, 7P(ab),89P(ab), Fleishman,Mi, 122P(ab) Frist, WH, 826 247P(ab) Ghaneemah,A, 131P(ab) 102P(ab) Flesher,J, 199P(ab) Fritzberg,A, 246P(ab) Ganju-Frishan,A, 224P(ab) Giacometti,A,1766 Farlow, DC, 1172 Flicker,5, 261P(ab) Fritzberg,AR,2111 Gansow,OA,241P(ab) Giap, MB,127P(ab), Fare, H-P, 219P(ab) Flivik,G,1646 Froelich,J, 2198,16P(ab), Ganti,V, 24P(ab),64P(ab) 191P(ab),192P(ab) Farrell, EL, 1818 Flores, AR, 1695 17P(ab) Ganz,W, 117P(ab), Giardino,EC, 173P(ab) Fass, J, 98P(ab),158P(ab) Floyd, C, 39 Froelich,JW, 1109,1119 137P(ab),174P(ab), Gibbons,Ri, 146P(ab), Favero,A, 1626 Floyd, CE Jr., 19P(ab), Froideville,JL, 99P(ab) 263P(ab) 148P(ab) Fawwaz, RA, 48P(ab), 20P(ab) Fmment,JC,22P(ab), Ganz, WI, 33P(ab),261P(ab) Giganti,M, l8P(ab) 99P(ab) Fogarasi,M, 109,1618(le), 103P(ab) Gao, Y, 31P(ab),243P(ab) Gilardi,MC, 137 Fazinni, E, 131P(ab) 59P(ab),234P(ab), Front, D, 1330,1826(le), Garada,BM, 723,2044, Gilbey,5,41P(ab) Fazio, F, 137,360,1460, 240P(ab) 2101 27P(ab),47P(ab),179P(ab), Gilderskeve, DL, 123P(ab) 5P(ab), 93P(ab), Fogarty,K, 32P(ab) Front,GMKD,141P(ab) 203P(ab),208P(ab), Oildersleeve,K, 13P(ab) 114P(ab), 154P(ab) Foged,C, 7P(ab),89P(ab) Frost, A, 165P(ab) 212P(ab),259P(ab) Gdi,H1@ 222 Febo, R, 106P(ab) Fogelman,I, 2236,2241, Frost, ii, 5P(ab),31P(ab), Garber,CE, 75P(ab), Gilland,DR, 26P(ab), Federici, M, 216P(ab) 2247,11OP(ab),141P(ab), 103P(ab),199P(ab), 85P(ab),152P(ab) 30P(ab),190P(ab) Fedio, V, 22N(4) 142P(ab),144P(ab) 228(ab) Garcia,E, 64P(ab),148P(ab), Gillardi,MC,5P(ab) Feinendegen,LE, 355,2222, Foisy, MF, 394,130P(ab) Frouin, V, 186P(ab) 251P(ab) Gilliand,DR,1577 32P(ab),107P(ab) Folio,T, 197P(ab),198P(ab) Frueh, B, 11OP(ab) Garcia,By,978,1494, Gillispie,SB, 60P(ab), Feistel, H, 47P(ab), 207P(ab) Folks, R, 1494, 87P(ab), Fuchs, J, 161P(ab) 96P(ab) 258P(ab) Felix, R, 31P(ab),164P(ab) 251P(ab) Fuji,R, 1543 Garcia-Larrea,L,22P(ab), Gilmore,M, 14P(ab), Feng, D, 185P(ab) Fonti, R, 213P(ab) Fujibayashi,Y, 147P(ab) 103P(ab) 46P(ab) Fenyvs, El, 9P(ab) Foote, C, 65P(ab) Fujii,R, 431,26P(ab), Garg, PK, 79P(ab),99P(ab), Gilmore,MP, 927 Ferdeghini,EM, 1175,2032 Forman, D, 215P(ab) 198P(ab),225P(ab) 191P(ab), 216P(ab) Gilsbach,I,222P(ab) Ferency, 5, 1031 Fornazzari,L, 1274 Fujii,T, 167P(ab) Garg, 5, 79P(ab),99P(ab), Gilson,M, 24P(ab) Ferlin, G, 161P(ab) Forrester, DM, 1990 Fujimori, K, 216P(ab) 216P(ab) Ginos,J, 1152,37P(ab) Fernandez, 0, 1485 Forsaith, A, 349 Fujimoto, J, 2030 Garin-chesa, P, 83P(ab) Gionfriddo,M, 244P(ab) Fernandez-Ulloa,M, Forster, AM, 222 Fujita,H, 57P(ab),198P(ab), Garlich,J, 33P(ab),244P(ab) Giordani,BJ, 4P(ab) 171P(ab),261P(ab) Forstrom, LA, 61P(ab) 199P(ab) Garmestani,K,241P(ab) Giorgianni,JA, 109P(ab) Fernando,JL, 9P(ab) Fossella,F, 134P(ab), Fujita,M, 199P(ab), Gamer, 5, 89P(ab), Gips,5,141P(ab) Ferone, D, 42P(ab),219P(ab) 223P(ab) 201P(ab),202P(ab) 132P(ab),135P(ab) Girelli,ME, 1626 Ferrari, E, 1472,45P(ab) Foster, CE, 18 Fujita,T, 194P(ab) Garreau,B, 1717,78P(ab) Gisclon,L, 109P(ab) Fessler, JA, 25P(ab), Foster, NL, 4P(ab),116P(ab) Fujiwara,T, 780 Garreau,L, 235P(ab) Ojedde,A, 31P(ab),51P(ab), 70P(ab),91P(ab),190P(ab) Foulon,C, 89P(ab) Fukuchi,K, 199P(ab), Garrido,3M,1520 57P(ab), 181P(ab), Fetterman, RC, 97P(ab) Fourie, PJ, 1828(k) 201P(ab) Garty, II, 61 198P(ab),199P(ab), Ficaro, EP, 30P(ab), Fourniere, BL, 135P(ab) Fukuchi,M, 126P(ab) Gascon,P, 53P(ab) 200P(ab), 201P(ab) 148P(ab) FourrÃ©,C, 1565 Fukuda, H, 780, 200P(ab) Gaskin,K,214 Gladding,R, 48P(ab) Ficken,Vi, 257P(ab) Fowler, JS, 246, 609, 619, Fukui, H, 1103,170P(ab) Gasparini,M, 219P(ab) Gladshteyn,M, 250P(ab) Fields,L, 245P(ab) 67P(ab),69P(ab),78P(ab), Fukumura,T, 288 Gatley,Si, 246,272,619, Glaser, B, 164P(ab) Fig, LM, 11P(ab) 102P(ab),103P(ab), Fukunaga,M, 208P(ab) 2208,49P(ab),69P(ab), Glass, EC, 88P(ab) Figulla,HR, 153P(ab) 131P(ab),200P(ab), Fukuyama,H, 839 78P(ab),131P(ab), Gleischman,SH, 18 Fib, RS,381 237P(ab) Fulton, RR, 1752 156P(ab) Glenn, S. 53P(ab),174P(ab) Fine,El, 250P(ab) Fox, JO, 171P(ab) Furlong,RB, 172P(ab) Gautherot,E, 1662 Glenn,SD, 1067 Fink, LM, 896 Fox, PT, 39P(ab) Furmanski,P, 1067 Gbur, CS, 153P(ab) Glick,5, 194P(ab) Finlayson,A, 179P(ab) Fragu, P, 1565 Furudate, M, 216P(ab) Gearhart,JP, 762 Glover,DK, 630,96P(ab) Finn, C, 818 Franceschi, D, 899, 43P(ab), Furusawa,T, 202P(ab) Geatti, 0, 166P(ab) Glowniak,JV, 1140,1392(Ie) Finn, R, 1152 222P(ab) Fusamoto,H, 1103,170P(ab) Gehl,HB, 183P(ab) Go, RT, 400, 1834(le), Finn, RD, 37P(ab),53P(ab), Franceschi, M, 222P(ab) Fuseau, C, 1739, 45P(ab), Oeissbuhler,A, 1367 190P(ab) 83P(ab),105P(ab), Francis, IR, 1420,127P(ab) 102P(ab) Gelfand,Mi, 614,52P(ab), Goins,B,2160,135P(ab), 114P(ab),214P(ab), Franck, 0, 1460 Fusselman,Mi, 56P(ab) 205P(ab), 227P(ab), 247P(ab) 239P(ab) Frank, A, 2278(le),7P(ab), Futami,5, 2091 255P(ab),261P(ab) Golan,H, l2l8Qe) Finstad,CL, 216P(ab) 20P(ab),21P(ab),55P(ab) Fyfe, A, 149P(ab) Gelormini,RG, 1169 Golberg,L, 213P(ab) FirOUZbahkt,ML, 69P(ab) Franken, PR, 152P(ab) Geitman,EM, 36P(ab) Golberg,LE,885 Fischman,AJ, 6, 879,1282, Franks, W, 204P(ab) Gabor, FV, 128,1389(le) Gemmell,HG, 30 Gold, DV, 214P(ab) 1303,1309,1529,1571, Fraunhofer,5, 63P(ab) Gachon,P, 255 Genna,5, 91P(ab) Goldberg,IE, 208P(ab) 1964,1975,2130,2176, Freedman,N, 27P(ab) Gadhoke,A, 65P(ab) Georgi,P, 217P(ab) Goldberg, MA, 260P(ab) 2253,15P(ab),24P(ab), Freeman,NMT, 311 Gage,HD, 182P(ab) Oeorgiou,M, 112P(ab), Goldberg,TE, 228P(ab) 25P(ab),39P(ab),47P(ab), Freemer,M, 257P(ab) Gagne,GM, 992,8lP(ab), 117P(ab),175P(ab), Goldenberg,DM, 61, 51P(ab),73P(ab),83P(ab), Frenkel,A, 141P(ab) 97P(ab),135P(ab) 249P(ab) 1028(k),1617(le),53P(ab), 88P(ab),104P(ab), Frey, EC, 72P(ab),188P(ab), Galati,0,12P(ab) OermÃ¡,JR, l46P(ab) 54P(ab),61P(ab),94P(ab), 172P(ab),173P(ab), 192P(ab) Galati,iS, 111P(ab) Germane,A, 82P(ab) 160P(ab),l72P(ab),

AuthorIndexâ€¢1993 2285 Gokflng

214P(ab),215P(ab), Green,MV,60P(ab), Gur,R, 210P(ab) Harkonen,R, 2068,3P(ab), Heim,M, 1075 217P(ab) 70P(ab),177P(ab), Our,RC,228P(ab) 107P(ab) Heimpel,H, 217P(ab) Goldbig,R, 1706 178P(ab) Our,RE,2201,198P(ab), Harr,DP,11P(ab) Heimsath,SJ, 112P(ab) Goldman,M, 109P(ab), Greenberg,HE, 1905 228P(ab) Hand, C, 178P(ab) Heisiger,E, 63P(ab) 261P(ab) Greenough,R, 6P(ab), Guthrie,A, 260P(ab) Harrell,CR, 125P(ab) Heiss, WD, 1460,1O1P(ab) Goldschmidt,H, 220P(ab) 43P(ab) Ovozdanovic,DV, 30 Harris, cX, 1587 Heller,GV, 134,75P(ab), Goldsmith,Si, 40N(12),465, Oreenwald,RA, 233P(ab) Harris, EW, 1326 85p(@,)15@p(ab) 1235,1536,56P(ab), Greer, KL, 1577,1998, Harris, OC, 184P(ab),2009 Heller, U, 14P(ab),130P(ab) 61P(ab),66P(ab),83P(ab), 26P(ab),30P(ab),80P(ab), Haapanen,A, 2068,3P(ab) Harris,J, 232P(ab) Hetiman,RS,44P(ab), 94P(ab),104P(ab), 81P(ab) Haaparanta,M, 1711,2064, Harris, TS, 68P(ab) 56P(@b),94P(ab) @ 143P(ab),145P(ab) Gregoiy,C, 150P(ab) 2068,3P(ab),21P(ab), Harrison,C, 218P(ab) I, 93P(ab) Goldstein,DS, 123P(ab), Grevitt, M, 144P(ab) 107P(ab) Harrison,KA, 896,111P(ab) Hen@m, KE, 93P(ab) 221P(ab) Grey, L, 7P(ab) Habbab, N, 172P(ab) Harrison,LA, 262P(ab) He@wi@,BJ, 992 Goldstein,J, 210P(ab) Oriffeth,LK, 1198,56P(ab), Haber, E, 2144 Harrison,R, 60P(ab), Hen@i@,D, 98P(ab) Goldstein, JA, 154P(ab) 81P(ab) Haberkorn, U, 12, 1075, 136P(ab) Heimer, B, 38P(ab) Golsch,0, 52P(ab) Griffin,TW, 1656 218P(ab),220P(ab) Hartman,ii, 717 Helus, F, 12, 1075,21P(ab), Golsch,GJ, 255P(ab) Griffloen,0, 1052 Habi, HA, 1818 Hartman,N, 242P(ab) 218P(@b) Gomez,AA, 589 Griffiths,GL, 1617(le), Hacker, H, 205P(ab) Hartmann,A, 32P(ab), He@@er, LA, 127P(ab) Goncalves,LM, 1441 54P(ab) Hagen,CA, 220P(ab) 204P(ab) Hendel, RC, 131P(ab), Goncalves,Ri, 256P(ab) Grimm,W, 161P(ab) Hahn, K, 161P(ab) Hartnett, 5, 1031 Gong,W, 68P(ab),91P(ab) Grimmel,5, 217P(ab) Hahn, SD, 134 Harwood,Si, 213P(ab) 149P(ab) Gonzales, PM, 165P(ab) Grimon, 0, 229P(ab) Haim, N, 2101 Hasapes, JP, 154P(ab) Hendry, ill, 133P(ab) Goodgold,HM, 120P(ab) Gritters,IS, 1420 Haire, WD, 896 HasÃ§elik,Z, 84P(ab) Hengstler,JO, 161P(ab) Goodman, MM, 159P(ab), Groch, MW, 35P(ab), Haken, RK'F, 105P(ab) Hasegawa, W, 176P(ab) Heflkin, RE, 1037 235P(ab) 128P(ab),151P(ab), Halama,JR. 256P(ab) Hasfeld,M, 45P(ab) Hennemann,0, 41P(ab) Goodwin, P, 250P(ab) 175P(ab) Halkar, R, 251P(ab) Hashikawa, K, 63P(ab), Heii@ich,MM, 87P(ab), 000neratne, N, 150P(ab) Grode,M, 37P(ab) Hall, A, 118P(ab) 171P(ab),207P(ab), 1Â°@â€•(@),217P(th), G_, SS, 189P(ab) Oroeneveld, ABJ, 230P(ab) Hall, H, 7P(ab) 209P(ab) Gordon,E, 223P(ab) Grogin,HR.151P(ab) Hall,ML,138P(ab) Hashimoto,5, 2216 He1113f,TR,1892,22P(ab) Gordon,EE, 1031,1839 Groom,ON, 4P(ab), Haildin,C, 7P(ab),89P(ab), Haskard, D, 62P(ab) HemyLCbraS,F, 194P(ab) Gordon, I, 118P(ab) 108P(ab),116P(ab) 102P(ab) Hasselquist,BE, 29P(ab) Henze, E, 17N(2) Gordon,L, 255P(ab) Oroontoonk,5, 1367 Hallgring,B, 723 Hatabu, H, 121P(ab) Hoc, J, 75P(ab),85P(ab), Gorenberg,M, 2101 Grootoonk,5, 26P(ab) Halpern, 5, 1565 Hatazawa,J, 780,92P(ab), 95P(ab) Gorey, J, 235P(ab) Oropkr, Ri, 36P(ab), Ham, HR, 1223, 1642, 200P(ab) HÃ©on,M, 136P(ab) Goris, ML, 1029(le), 1617(k) 86P(ab), 87P(ab), 106P(ab) 99P(ab), 166P(ab), Hattner, RS, 1922, 865(le), Hethst, CP, 330, 963 Gosfield,E III, 2191 Oroshar, D, 885 226P(ab) 1616(le),64P(ab),65P(ab) Herd, R, 141P(ab),142P(ab) Gosfield,TB, 12P(ab), Gross, M, 11P(ab),87P(ab), Hamamoto,K, 19P(ab), Haubold-Reuter,BO, 809 Herholz, K, 1460 162P(ab) 104P(ab) 98P(ab),167P(ab), Hauenstein,K, 375 Herman,C, 116P(ab) Ooshen, E, 82P(ab) Gross, MD, 787 222P(ab) Haugh, Cl, 65P(ab) Herman, SD, 75P(ab), Ooto, M, 1103 Grossman, HB, 6P(ab), Hamberg, LM, 73P(ab) Haumont, D, 1223 85P(ab), 152P(ab) Ootoh, E, 161P(ab) 223P(ab) Hambuechen,U, 98P(ab), Hauser, MF, 12P(ab) Herinus, AR, 163P(ab) Gottschalk, A, 353(le), 1109, Grossman, M, 1009 217P(ab), 222P(ab) Hawkins, H, 257P(ab) Hero, AO, 190P(ab) 1119,16P(ab),17P(ab) Grover-McKay,M, 834 Hamet,P. 58P(ab) Hawkins,PN, 118P(ab) Herold,Ti, 148P(ab) Gould,HR,6P(ab) Oruaz-Guyon,A, 1267,1662 Hamill,ii, 1OP(ab),192P(ab) Hawkins,RA,488,1198, Herranz,R, 1452 Goumnerova,LC, 1045 Gruber, M, 206P(ab) Hammer,HF, 168P(ab) 2009,2038,1832(k), Herrera, J, 116P(ab) Gracia,5, 32P(ab) Gruenwald,SM, 1172 Hammond,P. 41P(ab) 40P(ab),50P(ab),137P(ab), Herrero, P. 36P(ab),86P(ab), Grady,A, 157P(ab) Grummon,GD,135P(ab) Hands,N, 63P(ab), 183P(ab),184P(ab), 87P(ab) Graef,KJ, 164P(ab) Oninwald,F, 793,77P(ab), 171P(ab),209P(ab) 224P(ab) Herrlin,K, 1646 Grafton,ST, 679, 1198, 187P(ab),204P(ab) Handlin,11, 149P(ab) Hawman,EG, 1OP(ab), Herrmannsdoerfer,Al, 182P(ab) Guenther,R, 183P(ab) Handt,5, 164P(ab),217P(ab) 191P(ab),192P(ab) 229P(ab) Graham, D, 30, 129P(ab), Ouermazi, F, 117P(ab) Manna, M, fllP(ab), Hawman, PC, 191P(ab) Herrold, EM, 34P(ab), 244P(ab) Ouerra, 0, 249P(ab) 224P(ab) Hawthorne,MF, 1294 66P(ab) Graham,MC, 422, 1595, Guerra, UP, 126P(ab), Hanrath, P, 23P(ab) Hay, RV, 104P(ab) Herscheid,JDM, 649,1953 53P(ab),94P(ab),105P(ab), 166P(ab) Hansen,H, 89P(ab) Hayashida,K, 1931, Herscovitch,P, 155P(ab) 127P(ab),162P(ab) Guhike,5, 80P(ab) Hansen, Hi, 61, 1617(le), 14P(ab),24P(ab),107P(ab), Hertel, A, 126P(ab), Graham, MM, 1361, 21P(ab), Guidiy, OW, 3P(ab) 53P(ab), 54P(ab), 61P(ab), 120P(ab) 205P(ab) 137P(ab),257P(ab), Guignier,A, 1472,45P(ab) 94P(ab),214P(ab), Haynie,TP, 1087,33P(ab), Herzog,H, 355,2222, 258P(ab) Guillaume,M, 211P(ab) 217P(ab) 42P(ab),55P(ab),68P(ab), 32P(ab),107P(ab) Graham, W, 1964, 1975, Guilloteau, D, 235P(ab) Hansen, HW, 4P(ab), 88P(ab), 115P(ab), Herzog, SA, 462 2176,172P(ab),173P(ab) Oulenchyn,KY, 74P(ab) 50P(ab),154P(ab) 119P(ab),204P(ab), HeSIImatI,HM,387 Gramatzki,M, 172P(ab) Gullberg,OT, 19P(ab), Hansen, L, 39P(ab) 206P(ab),223P(ab) Heslip,P0, 2053 Orambow, D, 36P(ab), 30P(ab), 71P(ab), 80P(ab), Hanson, J, 22P(ab) Haynor, DR. 60P(ab) Hester, J, 119P(ab) 155P(ab) 81P(ab),91P(ab),176P(ab), Hanson,MW,39, 198,567, Hays,MT,12P(ab) Hetherington,HP, 92P(ab) Grana, C, 93P(ab) 187P(ab), 191P(ab), 1577, 1998, 7P(ab), Haze, K, 14P(ab) Hewitt, K, 242P(ab) Grandis,Di, 1695 196P(ab) 23P(ab),37P(ab) He, XS, 235P(ab) Heya,T, 215P(ab) Granowska, M, 82P(ab) Guludec, DL, 98P(ab) Hanson, RH, 232P(ab) He, Z-X, 1472, 45P(ab) Heyman, 5, 117P(ab) Grant, A, 1621 Ounalp, B, 889 Hara, M, 116P(ab), 177P(ab), Heath, U, 201P(ab) HeyndriCkx, 0, 15P(ab), Grassi, F, 5P(ab) Ounsenbeimer, B, 219P(ab) 247P(ab) Hebert, CB, 630 86P(ab) Gravelle,DR, 138P(ab) Guo, LW, 28P(ab) Ham, T, 1886 Hebert, Ti, 186P(ab), Hibbelin,JF, 747 Gray, B, 204P(ab) Guo, YZ, 135P(ab) Harada, K, 247P(ab) 189P(ab) Hichwa,RD, 181P(ab), Gray, C, 142P(ab) Gupta, N, 2278(le),6P(ab), Harapanhalli,RS, 133P(ab) Hegge,J, 210P(ab) 185P(ab) Gray, L, 567 7P(ab),20P(ab),21P(ab), Hardoff,R, 66P(ab), Heiba, SI, 74P(ab) Hickey,J, 208 Gray, LG, 1447 47P(ab), 50P(ab), 55P(ab), 141P(ab) Heide, 0, 222P(ab) Hicks, K, 68P(ab), 102P(ab) Green, MA, 228,1127, 73P(ab) Harkness,BA, 182P(ab), Heidecke,CD, 112P(ab) Hierhoizer,i, 31P(ab), 79P(ab),123P(ab) Gupta, SM, 169P(ab) 259P(ab) Heidorn,DB, 105P(ab) 164P(ab)

2286 TheJournalofNuclearMedicine Higashi,K, 414,773, Hohnan, 3M, 249P(ab) Hunter, Oi, 1571, 51P(ab), IshÃ¼,R, 208P(ab) Jiang,Y, 141P(ab) 2279(k) Holmes, R@A,232P(ab), 73P(ab),88P(ab) Ishii, S-I, 1936, 1944 Jimenez,H, 38P(ab) Higashi,N, 198P(ab), 248P(ab) Hunter, K, 155P(ab), Ishii,Y, 120P(ab) Jinnouchi,5, 2091 225P(ab) Holmgren,0, 118P(ab) 209P(ab) Ishikawa,M, 839 Jobert, A, 109P(ab) Higginbotham,C, 232P(ab), Holcye, P, 223P(ab) Hupp, T, 48, 139P(ab) Ishiwata,K, 780,1936, Joensuu,H, 1, 1711,21P(ab) 248P(ab) Holschbach,M, 68P(ab) Hurtig,R, 68P(ab) 240P(ab) John, 1@S,2169,248P(ab) Higginbotham-Ford,EA, 61 HolzgrabÃ³,U, 243P(ab) Hurwitz,GA, 138P(ab) Ishizu, K, l94P(ab) John, E, 260,246P(ab) Higley, B, 30, 222 Holzman,PS, 196P(ab), Husni, M, 138P(ab) Isikiar, I, 204P(ab) Johnson, BF, 239P(ab) Hijioka,T, 1103 203P(ab) Hutchins,OD, 83, 336,440, Isitman, A, 44P(ab), 56P(ab) Johnson,DK, 1656 Hill, MC, 165P(ab) Hombach,V, 87P(ab) 1287,50P(ab) Iskandrian, AS, 743, Johnson,0 III, 630 Hill, TC, 193P(ab) Honda, N, 1984 Hutchinson, Ri, 51P(ab), 75P(ab),85P(ab),95P(ab) Johnson, J, 75P(ab) Hilson,MW, 1163,138P(ab) Hong, CD, 130P(ab), 220P(ab) Israel,0, 1330,1826(le), Johnson,KA, 723,2044, Hilton, 5, 1656,94P(ab), 138P(ab) Hutton, BF, 1752 2101,l4lP(ab) 27P(ab), 179P(ab), 214P(ab) Honos, ON, 589 Huynh,TV, 144P(ab) Itagaki,Y, 63P(ab) 203P(ab),208P(ab), Hines, M, 260P(ab) HOORJand,D, 122P(ab) Huysmans,DA, 163P(ab) Ito,A, 170P(ab) 212P(ab),259P(ab) Hinge, D, 30 Hoogma,RPLM,873 Hwang, D, 8P(ab), 218P(ab) Ito, H, 200P(ab) Johnson, L, 153P(ab) Hinnefeld,JD, 42P(ab) HÃ´r,0, 126P(ab),205P(ab) Hwang, IR, 130P(ab) Itoh,H, 498 Johnson,T}@113P(ab) Hirano, T, 2085,42P(ab) Hori, M, 34P(ab) Hwang,YC,8P(ab) Itoh,K, 812 Johnson,VE, 20P(ab) Hiroe, M, 66P(ab) Horii, H, 26P(ab) Hyun, M, 1845 Itoh, T, 815 Johnston, DR, 185P(ab) Hironaka, F, 142P(ab) Hornig-Rohan,M, 48P(ab) Itoi, Y, 291 Jones, AO, 242P(ab) Hirose, Y, 1931 Horowitz,OR, 115P(ab) Ichihara,T, 2216,180P(ab), Ivanovic, M, 899, 9P(ab), Jones, AL, 214P(ab) Hisada, K, 1478, 2089, Horowitz,M, 582 193P(ab) 60P(ab),222P(ab) Jones,BE, 370 28P(ab),92P(ab),139P(ab), Horowitz,SF, 193,36P(ab) Ichise, M, 1274, 204P(ab) Iwasaki,Y, 839,1672 Jones, Bi, 2135 197P(ab), 223P(ab) Horton, 5, 257P(ab) Ichiya,Y, 288 Iyer, K, 256P(ab) Jones, M, 251P(ab) Hittinger,L, 1899 Hosain, F, 162P(ab) Ide, T, 431, 780, 103P(ab), Izembart,M, 387 Jones, P, 100P(ab) Hitzemann, R, 609, 67P(ab), Hoshi, H, 2091 240P(ab), 244P(ab) ken, D, 53P(ab) Jones, SR, 128 102P(ab), 103P(ab) Hoskins,W, 216P(ab) lenuso, R, 117P(ab) Jones, T, 1333,26P(ab) Hitzemann, Ri, 18P(ab) Hoskinson,M, 885 lervasi, 0, 2032 Jackson, H, 133P(ab) Jonides,J, 57P(ab) Hnatowich,Di, 109, Hosono, M, 815,1745, Ignaszewski, AP, 2053 Jackson,J, 41P(ab) Jonk, RIM, 170P(ab) 1618(Ie),59P(ab), 29P(ab),119P(ab), 11th,H, 498,1333,24P(ab), Jackson, LR, 171P(ab) ioraschky, P, 47P(ab) 234P(ab), 240P(ab) 215P(ab) 200P(ab) Jackson, NC, 157P(ab) Jordan, KO, 2188 Ho, B, 26P(ab) Hosono, MN, 215P(ab) lick, Y, 932,234P(ab) Jacobs, A, 211P(ab) Joseph, RC, 263P(ab) Hochberg,FH, 206P(ab), Hosten, N, 164P(ab) liji,0,291 Jacobs, M, 8P(ab),218P(ab) Joshi,V,237P(ab) 208P(ab) Hotze, A, 77P(ab),204P(ab) Ho,M, 1886 Jacobs, W, 137P(ab), Jouanne,E, 140P(ab), Hodgson, RI, 43P(ab) Hou,Y, 221P(ab) lizuka, T, 14P(ab) 263P(ab) 210P(ab) Hoekstra, Hi, 219P(ab), Hovi, I, 1428 Ikeda, M, 207P(ab) Jacobson,A, 164P(ab) iuillard, 0, 224P(ab) 225P(ab) Howell,RW,637,1801, huff, NT, 143P(ab) Jacobson,AF, 462, 16P(ab), iulian, D, 194P(ab) Hoekstra, OS, 1706 105P(ab), 133P(ab), Imahori, Y, 431, 1543, 33P(ab),74P(ab),218P(ab) iunaid, T, 233P(ab) Hoffer,PB, 1416,31P(ab), 134P(ab) 26P(ab),198P(ab), Jadali,F, 169P(ab) Junck, L, 116P(ab) 48P(ab),102P(ab), Howman-Giles, R, 214, 225P(ab) Jaffar, J, 63P(ab) Jung, Y-W, 123P(ab), 108P(ab), 109P(ab), 1828(k),52P(ab) Imai, T, 229P(ab) Jaffe,CC, 257P(ab) 135P(ab) 161P(ab),211P(ab), Howman-Giles, RB, 1435 Imaizumi, M, 291 Jahan, 5, 234P(ab) Juni, J, 16P(ab),17P(ab) 243P(ab),258P(ab) Hcyes, KP, 133P(ab) Imakita, @,1931 iaiii, D, 1254,1877 Juni, JE, 747,1109,1119, Hoffman,BJ, 1140 Hsieh, KS, 228P(ab) Imam, 5, 33P(ab) iaiii, RK, 73P(ab) 1789,158P(ab) Hoffman,El, 671, 1198, Hsieh, YL, 71P(ab), Imbriaco,M, 1602,1688, Jais, J-P, 387 Jurisson, @,641 136P(ab),137P(ab), 191P(ab) 147P(ab),153P(ab) Jakse, 0, 217P(ab) Jurisson,SS, 231P(ab) 180P(ab) Hsu, C-Y, 71, 1918,167P(ab) tad, T, 82P(ab) Janiar, F, 129P(ab) Juweid,M, 506, 1303,1866, Hoffman, JM, 39, 567, 1587, Hsu, HS, 138P(ab) Ingels,M, 211P(ab) James, P, 156P(ab) 76P(ab) 4P(ab),7P(ab),21P(ab), Hua, L, 9P(ab),190P(ab) Innis, RB, 31P(ab), 48P(ab), iamitzky, T, 163 Jyawook, 5, 1975, 83P(ab), 23P(ab),37P(ab),1O1P(ab) Huang,CI, 143P(ab) 90P(ab),102P(ab), Jang, 5, 1577,80P(ab) 171P(ab) Hoffman, Ti, 248P(ab) Huang,0, 9P(ab),195P(ab) 108P(ab),109P(ab), ianik, M, 228 Hoffschir,D, 18P(ab), Huang,S-C,488,679,1006, 201P(ab),205P(ab), ianisch, 5, 1039 Kabalka, OW, 235P(ab) 134P(ab) 2038, 1832(k), 4P(ab), 211P(ab),243P(ab) Janssen, AGM,2076, Kadrmas, Di, 181P(ab) Hofmeister, C, 257P(ab) 35P(ab),40P(ab),50P(ab), Inokuma,T, 6P(ab) 207P(ab), 209P(ab), Kahn, D, 185P(ab) Hogan, K, 58P(ab) 70P(ab),175P(ab), Inoue,T, 2085,14P(ab), 225P(ab) Kahn, 5, 259P(ab) Hoh,CK,488,1198,2009, 183P(ab),185P(ab), 19P(ab),29P(ab),42P(ab), Japanwalla, N, 249P(ab) Kaick, 0,12 2038, 1832(le), 50P(ab), 202P(ab) 167P(ab) iarritt, PH, 1778 Kaiser, Hi, 183P(ab) 137P(ab),183P(ab), Huang,W, 100P(ab) Inoue, Y, 1980,71P(ab), iari@r,M, 121P(ab) Kalaigian, H, 1595, 56P(ab), 184P(ab), 224P(ab) Huberty,iP, 39P(ab) 113P(ab),182P(ab) iaszczak, Ri, 1577,1587, 94P(ab), 114P(ab), Hohenberger, P, 218P(ab) Hubner,KF, 6P(ab), Intenzo,C, 255P(ab) 1998,1OP(ab),20P(ab), 127P(ab), 162P(ab) Hoit, BD, 1520 185P(ab),209P(ab), Intrator,J, 77P(ab) 26P(ab),30P(ab),72P(ab), K@ak, KA, 614 Hojo,H, 198P(ab) 261P(ab) Inu@ A, 92P(ab) 80P(ab), 81P(ab), 190P(ab), Kalkowski, Pi, 311 Holburn, 0, 86P(ab), Hudkins,RL, 236P(ab) lodice, A, 82P(ab) 191P(ab),195P(ab) Kflhlman, K-M, 69P(ab) 132P(ab),158P(ab) Hudson, C, 82P(ab) Iosilevsky,0, 141P(ab) Jatlow,A, 12P(ab),162P(ab), Kailmes,DF, 7P(ab) Holdeman,KP, 896, Hughes,A, 272 Isacson,0, 202P(ab) 163P(ab) Kalloo, AN, 168P(ab) 111P(ab) Hughes,JMB, 43P(ab) Isak, E, 889 Jay,M, 126P(ab) Kalus, ME ir, 860 Holden,JE, 481,8P(ab) Hui,TE, 106P(ab) Isaka, Y, 291, 171P(ab) Jayanthi,VR, 51P(ab) Kamada, T, 1103, 34P(ab), Holland,0, 121P(ab) Huijgens,PC, 1706 Isenmann, R, 225P(ab) Jeghers,0, 1642 63P(ab),170P(ab), Hoim, C, 122P(ab) HUitink,JM, 147P(ab), Isern, R, 47P(ab) Jehan, A, 163P(ab) l7lP(ab), 207P(ab), Hohnan, BL, 167,2044, 154P(ab) Ishibashi,K, 111P(ab), Jenike, MA, 47P(ab) 209P(ab) 27N(9),723,27P(ab), Humen, DP, 2053 170P(ab) Jeong,JM, 58P(ab), Kambara,H, 147P(ab) 47P(ab),179P(ab), Humes, HD, 87P(ab) Ishida, Y, 1931, 14P(ab), 215P(ab),233P(ab) Kameoka, Y, 161P(ab) 203P(ab),208P(ab), Humm,JL, 1811 24P(ab),34P(ab),55P(ab), Jester, D, l74P(ab) Kaminaga, T, 1931, 55P(ab) 212P(ab),242P(ab), Hundeshagen,H, 1770 107P(ab),120P(ab) Jeusset, J, 1565 Kaininski, MS. 127P(ab) 259P(ab) Hung,JC, 523(k), 148P(ab) Ishigaki,T, 2124 ii, K, 255P(ab) Kaminsky, DA, 868(le)

AuthorIndexâ€¢1993 2287 Kanaya, K, 174P(ab) Keelan,E, 62P(ab) Kimura,RL, 1990 Koeppel,JA, 181P(ab), Kreuzer, H, 153P(ab) Kanaya, 5, 174P(ab) Kegel,i, 95P(ab) Kinan, D, 65P(ab) 185P(ab) Krevsky, B, 11P(ab), Kang, S-B, 1651 Keiler,A, 1OP(ab) Kindseth,iM, 142P(ab) Koga, I, 288 169P(ab) Kanmaz,B, 961 Keilp,i, 77P(ab) King,iL, 400, 1834(k) Koga,5, 159P(ab) Kris, M, 213P(ab) Kanno, I, 498,92P(ab), Keinhans,E, 23P(ab) King,MA, 72P(ab),195P(ab) Kob, C-S, 1651,212P(ab) Krishna,L, 1574,173P(ab) 200P(ab) Kaiser, HR, 173 King,PT, 619 Koh, W-i, 21P(ab) Krishnan,R, 95P(ab) Kane, M, 95P(ab) Kelley,AP, 261P(ab) King,5, 217P(ab) Kohlmyer,S, 136P(ab) KriVOkapiCh,i, 2038, Kanselaar,P, 175P(ab) Kelly,ID, 222 Kinne, RW, 92 KOhn,H, 122P(ab) 183P(ab) Kao, C-H, 71, 1918, Kemp, B, 251P(ab),252P(ab) Kinney,18, Jr., 1995 Koivisto,VA, 2064 Kroger,LA, 1067,93P(ab), 167P(ab),208P(ab), Kempf,i, 172P(ab) Kinter, @M,103P(ab) Kojima,A, 1184,177P(ab), 128P(ab) 228P(ab),245P(ab) Kempner,KM, 70P(ab) Kinuya,5, 2169,28P(ab), 247P(ab) Krogsgaard-Larsen,P, K@no,T, 176P(ab), 185P(ab) Kenemans, P, 82P(ab) 58P(ab), 139P(ab), K.olbourn, MR, 8P(ab) 22P(ab), 103P(ab) Kapadvanjwala,M, Kennedy,DN, 208P(ab) 241P(ab) Kolodny,GM, 2101 Krohn, KA, 411,918, 174P(ab), 221P(ab), Keppler, BK, 220P(ab) Kipper, SL, 111P(ab) Koisky, KL, 237P(ab) 79P(ab), 237P(ab) 224P(ab) Kerdraon,i, 205P(ab) Kirch, DL, 113P(ab) Koltringer,P, 2278(k), Kmnauge,IF, 140P(ab), Kapilivsky,A, 171P(ab) Kerremans,R, 222P(ab) Kirchner,PT, 1607,68P(ab), 2280(k) 242P(ab) Kaplan,i, 229P(ab) Kertzman,C, 70P(ab) 188P(ab) Komaroff,A, 47P(ab) Kronmal,5, 243P(ab) Kaplan,JM, 169P(ab) Keske, U, 164P(ab) Kirach,0, 946 Kondo,T, 159P(ab) Kroode, K, 11OP(ab) Kaplan, MS, 60P(ab) Kessler, ML, 127P(ab) Kirsch, i, 99P(ab) Kondoh,Y, 98P(ab) Kroon, D, 1964,2130, Kaplan,WD, 74P(ab) Kessler, RM, 826,37P(ab), Kirsh, JC, 1274 Koneru, 5, 1859 104P(ab),173P(ab) Kappeler,C, 58P(ab) 38P(ab),132P(ab), Kishida,1, 111P(ab), KOnig,B, 122P(ab) Kropp, i, 946 Kappes, R, 210P(ab) 158P(ab),202P(ab), 170P(ab) Konishi,J, 815,839,1672, Kruschke,C, 41P(ab) Kapucu, 0, 2076, 207P(ab), 206P(ab) Kitakata, Y, 211P(ab) 1745, 2124, 6P(ab), Kiystal, iii, 205P(ab) 209P(ab) Ketring,AR, 38P(ab), Kitapci,M, 961 29P(ab),107P(ab), Kubo, A, 2216 Kayak,PK, 168P(ab) 231P(ab) Kitapc@MT,523(k),44P(ab) 119P(ab),120P(ab), Kubota,K, 419, 1936, Karczewski,D, 97P(ab), Kevin, KI@fF,1866 Kitchen, R, 8P(ab) 147P(ab),194P(ab), 103P(ab),240P(ab), 135P(ab) Keyes, JW Jr., 182P(ab) KlaUs,EC, 381 201P(ab),215P(ab) 244P(ab) Karl, B, 9P(ab) Khalkhali,I, 140P(ab), Klein,HA, 1228 Konstam,MA, 65P(ab) Kubota,R, 419,1936, Karlsberg,RP, 65P(ab) 231P(ab) Klein,i, 34P(ab) Kooba, A, 37P(ab),139P(ab) 103P(ab),240P(ab), Karisson, P, 7P(ab),89P(ab) Khan,A, 163P(ab), Klein, Mi, 1536 Kooij,PPM,873,2025, 244P(ab) Karp, JS, 2201,124P(ab), 165P(ab),173P(ab) Klein,5, 140P(ab) 175P(ab) Kuczynski,B, 641,15P(ab), 137P(ab),181P(ab), Khan, AS, 1574 Klein,WP, 474 Koops, HS, 219P(ab), 16P(ab),92P(ab) 190P(ab),195P(ab), Khan, 5, 249P(ab) Kkinhaus, U, 2101 225P(ab) KUdCIICa,AP, 88P(ab) 228P(ab) Khanna,S, 184P(ab) Klcmm,B, 77P(ab) Kocy, PPM,41P(ab) Kudoh,T, 815 Karvelis,K, 97P(ab) Khare, AB, 8P(ab),90P(ab) Kienner,T, 220P(ab) Kopecky,KK, 381 Kuhar, Ci, 18 Kasagi,K, 107P(ab) Khaw, BA, 1303,1507,2144 Kletter, K, 1397 Kops, ER, 355 Kuhar, Mi, 197P(ab) Kasahara, A, 1103,170P(ab) Khawli,LA, 114P(ab) Kkver, P, 98P(ab),183P(ab) Koral, KF, 524(le),113P(ab), Kuhi, D, 251P(ab),252P(ab) Kaschka, WP, 47P(ab) Khazaeli,MB, 29P(ab), Kline, BD, 190P(ab) 127P(ab) Kuhl, DE, 322,4P(ab), Kashiwagi,T, 1103, 53P(ab) Klipper,R, 2160,135P(ab), Korkinaz,M, 33P(ab), 22P(ab),25P(ab),51P(ab), 111P(ab),170P(ab) Khonsaiy,SA, 12P(ab), 247P(ab) 42P(ab),55P(ab),68P(ab), 56P(ab),108P(ab), Kasi, LP, 33P(ab),53P(ab), 257P(ab) Kloppenborg,P. 163P(ab) 119P(ab),204P(ab), 116P(ab),123P(ab), 119P(ab),134P(ab), Kiat, H, 1349,1485,1494, Knapp, DW, 123P(ab) 206P(ab),212P(ab) 158P(ab),207P(ab) 161P(ab),180P(ab), 64P(ab),130P(ab), Knapp, FF Jr, 946 Kornrumpf,D, 223P(ab), Kuhk, W, 35P(ab) 212P(ab),218P(ab), 148P(ab),189P(ab), Knapp, FF Jr., 15P(ab), 225P(ab) Kuble,WO, 488 223P(ab) 259P(ab) 54P(ab),197P(ab), Korupolu,0, 250P(ab) Ku@per,AFM, 737 I(miss, Al, 1175 Kijewski,MF, 2044, 236P(ab),243P(ab) Korupolu,OR, 1835(le) Kuiper, MA,207P(ab) Kasliwal,R, 197P(ab), 203P(ab),208P(ab) Knapp, FFR Jr, 649 Kostakoglu,L, 114P(ab), Kuji, E, 92P(ab) 202P(ab) Kilbourn,MR, 25P(ab), Knew, B-A,2264 216P(ab) Kuji, I, 197P(ab) Kasper, 5, 77P(ab) 123P(ab),236P(ab) Kneeland,B, 2191 Kotek, Ti, 260P(ab) Kukis, DL, 93P(ab) Kassis, A!, 123P(ab), Killion,D, 88P(ab) Knesaurek,K, 125P(ab), Kotler, iA, 61 Kuklenylk,Z, 39P(ab) 221P(ab), 241P(ab), Killius, DR, 69P(ab) 189P(ab) Kotoo, Y, 95P(ab) Kulkarni, PV, 9P(ab), 246P(ab),247P(ab) Kilty,iF, 1140 Knight,LC, 11P(ab), Kotoura, Y, 1745 124P(ab) Kastin, Si, 76P(ab) Kim,AS, 4P(ab),165P(ab) 17P(ab),66P(ab),169P(ab) Kouhl,aly,PM, 194P(ab) Kumar,PN, 259P(ab) Kataoka, M, 932 Kim, CK, 506,1214,1851, Knobloch,E, 112P(ab) Kouris, K, 1778 Kung,HF, 208,1910, Katsurgi,M, 2182 1866,12P(ab),17P(ab), Knapp, MV, 21P(ab) Koutcher,i, 1152 89P(ab),132P(ab), Katti, KV, 38P(ab) 43P(ab),73P(ab),76P(ab), Knapp, R, 187P(ab) Koutelou,MO, 75P(ab) 135P(ab),158P(ab), Katz, RD, 259P(ab) 92P(ab),162P(ab), Knust, El, 58P(ab) Kowaisky,WP, 172P(ab) 190P(ab),195P(ab), Katzenellenbogen,JA, 163P(ab),207P(ab) Knuuti,J, 224P(ab) Kozuka,T, 1103,34P(ab), 196P(ab),198P(ab), 18P(ab),49P(ab),56P(ab), Kim, D-I, 1987 Knuuti, Mi, 2064,2068, 170P(ab),199P(ab), 235P(ab) 79P(ab),160P(ab) Kim, E, 43P(ab) 3P(ab),107P(ab) 201P(ab) Kung,MP, 89P(ab), Kauffinann,P, 1260 Kim, EE, 26P(ab),33P(ab), Kobayashi,H, 815,1745, Kramer, EL, 1067,53P(ab), 132P(ab),135P(ab), Kaufman,H, 76P(ab) 42P(ab),55P(ab),68P(ab), 119P(ab),174P(ab), 63P(ab),128P(ab) 235P(ab) Kaul, B, 155P(ab) 119P(ab),204P(ab), 215P(ab) Krane, Mi, 65P(ab) Kuni, CC, 29P(ab) Kaul, 5, 728 206P(ab),212P(ab), Kobayashi,K, 301 Kranert, Wi', 205P(ab) Kunkel,SL, 104P(ab) Kavanagh,PB, 1349 223P(ab) Koch, A, 222P(ab) Krappel,C, 77P(ab) Kurolti,T, 301 Kavanab,MT, 2095 Kim, 111,124P(ab), Kodama,K, 211P(ab) Krasnow,AZ, 44P(ab), Kusakabe,K, 174P(ab) Kawabori,I, 1995 190P(ab),195P(ab), Koenders,E, 105P(ab), 56P(ab) Kuschinksy,W, 793 Kawai,Y, 288 198P(ab) 247P(ab) Krause, BJ, 205P(ab) Kuschinsky,W, 204P(ab) Kawakami,K, 161P(ab) Kim, M, 255P(ab) Koenders,EB, 1316 Krause, T, 375 Kusuoka,H, 34P(ab), Kawamoto,M, 107P(ab), Kim, MH, 76P(ab) Koeppe, RA, 322, 1190, Krausz, Y, 164P(ab) 199P(ab) 120P(ab),147P(ab) Kim, SB, 130P(ab),138P(ab) 4P(ab),13P(ab),22P(ab), Krejs, Oi, 168P(ab) Kuwabara,H, 31P(ab), Kawanaka,M, 126P(ab) Kim, SE, 199P(ab) 25P(ab),51P(ab),56P(ab), Krenning,EP, 873,2025, 57P(ab),181P(ab), Kawano, 5, 1103 Kim, SY, 169P(ab) 57P(ab),70P(ab),108P(ab), 41P(ab),118P(ab), 198P(ab),199P(ab), Keast, RK, 48P(ab), Kim,YT, 83P(ab) 207P(ab),220P(ab), 139P(ab),165P(ab), 200P(ab),201P(ab) 174P(ab) Kim,YY,83P(ab) 224P(ab) 175P(ab) Kuwabara,Y, 288

2288 TheJournalofNudearMedidne MaMbO

Kuwert, T, 355,32P(ab) Laubenbacher,C, 968, Leon, AR, 281 Under, KE, 18P(ab) Louie,iS, 144P(ab) Kwan, Al, 1045 41P(ab),112P(ab), Leon, JA, 99P(ab) Lindgren,L,448 Lowe,iL,754 Kwekkeboom,Di, 873, 155P(ab) Leonard,D,125P(ab) Lindheim,SR, 165P(ab) Lowe, Vi, 1998,7P(ab), 139P(ab) Lauer, I, 1403 Leonidas,iC,251P(ab) Lindhohn,P,1,1711, 17P(ab),21P(ab),37P(ab) Launspach,J,167P(ab) LePage,M, 209P(ab) 21P(ab),224P(ab) Lu, JO, 26P(ab) Labar, D, 15P(ab),86P(ab), Laurent, RTS,4P(ab) Leppo, JA, 927,1510,1722, Line, BR, 178P(ab), Lu, P, 66P(ab) 121P(ab) Lavenne,F, 22P(ab) 14P(ab),46P(ab),130P(ab), 229P(ab),262P(ab) Lubin, E, 152P(ab) Labarre, P0, 1260 Lawerence, 5, 38P(ab) 149P(ab) Linehan,WM, 173 Lubushitzky,R, 141P(ab) LaBresh, KA, 152P(ab) Lawrence,5K, 2185 I@ePrise,PY,182 Un& V,242P(ab) Lucas, JR, 64P(ab),65P(ab), Lacan,0,202P(ab) Lawson, D, 176P(ab) Larch, H, 3P(ab) Lingen,A, 1706 95P(ab),151P(ab) Lafontaine,E, 140P(ab) Law, JM,1695 Lerch, R, 46P(ab) Unggood,RM, 206P(ab) Lucignani,0, 137,360, Lage, AL, 123P(ab) I@c,N, 215P(ab),233P(ab) Lerner, E, 1416 Link@JM, 237P(ab) 5P(ab),93P(ab),154P(ab) Lahiri,A,30 Leahy,RM@ 182P(ab) Leroy, RF, 754,23P(ab) Linke, Mi, 61P(ab) Luck, iV Jr., l44P(ab) l.@ai,J,2152 Leapman,SB,381 Leroy-wiuig,A, 205P(ab) Linsley,P, 58P(ab) Ludbrook,PA,717 Lai, KH, 76P(ab) Lear, JL, 150P(ab), La Scao, Y, 1217(le) Lipp, RW, 168P(ab) Lueders@C,2222 !.@ainÃ©,J, 18P(ab),134P(ab) 197P(ab),202P(ab) Leskinen-Kallio,5,1,1711, lippit;B,222P(ab) Lufitin,R,224P(ab) Lalonde, D, 58P(ab) Lab, 0, 168P(ab) 21P(ab) Laps,P, 11OP(ab) bikes, i, 120P(ab) Lalush, DS, 27P(ab) LeBouthillier,0, 140P(ab) Leslie,WD, 165P(ab) Lipszyc,H,66P(ab), Luketic,V, 153P(ab) Lamb, GE, 130P(ab) Lebtahi, R, 1243,98P(ab) Lesser, I, 210P(ab) 67P(ab),104P(ab) Luliano,L, 67P(ab) Lambert, CA, 231P(ab) LÃ©cayon,M, 18P(ab), Lette, J, 1389(k),151P(ab) Lisbona,R,853,1992 Lull,Ri,1827Qe) L.ambert,CR, 243P(ab) 134P(ab) Leung,SO, 217P(ab) Lister-James,i, 17P(ab), Lusins,JO, l43P(ab) Lambert, R, 946,58P(ab), Leclerc,J, 119P(ab) LÃ©veillÃ©,J,96P(ab), 66P(ab),104P(ab), Luthra, 5K, 57P(ab) 96P(ab),118P(ab), I.ea@imc,i,1204 118P(ab),121P(ab), 156P(ab) Luurtsema,0,183P(ab) 121P(ab),140P(ab), Lecomte, R, 1O1P(ab), 140P(ab) L'Italian, 0, 149P(ab) Lyle, LR, 104P(ab) 226P(ab) 136P(ab) Lever, JR, 103P(ab) Little, JM, 1172 Lynch, Pi, 257P(ab) Lamberts,SWJ,873, LaDoussal,i-M,1267,1662 Lever, SZ, 18P(ab),135P(ab) Uftman,B,51P(ab),88P(ab) Lynch, RE, 2135 41P(ab), 118P(ab), Lee, AY, 122P(ab) Levine, B, 88P(ab) Livingston,RB,1839 Lyons, KP, 65P(ab) 139P(ab) Lee, BH, 167P(ab) Levine,0, 53P(ab),54P(ab), Lisbona,R, 1992 Lyster, DM, 235P(ab) Lambrecht, RM, 100P(ab), Lee, BY, 122P(ab) 61P(ab), 94P(ab) Liu, P, 1692 153P(ab) Lee, DS, 212P(ab) Levine, R, 22P(ab) LÃ±i,RS, 76P(ab),138P(ab), Lamers, CBHW, 1052 Lee, EK, 23P(ab) Levy, AV, 2019,40P(ab), 143P(ab),145P(ab), Ma, D, 231P(ab) Lamki, L, 119P(ab), Lee, FT, 100P(ab),153P(ab) 237P(ab) 185P(ab),238P(ab) Macapinlac,H, 1IP(ab), 256P(ab),260P(ab) Lee, H, 67P(ab) Levy, D, 1XP(ab),203P(ab) 1.Ã£u,Y,9P(ab) 37P(ab),56P(ab),94P(ab), Lammens,i, 227P(ab) Lee,HB,250P(ab) 12w,K,214P(ab) Livio,JJ, 84P(ab) 127P(ab),145P(ab) Lammertsma,AA, 26P(ab) Lee, HC, 251P(ab) 12w, R, 239P(ab) Uvn@ B,240P(ab) MacDonald,J, 232P(ab) Lamoureux,0, 49P(ab) l..ee,HK, 116P(ab) Lewandrowsh,K,210P(ab) I@gber@ M, 72P(ab), Macdonald,WBO, 1082 Lamy,1,182 Lee,H-P,1651 Lewellen,BL,1361 80P(ab),178P(ab) MacDonell,RC, 2185 Landais,P,103P(ab) I.ee,i,42P(ab) Lewellen,TK, 60P(ab), Ljunggren,K, 113P(ab) Macey,D, 33P(ab),53P(ab), Landmeier,Bi, 239P(ab) Lee, i-D, 1987,167P(ab) 136P(ab), 137P(ab), Ljungren,K,222P(ab) 127P(ab),134P(ab), Landolt, U, 809 Lee, iT, 167P(ab),215P(ab), 258P(ab) Llacer,J, 1198,184P(ab) 161P(ab), Landorn,C, 137,154P(ab) 233P(ab) Lewis,C,1766 Liewellyn,0,1377 191P(ab), Landy, BR, 106P(ab) Lee, K-S. 184P(ab), Lewis,DH,62P(ab) Ucyd, KO, 216P(ab) 218P(ab) Lang, EV, 345 224P(ab),235P(ab) Lewis,JP, 93P(ab) Lloyd-Still,ID, 226P(ab) MacFall,JR. 1587 Lang, JH, 345 Lee,KU, 130P(ab) Lewitt, RM, 137P(ab) Lobmeier,0, 212P(ab) MacGregor,R, 609 Lange, HW, 32P(ab) Lee,M-C,1651,212P(ab) Leyvraz,PF,84P(ab) Lobo,RA,165P(ab) MacGregor,RR, 67P(ab), Langen, KJ, 355,32P(ab) Lee,ME, 169P(ab) Li, J, 1OP(ab),26P(ab), Loc'h, C, 1717,1739, 102P(ab),131P(ab), Langhammer,HR, 41P(ab) Lee, MH, 76P(ab),83P(ab), 30P(ab),80P(ab),81P(ab), 102P(ab),124P(ab), 200P(ab) Langhans,i,223P(ab), 130P(ab),138P(ab) 188P(ab) 211P(ab) Mach, RH, 8P(ab) 225P(ab) Lee,Mi,260P(ab) Li, M, 28P(ab) Loessner,A,210P(ab) Machac,i, 67P(ab),77P(ab) Langley,OR,1377 Lee, RF, 169P(ab) Li, PY, 213P(ab) LOffler,5, 161P(ab) Machida,K, 1984 Langmore,5, 11P(ab) Lee,Ri,151P(ab) Li, OS, 173P(ab) Logan,i, 246,609,619, Maclntyre,Wi, 400, Langsteger,W, 2278(k), Lee,SK,76P(ab) Li, X, 185P(ab) 67P(ab),78P(ab),102P(ab), 1834(le), 190P(ab) 2280(k) Lee, T-Y, 252P(ab) Li, Y, 206P(ab), 249P(ab) 131P(ab),200P(ab) Maciunas,R, 37P(ab), Lanphier, EH, 143P(ab) Lee,VW, 2095 Liang,0, 38P(ab) Lobner, W, 37P(ab) 206P(ab) Lantto,T,1428 Lee,W, 256P(ab) Liao,5-0,71,1918 l@oizides,A,24P(ab), MacKenzie,Er, 241P(ab), Lapenta, L, 12P(ab) Lee, Yl, 83P(ab) Licence,5, 62P(ab) 64P(ab),131P(ab) 243P(ab) Larar,iN,1045 Leeds,N,55P(ab) L.icho,R, 194P(ab) Lomefla,Fi,77P(ab) Mackey,DWJ,232P(ab) Larsen, 5, 174P(ab) Lees,AM, 66P(ab) Lichtenstein,0,697 Lomuscio,0, 226P(ab) Macklis,RM, 1811 Larson, SM,422, 1595, Lees,RS,66P(ab) Lichtenstein,OL, 849 Loncaric,S,195P(ab) MacLean,0, 213P(ab) 1656,37P(ab),53P(ab), Uger, AF, 387 Lichtenstein,OR, 2276(k) London,ED,40P(ab), Maclean,JP, 165P(ab) 56P(ab),83P(ab),94P(ab), lAger, 0, 31P(ab) Lidgren,L, 1646 199P(ab) Macleod, MA, 1616Qe) 105P(ab),106P(ab), LeGuludec,D,981 Liebermann,i, 67P(ab), Longford,CPD, 7P(ab) Maddahi,J, 1494,2009, 114P(ab),127P(ab), Lehikoinen,P,1711,21P(ab) 102P(ab) Longobardi,5,42P(ab), 137P(ab),148P(ab), 145P(ab),162P(ab), Lehner, CE, 143P(ab) Liebes, L, 1067 219P(ab) 184P(ab),224P(ab) 213P(ab),214P(ab), L.ehur,P-A, 1662 Liedtke,Al, 16P(ab) Lopez, C, 233P(ab) Madden, T, 88P(ab) 216P(ab) Leibling,M, 144P(ab) Lilt,DW, 78P(ab) Lopez, D, 221P(ab) MaddOck,SW, 1020 Larsson, 5, 89P(ab) Leichner,PK, 938 Lilhimoe,K,76P(ab) Lopez-Pousa,A,1503 Madsen,JR, 1045 Laruelle,M, 31P(ab), Leisure, OP. 1000 Urn,CB,190P(ab) Lopez-Pousa,J, 13P(ab) Madsen,MT, 68P(ab), 48P(ab),108P(ab), Leitha, T, 1397 Limoges,R,58P(ab) Lorenz, c:H, 826 167P(ab),188P(ab), 211P(ab), 243P(ab) Lelord, 0, 78P(ab) 1_in,K, 70P(ab),183P(ab) Lorenz, R, 205P(ab) 193P(ab) Lastoria,5,12P(ab), Le@ Ri,297 LAn,iT, 143P(ab) Lorenz, W, 21P(ab) Maeda,M, 159P(ab) 42P(ab),82P(ab),115P(ab), Lena,I,235P(ab) Un,W-Y,71,1918, Losing,NA, 51P(ab), Maegdenbergh, VVD, 213P(ab),219P(ab) Lenihan,Di, 120P(ab) 167P(ab),245P(ab) 73P(ab),88P(ab) 1OP(ab) Latham, IA, 222 Leasing,AWA, 1834(k) Lind,P,122P(ab) Lossau, I, 222P(ab) Mass, A, 4P(ab) Latino,F,250P(ab) Lentle, BC, 1612 Lindenmeir,M, 63P(ab) Lotter, MO,330,963 Maflioli,IS, 219P(ab)

AuthorIndexâ€¢1993 2289 Magata,Y, 932,1672,2124, Markt, B, 122P(ab) Maurea,5, 173,1688, McPartlin,M, 222 Metz, KR, 241P(ab) 6P(ab),107P(ab),147P(ab), Markusse,MM, 118P(ab) 12P(ab),147P(ab) McPhail,NV, 74P(ab) Meyer,CR,1190 234P(ab) Marmion,ME, 135P(ab) Maurer,AH, 1447,11P(ab), McPhee,MS, 405 Meyer,E, 51P(ab),57P(ab), Magnani,P, 94P(ab), Mariner,A, 1877 17P(ab),66P(ab),169P(ab) McPherson,DW,946, 181P(ab),198P(ab), 114P(ab) Marois,LI, 74P(ab) Mausner,LF, 93P(ab), 197P(ab),236P(ab), 199P(ab) Magoun,5, 131 Marquardt,0, 205P(ab) 237P(ab) 243P(ab) Meyer,0-i, 1770 Maguire,OQJr., 128P(ab) Marrett, 5, 199P(ab) Maxon,HR. 42P(ab), McQuarrie,5, 213P(ab) Meyer,MA, 209P(ab), Maguire,WM,83P(ab), Marrie,Ti, 458 127P(ab),152P(ab), McSheny, BA, 130P(ab) 235P(ab) 166P(ab) Marriott, C, 1O1P(ab) 156P(ab), 248P(ab), Meadors, JN, 261P(ab) Meyer, WA, 238P(ab) MahmaIian,ii, 3P(ab), Marshall,Bi, 821 261P(ab) Messes,CF. 28P(ab), Meyerrose,0, 5P(ab), 54P(ab),75P(ab),95P(ab) Marshall,RC, 35P(ab) Maxon,HR III, 525(k) 81P(ab),93P(ab),94P(ab) 168P(ab) Mahmood,A, 242P(ab) MartiCh,V, 52P(ab), Mayberg,MS.5P(ab) Masse, RC, 237P(ab) Meylaerts,SAG,41P(ab) MahmOOd,MM, 142P(ab) 227P(ab) Mayeur,5, 1OP(ab) Mechanick,ii, 465 Micaily,B, 1574 Mahraj,RPM, 121P(ab) Martin, @C,39P(ab),50P(ab) Mayeur,SM, 576 Meder,i-F, 1243 Michel,C, 15P(ab),44P(ab), Mailliard,i, 6P(ab),20P(ab), Martin,D, 161P(ab) Mayeux,R, 1090 Meerdink,Di, 927 86P(ab),1O1P(ab), 21P(ab) Martin,Di, 193P(ab) Maynard,CD, 157 Meghdadi,5, 1397 121P(ab) Mainolfi,C, 115P(ab) Martin,EL, 51P(ab) Maze,A, 1204 Mehta, BM, 106P(ab), Michelot,J, 1949 Maislin,0, 117P(ab) Martin,OV, 918,79P(ab) MaziÃ©re,B, 1717,1739, 114P(ab) Michelot,JM, 1260 Majd,M, 52P(ab) Martin,M, 1662 102P(ab),124P(ab), Mehta,SL, 54P(ab), Michelson,RH,8P(ab), Majmundar,JIM, 1246 Martin,RH, 458 211P(ab) 149P(ab) 90P(ab) Makhoul, E, 166P(ab) Martin, SE, 281, 96P(ab), MaziÃ¨re,M, 102P(ab), Mehta, VD, 124P(ab) Michigishi, T, 139P(ab), Makino,M, 174P(ab) 146P(ab) 211P(ab) Meidell,RS,84P(ab) 223P(ab) Makler,PT Jr., 115P(ab) Martin,WG, 112P(ab) Mazoyer,B, 1899,36P(ab) Meignan,M, 2105 Mickala,P. 241P(ab), Malfetano,J, 262P(ab) Martinez,F, 43P(ab) Mazza,5, 205P(ab) Meihofer,M, 1574 243P(ab) Malison,R, 48P(ab), Martino,J, 63P(ab) Mazziotta,iC, 679,1198, Meilde,SR. 143,671,1752, Miedema,AR, 41P(ab) lO2P(ab) Marumo,F, 66P(ab) 1892 184P(ab) Migneco,0, 5P(ab) Mallavarapu,C, 85P(ab) Maruyaina,Y, 98P(ab) Mazzucchelli,L, 226P(ab) Meinken,GE, 237P(ab) Mignon,M, 98P(ab) Mallet,i, 150P(ab) Marzilli,LO,39P(ab) McAfee,JO,2169,48P(ab), Meister,E, 2278Qe),2280(le) Mikasa,K, 229P(ab) Mallett,R, 2111 Marzola,MC, 11OP(ab) 174P(ab),248P(ab) Melder,Ri, 73P(ab) Miklos,JA, 769 Main, W, 117P(ab), Masarotto,0, 1626 McAneny,DB, 2095 Mekga, W, 70P(ab), Miller,DD, 1823,85P(ab), 137P(ab),174P(ab), Mascheroni,L, 219P(ab) McCallister,SH, 747 183P(ab) 120P(ab) 224P(ab),261P(ab) Mason,OR, 231P(ab) McCandIeSS,BK, 1341, Melega,WP, 679 Miller,J, 112P(ab) Malmud,LS, 576,1OP(ab) Mason,NS, 132P(ab), 142P(ab),150P(ab), Melian,E, 94P(ab) Miller,K, 1218(le) Mandelbaum,A, 48, 158P(ab) 195P(ab) Melin,JA, 15P(ab),86P(ab), Miller,L, 15N(11),17N(12), 139P(ab) Mason, RP, 124P(ab) McCarter,i, 242P(ab) 121P(ab) 19N(12),23N(10),32N(11), Mandelkern,MA, 12P(ab), Massuger,L, 247P(ab) McCarthy,Ti, 69P(ab), Mcliii,iF, 44P(ab) 209P(ab) 257P(ab) Masters, PR, 255P(ab) 89P(ab) Melis,K, 52P(ab) Miller,MI, 20P(ab) Mandelmont,JC, 1260 Masterson,ME, 106P(ab) McCarthy,WH, 1435 Mello,NK, 723 Miller,RF, 1621 Mangles,SH, 992,81P(ab), Masterson,Ti', 244P(ab) McCartney,JE, 234 Melinan,A, 250P(ab) Miller,SH, 48P(ab) 193P(ab) Masuda,K, 288 McCartney,WH, 30P(ab) MÃ©lon,P, 155P(ab) Miller,SW, 1396(br) Mangner,Ti, 83,8P(ab), Masumoto,M, 159P(ab) Mc@iellan,JR. 75P(ab), Meltzer, @C,5P(ab) Miller,â€˜FR,1793,20P(ab), 25P(ab),224P(ab) Materassi,M, 117P(ab) 85P(ab) Memsic,LD, 18 106P(ab),192P(ab) MangoniDi S. Stefano,ML, Matheja,P, 45P(ab) McConnell,JR,203P(ab) Mena,I, 187,5P(ab), Mills,Bi, 131 1602 Mather, Si, 82P(ab), McCOrmick,LX, 2053 45P(ab),140P(ab), Mills,GO, 171P(ab) Mannan,RH, 405,885 246P(ab) McCOrmick,VA, 769, 210P(ab) Milne,N, 65P(ab) Manning,RO, 132P(ab), Mathews,D, 1239 158P(ab) Menard,IF, 205P(ab) Mimura,H, 208P(ab) 202P(ab) Mathias, Ci, 228, 1127, McCune, Wi, 207P(ab) Menard, 5, 213P(ab) Mm, Yl, 76P(ab) Manning,RM, 158P(ab) 79P(ab),123P(ab) McDermott,K, 1656, Mendelsohn,J, 213P(ab) Misaim,C, 144P(ab) Mannting,F, 601 Mathis,C, 7P(ab) 214P(ab) Mendelson,i, 723 Minear,OS, 48P(ab) Mannting, MOM, 601 Matoba, N, 1672 McDermott, M, 257P(ab) Meng, X-J, 25P(ab), Minn, H, 1, 1711, 21P(ab), Manolis,A, 65P(ab) Matsmoto,K, 198P(ab) McDevitt,MR, 260 232P(ab),236P(ab) 224P(ab) Mansfield,RK, 126P(ab) Matsubara,T, 95P(ab) McDonald,IA, 240P(ab) Menser,MA, 1082 Minnick,DK, 158P(ab) Mantil,JC, 8P(ab),218P(ab) Matsuda,OR, 2144 McDonald,1W, 6P(ab) Mensh,BD, 122P(ab) Minoshima,5, 322,22P(ab), Manttera,J, 1254 Matsuda,H, 92P(ab), McDougall,IR, 12P(ab) Menzel,C, 77P(ab),204P(ab) 25P(ab),56P(ab),57P(ab), Maple,L, 232P(ab) 197P(ab) McDowell,DM,48P(ab) Mercer,JR,405,885 70P(ab),108P(ab), Marcel, R, 14P(ab) Matsumoto, K, 1543, McEwan, A, 213P(ab) Merckx, E, 210P(ab), 116P(ab), 202P(ab), Marcus,C, 144P(ab) 26P(ab),225P(ab) McEwan,Al, 405,2053 222P(ab) 207P(ab),211P(ab) Mardirossian,0, 109, Matsumoto,M, 63P(ab), McEwan,AlE, 885 Merelet,P. 1739 Mintun,MA,322,57P(ab), 1618(le) 171P(ab),207P(ab), McEwan,i, 255P(ab) Merhige,ME,23P(ab) 224P(ab) Mardon,K, 1739,124P(ab) 209P(ab) MCOarity,W, 165P(ab) Merino,Mi, 24 Mintzer,PA, 112P(ab) Marek,K, 31P(ab) Matsuno,Y, 95P(ab) McOill-Clare,D, 172P(ab) MerIe@P. 981,1899, Miraldi,F, 523Qe),1000, Marek,Mi, 231P(ab), Matsuo,1,95P(ab) McOonigle,P, 132P(ab) 14P(ab),36P(ab),45P(ab), 239P(ab) 246P(ab) Matsuura,H, 2227 McOuire,AH, 56P(ab) 124P(ab) Mirick,OR, 93P(ab) Marenco,5, 9lP(ab) Matter, AG, 138P(ab) McKay,Wi, 666 Merola,B, 42P(ab),219P(ab) Misaki,T, 107P(ab) Margaron,P. 49P(ab) Mattay,VS, 228P(ab) McKusick,K, 16P(ab), Merriwether,WO, 100P(ab) Mitchell,DS, 51P(ab), Margouleff,D, 177P(ab), Matthay,KK, 1922 17P(ab),44P(ab) Meriy, M, 169P(ab) 220P(ab) 209P(ab) Matteucci,F, 2032 McKusick,KA, 879,1109, Messa,C, 5P(ab) Mitchell,K, 177P(ab) Margulis,0, 1218(le) Matthews,KL, 112P(ab) 1119 Messian,0, 226P(ab) Mittermayer,C, 164P(ab), Mariacaridad,T, 179P(ab) Matthysse,5, 196P(ab), McLoud,TC, 1571 Messinger,DE, 134, 217P(ab) Mariani,0, 1175,2032 203P(ab) McMahon,M, 1254,44P(ab) 152P(ab) Miura,5, 1333,200P(ab) Mariani,M, 82P(ab) Maublant,JC, 255,1949 McMillan,K, 33P(ab), Messmer,BJ, 23P(ab) Miyagawa,M, 222P(ab) Marini,RP, 171P(ab) Mauclaire,LP, 1260 244P(ab) Metkv, V. 232P(ab) Miyake,T, 107P(ab) Markey,i, 205P(ab) MauguiÃ¨re,F, 22P(ab), McNamara,D, 297 Mettler,FA, 260P(ab) Miyake,Y, 24P(ab) Markham,J, 87P(ab) 103P(ab) McNeil,B, 41N(12) Metz, CE, 1198,81P(ab) Miyaoka,RS, 60P(ab) Marks, OF, 54P(ab) Maul,FD, 205P(ab) McNeil,L, 179P(ab) Metz,J, 798 Miyasaka,M, 66P(ab)

2290 TheJournalofNudearMedicine O'Grady

Miyashita, K, 202P(ab) 171P(ab),207P(ab), Muls,V, 1642,99P(ab), Narula,J,1507,2264 Nishimura,K, 222P(ab) Miyatake, K, 107P(ab) 209P(ab) 166P(ab) Nassar, 0, 164P(ab) Nishimura,5, 95P(ab) Miyauchi,T, 28P(ab), Moriya,E, 161P(ab) Munda,R, 171P(ab) Nathan, M, 11P(ab), Nishimura,T, 1013,1103, 139P(ab),223P(ab) Morozumi,T, 34P(ah) Munley,MT, 19P(ab) 188P(ab) 1931, 14P(ab), 24P(ab), Miyazaki, C, 812 Morrell,NW, 370 Munz,DL, 153P(ab) Navia, B, 203P(ab),212P(ab) 34P(ab),55P(ab),63P(ab), Miyazawa,H, 780, 1886 Morris,0, 82P(ab) Murakami, M, 1936, Neal, CE, 262P(ab) 107P(ab),120P(ab), Miyazawa, Y, 301 Morris, ID, 133P(ab) 126P(ab), 200P(ab) Neary, J, 112P(ab) 159P(ab), 170P(ab), Mizrachi,H, 1067 Morris,iS, 238P(ab) Muraki,A, 1152 Nebeling,B, 355 171P(ab),199P(ab), Mnaymneh, W, 33P(ab) Morris,K, 19N(7),22N(4), Murali, D, 8P(ab) Nedelman, MA, 234 201P(ab), 207P(ab), Monk, SA, 233P(ab) 28N(10) Muranaka,A, 208P(ab) Neild,OH, 1163 209P(ab) Moase, A, 214 Morris, ST, 115P(ab) Murase,K, 19P(ab),98P(ab), Nd, MO,963 Nishimura, Y, 1103 Mochizuld,H, 42P(ab) Morrison,JC, 1169 167P(ab) Nellis,SH, 16P(ab) Nishizawa,5, 839, 147P(ab), Mochizuki,5, 161P(ab) Morrison,KS, 481 Murphy,K!, 262P(ab) Nelson, AD, 5236e), 1000 194P(ab), 201P(ab) Mochizuki,T, 98P(ab) Morrison, WB, 123P(ab) Murphy,P, 151P(ab), Nelson,C, 11OP(ab), Nitzsche,EU, 50P(ab), Model, JO, 211P(ab) Mornssey,Gi, 151 175P(ab), 186P(ab), 113P(ab) 88P(ab),137P(ab) Moeller,JR, 1090 Morrow,Ti, 56P(ab) 189P(ab) Neptune, M, 172P(ab) NOcOIai,E, 1602 Moffat,F, 214P(ab) Mortelmans,L, 4P(ab), Murphy, PH, 34N(3), 50N(6) Neubauer,U, 207P(ab) Nods, ElF, 92P(ab) 11OP(ab), 141P(ab), Murthy,S, 465,61P(ab) Neumann,DR, 400, 1834(le) Noel, P, 1223, 226P(ab) Mohammadpour, H, 2152 Mohan,MK,165P(ab) 222P(ab), 227P(ab) Muths,C, 7P(ab) Neumann,M, 1397 Nohara, R, l2OP(ab), Mortenson, T, 223P(ab) Muthuswamy,M, 105P(ab) Neumann,PH, 1341, 147P(ab) Mohan, R, 1595,162P(ab) Mortimer, iE, 56P(ab) Muzic,RF ir, 1000 150P(ab) Nomura, 5, 815 Mohr,K, 243P(ab) Morton, K, 251P(ab) Muzik,0, 83, 336, 13P(ab), Neumann,PD, 24,173, Nonogi,H, 14P(ab) Mohs, R, 116P(ab) Morton,KA, 128,195,455, 35P(ab), 36P(ab), 155P(ab) 351(le),2169,58P(ab), Nonomura, A, 139P(ab) Mohsin,J, 12P(ab), 1905,2135,1389Qe), Muzinic,M, 1235 215P(ab), 233P(ab) Nordman, E, 21P(ab) 162P(ab),163P(ab) 62P(ab),71P(ab),157P(ab), Myen, R, 26P(ab) Neumann, WL, 228 Norrgren, K, 448, 178P(ab) Moingeon,LI, 242P(ab) 176P(ab),196P(ab), Neumeyer, iL, 31P(ab), Northover,JMA, 82P(ab) Moms, N, 255 220P(ab),249P(ab) Nabeshima,M, 177P(ab), 243P(ab) Norton, JA, 24, 173 Moisan, A, 182 Mosbach, PE, 131P(ab) 247P(ab) Neuineyer, M, 197P(ab) Norton, NS, 203P(ab) Mok,DY, 178P(ab) Mosca,F, 1175 Nagai,K, 208P(ab) Nevo, E, 1877 Noujaim,A, 100P(ab), Mokotoff,M,231P(ab) Mosca, L, 155P(ab) Nagai,T, 63P(ab) Newberg,AB, 1681 126P(ab), 213P(ab) Molea,N, 2032,83P(ab) Moscatelli,0, 44P(ab) Nagamachi,5, 2091 Newell,DW, 62P(ab) Novales-Diaz,J, 853,1992 Molenaar, WM, 219P(ab) Moser,E, 375 Nagaraj,N, 127P(ab), Newell,J, 149P(ab) Nowak, PA, 8P(ab) MOllenstadt, 5, 219P(ab) Moses,WW, 1O1P(ab) 152P(ab), 171P(ab) Newkome,OR, 29P(ab) Nowotnik,DP, 18P(ab) MOller,H-i, 77P(ab) Moskowitz,OW, 166P(ab) Nagata,S, 107P(ab) Newman,MA, 24N(5), Nez, ME, 1067,2019, Momose, J, 174P(ab) Mostbeck@A, 122P(ab) Nagata,T, 201P(ab) 25N(9) 63P(ab), 128P(ab) Momose,T, 1984,71P(ab), Moster, M, 1447 Nagata,Y, 2124 Newman,OC, 104P(ab) Nozaki,T, 1944 113P(ab), Motomura,N, 2216, Nagel,â€˜FL,106P(ab), Newman, 5, 24P(ab), Nunn, AD, 641,924, 1058, Monetti, N, 1166,129P(ab) 180P(ab),193P(ab) 179P(ab) 64P(ab), 131P(ab) 15P(ab),16P(ab),18P(ab) Monforte,R, 1452 Mountz, iD, 58P(ab) Nagle,KR, 222 Newton,MR, 666 Nu8baumer,i, 219P(ab) Mongioj, V, 219P(ab) Mountz, JM, 58P(ab), Nagren,K, 1711,21P(ab) Ng, CK, 205P(ab) Nutila, P, 2064 Monti, L, 154P(ab) 64P(ab), 78P(ab), 92P(ab), Naidech,IU, 261P(ab) Ngai,WM, 99P(ab) Nun, R, 1367 Moon, DH, 76P(ab), 206P(ab), 211P(ab) Najafi,A, 237P(ab) Nguyen,D, 102P(ab) Nuttall, PM, 157P(ab) 83P(ab),130P(ab), Mourad, M, 129P(ab) Nakagawa, A, 180P(ab) Nguyen,N, 83, 13P(ab), Nuutila,P, 2068,3P(ab), 138P(ab) Moyer,BR, 104P(ab) Nakagawa,I, 247P(ab) 45P(ab),87P(ab) 107P(ab), 224P(ab) Moore, BA, 474 Mozky, D, 210P(ab) Nakahashi,H, 431 Nguyen,T, 124P(ab) Nuyts, J, 4P(ab),11OP(ab), Moore,H, 69P(ab) Mozky, LH, 228P(ab) Nakai, K, 1309 Nguyen,TO, 33P(ab) 141P(ab) Moore, RB, 405 Mozky, PD, 208, 1866, Nakajima,K, 1478 NichOls,D, 22N(4) Moore, RH, 199,1616(le), 1910, 12P(ab), 48P(ab), Nakajima, T, 202P(ab), Nichols,K, 1871,24P(ab), Oakes,TR, 8P(ab),69P(ab), 2277(le) 76P(ab),92P(ab),117P(ab), 215P(ab) 64P(ab),131P(ab), 157P(ab) Moore, SC, 188P(ab) 158P(ab), 162P(ab), Nakajima, Y, 258P(ab) 150P(ab) Gates, E, 953 Moore, W, 151P(ab), 163P(ab),190P(ab), Nakaki, M, 1282,1309 Nickerson, i, 218P(ab) O'Bannon, DD, 240P(ab) 175P(ab),186P(ab), 195P(ab),198P(ab), Nakamura,M, 103P(ab) Nickles,Ri, 1058,8P(ab), Oberdorfer, F, 12, 1075, 189P(ab) 207P(ab), 228P(ab) Nakanishi,T, 1980 16P(ab), 69P(ab), 157P(ab), 220P(ab) Moots, P, 206P(ab) Msaki, P, 136P(ab) Nakashima,R, 1184, 184P(ab),248P(ab) Obermueller, SD, 3P(ab) Morais, J, 145P(ab) Mueller,B, 158P(ab) 177P(ab), 247P(ab) Nicol, PD, 2144 Ochi, H, 301 Morand,P, 1472,45P(ab) Mueller,PR,260P(ab) Nakata, Y, 221P(ab) NicolÃ¡,JM Ma M Catafau, O'Connell,JW, 65P(ab), Morawsky, L, 131P(ab) Mueller-Gartner,HW, Nakatani,N, 98P(ab) RamÃ©nEstruc, 1452 151P(ab) Moreau, MFC, 1260 5P(ab) Nakatsuka,I, 932 Nicolai,E, 1688,147P(ab), O'Connell,Wi, 303 Moresco, RM, 360, Mukai,T, 839,29P(ab), Nakayama,M, 247P(ab) 153P(ab) O'Connor, MK, 146P(ab), 102P(ab),154P(ab) 59P(ab),194P(ab) Namavari,M, 238P(ab) Nieweg, 0, 219P(ab), 148P(ab), 166P(ab) Morgan,HT, 30P(ab), Mukherjee,J, 798,239P(ab), Namba, R, 221P(ab) 225P(ab) Oda, H, 95P(ab) 71P(ab),80P(ab), 243P(ab) Nambu,K, 193P(ab) Nigh, E, 345 Odano, I, 32P(ab), 198P(ab), Morgan,LI, 84P(ab) MUkhOpadhyay,5, 123P(ab) Nance,RWir, 294 N@jran,KS, 370 202P(ab) Morguet,Al, 153P(ab) Mulholland,OK, 123P(ab) Nancy, A, 126P(ab) Nijs,J, 141P(ab) Odhner,D, 256P(ab) MoÃ±,T, 107P(ab) Mull, M, 222P(ab) Nappi,A, 1602,1688, Nikkels,P, 55P(ab) O'Driscoll, GA, 196P(ab), Mon, Y, 122P(ab) Mullan,BP, 12P(ab), 147P(ab),153P(ab) Nilsson, R, 448 203P(ab) Monce, P, 182 61P(ab), 166P(ab) Narabayasi,I, 221P(ab) Nimeth, C, 212P(ab) Oei, HY, 41P(ab),118P(ab), Moriel,M, 34P(ab),148P(ab) Mullani,NA, 1831Qe) Narahara, ICA,187 Nimmon,CC, 845 139P(ab), 175P(ab) Morikawa, A, 42P(ab) Muller, D, 968 Narendula, 5, 256P(ab) Nishida,Y, 95P(ab) Oesch, F, 161P(ab) Morin, P-P, 1217(k) MUller,L, 7P(ab) Narita, N, 229P(ab) Nishigauchi,K, 1980 Oettgen,HF, 213P(ab) Morisco,C, 1688,147P(ab), Muller,P, 4P(ab) Narra, RK, 641,15P(ab), Nishiguchi, @,301 Offord,Si, 109P(ab) 153P(ab) Muller,SP, 58P(ab) 146P(ab) Nishihara, H, 2182 Ogawa,K, 2216,176P(ab), Morise, A, 150P(ab) Muller-Schauenburg, W, Narra, VR, 637,133P(ab), Nishihara,M, 32P(ab) 192P(ab) Month, K, 208P(ab) 1770 134P(ab) Nishikawa,J, 71P(ab), O'Orady, LF, 53P(ab), Moriwaki,H, 63P(ab), Mulnix,T, 16P(ab) Naruki,Y, 98P(ab) 113P(ab),182P(ab) 93P(ab)

AuthorIndexâ€¢1993 2291 Ogils

Ogris, E, 1039, 122P(ab) Ozawa,K, 6P(ab) Park, iS, 130P(ab),138P(ab) Pham,H, 231P(ab) Pratt, JR. 197P(ab) Ohishi,H, Ozguven,M, 889 Park, 5, 138P(ab) Phaneuf,DC, 96P(ab) Pratur@R,294 Ohmomo,Y, 234P(ab) Ozker, K, 56P(ab) Park, SO, 233P(ab) Phelps, ME, 488, 679, 1006, Praturlon,5, 126P(ab) Ohmori,Y, 431,1543, OztUrk,E, 889 Parker, J, 141P(ab), 142P(ab) 2009, 2038, 1832(le), Preece, AW, 156P(ab), 26P(ab),198P(ab), Parker,iA, 1355 4P(ab),70P(ab),137P(ab), 159P(ab) 225P(ab) Puns, AMJ, 183P(ab), Parkey, RW, 9P(ab) 183P(ab),184P(ab), Prekeges, iL, 169P(ab) Ohnishi,T, 2091 219P(ab), 225P(ab), Parkman,HP, 169P(ab) 202P(ab),224P(ab) Prellwitz, JA, 238P(ab) Ohno, M, 177P(ab) 241P(ab) Parliament,MB, 885 Philips,L, 165P(ab) Prescott, MC, 159P(ab) Ohta, Y, 66P(ab) Pabst, HW, 41P(ab), Parmett, 5, 2101,64P(ab) Phillips,C, 194P(ab) Pretorius, PH, 330,963 Ohtake, T, 71P(ab), 63P(ab),112P(ab), Pasqualini,R, 18P(ab), Phillips,RL, 40P(ab) Prevett, MC, 57P(ab) 113P(ab),181P(ab), 219P(ab) 134P(ab) Phillips,WT, 2160,135P(ab), Price, DC, 39P(ab) 182P(ab) Pace, L, 1602,1688, Pastan, I, 241P(ab) 247P(ab) Price, i, 228(ab) Ohye, C, 2085 147P(ab) Pastor, E, 142P(ab) Philpott,OW, 28P(ab), Price,JC, 27P(ab) Okada, RD, 630 Pacheco,EM, 143P(ab) Patch,00, 1905 81P(ab),134P(ab), Prigent,FM, 1845 Okada, 5, 63P(ab),211P(ab) Packard,A, 151P(ab) Pate, BD, 481 216P(ab) Prince, JR, 190P(ab) Okazaki,Y, 63P(ab), Packard, AS, 1045 Patel,B, 15P(ab),146P(ab) Piatti, PM, 154P(ab) Prior,JO, 9P(ab) 171P(ab),207P(ab), Packer,R, 52P(ab) Patel,D, 24P(ab),64P(ab) Picard,D, 145P(ab) Prohovnik,I, 1090 209P(ab) Padhy,AK, 845 Patel,M, 234P(ab) Picard, M, 145P(ab) Pruim, J, 55P(ab), 183P(ab), O'Keefe, iN, 75P(ab), Paganelli, 0, 92, 94P(ab), Patel,NH, 16P(ab) Pickett, PD, 222 219P(ab), 225P(ab) 149P(ab) 114P(ab) Patterson, Di, 169P(ab) Piepenburg,R, 161P(ab) Pulmano,C, 131 Oku, N, 63P(ab),171P(ab), Page,RL, 216P(ab) Patterson,RE, 281,978, Pkpsz, A, 1223, 117P(ab), Punja, U, 804 207P(ab), 209P(ab) PaM,ii, 190P(ab) 29P(ab),36P(ab),44P(ab), 226P(ab) Purdy, PD, 1239 Oku, 5, 71P(ab),113P(ab), Pal, LH, 241P(ab) 96P(ab),146P(ab), Pierce,M, 37P(ab) Purcell, OL, 896 182P(ab) Paik, C, 48P(ab),58P(ab), 179P(ab) Pierce, PF, 259P(ab) PÃ¼spOck,i, 212P(ab) Okubo, M, 32P(ab) 215P(ab),233P(ab), Pattillo,RA, 56P(ab) Pieri, P, 879 Put, E, 211P(ab) Okuda, K, 120P(ab) 241P(ab) Patton, DD,474 Pieri, PL, 44P(ab) Putnam, J, 42P(ab) Okunieff, P0, 206P(ab) Paik,CH, 2169 Patz, EF, 21P(ab) Piers, DA, 354(le) I'yau, B, 237P(ab) Old,LI, 83P(ab) Paine,5, 21P(ab),23P(ab) Paul,R, 1428 Pierson,RN Jr, 895 Oldhoff, i, 219P(ab), Pajeau, TS, 49P(ab), Pauli, 5, 89P(ab) Pietrzyk,U, 1O1P(ab) 01,P,100P(ab) 225P(ab) 160P(ab) Pauw, BKH, 873 Piffanelli,A, 18P(ab) Qian,J, 20P(ab),151P(ab) O'Leaiy, DS, 68P(ab) Pak, K, 247P(ab) Pauwels, EKJ, 737, 1052 Pike, MC, 1964,173P(ab) Quadri,5, 2152 Olken, NM, 787 Pakzaban,P, 202P(ab) Pavel, DO, 188P(ab) Pilcher, WC, 44P(ab) Quadri, SM, 938 Oilier,M, 1949 Palestro,Ci, 818,1235, Pawlowski,J, 9P(ab) Pinheiro,E, 142P(ab) Quaife,PA, 84P(ab) Olsen, J, 11P(ab) 61P(ab),83P(ab),166P(ab), Pawlyk, D, 53P(ab), 54P(ab), Pinsky, CM, 61, 214P(ab) Qualm, SM, 2222 Oltrogge, J, 126P(ab) 233P(ab), 251P(ab), 94P(ab), 160P(ab) Pinto, Al, 1441 Qu@ley,F@MM,111P(ab) O'Malley,iP, 259P(ab) 262P(ab) Paxton,Ri, 1294 Pipes, D, 38P(ab), 232P(ab) Quinlan,D,116P(ab) Ombetta, J-E, 235P(ab) Palevsky,H, 1851,43P(ab), Payer,F, 116P(ab) Pine, i, 15P(ab), 92P(ab) Quinones, N, 12P(ab), Omri, F, 1565 229P(ab), 230P(ab) Payne, JK, 754, 68P(ab), Pitt, H, 76P(ab) 257P(ab) O'Neil,iP, 18P(ab) Palmas,W, 130P(ab), 91P(ab) Pitt, 5, 148P(ab) Quint, LE, 1190 O'Neill, M, 257P(ab) 150P(ab) Payne, 5, 129P(ab) Pitts, N!..,1169 Quint, R, 153P(ab) O'Neill, P, 1172 Palmer,AM, 156P(ab), Pecherstorfer, M, 1039 Piwnica-Worms, D, 140P(ab) Ono, 5, 147P(ab), 208P(ab) 159P(ab) Peck, Di, 97P(ab) Pizzolitto, 5, 166P(ab) Rabinovitch, MA, 589 One, Y, 24P(ab), 55P(ab) Palmer, BM, 203P(ab) Pedrosode Lima,ii, 1441 Plagne, Ri, 1260 Rabito,C, 51P(ab),88P(ab), Oncyama, Y, 215P(ab) Palmer,EL, 527(br),661, Pelizzari,C, 94P(ab) Plotzke,KP, 787 250P(ab) Oohashi,H, 95P(ab) 1837(br) Pelizzari,CA, 1587 Podoloff,D, 33P(ab), Rabito, CA, 199, 1616(le), Opie, L, 867(le) Palmer, S, 8% Pellerin,M, 140P(ab) 42P(ab),53P(ab),55P(ab), 2277(le) Oppermann, H, 234 Palombo-Kinne,E, 92 Peltier,P, 1267 88P(ab),115P(ab), Racadio,J,257P(ab) Ordonez,CE, 186P(ab) Palowski,J, 195P(ab) Peng,NJ, 76P(ab) 119P(ab), Radford,DM,56P(ab) OrduÃ±a,E, 32P(ab) Paltiel,Hi, 614,255P(ab) Penney, BC, 195P(ab) 212P(ab),218P(ab), Radtke,RA, 23P(ab) Orenstein, SR. 1228 Pan,3W,92P(ab) Penninckx,F, 222P(ab) 223P(ab) Rafael, JAS, 1441 One, JE, 1695 Pan,T-S, 195P(ab) Pentlow, K, 94P(ab), Poewe, W, 31P(ab) Raffel,D, 1739,124P(ab) Onto, T, 159P(ab) Pan,X, 112P(ab) 127P(ab),162P(ab) Pohost, GM, 92P(ab) Ragosta,M,728 Oriuchi, N, 2085, 14P(ab), Pancholy,5, 75P(ab), Pentlow, KS, 1595 Poland,5, 257P(ab) Rahmouni,A,2105 42P(ab) 85P(ab) Pepys, MB, 118P(ab) Pollack,5, 2095 Raijmakers, POHM, O'Rourke, MF, 238P(ab) Pandurangi,R, 232P(ab) Perani, D, 1460, 5P(ab) Pollard,KR,60P(ab) 230P(ab) Orsolon,P0, 166P(ab) Pang, 1W,474 Perez,EA, 53P(ab) Pommier,R, 11P(ab) Rain, B, 229P(ab) Osieka, R, 164P(ab) Pang,RHL,234 Penman, SB, 22P(ab) Poncin,D, 226P(ab) Raja,5, 209P(ab) Ossenkoppele,01,1706 Panico,FO, 250P(ab) Pernegger,C, 1OP(ab) Ponto, LLB, 181P(ab), Rajagopalan,R, 135P(ab) Oster, ZH, 197P(ab) Pannier, L, 226P(ab) Perrone-Filardi,P, 311 185P(ab) Rajeevan,N, 195P(ab) Ostertag,H, 1075,21P(ab), Papageorgiou, I, 46P(ab) Pescatore, F, 172P(ab) Poppa, 0, 141P(ab) Raju, N, 146P(ab) 220P(ab) Papon,iM, 1260 Pesi,H, 1OP(ab),212P(ab) Porenta, 0, 35P(ab) Rakow, ii, 1326 Ostrem,iL, 228P(ab) Pappas,AA, 896 Peters, AM, 706,1390(le), Port, SC, 131P(ab) Rem,5,100P(ab) Otsuka, M, 288 Pappas, N, 102P(ab), 2276(le),41P(ab),43P(ab), Postema, FFE, 41P(ab) Ramalingam,K,641,18P(ab) Otsuka, N, 208P(ab) 103P(ab),131P(ab) 62P(ab),118P(ab) Poston,3W,714 Ramanna,L,18,37P(ab), Otsuka, 5, 98P(ab) Pappata, 5, 109P(ab) Petersdorf, 5, 1031, 1839 Potts, iM, 255P(ab) 77P(ab), 139P(ab), Otto, AC, 963 Paradise, AR, 51P(ab) Peterson, A, 237P(ab) Poublon,RML,41P(ab) 168P(ab) O'Tuama, LA, 1045 Pardo, FS, 206P(ab), Peterson, C, 8P(ab), Pouillart,F, 14P(ab) Ramirez, LF, 22P(ab) Ouellet, RO, 59P(ab) 208P(ab) 218P(ab) Pounds, â€˜FR,64P(ab), Ramos-Gabatin,A,1169 Owens,E, 215P(ab) Parekh,J, 162P(ab), Pettigrew,RI, 96P(ab) 65P(ab) Ramzi,E, 1246 Owunwanne,A, 233P(ab), 230P(ab) Pettinger, WA, 251P(ab) Powe, El, 151 Rana,5, 24P(ab),64P(ab) 234P(ab) Parellada,E, 77P(ab) Peyron, R, 22P(ab), 103P(ab) Powers,ER, 728 RandÃ©,JLD, 1899,36P(ab) Oya, N, 2124 Parisi,MT, 1922,865(le) Pfleffer, N, 208 Pozza,G, 154P(ab) Rao, DV, 637,1801, Oya,5, 135P(ab) Park, CH, 255P(ab) Pflster, D, 213P(ab) Prakash,D, 51P(ab) 105P(ab),133P(ab), Oyen, WiO, 1621, 62P(ab), Park, CY, 1987, 167P(ab) Phalen,ii, 238P(ab), Prato, F, 251P(ab), 252P(ab) 134P(ab) 105P(ab) Park,H-M,381 240P(ab), 251P(ab) Pratt, JP, 150P(ab), 202P(ab) Rao, MO, 997

2292 TheJournalof NuclearMedicine Schroeder

Rapaport,E, 232P(ab) Richmond, JCW, 181P(ab), Rousseau, J, 49P(ab), Sahu, 5K, 241P(ab) Sax, El, 2095 Rapp,M, 1949 185P(ab) 1O1P(ab) Saika,Y, 221P(ab) Sayer,J, 115P(ab) Rapun, R, 172P(ab) Richter, W, 31P(ab) Rowan, M, 1467 Saji, H, 932, 201P(ab), Scalliet,P, 186P(ab) Rasey, JS, 918,21P(ab), Rickard-Dickson,KJ, 1294 Rowe,CC, 666 234P(ab) Scanley, BE, 31P(ab), 79P(ab) Rieger, P, 53P(ab) Rowe,RK, 474 Sakahara,H, 815,1745, 243P(ab) Rath, P, 82P(ab) Rieker, 0, 77P(ab) Rowen,M, 54P(ab),85P(ab) 29P(ab),119P(ab), Scasnar,V, 1O1P(ab) Rath, U, 97P(ab) Rijks,LJM, 225P(ab) Royal,HD, 260P(ab) 215P(ab) Schaefer, C, 77P(ab) Ratliff,BA,908,2111 Rijntjes,M, 58P(ab) Rozanski,A, 1845,24P(ab), Sakai, K, 32P(ab),202P(ab) Schaeken, B, 186P(ab) Rattner, Z, 211P(ab) Rippon,MB,53P(ab) 34P(ab),64P(ab) Sakakura, K, 159P(ab) Schafers,M, 45P(ab) Ratzlaff,N, 65P(ab) Riva,P,44P(ab) Rozen, 5, 69P(ab) Sakamoto,T, 211P(ab) Schaible,T, 178P(ab) Rauch, SL, 47P(ab),57P(ab), Rizzo, G, 137, 5P(ab) Rubello,D, 1626,161P(ab) Sakowski,R, 199P(ab) Scheff,AM, 115P(ab) 71P(ab),196P(ab), Roamano, J, 66P(ab) Rubenfire,M, 36P(ab), Saladini,0, 1626,161P(ab) Scheffel,U, 120,18P(ab), 203P(ab) Roberson,PL, 105P(ab) 155P(ab) Salako,0, 53P(ab),93P(ab) 25P(ab), 103P(ab), Rauh, D, 2130, 104P(ab), Robert, P. 5P(ab) Rubertone, JA, 99 Salako,QA, 1067 197P(ab), 199P(ab), 157P(ab),172P(ah), Roberti,RR, 193 Rubin,NT, 51P(ab) 5aleh, MN, 53P(ab) 234P(ab) 174P(ab) Robertson,EF, 262P(ab) Rubin,RA, 697,849, Salensky,H, 150P(ab) Scheibe,P0, 1020 Rauth, AM, 242 Robertson,iS, 1382 2276(le) Salet, A, 170P(ab) Scheinberg,DA, 422, Rubin, RH, 1964, 1975, Salk, D, 2111 53P(ab),105P(ab) Ravert, HT, 120,25P(ab), Robeson,W, 177P(ab), 31P(ab),86P(ab),103P(ab), 2130,2176,51P(ab), Salkowski,LR, 151P(ab) Scheinman,M, 151P(ab) 180P(ab), 209P(ab) 109P(ab), 132P(ab), 83P(ab),88P(ab),104P(ab), Sallan, SE, 1045 Schelbert,HR, 488,2038, Robey, RL, 240P(ab) 133P(ab),197P(ab), 172P(ab),173P(ab), Salmon,E, 1460 1832(le), 4P(ab), 35P(ab), Rocco,T, 151P(ab) 199P(ab), 228P(ab), 250P(ab) Salvadori,PA,1175 50P(ab), 88P(ab), 154P(ab), 234P(ab) Rocque, PA, 28P(ab) Rubin,SC, 216P(ab) Salvatore, M, 1602, 1688, 165P(ab), 183P(ab), Raylman,RR,440,50P(ab), Roden,W, 68P(ab) Ruckert, ACF, 56P(ab) 12P(ab),42P(ab),82P(ab), 184P(ab) 93P(ab),106P(ab), Rodriguez,B, 215P(ab) Rucknagel,DL, 614 115P(ab),147P(ab), Scheld, H, 45P(ab) 107P(ab), 113P(ab) Rodriguez,0, 91P(ab) Ruddy, TD, 74P(ab) 153P(ab),213P(ab), Schelosky,L, 31P(ab) Raynaud, C, 1717, 78P(ab) Rodriguez-Sierra, iF, Rudolph, AS, 2160, 135P(ab) 219P(ab) Scherrer, M, 14P(ab) Reath,DB, 109P(ab) 203P(ab) Ruijs,J, 163P(ab) Samarasekara,5, 124P(ab), Schiebler, M, 121P(ab) Reba, RC, 32N(9),2169, Rogan,L, 1818 Ruiz, M, 96P(ab) 256P(ab) Schiepers,C, 4P(ab), 233P(ab) Rogers,M, 68P(ab) Rumsey,WL, 15P(ab), Samman,B,134 11OP(ab),141P(ab), Reese, L, 251P(ab),252P(ab) Rogers,WL,9P(ab), 16P(ab),146P(ab) Samoszuk,MK, 1246 210P(ab),222P(ab), Rege,5, 137P(ab),224P(ab) 30P(ab),90P(ab),148P(ab), Ruotsalainen,U, 1, 1711, Sampson,WFD, 1616Qe) 227P(ab) Rehm, PK, 227P(ab) 190P(ab) 2064, 2068, 3P(ab), Samson,Y, 78P(ab), Schiff,RO, 166P(ab), Reiber, C, 12 Rogulski,MM,27P(ab) 21P(ab),107P(ab), 109P(ab), 205P(ab) 251P(ab) Reich,5, 31P(ab) Rohe,RC,156P(ab), 224P(ab) Samtani,5, 165P(ab) Schiffer,JO, 168P(ab) Reichmann, K, 187P(ab) 205P(ab) Rupich, RC, 227P(ab) Sanders, i, 135P(ab) Schifter,T, 567,7P(ab) Reid,RH,52P(ab) Roizenblatt,5, 142P(ab) Rusckowski,M, 109, SandIer, ED, 1922 Schilling,T,1039 Reijs,AEM,175P(ab) Rojas-Burke,J, 13N(1), 1618(le), 59P(ab), Sandier,MP,826,86P(ab) Schippers, Di, 35P(ab) Reilly,RM,99P(ab) 19N(3),20N(1),23N(5), 234P(ab), 240P(ab) Sandrock, D, 24 Schiag,P, 1075 Reiman,R, 7P(ab),144P(ab) 25N(2), 26N(4), 47N(6) Rusinek,H, 2019,40P(ab) Sanford, I, 65P(ab) Schlick,W, 1397 Reinbold, F, 48 Romagnuolo,J, 54P(ab), Russell,CD, 1761,249P(ab) Sanger,ii, 515,1835(le), Schiom,J, 53P(ab), Reiners, C, 58P(ab) 149P(ab) Ruth,Ti, 481 63P(ab),128P(ab) 127P(ab), 214P(ab) Reinhardt,CP, 1510,1722, Roman,R, 1574 Rutishauser,W, 46P(ab) Sansoy,V, %P(ab) Schlyer,D, 609,619, 14P(ab),46P(ab) Roman, RA, 163P(ab), Ryan,J, 171P(ab) Santos,CA,1441 67P(ab),69P(ab),102P(ab), Reissman, R, 231P(ab) 173P(ab) Ryan,PJ,11OP(ab), Santos-Ocampo, CD, 131P(ab), 200P(ab), Remes,K, 1428 Romaniello, 0, 135P(ab) 141P(ab),142P(ab), 75P(ab),85P(ah),152P(ab) 237P(ab) Renn, 0, 94P(ab) Roodenburg, JLN, 55P(ab) 144P(ab) Saraste, M, 2068, 3P(ab) Schmarkey,LS, 281, Renner,F, 212P(ab) Roos,JC, 82P(ab),11OP(ab) Rydhoim, U, 1646 Saravis,C,247P(ab) %P(ab),146P(ab) Rennie,BA, 235P(ab) Ropchan, JR, 12P(ab), Rylatt,DB, 100P(ab), Sasaki,M, 288 Schmidlin,P,48 Renoux, M, 255 257P(ab) 153P(ab) Sasald,T, 1936,1944 Schmidt,D, 132P(ab), Renshaw,PF, 1101 Rosa, E, 106P(ab),114P(ab) Rysavy,J, 6P(ab),21P(ab) Sasaki,Y, 14P(ab),71P(ab), 158P(ab),202P(ab) Renstrom,B, 16P(ab) Rosadini, 0, 91P(ab) Ryu,iS, 76P(ab),83P(ab), 113P(ab),181P(ab), Schmidt,EV, 206P(ab) Repp,R, 172P(ab) Roach, F, 2222 130P(ab),138P(ab) 182P(ab),229P(ab) Schmidt,KC, 360 Reske,SN, 87P(ab), Rose, CP, 589 Sasayama, 5, 1672, 120P(ab) Schmidt,MA, 135P(ab) 217P(ab),223P(ab), Rose, MR, 159P(ab) Saul,J-P, 1899 Sass, KA, 231P(ab) Schmidt,PF, 100P(ab), 225P(ab) Rosen, BR, 206P(ab), Sabia,PJ,728 Sassaman,MB, 235P(ab) 153P(ab) Resnick,SM,2201 208P(ab) Sabourin, CL, 239P(ab) Sasso, D, 244P(ab),245P(ab) Schnall, M, 32P(ab) Rettenbacher,L, 122P(ab) Rosen, 0, 139P(ab) Sabry, 5, 1739 Sastry, J, 231P(ab) Schnedl,W, 168P(ab) Rettig,W, 83P(ab) Rosenblatt, B, 226P(ab) Sackeim,H, 1090 Sastry, KSR, 637 Schneider, Al, 230P(ab) Reubi,JC,118P(ab) Rosenblum, MG, 53P(ab) Sackellares, JC, 22P(ab) Satlin, A, 2044, 27P(ab), Schneider,JA, 145P(ab) Reynolds, JC, 173, 233P(ab) Rosenfeld, 5, 567 Sacks, SL, 235P(ab) 208P(ab) Schneider,PM, 175P(ab) Rezai, K, 1607, 68P(ab) Rosenfeld, 55, 206P(ab) Sadanega,Y, 1980 Sato,M, 174P(ab) Schneider,R, 64P(ab) Rhodes, BA, 231P(ab), Rosenthal, D, 205P(ab) Sadato,N, 1672,147P(ab) Sato,T, 780 Schneider,RF, 135P(ab) 244P(ab), 246P(ab) Rosenthal, iT, 88P(ab) Sadek,5, 233P(ab) Satou,T, 211P(ab) Schneider-Eicke, J, 112P(ab) Ribe, JY, 12P(ab), 257P(ab) Rosenthal,MS. 1228 Sadik,A, 172P(ab) Sattenberg,R,250P(ab) Schnell,P.0, 89P(ab) Ricaurte,0, 25P(ab), Rosenthall,L, 119P(ab) Saelens,E, 1217(le) Satter, M, 8P(ab), 218P(ab) Schnobrich,KE, 1656 197P(ab) Rosier,AM,31P(ab) Safavy,A, 29P(ab) Satterly,W, 240P(ab) Schober,0, 3P(ab),45P(ab) Ricaurte,GA, 120 Rossi,V, 117P(ab) Saffer,JR. 61P(ab), Satyamurthy, N, 202P(ab), Schoen,Fi, 65P(ab) Ricciardi,R, 250P(ab) Roth,CA,248P(ab) 124P(ab), 178P(ab) 238P(ab),239P(ab) Schofield, TD, 1995 Rice,KC,235P(ab) Rothley, J, 968, 155P(ab), Saga, T, 2169, 58P(ab), Sauerberg, P, 7P(ab) Schooler, NR, 78P(ab) Rich, D, 205P(ab) 158P(ab) 215P(ab),233P(ab) Saunders, M, 156P(ab) Schrag,A, 31P(ab) Richardson,5, 118P(ab) Rothstein,RD,506 Sagar,KB, 94P(ab) Saunders, R, 235P(ab) Schrell,U, 37P(ab) Richie, JP, 123P(ab), Rottenberg, DA, 200P(ab), Sago, M, 107P(ab) Sawada,5,968 Schriver, C, 11P(ab) 221P(ab) 203P(ab) Saha, GB, 400, 1834(le), Sawaki, M, 229P(ab) SchrOck,H, 793,204P(ab) Richman, CM, 53P(ab) Rousseau, C, 194P(ab) 190P(ab) Sawaya,R, 206P(ab) Schroeder,JM, 222P(ab)

AuthorIndexâ€¢1993 2293 Schuemichen

Schuemichen, C, 375 Sallow,RB,1828(Ie) Shiue, GO, 238P(ab), Slizofski,Wi, 1574, South, M, 53P(ab) Schuler,P, 207P(ab) Setoain,i,77P(ab) 240P(ab) 163P(ab),173P(ab) Southwick,SM, 205P(ab) Schuller,M, 68P(ab) Seymour,A,118P(ab) Shivalkar,B, 4P(ab) Slomka,PJ, 179P(ab) Sovel,M, 214P(ab) Schulman,DS, 1695 Seymour,iC,658 Shively,iE, 1294 Sloof,OW, 649,15P(ab) Spaeth,i, 2188 Schulte, L, 126P(ab) Sfakianakis,ON, 33P(ab), Shoemaker,RL, 27P(ab) Slosai, J, 9P(ab) Spanne,P, 160P(ab) Schumpelick,V, 98P(ab), 112P(ab), 117P(ab), Shoup, T, 25P(ab), 73P(ab), SlOth, M, 1646 Specht, HD, 352(le) 158P(ab), 183P(ab) 137P(ab),172P(ab), 202P(ab) Small,M, 119P(ab) S@l, D, 241P(ab) Schwab, Al, 589 174P(ab), 175P(ab), Shpitz, B, 99P(ab) Smalley,SR,262P(ab) Spector,J, 34P(ab) Schwab, ME, 138P(ab) 214P(ab), Shreve, P, 87P(ab),223P(ab) Smart,RC,1619 Speelman,ID, 207P(ab) Schwaiger,M, 83, 336,968, 224P(ab),249P(ab), Shuke, N, 1478, 28P(ab), Smart, SC, 44P(ab),94P(ab) Spehi,M, 1223 1287,13P(ab),30P(ab), 260P(ab),261P(ab), 92P(ab),139P(ab), Smith,AM, 91P(ab), Sperling,M, 207P(ab) 35P(ab),36P(ab),45P(ab), 263P(ab) 223P(ab) 157P(ab),159P(ab) Spading,MI, 127P(ab) 50P(ab), 87P(ab), 107P(ab), Sgouros,0, 422,689,1020, Shulda,R, 217P(ab) Smith,AP, 91P(ab) Spetsieris,P, 180P(ab), 148P(ab), 155P(ab) 1028Qe),1595,53P(ab), Shulkin,B, 865(le) Smith,C, 131P(ab) 209P(ab) Schwartz,RB, 47P(ab) 94P(ab),1OSP(ab), Shulkin,BL, 13P(ab), Smith,EE, 57P(ab) Spicer,KM, 106P(ab), Schwartz,7@,104 127P(ab),160P(ab), 51P(ab),220P(ab) Smith,EO,161P(ab), 179P(ab),245P(ab) Schwarz,A, 92 162P(ab) Shuhnan,A, 210P(ab) 211P(ab),258P(ab) Spiegel, TA, 169P(ab) Schwarz,SW, 28P(ab), Smith, FW, 30 Spiegelboff,DR, 151P(ab) Shah, A, 78P(ab) Shyti,HL, 143P(ab) 81P(ab),134P(ab), Smith,0, 206P(ab) Spies, SM, 131P(ab) Shanahan,M, 17N(10) Sibomana,M, 121P(ab) 216P(ab) Smith,OS, 63P(ab),67P(ab) Spieth,M, 1835Qe) Sham, J, 104 Siccardi,AO, 94P(ab) SciagrÃR, 117P(ab), Smith,OT, 6P(ab),109P(ab), Spieth, ME, 1990 Shapiro,B, 865(le),1638, Siddiqul,AR, 381 Sclarovsky,5, 152P(ab) 185P(ab),209P(ab), Spinelli, A, 44P(ab) Scott, AM, 1656,11P(ab), 11P(ab),104P(ab), Sidhu,S, 168P(ab) 261P(ab) Spinks,1, 26P(ab) 37P(ab),53P(ab),56P(ab), 166P(ab) Sidibe,5, 229P(ab) Smith, HS, 142P(ab) Spitz,J, 1403 83P(ab),94P(ab),105P(ab), Shapiro,CL, 74P(ab) Siegel, BA, 1828(k), Smith, i, 31P(ab) Spreer,J, 205P(ab) 106P(ab),114P(ab), Sharkey,RM,61, 1028(k), 56P(ab),81P(ab) Smith,JR, 196P(ab) Sprengelmyer,i, 77P(ab), 127P(ab),145P(ab), 53P(ab),54P(ab),61P(ab), Siegel,RI, 144P(ab) Smith, MF, 72P(ab), 168P(ab) 213P(ab),214P(ab) 94P(ab), 160P(ab), Siegel,iA, 53P(ab),54P(ab), 187P(ab) Squifiuet,iP,129P(ab) Scott,J,510 214P(ab), 215P(ab) 160P(ab) Smith, RI, 124P(ab), Sr., 23P(ab),68P(ab), Scott,iA,171,172,527(br),Sharma,IlL, 133P(ab), Siegel,ME, 1990,144P(ab), 181P(ab) 91P(ab) 661,870(br),1220(br), 157P(ab),159P(ab) 261P(ab) Smith,T, 30 Srinivasan,A, 135P(ab) 1221(br),13%(br), Sharma,5, 256P(ab) Siegel,5, 4P(ab) Smith,TD, 156P(ab) Srivastava,SC, 93P(ab), 1837(br), 1838(br), 2272 Shattuc,5, 74P(ab) Sievert,T, 205P(ab) Smith,WH, 728,96P(ab) 237P(ab) Scott,R,510 Shattuck,L, 129P(ab), Siewert,JR, 112P(ab) Smulian,AG, 61P(ab) Stabin,M, 1031,155P(ab), Scott,RM, 1045 244P(ab),246P(ab), Signora,A,246P(ab) Snow,GB, 1953 156P(ab),158P(ab) Scott,W, 20P(ab) 250P(ab) Signorini,C, 117P(ab) Snow,Bi, 481 Stable, MO, 695,1910 SCUderi,Al,455 Shaw, HM, 1435 Slkorska,H, 49P(ab) Snyder,H, 117P(ab) Stadalnik,RA, 2120 Seabold,JE, 11P(ab) Shaw, P, 52P(ab) Silagan,0, 1494,64P(ab), Snyder,SH, 31P(ab) Stafford,K, 13P(ab), Seasholtz,JI, 234 S_, E, 109P(ab), 148P(ab) Sobel,BE, 717 45P(ab),148P(ab), Seed,WA, 370 197P(ab),198P(ab) Silber, H, 130P(ab) Sobhani,I, 98P(ab) 155P(ab) Segall,GM, 345,865Qe) Shea, C, 246, 609, 131P(ab) Silberman,A, 139P(ab) Sobnack,R,82P(ab) Staib, L, 205P(ab) Seibyl,i, 31P(ab),102P(ab), Shealy, Di, 234 Silberman,AW, 18 Soffer, EE, 167P(ab) Stapkton, JM, 40P(ab) 109P(ab),161P(ab), Sheehan,FH, 23P(ab) Silberstein,EB, 61, Sohn, M-H, 2135,220P(ab) Starksen,N, 65P(ab) 205P(ab),211P(ab) Sheldon,K, 242P(ab) 205P(ab),261P(ab) Sokok-Busemann,E, 2076, Starling,MR, 747 Seidel,J, 60P(ab),70P(ab), Sheihamer,i, 1854 Siler,K, 214P(ab) 209P(ab) Stathis,M, 18P(ab) 177P(ab) Shelton,ME, 717 Silva,DA, 641 Sokoloff,L, 360 Staudenherz,A, 36P(ab), Seiffert,E, 12 Shen,5, 128P(ab),189P(ab) Silva,F, 32P(ab) Solanki,I@K,119P(ab) 87P(ab) Sailer,CA, 2111 Shen,YY, 145P(ab) Silveira,ST, 826 Solin,0,69P(ab) Stearns, CW, 1O1P(ab) Seipp,C, 205P(ab) Shepard,J-AO, 1220(br) Silver,K, 226P(ab) Solomon,HF,1964,1975, Steelhammer,L, 115P(ab) Seki, C, 86P(ab),199P(ab) Shepherd, JH, 82P(ab) Silverman,IF., 1009,1447 2130,83P(ab),104P(ab), Steen, L, 118P(ab) Seki,@,301 Sherman,PS, 8P(ab), Simkowitz,P, 67P(ab) 172P(ab),173P(ab), Steenbergen,C, 39 Sekine,H,161P(ab) 123P(ab),236P(ab) Simon,0,92 174P(ab) Stefan, H, 207P(ab) Sela,J, 104 Shevitz,i, 217P(ab) Simon,i, 33P(ab),244P(ab) Soltanian-Zadeh,H, 97P(ab) Stefani,I, 154P(ah) Selikson,MH, 208, 1910, 5k, B, 214P(ab) Simon,P, 257P(ab) Som, P. 197P(ab),243P(ab) Steigman,J, 233P(ab) 158P(ab) Shi, O-X, 97P(ab) Simonneau,0, 229P(ab) Sone,N,119P(ab) Stein, 5, 70P(ab) Selin, CE, 154P(ab) Shi@bazaki,T, 2085 Simpson,N, 7P(ab) Song,iH, 138P(ab) Steiner,RM,261P(ab) Sells, A, 212P(ab) Shibuya,K, 815 Sinaki,M, 142P(ab) Songin@C, 94P(ab), Stephens,AD, 804 Semmler,W, 31P(ab) Shieh,SH, 176P(ab) Singer, Mi, 97P(ab) 114P(ab) Stern, H, 99P(ab) Sample,WE, 1000 Shields, J, 144P(ab) Singh,A, 142P(ab) Sonmezoglu,K, 845 Stem, Y, 1090 San,C, 1235 Shigeta,M, 42P(ab) Singh,N, 52P(ab) Sood, VK, 48P(ab),233P(ab) Stevens,JS, 294 Senda, M, 1672,1936,1944 Shili, W-i, 131, 1218Qe) Singh, PR, 38P(ab) Soricelli,A, 153P(ab) Stevens,MM, 1082 Senekowitsch,R, 219P(ab) Shihab-Eldeen,A, 233P(ab) Sinusas,Al, 1254,97P(ab) Sorsdahl,0,251P(ab) Steventon,R, 11P(ab) Senneff,Mi, 717 Shimada,5, 201P(ab) Siraj,0, 119P(ab) Soskolne,WA, 104 Stewart,JA, 589 Seracini,D,117P(ab) Shimonagata,T, 14P(ab), Sired, SN, 48P(ab) Sossi,V,481 Stewart,iC, 237P(ab) Serafini,A, 33P(ab), 24P(ab),55P(ab),107P(ab), Sisson,i, 13P(ab),11OP(ab) Sostman,D,16P(ab), Stobbe,DE, 65P(ab) 117P(ab), 172P(ab), 120P(ab) Sitomer, i, 968, 155P(ab) 17P(ab) StOcklin,0, 2222,68P(ab), 174P(ab),214P(ab), Shimosegawa,E, 92P(ab) Sixt, R, 118P(ab) Sostman,lID, 1109,1119 80P(ab),107P(ab) 221P(ab),224P(ab), Shin, Mi, 83P(ab) SjOgren,H-O, 448 Sostre,5,762,1701,5P(ab), Stocks, 0, 184P(ab) 263P(ab) Shiode,M, 222P(ab) SjÃ´gren,K, 9P(ab) 76P(ab),168P(ab) Stoddard,H, 193P(ab) Serafini,AN,61 Shiomi, @,301 Skinner,RS, 104P(ab) Soto, RF, 260P(ab),261P(ab) Stoffel,M, 129P(ab) Serafini,5, 137P(ab) Shirato,M, 1745,119P(ab), Skinner,5, 787 Soucy,iP,59P(ab) StOhr,M, 220P(ab) Serfontein, DE, 330 215P(ab) Skinner,SF, 169P(ab) Souder,F, 1681,116P(ab), Stoiber,TR, 94P(ab) Serizawa,1,181P(ab), Shiue, CY, 203P(ab), Slama,M, 981 210P(ab) Stoltz,ML, 240P(ab) 182P(ab) 238P(ab),240P(ab), Slanetz,Pi, 1221(br) Soufer,R, 84P(ab),205P(ab) Stone, CK, 1058,16P(ab), Saturn,iF,1416 251P(ab) Slater, LM, 1246 Souteyrand,PA, 1260 184P(ab),248P(ab)

2294 TheJournalofNudearMedicine Valance

Storey,AE, 222 Swyer,Al, 83P(ab) Tang,J, 71P(ab) Tobin, M, 259P(ab) Tulchinsky,M, 121P(ab) Stowasser,0, 1OP(ab), Sy, WM, 17N(5) Tange,5, 174P(ab) Tochon-Danguy,Hi,1367 Tumeh,SS, 173 212P(ab) Sybirska,E, 102P(ab) Tangoren,A, 16P(ab) Toeniskoetter,PD, 86P(ab), Tune, LE, 5P(ab) Strakowski,5, 196P(ab), Sychra,ii, 188P(ab) Tanihata,5, 95P(ab) 87P(ab) Twig,CH, 71P(ab) 203P(ab) Sykes,T, 100P(ab),213P(ab) Tansey, W, 68P(ab) Tohyama,M@199P(ab), Turchi,5, 2032 Strand, 5-E, 448,9P(ab), Syravanh,C, 188P(ab) Taoka, Y, 59P(ab) 201P(ab) Turek, P, 117P(ab) 113P(ab), Syrota,A,981,1717,1739, Tarbell,Ni, 1045 Tokuda,T, 107P(ab) Turetsky, B, 2201 178P(ab),222P(ab) 1899,14P(ab),36P(ab), Tartaglia,D, 58P(ab) Tolbert, LC, 78P(ab) Turkington,TO,1587, Strandh, M, 160P(ab) 45P(ab), 78P(ab), 102P(ab), Tashiro,T, 2182 Tolkoff-Rubin, N, 250P(ab) 26P(ab), 81P(ab), 1O1P(ab), Strashun,A, 210P(ab), 109P(ab),124P(ab), Tateno, M, 2085,14P(ab), Tomiguchi,5, 1184, 190P(ab), 191P(ab) 233P(ab) 186P(ab),205P(ab), 42P(ab) 177P(ab),247P(ab) Turner, FE, 1140 Stratmann, HO, 85P(ab) 211P(ab) Tatsu, Y, 221P(ab) Tomiyoshi,K, 2085,42P(ab) Turpin,5, 118P(ab) Strauss, H, 24P(ab) Szabo, Z, 25P(ab),86P(ab), Tatum, JL, 153P(ab) Tommasino,C, 93P(ab) Tunis, D, 166P(ab) Strauss, HW, 17N(6),879, 199P(ab) Taylor,A, 1766,87P(ab), Tomomitsu,T, 208P(ab) Turzo, A, 12170e) 1282,1303,1309,1507, 251P(ab) Tompkins,RO, 1964,2130, Tutrone, RE, 123P(ab), 1529, 1616(le), 1825Qe), Taavitsainen,M, 1428 Taylor,A Jr., 467,39P(ab), 2176 221P(ab) 2130, 2253, 2264, 2274, Tada, M, 780,240P(ab), 129P(ab), 250P(ab) Tonami, N, 2089, 28P(ab), Tuvia,JE, 251P(ab) 15P(ab), 44P(ab), 244P(ab) Taylor,AM II, 23P(ab) 139P(ab), 223P(ab) Tweedle,MF, 1826(le) 104P(ab), 171P(ab), Tadamura,E, 6P(ab), Taylor, D, 246 Tondeur, M, 1223, 226P(ab) 172P(ab) 107P(ab),147P(ab) Taylor, 1W, 109P(ab) Tong,CKS,26P(ab) Uccelli,L, 18P(ab) Strauss, LO, 12, 1075, Tagare,H, 187P(ab) Taylor, M, 144P(ab) Toni, MO, 2032 Uchida,H, 229P(ab) 218P(ab), 220P(ab) Taillefer, R, 96P(ab), Taylor, 5, 7P(ab) Toorongian,SA, 1287 Uchida, Y, 211P(ab) @ Strazhnik,B, 115P(ab) 118P(ab), 121P(ab), Taylor, Topchil(,5, 33P(ab) Uchisako, H, 1980 Striano, 0, 137, 360, 140P(ab) Testes, CD, 162P(ab), Toppet, V, 1223 Udem, 5, 61P(ab) 154P(ab) Taillon,LA, 394,35P(ab), 230P(ab) Torizuka,T, 6P(ab), Udupa, iK, 124P(ab), Striepecke,E, 222P(ab) 130P(ab) Teerling,T, 649 107P(ab),147P(ab) 256P(ab) Stritzke,P, 77P(ab) Tajima,K, 234P(ab) Telepak, Ri, 2188 Tornai, MP, 180P(ab) Uebis, R, 23P(ab), 148P(ab) Stromswold,K, 57P(ab) Takagi,T, 815 Tellier, P, 865(le), 1825(le) Torres, 0, 1503,13P(ab), Ueda, R, 215P(ab) Strother, SC, 200P(ab), Takahashi,A, 24P(ab) Teoh, 5K, 723 145P(ab), 146P(ab) Ueda, 5, 431, 1543,26P(ab), 203P(ab) Takahashi,H, 2030, Teplick,RS, 250P(ab) Torn, 0, 93P(ab) 198P(ab),225P(ab) Stubbs, JB, 821, 1910, 198P(ab) TerIs,M, 1711,2064,2068, Tou, ZW, 179P(ab),245P(ab) Ueda, T, 301,2091 155P(ab),156P(ab), Takahashi,J, 780 3P(ab),21P(ab),107P(ab), Toudou, K, 2182 Uehara, T, 14P(ab),24P(ab), 158P(ab),159P(ab) Takahashi,M, 1184, 224P(ab) Touliopoulos,P,953 34P(ab),63P(ab),107P(ab), Studier-Fischer, B, 375 177P(ab),247P(ab) Terry, J, 7P(ab),251P(ab) Touma,H, 104 120P(ab),171P(ab), Studnicka,M, 1397 Takahashi,N, 32P(ab), Teule,OJJ,1706,82P(ab), Tow, D, 151P(ab),188P(ab) 207P(ab),209P(ab) Stuhimuller,JE, 1607 120P(ab),202P(ab) 11OP(ab),147P(ab), Townsend,CE, 1778, Uemura, K, 92P(ab), Subramanian,0, 97P(ab), Takai, M, 247P(ab) 154P(ab), 230P(ab) 138P(ab) 200P(ab) 135P(ab) Takaki,Y, 1184,177P(ab) Thakore, K, 87P(ab), Townsend,DW, 1367 Uezono, T, 59P(ab) Subramanian, M, 221P(ab), Takamiya,M, 1931 165P(ab) Tcyama, H, 1274 Ugur, 0, 106P(ab) 224P(ab) TakainOri,M, 223P(ab) Thakur, ML, 260,144P(ab), Tcyama,T, 55P(ab), Ungar, DR, 51P(ab), Sudati, F, 94P(ab) Takano, M, 98P(ab) 246P(ab) 120P(ab) 220P(ab) Suehiro,M, 120,25P(ab), Takashima,T, 139P(ab) Theiss, A, 87P(ab) Tran, 1W, 256P(ab), Unlenen,E,84P(ab) 126P(ab),234P(ab) Takata, 5, 1478 Theriault,C, 1927 260P(ab) UnIO, M, 84P(ab) Sueyosi,K, 221P(ab) Takatsu, H, 198P(ab) Thie, JA, 185P(ab) Trankie,C, 243P(ab) Uno, K, 211P(ab) Suga,K, 1980 TakeChi,T, 98P(ab) Thierauf,P, 37P(ab) Tranquart,F, 194P(ab) Unsal, IS, 84P(ab) Sugarbaker,PH, 804 Takeda, K, 180P(ab) Thjs, LO,230P(ab) Travis, Ml, 75P(ab),85P(ab) Urbain, D, 1642,99P(ab), Sugawara, Y, 19P(ab), Takei, Y, 1103 Thomas,FD, 992,97P(ab), Trebossen, R, 186P(ab) 166P(ab) 167P(ab) Takemoto,K, 1485 135P(ab) Treffert,ID, 175P(ab) Urbain,JL, 11P(ab) Sugii,A, 247P(ab) Takeuchi, A, 159P(ab) Thomas,JR. 90P(ab) Tremblay, J, 58P(ab) Urbain, JLC, 576 Sugiyama,A, 95P(ab) Taki, J, 1478,139P(ab), Thomas,PA,61P(ab) Trenkler,I, 48P(ab) Urbano-Marquez,A, 1452 Sub, .1-H,1987 223P(ab) Thomas,RO, 260P(ab) Trepashko,DW, 188P(ab) Ureles, AL, 1829(le) Suhara, T, 89P(ab) Takikawa,5, 180P(ab), Thomas,SN, 1778 Treves, 5, 151P(ab), Uren,R, 214,1827(k), Sumiya,H, 92P(ab) 209P(ab) Thomas,SR. 42P(ab), 177P(ab) 52P(ab) Sun, B-F, 28P(ab) Tall, JO, 227P(ab),259P(ab) 156P(ab),205P(ab) Treves, ST, 1045 Uren,RF, 1435 Sun, KT, 2038,4P(ab), Tamahashi,N, 103P(ab), Thompson,B, 256P(ab) Trimarco,B, 1602,1688, Urita, Y, 98P(ab) 50P(ab), 154P(ab), 244P(ab) Thompson, JF, 1435 147P(ab) Urtasun, RC, 885 183P(ab) Tamaki,i, 111P(ab), Thompson, NW, 13P(ab) Troup, C, 232P(ab) Usman, M, 190P(ab) Sun, WY, 184P(ab) 170P(ab) Thorpe, P, 251P(ab) Truckenbrodt,R, 219P(ab) Ussov, V, 43P(ab) Sunderland,J, 21P(ab), Tamaki,N, 839,1220(br), Thorson,A, 55P(ab) Truex, 01, 148P(ab) Uszler, M, 164P(ab) 50P(ab),55P(ab),238P(ab) 1672,2124,6P(ab), Thrall,J,1109,1119, Tsang, BW, 1127,79P(ab) Utsunomiya, K, 221P(ab) Sung,C, 1552,2559(ab) 107P(ab), 120P(ab), 16P(ab),17P(ab) Tsay, DO, 76P(ab) Uyan, C, 889 Supino, P0, 34P(ab) 147P(ab), 194P(ab) Thrall,JH,260P(ab) Tse, K, 1866,2049,76P(ab), Suresh,MR,126P(ab) Tamesis,BR, 85P(ab), Thrall, R, 244P(ab) 169P(ab) V. Schulthess, OK, 809, Susskind,H, 899,43P(ab), 120P(ab) Thron, A, 222P(ab) Tse, N, 137P(ab) 1%P(ab) 222P(ab) Tamm,C, 46P(ab) Thule,P, 165P(ab) Tseng,C-Y, 153P(ab) Vaalburg,W, 49P(ab), Sutor, R, 968, 36P(ab) Tamura, M, 2085 Thys,0,1642 Tsuchiya,K, 812 55P(ab),183P(ab), Suwondo, P, 190P(ab) Tamura,Y, 24P(ab) Tibben,C, 247P(ab) Tsuda, T, 19P(ab),167P(ab) 219P(ab),225P(ab), Suzuki,H, 42P(ab) Tan,JC,46P(ab) Tilbury,R, 33P(ab),42P(ab), Tsuhi,A, 1184 241P(ab) Suzuki,T, 14P(ab) Tan,P. 1752 55P(ab),68P(ab) Tsui, BMW, 20P(ab), Vafaee,M, 51P(ab), Swahn, C-G, 7P(ab), 89P(ab) Tanabe, H, 207P(ab) Tillman,JU, 131P(ab) 27P(ab),30P(ab),72P(ab), 181P(ab), Swanson,D, 231P(ab) Tanada, 5, 19P(ab), Ting,Y, 188P(ab), 192P(ab) Vagg, R, 53P(ab), 54P(ab), Swarna, US, 3P(ab) 167P(ab),222P(ab) Tintner, R, 11SP(ab) Tsui,W-H,2019 61P(ab),94P(ab) Swayne, LC, 61, 53P(ab), Tanahashi,K, 234P(ab) Tisselli,A, 44P(ab) Tsuji,5, 92P(ab),197P(ab) Vaidyanathan,0, 191P(ab), 54P(ab),61P(ab),94P(ab) Tanaka,A, 6P(ab) Tittel, K, 1403 Tsuruo,T, 114P(ab) 218P(ab) Swenson,L, 262P(ab) Tanaka, F, 201P(ab) Tjuvajev, J, 1152, 37P(ab) Tsutsumi,K, 1984 Valance,I, 116P(ab)

AuthorIndexâ€¢1993 2295 VaidMa

Valdivia,5, 455,1905, Vanregemorter,J, 186P(ab) Visser,FC, 649, 15P(ab), Walter, K.A, 228(ab) Weinstein,iN, 1552, 62P(ab),71P(ab),157P(ab), van Rensburg, Al, 330 147P(ab),154P(ab) Waither,MCM,173 215P(ab), 216P(ab) 176P(ab),196P(ab), van Rijk, PP, 22P(ab), Visser,0, 1706,1953, Walzer,PD, 61P(ab) Weise, 5, 51P(ab), 71P(ab) 249P(ab) 170P(ab), 179P(ab), 147P(ab) Wand, 0, 132P(ab), Weisman,HF, 234 Valette, H, 1739,1899, 223P(ab),227P(ab) Visser,OM,49P(ab), 133P(ab), Weiss,M, 1OP(ab),212P(ab) 14P(ab), 45P(ab), 124P(ab) van Roermond,PM, 225P(ab), 241P(ab) Wang,D, 97P(ab) Weissleder,R, 39P(ab) Vallabhajosula, @,1536, 227P(ab) Visser,Ti, 2025,165P(ab) Wang,F, 1246,148P(ab) Weissman, A, 43P(ab), 61P(ab),66P(ab),67P(ab), van Royen, EA, 2076, Vleugels,5, 11OP(ab), Wang,0-i, 609,18P(ab), 11OP(ab) 83P(ab), 104P(ab), 41P(ab),207P(ab), 222P(ab) 67P(ab), 102P(ab), Weissman,AF, 958 156P(ab) 209P(ab), 225P(ab) Vo, C, 235P(ab) 103P(ab),131P(ab), Weissman, DE, 961 vanAswegan,A, 963 Vansant,i, 165P(ab) Vogt-Mcykopf,I, 21P(ab) 197P(ab),200P(ab), Welch,AE, 71P(ab), van Aswegen,A, 330 VanScoy-Mosher,M, Voipio-Pulkki,L-M, 2064, 243P(ab) 187P(ab) van Beek,FiR, 1834(le) 139P(ab) 2068, 3P(ab), 107P(ab) Wang, H, 1OP(ab),80P(ab), Welch,Mi, 1728,18P(ab), VanBrocklin, HF, 79P(ab) Van Sickk, I(L, 255P(ab) Volkert, WA, 38P(ab), 195P(ab) 28P(ab), 49P(ab), 56P(ab), VanBuren,DH, 2185 Van Steelandt,H, 12170e) 232P(ab), 248P(ab) Wang, iK, 176P(ab), 59P(ab),69P(ab),79P(ab), Vanbutsek, R, 86P(ab) VanTosh,A, 193 Volkow,ND, 246,609,619, 185P(ab) 81P(ab), 89P(ab), 134P(ab), VanCamp,0, 152P(ab) VanTrain,K, 64P(ab), 18P(ab), 40P(ab), 43P(ab), Wang,P. 204P(ab) 160P(ab),216P(ab) VanCauteren,J, 576 148P(ab) 67P(ab), 78P(ab), 102P(ab), Wang,PJ,65P(ab) Weilman,HN, 381 VanCauteren,JLUJ, VanTrain, KF, 1494 103P(ab),131P(ab), Wang,R, 109P(ab) Welsh,P, 218P(ab) 1OP(ab) VanTrigt,P, 39 200P(ab) Wang,5, 31P(ab),243P(ab) Welt,5, 83P(ab) Vance, ML, 162P(ab) vanUrk,H, 873 vom DaM,J, 23P(ab), Wang,S-J,71, 1918, Wen,PYC,241P(ab) van de Flierdt, E, 41P(ab) Vanuzzo,D, 126P(ab) 155P(ab) 167P(ab),208P(ab), Wendt, R, 175P(ab), VandenAbbeek,AD, 1175, van Waarde, A, 49P(ab), Vonorta, K, 249P(ab) 228P(ab),245P(ab) 186P(ab) 123P(ab),221P(ab), 183P(ab),241P(ab) Voong,C, 163P(ab) Wang,TST, 99P(ab) Weng, Y, 80P(ab) 241P(ab),246P(ab), Vanzetto,0,57 Verne,M, 1428 Wang, YL, 228P(ab) Wensveen,M, 1367 247P(ab) Vaquero,ii, 178P(ab) Votaw,DB, 158P(ab) Wanklin,Ri, 235P(ab) Wenzel,KW, 164P(ab) Vandenbosch,WA, 41P(ab) Vardareli,E, 889 Votaw, JR, 826, 86P(ab), Ward,Ri, 2095 Weprin, R, 8P(ab) vandenBmek,WJM, Vargas-Cuba,R, 172P(ab), 132P(ab),158P(ab), Warnaar,5, 247P(ab) Werner,OS, 153P(ab) 112P(ab) 214P(ab),224P(ab) 202P(ab) Warnick,A, 164P(ab) Werns,5, 36P(ab) vandenHoff,i,1770 Varma,VM, 2169,165P(ab) Vriesendorp, HM, 938, 2152 Warren, FD, 234 West,JH, 658 VandenMaegdenbergh,V, Varrella,P, 12P(ab),42P(ab), Wartski,M, 229P(ab) Waster,Hi, 80P(ab) 576 82P(ab),115P(ab), Wackers,FiT, 1254,1877, Washburn, LC, 42P(ab), Westera,0, 1%P(ab) Vanderheyden,JL, 135P(ab) 219P(ab) 44P(ab), 84P(ab), 97P(ab), 120P(ab), 248P(ab) Wetzel, LW, 262P(ab) vanderMeer,J,1621 Vasile, R, 47P(ab) 257P(ab) Waskin,HA, 567 Wheatley,J,127P(ab) van der Meer, JWM, 62P(ab) Vazquez, IC, 112P(ab) Wade,A, 41P(ab) Wasserkben, V, 75P(ab) Wheeler, Wi, 240P(ab) van der Pluijm, M, 2025 Vekemans, MC, 576, 1OP(ab) Wagner,uN ir, 120,165, Watanabe,A, 208P(ab) White,CL Ill, 115P(ab) Vanderschot, P. 141P(ab) Veklerov,E, 1198 17N(8), 27N(9) Watanabe,K, 2091,222P(ab) White,0, 52P(ab) van der Sluys Veer, A, 1052 Veksler,A,853 Wagner,HN Jr., 18P(ab), Watanabe,N, 2085,42P(ab) White,J, 241P(ab) VanderVusse,OJ,649 Velasquez-Rocha, Si, 25P(ab), 86P(ab), 143P(ab), Watanabe,5, 95P(ab) White, MP, 97P(ab) van der Wall, EE, 737 46P(ab) 197P(ab),199P(ab), Watanahe,T, 71P(ab), White,SB, 73P(ab) van der Zant, FM, 41P(ab) Ven,M, 112P(ab) 234P(ab) 113P(ab), 182P(ab) White,TA, 474 Vandevivere, J, 186P(ab) Ventura, B, 193 Wagner-Manslau, C, Watanabe,Y, 139P(ab), Whiteman,ML, 261P(ab) van Dijk, A, 223P(ab) Venz,5, 164P(ab) 41P(ab),63P(ab) 223P(ab) Whiting, JH, 62P(ab), van Dongen,A, 227P(ab) Vera, P. 205P(ab) Wahl,RL, 75,414,773,787, Watkins, OL, 181P(ab), 249P(ab) van Dongen,0, 1953 Verani, MS. 3P(ab), 54P(ab), 958, 1147, 1190, 1420, 185P(ab) Whiting, IH ir, 128, 1389Qe), VanDort,ME,8P(ab), 75P(ab),95P(ab) 2279Qe),6P(ab),41P(ab), Watson, C, 172P(ab) 2135 236P(ab) Verbanck, @,1859 43P(ab), 73P(ab), 74P(ab), Watson, DD, 728, %P(ab) Wichter,T, 3P(ab) VanDyck,ai, 48P(ab) Verbruggen,A, 11OP(ab), 93P(ab),104P(ab), Watters, OV, 226P(ab) Wiebe,U, 405,885 van Eck-Smit, BLF, 737 129P(ab),210P(ab) 106P(ab),113P(ab), Waxman,A, 37P(ab), Wieland,D, 13P(ab),45P(ab) Vang,M, 256P(ab) Vergara,E, 12P(ab), 127P(ab),223P(ab), 77P(ab), 139P(ab), Wieland,DM, 1287,13P(ab), Vanhagen,PM, 118P(ab) 42P(ab),82P(ab),11SP(ab), 224P(ab), 245P(ab) 168P(ab) 25P(ab),123P(ab), van Heerden, B, 228(ab) 213P(ab), 219P(ab) Wahner,HW, 11OP(ab), Waxman,AD, 18 135P(ab), 220P(ab), VanHeertum,P1, 61, Verhoeff, NPLG, 2076, 141P(ab), 142P(ab) Wazer, DE, 953 236P(ab) 48P(ab),60P(ab),99P(ab), 41P(ab), 207P(ab), Wakasugi,5, 1282,1529, Webber,MM, 122P(ab) Wienhard,K, 1O1P(ab) 125P(ab) 209P(ab) 15P(ab) Webbon,PM, 222 Wiens,RD, 85P(ab), van het Schip, AD, 223P(ab) Verley,0, 194P(ab) Wakeman, J, 77P(ab) Weber, C, 165P(ab) 120P(ab) VanHorn,3D,228P(ab), Vermey,A, 55P(ab) Wakisaka,5, 2091 Weber, DA, 899, 9P(ab), Wiersinga,WM,41P(ab) 67P(ab) Vermorken,JB, 82P(ab) Wakita, K, 431, 1543, 43P(ab),60P(ab),222P(ab) Wiesnewsld,0, 108P(ab) van Huffekn, AC, 22P(ab) Vernon, C, 1031, 1839 26P(ab), 198P(ab), Webner, P, 465 Wight,JN Jr., 65P(ab) van Isselt, 1W, 22P(ab), Verspaget,HW, 1052 225P(ab) Wegeius, U, 2064, 2068, Wihship,Mi, 172P(ab) 170P(ab) Veyre, Al, 255,1260,1949 Walker,BS, 1239,23P(ab) 3P(ab),21P(ab),107P(ab) Wijngaarde,R, 41P(ab) vanKaick,0,48,1075, Vezina,0, 52P(ab) Walker, KZ, 153P(ab) Weiden,PL, 908,2111 Wijns, W, 15P(ab), 44P(ab), 21P(ab),139P(ab), Vezzoli,M, 154P(ab) Walker, RW, 190P(ab) Weigand,H, 1403 86P(ab), 121P(ab) 218P(ab), 220P(ab) Viacava,P, 1175 Wallace, E, 31P(ab), Weiller, C, 58P(ab) Wilder,5, 246P(ab) van Leeuwen, OR, 147P(ab), vl_, A, 161P(ab) Weinberger,DR, 67P(ab), Wilkinson,R, 1282,1303, 154P(ab) Vigushin, DM, 118P(ab) WaIIiCh, R, 220P(ab) 228P(ab), 235P(ab) 1309,1529 van Lier, JE, 49P(ab), Villa,E,94P(ab) Wallis,i, 34P(ab) Weindi, A, 32P(ab) Wilkinson,RA, 39P(ab), 1OIP(ab) Villanueva-Meyer,i, 187 Wallis,iW, 1793,20P(ab), Weiner,M, 1326 83P(ab), 171P(ab) van Lingen, A, 11OP(ab), Villegas,Bi, 14P(ab), 106P(ab),154P(ab), Weiner,MF, 115P(ab) Wilkmsen,ATM, 183P(ab), 147P(ab), 230P(ab) 130P(ab) 176P(ab), 192P(ab) Weiner, R, 351(le), 244P(ab), 219P(ab), 225P(ab) van Luijk, WHJ, 354(le) Viliringer,K, 63P(ab) Walovitch,RC, 199P(ab) 245P(ab) W@illett,GD, 232P(ab) VanNerom,C, 129P(ab) Vilner,RI, 2169 Walsh,iF, 36P(ab),86P(ab), Weinheimer,Ci, 86P(ab), Williams, CC, 469 Vannoy,SD, 60P(ab) Violi, F, 67P(ab) 87P(ab) 87P(ab) Williams,Di,1163 van Osdol, WW, 1552 Virzi,F, 109,1618(k), Walsh,RA, 1520,120P(ab), Weinstein, H, 1510, 1722, Williams,H, 251P(ab) Van Pachterbeke,1, 1223 59P(ab) 153P(ab) 46P(ab) Williams,ii, 1O1P(ab)

2296 TheJournalofNudearMedicine @an

Williams, iR, 938, 2152 Wong,CrC, 899 Yamamuro,1, 1745 YOshitake,A, 932 Zenorini, A, 5P(ab) Williams, iS, 256P(ab) Wong,CY, SP(ab),143P(ab) Yamanouchi,N, 211P(ab) Young,AR,241P(ab) Thang, a;, 250P(ab) Williams, KA, 394, 35P(ab), Wong,DF, 40P(ab), Yanagimoto,5, 208P(ab) Young,H, 243P(ab) Thang, HZ 53P(ab) 130P(ab) 109P(ab),132P(ab), Yang,D, 26P(ab),55P(ab) Young,JK, 29P(ab) Thang, i, 37P(ab), 56P(ab), Williams,LE,1294 133P(ab), 197P(ab), Yang,HI, 212P(ab) Young,TM, 193P(ab) 94P(ab), 114P(ab), Wilhiard,W, 11P(ab) 198P(ab) Yang,S-O, 83P(ab) Younis, LT, 85P(ab) 127P(ab),213P(ab), Wilson,A, 228(ab) Wong,F, 26P(ab),33P(ab), Yang, WS, 130P(ab) Yrizzaiy,i, 249P(ab) 255P(ab) Wilson,DA,244P(ab) 42P(ab), 55P(ab), 68P(ab), Yang,Z-Y, 239P(ab), Yu, D-C,679,70P(ab), Zhang,L,187P(ab) 204P(ab), 206P(ab) 183P(ab),185P(ab), Wilson,DW, 20P(ab) 243P(ab) Zhang, Y, 9P(ab), 190P(ab) Wong,WH, 33P(ab), 202P(ab) Wilson,MA, 143P(ab) Yaoita,H, 1303 Zhang, Z, 255, 1949 42P(ab), 55P(ab), 68P(ab), Yu,iN, 182P(ab) Wilson,ME, 148P(ab) Thang,ZM,242 102P(ab),206P(ab) Yasillo, NJ, 112P(ab) Yu, MD,238P(ab) Wilson,RA, 1518 Woo, DV, 99 Yasuda, T, 2227 Yu, SM, 138P(ab) Zhao, XD, 30P(ab) Wilson,T, 109P(ab) Woo, P, 118P(ab) Yasuhara,Y, 200P(ab), Yu, X, 182P(ab) Thou,T,58P(ab) Winder,DP, 137P(ab) Woo,TK, 100P(ab) 201P(ab) Yuan, A, 93P(ab) Thu,X,208 Windham,JP, 97P(ab) Woods,R, 86P(ab) Yasunaga,K, 119P(ab) Yuan,i,38P(ab) Thu, YY, 303, 64P(ab), Winn,HR, 62P(ab) Woods,5, 102P(ab) Yeh,5, 11P(ab),37P(ab), Yuasa,T, 170P(ab) 95P(ab) Wâ€¢mnard,P,59P(ab) Woolfson,RO, 1163 56P(ab), 145P(ab) Yuille,DL, 955,1748, Zhuang, 72, 89P(ab) Wâ€¢mnard,P ir, 109, 1618Qe) Worsley, DF, 1612,1851, Yeh, SD, 38N(12) 151P(ab) Ziady,0,1695 W@ioland,M, 1410 16P(ab),17P(ab),121P(ab), Yeh, SH, 76P(ab),138P(ab), Yung, A, 55P(ab), 204P(ab), Ziegler,R, 1039 Wironen, i, 1722, 46P(ab) 229P(ab), 230P(ab) 143P(ab), 145P(ab), 206P(ab) Ziegler,5, 12 Wise, 5, 88P(ab) Worth, JI@,203P(ab), 167P(ab),176P(ab), Yung, BCK, 762,1701, Ziessman, HA, 227P(ab), Wiseman,GA, 12P(ab) 212P(ab) 185P(ab),208P(ab), 76P(ab),109P(ab), 259P(ab) Wishart,JM,582 Worthy,M, 44P(ab), 228P(ab), 238P(ab), 132P(ab),133P(ab), Zilbovicius, M, 78P(ab), Wisniewski, 0, 161P(ab), %P(ab), 146P(ab) 245P(ab) 197P(ab) 205P(ab) 211P(ab), 258P(ab) Worthy,MA,281 Yelon, WB, 231P(ab) Zilkruelo, 0, 249P(ab) Withers,5, 242P(ab) Wortzman, 0, 204P(ab) Yemul, 5, 99P(ab) Zimmerman, RE, 179P(ab), Wright, LM, 54P(ab), Zafrani,E-S,2105 Wittry, MD,85P(ab), Yen,SH, 145P(ab) 203P(ab), 212P(ab), 149P(ab) Zafrir, N, 152P(ab) 120P(ab) Yeung, DW, 122P(ab) 259P(ab) Wu,C, 40P(ab),112P(ab), Zalutsky,MR, 1OP(ab), Wlodkowski,Ti,61 Zingraff,i,128P(ab) 186P(ab) Yki-iSzvinen,H, 107P(ab) 79P(ab), 99P(ab), 191P(ab), Woda, A, 506,1866, Wu,JC,237P(ab) Yoder, iii, 255P(ab) 216P(ab),218P(ab) Zinn, KR, 28P(ab), 81P(ab), 48P(ab),76P(ab) Wu, LC, 138P(ab),176P(ab), Yokoi,T, 498 Zamora, P0, 231P(ab), 134P(ab),216P(ab), Wojno,T, 467 185P(ab) Yokota, I, 1931 244P(ab), 246P(ab) 238P(ab) Wolber,0, 218P(ab) Wu,IL, 138P(ab) Yokoyama,A, 932,29P(ab), Zan&ZM,268 Zito, F, 5P(ab), 94P(ab) Wolf,AP, 246,609,619, Wuilner,U, 202P(ab) 59P(ab),234P(ab) Zanal, I, 171P(ab) Zlotikamien, B, 152P(ab) 18P(ab),67P(ab),69P(ab), Wynick,D,41P(ab) Yokcyama,I, 181P(ab), Zanzon@, PB, 66P(ab), Zoghbi,5, 31P(ab),48P(ab), 78P(ab),102P(ab), Wynsen,iC, 94P(ab) 182P(ab) 133P(ab) 90P(ab), 102P(ab), 103P(ab),131P(ab), Yokoyama,K, 28P(ab), Zaret,BL,1254,1877, 108P(ab),201P(ab), 237P(ab) 139P(ab),223P(ab) 84P(ab), 97P(ab) 211P(ab), 243P(ab) Wolf, F, 92, 37P(ab), Xu,i, 20P(ab) Yonekura,Y, 839,1672, Zasadny,K,41P(ab), Zonnenberg, BA, 223P(ab) 47P(ab),172P(ab), Xu, X-L,200P(ab) 6P(ab),107P(ab),120P(ab), 74P(ab),127P(ab),224P(ab) Zubal,0,125P(ab), Zasadny,KR,1420 207P(ab) 147P(ab), 194P(ab), 161P(ab),178P(ab), Zea-Ponce, Y, 31P(ab), Wolf, i.E. 57 201P(ab) 187P(ab),205P(ab) Yacoub,T, 233P(ab) 48P(ab), 90P(ab), 102P(ab), Wolfangel, RG, 38P(ab) Yadegar,J, 18, 139P(ab) Yoo, HS, 167P(ab) 108P(ab),109P(ab), Zubal, 10, 1390(le), 1416 Wolfe, E, 336, 35P(ab) Yagyu,T, 198P(ab) Yoo, K, 131P(ab) 211P(ab),243P(ab) Zubieta, iK, 108P(ab) Wollenweber,SD, 181P(ab) Yamada, 5, 419, 103P(ab), Yorkston,i, 100P(ab) Zeffiro, T, 70P(ab) Zuckier, IS, 1835(k), Wohner, I, 85P(ab) 240P(ab), 244P(ab) Zemacnlk,PC,232P(ab) 250P(ab) Woloszczuk,W, 1039 Yamagami,H@34P(ab) 7.eng, OL, 19P(ab), 30P(ab), Zwas, SI, 82P(ab) WOhild, A, 92 Yamaguchi,K, 780 71P(ab),80P(ab),81P(ab), Zweit,J, 243P(ab) Walters, BC, 207P(ab) Yamamoto,K, 2182,6P(ab), 1%P(ab) Zwinderinan,All, 737 Woltz, M, 1397 120P(ab) 7.cnh,OL,191P(ab)

AuU@orIndexâ€¢1993 2297 A Alcohol intra-abdominal massive deposit, absorption,erythromycineffectson, 582 ACMUI. See Advisoty Committee on the Medical @Fc(V)DMSAuptake in, 815 Use of Isotopes effectsof detoxificationon regionalbrain Anderson, Carolyn 1., Medi-Physics Award, ACNP.See AmericanCollegeof Nuclear â€”metabolism,409(ab) 22N(7) Physicians effectson brain, 798 â€” @muaod@@as(AIDS).See regional cerebral blood flow SPEC!' in chronic comparedwith sensitivityof dual isotope dcc Human immunodeficiency virus alcoholism,relationto perfusionimagingfor detectionof (H@ neuropsychologicaltesting, 1452 specific atherosclerotic lesions, 254(ab) cerebralinfectionsvs. lymphomain, accuracy Algorithms coronary of PETFDGstudiesindistinguishing, backpr@ectionfiltering,for variabk focalkngth normal, reversible @Â°â€˜T1perfusion defects in 142(ab) collimator, 320(ab) right bundle branch block and, 1218(le) classificationof AIDSdementiacomplexbrain diagnostic, uniformity oflung scan prognostic efficacy in patients with and perfusionpatternby qualitativeand interpretation and, 661 withoutpriormyocardialinfarction, quantitative SPECF, 964(ab) expectationmaximization,madepracticalfor 127(ab) lymphomavs. nonmalignantCNS lesionsin, clinicaluse in SPECFby Tanaka's @nary filterediterativereconstructionmethod, FDO-PETin differentiation,567 prevalence of thromboembolic disease in prospectiveevaluationof sequential @Â°â€˜11 68(ab) patients with intermediate probability chlorideand 670a-citratescans in, expectationmaximizationreconstruction, lung scans, 55(ab) 834(ab) frequency-domainbehaviorof, 846(ab) SPECF/MRbrain imagefusionin AIDS fast 3-Dreconstruction,for PET, 546(ab) regionaldistributionof pulmonaryemboli, dementiacomplex,999(ab) fast iterativereconstruction,for cone beam 56(ab) Adenocardno.ua SPECF, 317(ab) serial,recoveiyofmyocardialfunction humancell line, early responseto radiotherapy, iterative reconstruction followingcoronaryrevascularization, assessment of agents for monitoring, 773 is the slow way really best?, 913(ab) 84(ab) ovarian, xenografts of, intra-tumoral distribution with naturalpixel basis, 66(ab) @phy,rathonud@e of 2-DOand monoclonalantibodiesin, noise and spatial resolution properties of firstpass, with new highperformancesingle autoradiographic evaluation of, 75 ML-EM reconstructedimages,69(ab) crystalcamera,741(ab) M@oma practical,for assessingfloodfielduniformityin first-pass parathyroid clinicalnuclearmedicine,847(ab) quantitative measure of left ventricular comparative study of @â€˜I@csestamiW@Â°!fl three-dimensionalBayesianreconstructionfor systolic and diastolic performance, with @Fcpertechnetate subtraction SPECI@,70(ab) 130(ab) scintigraphy and ultrasonography in weightedkast squares-conjugategradient,for 99mTc,left ventricular function, 394 localization of, 804(ab) SPEcr, 98(ab) MIBO evaluation as potential tracer for relative 20!n and @FcMIBI uptake in, Mk@ monitoringdoxorubicincardiomyopathy, 807(ab) human cardiac transplant, evaluation of 1282 pituitary vasculopathyby @Â°â€œTcteboroxime systolicpressurealterationeffecton combineduse of him PAOand3-stepISO washout,734(ab) measurements of left ventricular filling with anti-CgA monoclonal antilxxly in renal, MRI and SPEC!' bone scans, 381 dynamics,747 diagnosis of, 456(ab) Mzholm&sd@es@ Anglosarcomi, Scintigraphic â€œdoughnutsignâ€•on imaging using @Fc(V)DMSA, 160(ab) ageof onset of, effecton regionalcerebral skeletalimaging,297 thyroid, unusual scintigraphic findings, 465 glucosemetabolism,7(ab) Animal-remains disposal, cost is reducible, 30N(8) @ Adeoosine, 20vfl 5p@, comparison of results probable Aolms@ using four- vs. six-minute infusion comparabilityof FDO PEF studiesin, 7(ab) high resolution pinhole SPECF for imaging, protocol,737(ab) differentialdiagnosisusingNeuroSPECTand 27(ab) Adherence, WBC, quality assurance of labeling neuropsychologicaltests, 460(ab) high resolution slit aperture for SPECF imaging, with test based on, 345 high resolution @FcHMPAO vs. FDO PET 26(ab) in,10(ab) @ Mnn@ pinhole collimation for ultra-highresolution, mildto moderatedegreeof â€˜@IMIBOuptake regional cerebral blood flow in, major SPECF studies, 29(ab) mustbe carefullyinterpretedfor depressionvs., 1090,1101 whole body cylindrical detector for imaging, diagnosisof phnochromocytoma,39(ab) regionalglucosemetabolicactivityin, paragangliomas,â€˜@â€˜IMIBOscintigraphyin quantitationof, after correctionfor 25(ab) preoperativeand postoperative effectsof atrophy,8(ab) Antibodies. See aLso Monoclonal antibodies evaluation,173 response to visual cognitive stimulation anthnyosin,imagingfor identificationof catheter Adrtamydui.SeeafroDoxorubicin assessedby @FcHMPAO in,1l(ab) ablationinducedmyocardialnecrosis, cardiomyopathy, myocardial substrate AmericanCollegeOtNudearPliysidans(ACNP), 256(ab) utilizationand leftventricularfunctionin, government relations update, 22N(4), antithyroidhormoneautoantibodies,antigen 52(ab) 19N(7) responsiblefor formationof, 506(ab) Ad@ Committee on the Medical Use of Isotopes AmericanSocietyOtNucIsarCard1oIo@y(ASNC), directlyandindirectly@fclabeled,109 (ACMUI), 20N(7) formation, 28N(4) DTPA-conjugated,semi-preparative Aging.SeeaLcoEJdCIiy Ameridum-241,comparedwith Â°Â°â€œTcas isoelectrophoresis leads to isolation of comparisonof clinicalpresentationand outcome transmissionsourceforattenuation antibodyisoformswith different of pulmonaryembolisminyoungervs. correctionof x*fl cardiacSPECF, immunoreactivities, 1146(ab) older patients, 1073(ab) 113(ab) guided therapy of CEA positive tumors using effectof ageof onset on regionalcerebral Amlodaroiie,andmyocardialuptakeof1@IMIBO biotinylated monoclonal antibodies, glucosemetabolismin Alzheimer's inleftventricularhypertmphysecondary avidin and 90Y-DOTA-biotin, 373(ab) disease,7(ab) tovalvularaorticstenosis,57 â€œ11nCilOradioimmunoscintigraphyin effectof aminoacidtransportfrombloodto colorectalcarcinoma,1656 brain in humans using â€˜@Fphenylalanine, dialysis-related, metabolic studies of novel biological method to evaluate chelating 951(ab) radioiodinated serum amyloid agents for labeling of, with metallic AIDS.See Acquiredimmunodeflciencysyndrome P-componentand, 513(ab) radionucides, 230(ab)

2298 TheJournalofNudearMedicine Blood flow

radiolabeled,simpleTLC assay to assess channel ratio method for radionucide image Beizod1sie@,receptors percent immunoreactivefractionof, quantitation,330 bindingcomparedwith cerebralperfusionin 1079(ab) inclinicalcardiacSPECF,111(ab) gerbilbrain after transientischemia, @Â°â€œTcand IsoRe labeled, can blood retention be comparisonof Am-241and @Â°â€œTcas 955(ab) @ predictedin vitro by challengewith transmissionsourcesfor, in @@11 1231Iomazenil SPEC@ in presurgical work-up of cysteine?, 1142(ab) SPECF, 113(ab) patientswith medicallyintractablefocal @Fcantigranulocyte antil,odyftugment, count-limitedtransmissiondata in PET, 143 epilepsy, 80(ab) immunoscintigraphyof infection,240(ab) emissionbased techniquefor obtainingdata for 1231lomazenil study of cerebral distribution in @Â°â€œTclabeled, 1617(le) myocardialSPECF studies,898(ab) anxietydisorders, 181(ab) can cysteine-challengeassay predictin vivo new selectiveradioligandsfor examinationof, evaluationof new post-reconstructionmethod stabilityand biodistributionof?, 231(ab) 352(ab) Antiferritinantibody,evaluationof â€˜@â€˜In@and forquantitativeSPECF,916(ab) potentialimagingagentfor SPECI' Â°Â°Y-labeledlinker-immunoconjugatesin fast transmissionCI' for determiningattenuation investigationsof, 932 nude mice and dogs, 938 mapsusingcollimatedlinesource, quantificationin vivo in humanbrain, 433(ab) An@n rotatabk air-copper-lead attenuators and regionalalterationof distributionin refractory antibodyimagingfor identificationof catheter fan-beamcollimation,1577 tem@ lobe epilepsy revealed by group ablationinducedmyocardialnecrosis, importanceof attenuationcompensationand its averagingtechniques,81(ab) 256(ab) implementationin cardiacSPECF regionaldiscordancebetweendistributionand â€˜111n,cardiOtoxicityassessmentby imaging,110(ab) glucosemetabolismin ischemic bolus administrationvs. continuousinfusion measurementswith positiongatingand cerebrovasculardisease,977(ab) of doxorubicin,43(ab) time-of-ffightwindowingto reject Be*IOe-YsIOWAWard,MichaelJay and Robert K. 1231MIBO vs., 44(ab) emissionevents frompatient,543(ab) Mansfield,30N(7) @Â°â€œTc-iabeled,recombinantsingle-chainFv, noiseand spatialresolutionpropertiesof BGO blockdetectors,rotatingPET scannerusing, rapidinfarctimaging,234 ML-EMreconstructedimages,69(ab) 1367 Anti-senseollgonucleotldes,use to predict non-uniform Bile.See aLsoHepatobiliazytract chemotherapyresistanceof tumors, for quantitativethorax SPECFbased on lung leakfromgallbladderperforationmimicking 23N(5) emission,908(ab) bowelactivityand false-negativeresult in Arsenic-fl, for therapy, dosimetricbasis of, techniqueforfilteredbackprc@ection,920(ab) morphine-augmentedcholescintigraphy, 789(ab) non-uniformcompensationfor @â€œTccardiac 131 SPECTusingacquiredtransmissiondata, B1ot1n@ilstedlodo-polyjymlne,for pretargeted cerebral 112(ab) radiationdelivery,1147 Blastos@ycosls,NorthAmerican posterior,infarction,and relatedvisualfield PET, noisereductionby maximumlikelihood â€¢7Ga-citrateandboneScintigraphy,458 defects, SPECT and MRI in, 1009 histogramsharpeningof attenuation @ SPECF HMPAOand balloontest occlusion, successful67@ of, 958 images,101(ab) predictingtoleranceprior to permanent Bleed flow occlusionof, 1243 planar,of geometricmeanimages,237(ab) accuratelocalmeasurementswith dynamic coronary, transientocclusion,simultaneous post-reconstructionartificialneuralnetworkfor, PET, fast determination of input function assessmentof myocardialperfusionand in SPECF, 67(ab) delayand dispersionby multilinear leftventricularfunctionduring,1(ab) pulsetransmission,with cone-beamSPECF, minimi7ation,1770 examinationof errors introducedby alternative 927(ab) automatedanalysisprogramfor evaluationof approachesto characterizationof arterial scanninglinesourcefor simultaneousemission PET studies, 968 inputfunctions,884(ab) and transmissionmeasurementsin cerebral noninvasive monitor, for quantitative â€˜@Owater SPECF, 1752 abnormalregionalresponseto auditory bloodflowstudies, 1000 Atteuiaa*loiscam, PET, cardiac,three-dimensional stimulationin childhoodautism,307(ab) plasma,modelingapproachto eliminateneed to registrationof, 311 duringbehavioralchallengeinobsessive separate, in â€˜@oinhalatiOnPET, 1333 Autoimminity,nuclearimagingof toleranceloss in com@ve disorder,180(ab) plasma activity curve for PET measurement of autoimmune mice, 227(ab) andbenzodiazepinereceptorin animalmodel regionalcerebralmetabolicrate for for Alzheimcr'sdisease, 943(ab) glucose,152(ab) changesin localcerebralglucoseutilizationin couplingwithglucosemetabolismin radial,effectof smear-correctingbloodactivity awakerat duringacute and chronic Alzheimer'sdisease, 463(ab) curveson FDO-PETmeasurementsof ethanoladministration,793 doubletracer autoradiographyusing1-125 cerebral metabolic rate for glucose, double tracer, using â€˜@IIcmazenil and @Â°â€œâ€œFc lomazeniland Â°Â°@cHMPAOin %2(ab) HMPAO in experimental brain isChemia, experimentalbrain ischemia,935(ab) trial arterialocclusion,brainbloodflowSPECF 935(ab) dynamicquantitative133XeregionalSPECF in,1239 dualisotopeanalysisofeffectsofdecreased on PRISM3-headedtomograph,266(ab) Artificialneuralnetwork flowon benzodiazepinereceptortracer effect of hyperca@ and hyperventilation in classifierfor MAO3renogramanalysis,844(ab) uptakein rat brain, 953(ab) moyamoyadisease,246(ab) post-reconstruction,for compensationof dual tracer, of cerebralacetatemetabolism, evaluationin acute and subacuteclosed-head collimator,attenuationand scatter effects 936(ab) injuryby meansof @TcHMPAO inSPECr,67(ab) evaluationof intra-tumoraldistributionof 2-DO SPECF, 998(ab) Ascorbiaadd, as radioprotectoragainstâ€˜@â€˜I,637 and monoclonalantibodiesin xenografts genderdifferenceswithPET,264(ab) Asiaand OceaniaCongressInNuclearMedicine of humanovarianadenocarcinoma,75 ictalregionalSPECF in temporallobe and Biology,scientifichighlights,17N(5) Avascularnecrosis epilepsyrelativeto surgicaloutcome, ASNC.See AmericanSocietyof Nuclear earlydetectionof, animalmodelof, 71@ab) 82(ab) Cardiobgy MRIand SPECFbone scans in renalallograft in locked-in syndrome, 291 Astatine-211, measuring distributions with SPECF, recipients,381 in major depression vs. Alzheimer's disease, 911(ab) 1090,1101 Atrephy,quantitationof regionalglucose mildto moderateregionalabnormalities, metabolic activity in Alzheimer's disease B 99@@FcECD vs. 133XeSPECF in, 747 after correction for effects of, 8(ab) noninvasiveregionalmeasurementsusing Mtomm@onco@ Bayesianreconstnictioa,three-dimensional,for Â°@â€œTchexamethyipropyleneamine can liquidsbe used to predictabnormalsolid SPECT, 70(ab) oQdme,366(ab) phasegastricemptying?,33(ab) â€œBelowregulate., concernâ€•(BRC)exemptions, partitioncoefficient,graphicplot analysis,â€˜@I of cardiac5PECF,scatterimagingwithexternal Congresserects ambiguouswalla@t, IMPand dynamicSPECTvalidation source for, 926(ab) 20N(1) studies using â€˜@Owater and PET, 498

Subject Indexâ€¢1993 2299

@@RÃ¤diations,171 @ Biood imaging

regional effect of amphetamine during penile,tumescence,523(k) enthesopathyof patellartendoninsertion, cognitiveactivation,1067(ab) PET functiOnalbrain mapping, comparison and isotretinointherapy,455 regionaleffectof intravenouspersantinein optimizationof data acquisition femoral and lumbar mineral density in normal subjects, 265(ab) strategies,150(ab) ankylosingspondylitis,704(ab) regionalstatedependentchangeduring posteriorcerebralartery infarction,and related fractures,scintimetricevaluationof remodeling cravingfor alcoholin alcoholics,by visualfielddefects, SPECI' and MRIin, after, 1403 repeat @FcHMPAO SPECF, 996(ab) 1009 functionalstagingof cancer patientsin sequentialquantitativemeasurementsusing prefrontal,in schizophrenia,305(ab) predictionof therapeuticresponseand splitdose â€˜@IIMPSPECI'method, pulmonarysystemic,evaluationusingECO survival,1087 986(ab) gatedacquisition,1441 imagingwith energy-weightedacquisition,997 single-passcerebralextractionand capillary quantitativeâ€˜@owater studies, noninvasive measurementsof mineralin thoracicspineby permeabifity-surfacearea productof arterialmonitorfor, 1000 fan beam dual energy x-ray severalimagingagents,641 quantitativePET, 1006 absorptiometiy,701(ab) SPECT HMPAO and balloon test occlusion, regional FDG uptake vs., in untreated primary metabolic disease, bone scanning in, 2247 predictingtoleranceprior to permanent breast cancers, 290(ab) metabolismin corticaland trabecularbone in relationshipof functiOnaloutcomeand, after cerebral artery occlusion, 1243 normalwomenand womenwith coronaryrevascularization,761(ab) osteoporosis,703(ab) SPECT in temporary balloon occlusion of Tc-94mteboroximesynthesis,dosimetryand metastasis carotidand intracerebralarteries, 1239 initialPETimagingstudies,1058 inbreastcancer,291(ab) decreasedcoronaryreserve in idiopathicdilated teboroxime as markerfollowing reperfusion of EXAFSstructuralcharacterizationof cardiomyopathyassessedusingPET with myocardialinfarction,48(ab) solutionsof lesReHEDPtherapeutic â€˜sowater,134(ab) tissue, simplemethodfor estimationusing agentfor, 146(ab) effectof changeson distributionvolumeof 11C Cu-PTSMand PET, 1132(ab) FDA approvesnew therapyfor, 30N(8) raclopridebinding,949(ab) BloodpoolImaging MRIand SPECF in renalallograftrecipients, localrenal, mappingwith PET and â€˜@owater, developmentof syntheticpolymerbased agent 381 196(ab) labeledwith @Â°â€œTc,149(ab) osteosarcomapresentingas intestinal m@ evaluationof iflIn polyclonalIgGto quantitate obstruction,1990 assessmentof endotheial functionwith PET atherosclerosis in Watanabe heritable Paget'sdisease,in patientwithbreastcancer, cold pressor test in patientswithvarious hyperlipidemicrabbitswith scintigraphy, 1214 degreesof atherosclerosis,137(ab) 1316 Pancoasttumor as causeof reflexsympathetic biokinetics of Â°Â°â€œTctetrofosmin and, 1254 inhomogeneityof gatedandungatedbull's-eyes, dystrophy, 1992 comparisonof factors influencing @Â°â€œFcsestamibi vs. arl'j1, 281 rib infarctionand pulmonaryinfiltrates, cost-effectivenessof diagnosisand metastaticmalignancymasqueradingas hepatic simultaneousoccurrencein sicklecell managementof coronarydisease, 136(ab) hemangioma on labeled RBC diseasewith acute chest syndrome,614 comparisonof 13Nammoniameasurement scintigraphy,1172 scans techniques,192(ab) MLBGevaluationas potentialtracer for comparedwith x-ray findingsin osteoporotic dynamicand gated PET â€˜3Nammonia monitoring doxorubicin cardiomyopathy, vertebralfractures,439(ab) imagingconfirmsinhomogeneoustracer 1282 correlation with serum PSA levels in retention but homogeneous perfusion in quantitativegatedSPECT,enhancedsensitivity treatmentof prostate cancer, 121(ab) normalsubjects, 132(ab) fornon-invasiveassessmentof coronary MR.!vs., in detectingspinalmetastases,2191 identificationofviable myocardiumin artery disease, 131(ab) radiographiccorrelationof suspiciouslesions patientswithchroniccoronaryartery removalof earlynon-specificactivityfrom on, 716(ab) diseaseusingâ€˜@owater and PET, 88(ab) antifibrinimages,applicationto rat model three-phase,comparativevalue of MRIin is Patlak graphical analysis method applicabk of pulmonaryembolism,855(ab) musculoskektalinfection,329(ab) to measurement with 13N ammonia?, moodsompling scintigraphy 1831(le) high-speedautomateddiscrete, for PET, 1357 comparedwith MRIin diagnosisof skeletal measurementby radiolabeledtracers,1518 â€˜@0waterandâ€˜@olabeledRBCrequireseparate metastasesin prostatecancer at initial parametricimagesfor quantitative externaldispersioncorrections,197(ab) presentation,1@ab) measurementsin humans,862 radioactivity,orbital @â€˜@InDTPAoctreotide difference in intervertebral fusion rate of PET measurement permits recognition of accumulationin Graves' orbitopathynot cervicaland lumbarspineassessmentby, viable and non-viable myocardium in based on, 158(ab) 712(ab) chronicmyocardialinfarction,87(ab) BlOOd-tImeactivitycurve,new estimationmethod disseminatedNorth Americanblastomycosis, accountingfor PET accumulatedcounts 458 quantification using â€˜3Nammonia and dynamicPET, 488 in tracer kinetic modeling, 154(ab) â€œdoughnutsignâ€•due to Bone.See also Skeleton hemangicendothelioma, 297 quantification using PET and â€˜3Nammonia in absorbeddose calculationsin Haversiancanals effectof clodronatetreatmentin metastatic patientswith angiographically for severalbeta-emittingradionucides, breast cancer, 1039 documented coronary artery disease, 1361 670n,intuberculousandnontuberculous 133(ab) can mineralin hip be predictedfromspinal infectiousspondylitis,853 rest and hyperemic, during estradiol therapy bone mineral density measurements in intraosseousmeningiomaappearanceover inpost-menopausalwomenby â€˜3N clinicalpractice?,706(ab) fiveyears,961 ammoniaand PET, 802(ab) â€œcoldhipâ€•sign vs. avascular femoral head, inmetabolicbonedisease,2247 resting,maintenancein dysfunctional 1827(le) oncologyand infection,2236 myocardiumwith 20!flredistribution, comparisonof 111InIgO, Â°@FcHMPAOWBC, orthopedicscanning,2241 171(ab) andso@@@Tcr@miimagingand quantitative,for evaluationoflower limb simultaneousmeasurementof oxygen conventional x-ray in rabbitmodel of growthplate activityin normalchildren, consumptionand,â€˜1Cacetate, acute and chronic osteomyeitis, 328(ab) 1063(ab) compartmentalmodelfor, 4(ab) density,estrogenand,803(ab) value in childrenwith unilateralcongenital @â€œTcteboroxime, uptake, vs. @Â°â€˜Tland detectionof hypervascularbrown tumorson growthdisorders,1064(ab) Â°Â°â€œTcsestamibi, 255 three-phasescan, 2188,2198 yieldfor identifyingoccultmalignancyin validationof â€˜3Nammoniatracer kinetic disorders,regionalassessmentof skeletal patientswithmusculoskeletalpain, modelfor quantificationusingPET, 83 fluoridekineticswith18FPETin, 437(ab) 122(ab) myocardialextractionof Â°Â°â€œTcMB!in isolated earlydetectionof avascularnecrosis,animal â€˜53SmEDTMPbiodistributionanddosimetry rabbit heart, 927 modelof, 710(ab) estimation, 1031

2300 TheJournalofNuclearMedicine Brain

â€˜53SmEDTMPinmetastasesof hormone MRJ: Cardiovascular System, 1396 comparison of phantom and human gray/white refractoryprostate carcinoma,1839 New Developments in Myocanlial Imag@g, 527 matter ratios, 933(ab) co-registrationmethodsfor three-dimensional SPECF, diagnosis of partial and total physeal NuclearMedicineAnnual 1992, 172 NuclearMedicine Procedwe Manual, 1837 images,274(ab) arrest by, 1410 correctionstrategyfor headmovementduring SPEC!' in recent meniscaltears, 713(ab) NuclearMedicine Procedure Manual 1992, 527 imaging,276(ab) spineandfemurmineraldensityinvarying Ortha;@edicRadiology: A Practical Approach, 2nded,ition, 1221 â€œCraclopride binding in, reproducibilityof severity spinal osteoporosis, 702(ab) repeatedmeasures,609 99mTc HMDP negative tumors, 18F FDO PET Phow@; Electron, F@vtonand Neutron Interaction DataforBody Tissues, 171 death,re@@@TcHMPAOindeterminationin in, 288 children,203(ab) 99mTc MDP uptake and biodistribution during Positron EmLcsion TomognzpI@yofthe Heaii, 1220 decreasedhippocampalbloodflowduring rat tibial bone repair, 104 episodeof transientglobalamnesia, hvzctical NuclearMedicine, 869 99mTc nanocolloid scintigraphy in orthopedic 981(ab) infections,comparisonwith â€œfulabeled RadiologicalAssessment: Sources and distributionof D2dopammnereceptorsin Evposu@rs, 869 leukocytes,1646 healthymen, MRIbased analysisof Readi@@the Chest Radiogmph A Physiologic therapyin nuclearmedicine,1037 SPECFimagesacquiredwith â€˜@IIBF, Approach, 1396 tumors, use of early, late and SPEC!' thallium 940(ab) SelectedAtlases ofBone Scintigraphy, 1220 dopammnergicD2 receptorSPECF imagingin imagingin evaluatingactivityof, 123(ab) Update on Nuclear Cardiology: Advances in upperspine,radiationdosefromtherapeutic Rett syndrome,increaseof specific Thallium Perfusion Imaging, 1221 bindingin striatum,1717 administrationsof â€˜@â€˜isodiumiodide,695 Brain Boneman@w doubletracer autoradiographyusing1-125 acetatemetabolism,dualtracerautoradiography lomazeniland @FcHMPAOin ablation of, 936(ab) experimentalisChemia,935(ab) designof treatmentplanningstrategyfor activation oflexical decision in psychopaths dual isotopeSPECF imagingfor monitoring radionucide therapy, 1026(ab) using SPECF, 306(ab) cognitiveactivation,initialstudiesin estimationof red marrowdoses fromHo-166 affinitylabelingof neuroreceptorsusinggamma humans,267(ab) administeredfor, 786(ab) rays, 95(ab) equilibriumquantificationof human Ho-166 DOTMP for, 125(ab) alcoholeffects,798 benzodiazepine receptors with use of â€œC antigranulocyteantibodyscans in cancer benzodiazepinereceptordistributionin anxiety flunrazeniland PET, 432(ab) patients with suspected bone superscan, disorders,studywith â€˜@Ilomazenil, evaluationof swineglucosemetabolismin 720(ab) 181(ab) thioacetamide-inducedhepatic assessmentin Paget's disease,with @Â°â€œTc biodistributionanddosimetryof @IIBF, 1910 encephalopathy using FDO PET, 961(ab) antigranulocyteantibodyBW250/183, blood flow examinationof neuralcontrolof eye movements 721(ab) inlocked-insyndrome,291 with PET, 932(ab) changes in end plates in association with disc and partition coefficient, graphic plot analysis, firstexperiencewith new D2 ligandâ€˜@IIBF, degeneration,SPECI'andlumbarMRIin 498 comparisonwith 123!IBZM,934(ab) back pain with emphasis on, 711(ab) regionalimprovementwithtreatmentin functionalimagingin elderly, 1101 changesin @Â°â€œTcnanocolllocalizationas result chroniccocainepolydrugusers,723 functionalintercorrelationsamongmulti-focal of treatmentwithrecombinanthuman single-passcerebralextractionand capillary responsesto thermalpain in humans, granulocyte colony stimulating factor in permeability-surface area product of 220(ab) caninemodel,840(ab) several imaging agents, 641 functionalmappingof flowand back-diffusion rateof â€˜@IIMP,839 dosimetry for radloimmunotherapy, 689 cerebral artery, SPECF HMPAO and balloon theoreticalderivationof red marrowto blood testocclusion,1243 fusionof morphologicalMRIand CT images withfunctionalSPECTimagesin studies activityconcentrationratio, 782(ab) cerebral cortical activation and spreading corticaldepressionvisualizedby of, 499(ab) immunoscintigraphyin stagingof low, glucosemetabolismresponseto GABA-A intermediate, and high grade mAChR-linkedphosphatidylinositide responsewith â€œClabeleddiacyiglycerol, stimulationstudiedwith PET in temporal non-Hodgkin'slymphoma,comparison lobeepilepsy,78(ab) withiliaccrestbiopsy,100(@ab) 941(ab) cerebralinfarctionwithin6 hoursafter onset, high-resolutionSPEC!', somatostatinreceptor myelosuppressionsecondaryto 1311Lym-1 imagingin pituitaryusing,159(ab) therapyforB-cellmalignancies,512(ab) 367(ab) cerebralpalsypredictionin high-riskneonates, high-resolutionSPECTimager,feasibilityof, usefulnessof immunoscintigraphyusing @Â°â€œ1@c 1223 99(ab) antigranulocytemonoclonalantibodyin cerebral vasodilatory capacity mapping using histopathologicvalidationof bloodflowSPECT patients with suspected bone metastases, @FcDTPA-HSA SPECF and indifferentialdiagnosisof dementias, 1002(ab) acetazolamide in moyamoya disease, 461(ab) Bonte,FrederickJ., peoplein nuclearmedicine, 1984 hypermetabolicfimgalinfectionwith PET FDO 20N(6) cerebrovascumaraccidentassociatedwith studies, 143(ab) Bookreviews dipyridamole201@flmyocardialimaging, hyperperfusionin late lifechronicfatigue Atlas ofNuclearMediczne Imaging 2nd edition, 128 syndromeand late lifedepression, @ 1837 childhood tumors, vs. @Â°â€œ1@cMIBI SPECF 993(ab) Cancer Imaging Manual, 1396 inevaluationof, 1045 ictalSPECFusingÂ°@cHMPAO,methodsfor Cardiologia Nuclear, 171 cholinergicneuronsin, invivo mappingusing rapidpreparationandoptimal Dose and Risk in Diagnostic Radiology: How SPEC!'and(-)-5.'@IIBVM,93(ab) deployment during spontaneous seizures, B@?HowLitt1e?, 1838 circulation in moyamoya disease, effect of 666 FifthInternationalRadiophannaceutical hypercapniaand hyperventilationon, 1-1252'-IDZas potentialimagingagentfor Dosinzetiy Symposium May 7-10, 1991, 246(ab) SPECF investigations of benzodiazepine 527 clinicalevaluationof interictal18FFDO PET in receptors,932 H@h Resolution CTofthe Lung, 1220 partial epilepsy, 1892 1-125implants,verificationwith dedicated Imaging ofSpotls Injuries: A MU1tÃœnOdaIUY clinicalevaluationof @Â°â€˜T1SPECFin SPECT camera, 892(ab) Approach, 870 supratentorialgliomas, 2085, 2089 imagingof primaryand remoteischemiclesions Imaging Techniques ofthe CNS of the collateral perfusion assessment with @â€œTc by inviva autoradiography, Neonate, 171 HMPAO SPECF during temporary benzodiazepinebindingsites and glucose Measurement ofDose Equivalents from internalcarotidarteryocclusion,1235 metabolism, 957(ab) External Photon and Electron comparabilityof FDG PET studiesin probable increasedcerebralperfusionafter detachable Radiations, 171 Alzheimer'sdisease, 1460 balloonembolizationof carotid

Subject index â€¢1993 2301 BRC exemptions

cavernousfistulaon @Â°â€œTcHMPAO atrophyweightedtotal brain metabolism influencedby biologicalpropertiesof SPECr, i9@7 and absolutewholebrain metabolismas radioligand,184(ab) infections,PET FDO accuracyin distinguishing reliablediscriminators,1681 three-dimensionalimaging,stationary lymphomafrom, in AIDS, 142(ab) quantitativeSPECr discriminatesAlzheimer's hemisphericalSPECF, 474 influenceof acute an chronicadministrationof diseasefromnormalaging,982(ab) three-dimensionalPET-PETimageregistration ethanolon localglucoseutilizationof rat, quantitativeSPECTin Alzheirner'sdiseaseand and enhancementof signal/noiseratio in 968(ab) normalaging,2044 functionalpatterns, motor task and, intraoperativeassessmentof malignanciesusing regionalcerebralbloodflowabnormalities,mild 151(ab) ar1@fl, 138(ab) to moderate, @Â°â€œTcECD vs. â€˜33Xe 3-Dregistrationof SPECF and MRI images, investigationof functionalneuroanatomyof SPECF in, 754 893(ab) syntactic processing and sentence regionaldistributionand metabolismin guinea tissue heterogeneityeffectson FDO parameter comprehension using PET, 222(ab) pigsof â€œCCP-96,345non-peptideNK-1 estimates, 153(ab) in viva dopamine transportersites imaging in antagonist,1121(ab) 20111 uptake from tSF compartment, 99 humanusingâ€œCWIN 35,428PET, regionalglucosemetabolism trapezoidrule improvescalculationof tissue 938(ab) inAlzheimer'sdisease,effectof ageof onset radioactivity,869(ab) localglucoseutilization,changesin awakerat on, 7(ab) tumorcharacterizationusingdual-isotope duringacute and chronicethanol modelingplasmaactivitycurvefor PET SPECF with thallium, somatostatin administration,793 measurementof, 152(ab) analog, anti-EOF antibody, %9(ab) malignanttumorchemotherapyefficacy,utility tumordetectionby SPETusingx@@11and @â€˜Tc regionalglucosemetabolismincoma,vegetative of @Â°â€˜TlandÂ°Â°@â€˜FcsestamibiSPECTfor labeledBC-2monoclonalantibody, and persistentvegetativestate, 369(ab) early detenninationof, 974(ab) 459(ab) metabolismof 6-[1@FJFDOPAis enhancedin regionalglucoseutilizationwith â€˜@FFDO and tumorgrowth,IUDRuptakeand retentionas patientswith Parkinson'sdisease, 114(ab) PET in heterogeneous tissues, 360 measureof, 1152 methotrexate-inducedneurotoxicity,appearance regionally differentialvascular reactivity to tumorproliferativeactivity,assessmentusing vibrotactilestimulationof rightfingers, @ on WBC, 70a-citrateandar@Tl @3@jIUDR, 139(ab) chloridescintigraphy,1377 223(ab) tumors, â€œInoctreotideSPECFin, 140(ab) mirror movements during recovery from stroke, responseto visualcognitivestimulation unifiedprocessingenvironmentfor image 225(ab) assessedby @FcHMPAOinAlzheimer fusion, 863(ab) modelingapproachto eliminatethe need to type dementia,11(ab) whok bodydistributionof newselective separatearterialplasmain â€˜@oinhalation scintigraphicstudiesof oropharyngo-esophageal muscarinicantagonist,radioiodinated PET, 1333 functionin stroke and other neurologic IQNP, 937(ab) neutral TcN-dithiocarbamate complex bearing disorders, 34(ab) wholebody distributionof new sekctive ester groupsas potentialimaghigagent serotoninuptakesites, â€œCMcN-5652Zas PET muscarmnicantagonistradioiodinated for cerebral perfusion, 63(ab) radiotracer for study of, 120 IQNP, 937(ab) oxygenutilization,individualcorrectionof SPECF BRCexemptions.See â€œBelowregulatoryconcernâ€• dispersiondid not alter estimatesof, neuralnetworkclassifierfor, 100(ab) exemptions 942(ab) inpatientswithcorticalvisualloss, 1447 Breast patterns of regionalglucosemetabolismin Â°@FcHMPAO, segmental analysis of, high cancer unipolarand bipolardepressive correlationbetweentemporaldefectsand bonemetastasesin, 291(ab) disorders,183(ab) memoryloss in, 9(ab) new monoclonalantibody @Fc170H.82for perfusion imaging with @FcECD, normal ar@11m childhood brain tumors, 201(ab) imaging,1003(ab) pattern in children,990(ab) SPECF activation images, propagation of Paget's diseasein patientwith, 1214 PET, FDOPA in, quantitation of putamen registration errors in, 900(ab) radioimmunotherapywith Â°Â°Y/â€•NBRE-3, uptakeconstantof, 679 SPECT and MRI in posterior cerebral artery 204(ab) PET and autoradiographicmethod with infarctionand relatedvisualfielddefects, @FcMIBI in evaluation of patients with continuousinhalationof â€˜@ogas, 1672 1009 primarycarcinomaof breast, 557(ab) PETfUnctiOnalmapping,comparisonand SPECF and planar imaging in crack abuse, 899 @Fcsestamibi prone breast imaging in optimizationof data acquisition spectrumof regionalglucoseconsumptionin patientswithsuspicionof, 559(ab) @ strategies,150(ab) choreaticdisorders, 118(ab) complementary role with PET studies ofworking memory in humans, stereotacticlocalizationof fimctionalimages, mammographyin diagnosisof, 2095 221(ab) automateddetectionof intercommmssural untreated,regionalFDOuptakevs. blood phantom,accuracyof registrationof PET, line for, 322 flowin, 290(ab) SPECF and MR images of, 1587 stereotactictransformationof PET scansby mass abnormalities, @Â°â€˜11scintigraphyin phosphoinositideturnoverimaginglinkedto deformation of standard atlas, 279(ab) evaluationof, 18 muscariniccholinergicreceptorin central synthesisand mouseuptakeof â€œC-labeled PET assessment with FDO and FES, 218(ab) nervoussystemby PET, 1543 inhibitors of prolyl endopeptidase, 23(ab) @Fcsestamil,i prone imaging in patients with physicalperformanceof dedicatedannular synthesisof new classof imagingagents suspicion of breast cancer, 559(ab) scannerâ€œCeraspect,â€•894(ab) containing TcN multiple bond, 537(ab) Brouaiae-76FLB457,highaffinityPET igand for practicalproceduresand pharmacological @cHMPAOperfusionSPECF,â€˜@IIBZM StudyingdopamineD2receptors, applications of quantitative PET, 1006 dopamineD2 receptorand, Huntington's evaluationin baboonand human, 407(ab) primate,PET imagesof phosphoinositide diseaseand, 1274 Brosnlne-76MBBG responseÃ¼i,94(ab) @FcHMPAO SPECF, in detection of postural analogof norepinephrinefor PET investigation principalaxes and surfacefittingmethodsfor cerebral hypoperfusion in patients with of heartadrenergicreuptakesystem, three-dimensionalimageregistration, cerebrovasculardisease, 1931 494(ab) 2019 @FcHMPAOSPECF evaluationof autistic asPETradiotracerformappingsympathetic prognosticand diagnosticusefulnessof disorder,308(ab) nervesof heart, 1739 FDO-PET in primary tumor @FcHMPAO SPECF in diagnosis of chronic management,141(ab) fatiguesyndrome,182(ab) C proteinkinaseC imagingusingâ€œC-labeled @Â°â€œTcHMPAO SPECT perfusion studies, phorbolesters, 431 test-retestvariabilityin normalhuman CAD. SeeCoronaryarterydisease qualitativeanalysisof regionalcerebralfunction sut@ects,248(ab) Camera inhealthyvolunteers,normalpatterns @FcHMPAO SPECF scan in schizophrenia, beta, improved detectability in low activity and changeswith age, 991(ab) 309(ab) applications,449(ab) quantitativeanalysisof PET and MRIdata in temporal lobe findings in SPECT studies of dedicatedannularbrain scannerâ€œCeraspect,â€• normalagingand Alzheimer'sdisease, patientswithmooddisorders,maybe physicalperformanceof, 894(ab)

2302 TheJournalof NudearMedicine Cardiomyopathy

@ dedicated SPECF, come of age, 1789 thyroid Carboa4l gamma,slat collimationfor highsensitivity2D high-activity @23Ifor diagnosticevaluationof binding in human brain, reproducibility of and 3D emissionimaging,28(ab) patientswith, 161(ab) repeatedmeasures,609 multi-detector,detectionand correctionof medullary, 1267 dopaminergic-cholinergicinteractionmeasured patientmotionin dynamicand static versatileimagingpeptidenears FDA approval, with PET and, in normal human myocardialSPECF using, 1349 33N(7) s@cts, 263(ab) pinholecollimationforultra-highresolution, Ca@11 sensitivityof PET measurementsto changesin small-field-of-viewSPECF studies,29(ab) estimationof upper limitson humanradiation endogenous dopamine, 262(ab) scintillation absorbeddoses fromcompoundslabeled Carbon-il TBZ, PET and, in viva humanimaging channelratio methodof scatter correctionfor with,2208 of monoaminergicnerveterminalsusing, radionudideimagequantitation,330 novelmethodfor introductionof, 272(ab) 92(ab) highresolutionpinholeSPEC!' for small preparationof three novelfunctiOnalMl Carbon-iltrlamclnoloneacetoulde,synthesisfor animalimaging,27(ab) sekctive muscarinicagonists,18(ab) PET, 1111(ab) Cancer.See afro Carcinoma;Metastasis; Carbon-il acetate Carbon-il WIN35,428,PET, in viva dopamine Oncology;Tumors cerebralmetabolismof, dualtracer transporter sites imaging in human using, accuratedetectionof liver metastasesin autoradiographyof, 936(ab) 938(ab) patientswithprimarymalignanciesusing modelingof myocardialkineticsby Carboa.14 urea, breath test, radiation dose simultaneously fitting data from multiple estimatesfor, 821 PET-FDO imaging, 13(ab) ROIS,193(ab) Carbondioxide,enriched0-18, cryogenicsolid athymicmicebearingcoloncancerxenografts, Carbon-il CGP20712A,beta 1-selective target for production of â€˜@Ffrom, 269(ab) Â°Â°9'clabelingof trisuccinconjugatedto adrenoceptor ligand for cardiac imaging, CarbondioxideTCD,cerebrovascularvasodilatory @ monoclonalantibody 107(ab) synthesisand evaluationof, 188(ab) tests, 244(ab) bladder,radioiodinatedIUDRin, 493(ab) Carbon-li CO, improvedcatalystmethodfor Ca@k eadgea (CE@ blood glucose concentration influence on FDO productionof, 1103(ab) anti-CEAantibodyimagingin coloncancer, uptake in, PET study of, 1 Carbon-li DAG 324(ab) boneScintigraphy,2236 PET, of phosphoinositide response in primate anti-CEAmonoclonalantibody breast, radioimmunotherapywith Â°Â°YIâ€•N brain, 94(ab) in colorectalcarcinoma,1656 BRE.3,204(ab) phosphoinositideturnoverimaginglinkedto phase I radioimmunotherapywith, 206(ab) cardiacandwhole-bodyâ€˜@FFDO studiesin muscarmniccholinergicreceptorin central anti-CEAmonoclonalantibodyconjugatedto septumlessPET scanner, 868(ab) nervoussystemby PET, 1543 bifunctionaltransitionmetalcarborane colon,refractory,phaseII trialof CC-49in, rapidincorporationinto membrane complex,pharmacokineticsin 205(ab) phospholipids in c@6-giomaas probe for tumor-bearingmice, 1294 differentiationof benignand malignant tumorproliferatingpotential,1054(ab) highaffinityanti-CPAmurinemonoclonal pulmonaryopacitieswith FDO-PET, Carbon-li dapoxetine,potentialagentfor PET antibody,successfulhumanizationof, 73(ab) studiesof serotoninreuptake, 11l7(ab) 102@ab) dose uptake ratio, 286(ab) Carbon-il dlprenorphine, different kinetics in @23Imonoclonal antibody fragments, in estrogenreceptor-positive,1-125IVME2vs. â€˜@I patientswith absenceepilepsywith and colorectalcancer imaging,61 IBHPE in, 272 withoutprovocationof seizures,224(ab) Carcinoma,brondulal,plasmaglucoselevelsand evaluationof suspectedmalignantpulmonary Carbon-il EPI â€˜8FFDO uptake, 355 lesions with 2o11@ISPECF, 556(ab) â€œCHED vs., for evaluationof sympathetic Carcinoma,broncbogenlc,stagingof, FDO-PET EXAFS structuralcharacterizationof solutions neurons of heart, 42(ab) in, 74(ab) of â€˜@ReHEDPtherapeuticagentfor evaluationin isolatedworkingrat heart, 174(ab) Carcinoma,hepatocellular,FDO-PETvs. bone metastasis, 146(ab) Carbon-il forskolln, ligand for visualization of histologicalfindingsin assessmentof, FDG-PET,6 adenylate cyclase-related second 12(ab) FDO-PET evaluation ofvertebral compression messengersytem in brain, 1117B(ab) Carcinoma,lung,PET followup studiesfor fracturesin, 17(ab) Carin@@-11HED evaluationof treatment responsein, fit-constrained parametric images using FDO, â€œCEPI vs., for evaluation of sympathetic 75(ab) 155(ab) neurons of heart, 42(ab) Carcinoma,ovarian.See aLsoOvarianneoplasms functionalstagingof patientsin predictionof myocardialkineticsof, retentionmechanisms quantitationof CA-M0v18antigenin sections therapeuticresponseandsurvival,1087 and effectsof norepinephrine,1287 of, 1004(ab) fusion of FDO PET with CT or MRI to localize synthesis of, 1102(ab) supra-additiveeffectof 32Pchromicphosphate fociof increasedactivity, 1190 Carbon-il MeN,serotoninuptakesite imaging andCDDPin, 217(ab) headandneck,advanced,FDGimagingafter with, Carcinoma,testicular,refractory,phase I chemotherapy,12 Carbon-li McN-5652Z, PET radiotracer for radioimmunotherapytrialswith â€˜@â€˜I studyingserotoninuptakesites, 120 5F9.3monoclonalantibody,208(ab) lung, detection with @â€œFcsestamibi, 558(ab) Cathon4l MET C@ @M myeloid leukemias, â€˜@â€˜IM195 â€˜8FFDOvs.,inheadandneckcancer,1711 circulatingâ€˜@â€˜ithyroxinein, 36(ab) radioimmunotherapy trials in, 207(ab) uptake in head and neck cancer, 77(ab) differentiatedtumors,imagingwith NDAsoughtfor cancer imagingradiolabeled Carbon-il methyl hypofluorfte, development of, @Fc(V)DMSA,37(ab) peptide,24N(1) 272(ab) imagingwith PET FDG, 38(ab) occult,yieldof bone scintigraphyfor Cathon-11methyltriflate,on-linemethodfor metastatic,bronchogeniccarcinomamimicking, identificationin patientswith production,268(ab) 809 musculoskeletalpain, 122(ab) Carbon-il MQNB, quantification of myocardial papillary,false-positivescans in, 2280(le) parathyroidhormone-relatedproteinradioassay muscarinicreceptors,981 forevaluationof humoralhypercalcemia Carbon-li N-methylnorfenfluramlne,D- and U, ASNCformation,28N(4) of malignancy,505(ab) in-viva behavior as serotonin reuptake proselytism,retroversionand fiscalnihilismin, prostate, correlation of bone scans and serum ligandsin rats and monkeys,90(ab) 1823 PSA levels in treatment of, 121(ab) o-Ca,ton-11 @mltIcadd, synthesisand initial U_S. radiopharmaceuticalsales, 28N(4) proteinsynthesisratedeterminationwithâ€œC evaluation as cardiac imaging agent, tyrosine,876(ab) 311(ab) Mdamycin Re-188generatorreadiedfor clinicaltreatment, Carbon-il phorbolesters,proteinkinaseC MIBOevaluationas potentialtracer for 33N(7) imaging,431 monitoring, 1282 @ suspectedmalignantsolitarypulmonary Ca@11 inhthfton, myocardialsubstrateutilizationand left nodules,PET-FDOpre-surgical synthesisand mousebrain uptakeof, ventricularfunctionin, 52(ab),1529 evaluationof patientswith, 72(ab) 23(ab) dilated

Subjectindexâ€¢1993 2303 Ca@

effects of beta-blockade therapy with ACE! Channelratio method,scatter correctionfor comparison of parallel beam, fan beam, and onglobalandregionalleftventricular radionuclideimagequantitation,330 cone beam for 3D SPECF brain imaging functionin patientswith, 128(ab) Chemotacticp@dea, highaffinity,Tc-labeled, based on mutual information criterion, idiopathic,decreasedcoronaryreserve 62(ab) 930(ab) assessedusingPETwith â€˜@owater, Chemotherapy cone beam, for magnification SPEC!' bone 134(ab) enhancementof Â°9@csestamibiaccumulation imaging of extremities, 708(ab) hypertrophic,complicatedwithventricular in multidrugresistant cells by cytotoxic cone beam and fan beam and parallel beam in aneurysmandinyocardialnecrosis,2227 drugsand MDRreversingagents,560(ab) SPEC!',evaluationof lesiondetectability ischemicand nonischemic,humanpathologic FDO imagingof advancedhead and neck by continuousROCanalysis,321(ab) correlationwith PET in, 39 cancer after, 12 evaluationof â€œInpolydonal IgOto quantitate @ leftventriculardilatation,significantcauseof forHodgkin'sdisease,ar@11 f@ atherosclerosisin Watanabeheritable @ decreasedspecificityin myocardialÂ°Â°@c assessmentof 67@ mediastinal hypedipidemic rabbits with scintigraphy, sestamibitomography,48l(ab) massfollowing,1326 effect of age and treatment with @ outcomeof, predictionusing MIBO regional,efficacyassessmentin soft tissue antioxidantsor ethinylestradiol,1316 myocardialSPECT,46(ab) sarcomasby FDG-PET,1053(ab) andfiltersekction,simulating @â€œTccerebral @ primaryhypertrophic, MIBOScintigraphy tumorresistanceto, use of anti-sensefor perfusionstudieswith three-dimensional as indexof severityin,45(ab) predictionof, 23N(5) Hoffman brain phantom, 929(ab) Ch@ high resolution slit aperture for imaging small serialcourseofleft ventricularfunction, acute chest syndrome,simultaneousoccurrence animals with SPECF, 26(ab) perfusion and fatty acid uptake in, in of rib infarctionand pulmonaryinfiltrates investigation of effects and design of source hamster, 1309 in sickle cell disease with, 614 collimationfor transmissionimagingin Cardiotoxicity,assessmentby â€œInantimyosin tumors, residualor recurrent,PET SPECr, 899(ab) studies differentiationfromposttherapychanges, MCSPECF I!, 24(ab) bolusadministrationvs. continuousinfusionof 162(ab) phantom study of breast tissue attenuation in doxorubicin,43(ab) x-ray myocardial imaging, 992 123! MIBO vs., 44(ab) fallacyas basisforcomparingradiogenic pinhole collimation for ultra-his) resolution, Cardiovascularsystem.See also Heart risks, 532(ab) small-field-of-viewSPECTstudies, 29(ab) comparison of factors influencing findings in patients with pulmonary embolism, planaractivityquantitationusinglow resolution cost-effectivenessof diagnosisand 1074(ab) measured attenuation scans, 858(ab) management of coronary disease, 136(ab) wQmatchislesslikelytorepresent post-reconstructionartificialneuralnetworkfor disease,research fellowshipsawardedto pulmonaryembolismif 0 is â€œdecreasedâ€• compensationof, in SPECT,67(ab) investigatorsof PET and SPEC!' rather than â€œabsent,â€•58(ab) slat coffimationfor highsensitivity2Dand 3D diagnoses,29N(7) Children. See PediatriC patients emissionimaging,28(ab) dynamicand gated PET â€˜3Nammoniaimaging Coloiectai neo@ confirmsinhomogeneousmyocardial acute bispecificmonoclonalantibody-mediated tracer retentionbut homogeneous delayed imaging has unacceptably low targetingof â€œInDTPAdimerto primary perfusionin normalsubjects,132(ab) positive predictive value when compared colorectaltumors, pharmacokinetics, infections,detectionwith radiolabeled to morphine augmentation, 300(ab) biodistnbution,scintigraphyand immune leukocytes,868Qe) morphine-augmentedvs. delayed response, 1662 novel approach to quantifying extent and hepatohiliaryscintigraphy,506 clinicalcomparisonof radiolocalizationof two severityof perfusiondefectson canine morphine-augmentedcholescintigraphyin, anti-TAO-flmonoclonalantibodies, myocardiumby PET polarmapping, false-negative,bile lankfromgallbladder 1009(ab) 756(ab) perforationmimickingbowelactivity current imagingstrategies,537(suppl) relationship of segmental uptake of @Â°â€˜9'c and, 131 â€˜@I-IabeledCEA monoclonal antibody sestamibito restingregionalwallmotion, Chek@ (COn fragments in imaging, 61 728(ab) interactionwith erythromycinin vitro,on immunoscintigraphy in surgical management, user-definable bullseye database analysis, gallbladder contraction in prairie dog 541(suppl) 738(ab) model,298(ab) phaseIItrialof CC-49inrefractorycolon CCL See Cholecystokinin pre-scintigraphic administration of, efficacy for cancer, 205(ab) CEA.See Carcinoembiyonicantigen hepatobiliary scans in patients with radioimmunoscintigraphy with @â€œFcIgO3 Centerfor Devicesaiai RadiologicalHealth systemic illnesses, 299(ab) labekd whok human monoclonal (CDRH),FDA seekingadvisorsfor Chromium-Si,complexes,rapid synthesisat antibody 88BV59, 1007(ab) committee,32N(5) tracer concentrations,1089(ab) repeatedadministrationof OncoScintin, interim Centralnervoussystem Clean Air Act, EPA, 24N(4), 34N(7) report of safety, efficacy and HAMA nonmalignantlesions,FDO-PETin lymphoma ciodronate, effect of treatment on bone development, 1006(ab) differentiationfrom,in AIDS,567 scintigraphy in metastatic breast cancer, tumor targeting in viva and metabolic fate of primarylymphomain non-AIDSpatients, 1039 1-125IUDRfollowingintratumoral comparisonof @Â°â€˜TlSPECF and â€˜8F Cobalt-55 monoclonal antthodles, for tumor injectionin patientswith, 1175 FDG PET with MR.!in evaluationof, imaging with PET, l104(ab) 219(ab) Condas application of effective dose equivalent to Cerebralbloodflow.See Bloodflow,cerebral chronicpofydrugusers, regionalcerebralblood nuclearmedicinepatients,714 @ Cerebra] P@d1ct10flin high-riskneonates, flow improvement with treatment in, 723 debate sparkedby, 1825Qe) @â€œTcHMPAO SPEC!' study of, 1223 crack abuse, SPEC!' and planarbrain imaging disposal of small quantities of radioactive Cei'elwospinalfluidcompartment,brain uptakeof in, 899 materialsin locallandfills,349 20!flfrom,99 Coded apertures, stationary hemispherical SPECF future of nuclear medicine, 27N(9) Cerelwovasculardlsease See aLsoStroke imagerfor three-dimensionalbrain Linesfromthe President,34N(3),50N(6), dipyridamoletestingin patientswith, 1389Qe) imaging, 474 32N(9) identificationof diaschisisusingDiamoxÂ°@â€œTcColitis, pseudomembranous, unsuspected, in medical imaging in the nineties, 157 HMPAO SPECT measures of critical care patients, â€œInleukocyte proselytism, retroversion and fiscal nihilism in cerebrovascularreactivity,249(ab) scintigraphic detection of, 35(ab) nuclear cardiology, 1823 quantitativeassessmentof cerebrovascular CollImator scientifichighlightsof Asiaand Oceania reserve usingâ€˜@IIMPSPECTsplitdose astigmatic (neurofocal), contrast recovery, Congress in Nuclear Medicine and method,245(ab) sensitivity,and resolutioncomparedwith Biology,17N(5) vasodilatorytests, DiamoxSPECFand @O2 standard parallel hole collimators for SNM/ACNPgovernmentrelations,22N(4), TCD, 244(ab) SPECT brain imaging, 910(ab) 19N(7)

2304 TheJournalofNuclearMedicine Coronaryarterydisease(CAD)

SNMannualmeetinghighlights,13N(8) likelihoodestimatorimagesin FDG PET enhancedsensitivityfor non-invasive toughchoices:who is to makethe call?, 860 studies, 1198 assessmentof, quantitativegatedblood Com@ 2272 scanning line source for simultaneous â€”SPEC!'imagingand,131(ab) Computed tomography (CT) emission and transmission measurements evaluationof â€œInpolyclonalIgOto quantitate alignment of data with planar nuclear medicine inSPEC!',1752 atherosclerosisin Watanabeheritable images,498(ab) systolicpressure alterationeffectson hyperlipidemic rabbits with scintigraphy, colorectal cancer imaging, radionucide measurementsof left 1316 radioimmunodetection complementing, ventricular filling dynamics, 747 familyhistoryof, evaluationof coronaryflow 61 unifiedprocessingenvironmentfor image reserve in asymptomatic males with comparativeefficacyof PET-FDOin detection fusion,863(ab) hyperlipidemiaand, 760(ab) of tumorsitesinpatientswithabdominal versatilelibraryfor medicalimageprocessing glycogenaccumulationin chronically and pelvicmalignancies,215(ab) using object-oriented language, 453(ab) hypoperfused myocardium with conebeam,orthogonal-viewtransmission 3-D reconstruction of gastric contents and maintainedFDO uptake, 5(ab) maximumlikelihoodfor, 319(ab) sequentialratiosof simultaneousdouble immediatearm11reinjectionfollowingstress FDO PET fusion with, to localize foci of head recordingsdemonstratinggastric imaging,in myocardialviability increased activity, 1190 displacement due to body position, detection,737 Computer-aided transcription, graphic user 814(ab) impact of antianginal medications, peak heart interface-basednuclearmedicine Conduction defects, right bundle branch block, rate and stress level on prognostic value reportingsystem, 515 normalcoronaryangiogramand, of normal exercise myocardial perfusion Computer and Instnimentatlon Council, SNM and, reversible 20111perfusion defects in, imagingstudy, 1467 co-sponsoring symposium on desktop 1218(le) improveddetectionby Bayesianenhancement computing in nuclear medicine, 18N(1) of myocardial perfusion scintigraphic Computers erects ambiguouswallagainstBRCexemptions, images, 739(ab) artificialintelligence,use in medicaldiagnosis, 20N(1) initial results in detection and localization, using 510 low-level radioactive waste policy, 34N(7) â€˜3Nammonia,automatedanalysis desktop, 18N(1) NRCinquiries,20N(7) programfor PET study evaluation,968 enhancedMAO3highresolutionrenal subcommittees, radiation protection, 22N(4) knownor suspected,safetyand clinicalutility parenchymal imaging, focal renal supercolliderkilledin House,32N(8) of combined intravenous parenchymal abnormalities on, 549(ab) Copper.62 FJ'SM, initial evaluation as tumor blood dipyridamole/symptom-limitedexercise highresolutionb/wprinters,blue-noisedithering flow agent in man, comparison studies stress test with @Â°â€˜11imagingin, 2053 forprintingscintigramson, 860(ab) withâ€˜@Owater,1052(ab) leftventricularmassandinfarctsize estimation massivelyparallel,applicationfor from â€˜3NammoniaPET, 826 three-dimensionalmaximuma posteriori high specific activity, production and long-termfollowupof myocardialperfusion reconstructionin SPECT,71(ab) purificationfor PET imaging,1108(ab) abnormalities in patients with Kawasaki multicenterevaluationof new automated testedas radioimmunotherapyagent,22N(7) disease, 213(ab) analysisprogramfor PET flowstudies, Cop@ monodonal antibody lowlikelihoodof coronaryeventsinyoung 759(ab) anticolon-carcinoma,initialclinicalstudy in patients with normal @Â°â€˜11SPEC!', nuclear medicine network for remote viewing colorectal cancer, 322(ab) 210(ab) anddistributedprocessing,859(ab) optimizationof preparationof fragmentsfor lung/heartratio fromdipyridamolethallium openarchitecturenudearmedicineprocessing improvedbiodistribution,105(ab) imagespredicts,followingcardiac system, 452(ab) potential for radioimmunotherapy, 1018(ab) transplantation,750(ab) qualitycontrolexpertsystem,objectoriented Cop@7 monodonalantibody,potentialfor MIBO evaluation as potential tracer for approachto, 862(ab) radioimmunotherapy,1018(ab) monitoringdoxorubicincardiomyopathy, quantitationof Â°7Oalunguptake, 1076(ab) â€”ertesythamse(CAD) 1282 rapidly converging iterative reconstruction assessmentof endotheial functionwith PET multiple vessel, improved identification by algorithms in SPECF, 1793 cold pressor test in patients with various additionof exercisewall motionanalto simulationstudyof falsemyocardialperfusion degreesof atherosclerosis,137(ab) Â°Â°â€˜@Tcsestamibi myocardial perfusion defects, 109(ab) atherosclerosisimaging,1321 SPEC!',519(ab) software biokineticsof @â€œ1'ctetrofosminand, 1254 myocardial perfusion defect size after early and accuracyof registrationof PET, SPECTand cardiacPET, 978 delayedÂ°Â°â€œTcsestamibiSPEC!' after MR images of brain phantom, 1587 characterizationof reinjection @Â°â€˜11image,879 stress, 187 advantagesand disadvantagesof chronic, identification ofviabk myocardium myocardial perfusion imaging and dynamic SCANWriterreport generatingprogram, using â€˜@Owater and PET, 88(ab) analysiswith Â°Â°â€œTctetrofosmin,1478 1835(le) clinicalvalue in addingfirst-passfunction negative 20r11SPECF and positive Rb-82 PET automateddailyqualitycontrolprogram, imagingto perfusionimagingwhen using myocardial perfusion imaging, 400 853(ab) coronaryvasodilator,523(ab) recovery of myocardial function following boneimagingwithenergy-weighted comparisonbetweendipyridamoleand coronaryrevascularization,84(ab) acquisition,997 dobutaminefor detectionof, ar@Tl relationship between acute coronary flow correction and characterization of scattered perfusion imaging with pharmacologic reductionand teboroximescan defectsin events in three-dimensionalPET using intervention and, 381(ab) patients undergoing PTCA, 521(ab) scannerswith retractablesepta, 671 comparison of factors influencing relationshipof bloodflowand functional graphic user interface-based nuclear medicine cost-effectivenessof diagnosisand outcome after coronary reportingsystem,515 managementof, 136(ab) revascularization, role of PET, 761(ab) iterativereconstructionmethodsfor comparisonof Â°@â€œFc03 and ar@Tlfor detection reverse redistribution on resting ar@11cardiac nonuniform attenuation distribution in in man, 478(ab) imaging in, relation to coronary anatomy SPECF, 1204 deoxyglucose and @Fcglucarate distribution and ventricular function, 725(ab) methods for improving quantitation of in, 1303 reversible 201'flperfusion defects in right bundle putamenuptakeconstantof FDOPAin diagnosison 3â€•@flimaging,ROCcomparisonof branchblock and normalcoronary PET studies, 679 simultaneous transmission emission angiogram, 1218Qe) public-domainsimulationsystemfor emission tomographyto routineSPEC!' for, risk stratificationin elderlypatientafter tomography,233(ab) 281(ab) coronaryartery bypass grafting, quantitative same-day rest-stress Â°@Tc dipyridamole SPECF isonitrile perfusion prognosticvalue of radionudlide sestamibi SPECf, 1494 imagingvs. dobutammnestress cineangiography in, 126(ab) resultsof clinicalROCstudy comparing echocardiographyfor detectionof, teboroxime, sestanribi and @Â°â€˜Tlas markers of filteredbackprojectionand maximum 376(ab) myocardial hypoperfusion, comparison

Subject index â€¢1993 2305 CT

by quantitative dual-isotope 15-in-Iodoobenvft-3J-Dimethvloeatadecanolcadd quantificationof bindingpotentialin striatum autoradiographyin rabbits, 1510 (Ã±MIjq1@A),uptake, OxidatiOn,and lipid with â€˜@IIBZM SPECF, 987(ab) three-vessel,radionudlidecineangiography distribution,vs. IHDAand pIPPAin radiohalogeno derivatives of tropapridefor duringexerciseand therapeutic normal myocardium, 649 PET and SPEC!' investigations of, implicationsin stablepatientswith, Dipyridamole 995(ab) 129(ab) highdosevs. standarddose, comparisonof side striataland extrastriatal,quantificationusing 20111 myocardial perfusion tomography one to effectsand hemodynamicchangeswith, NFPE, 528(ab) fiveyears after successfulcoronary 748(ab) striatalimagingby IBZM-scintigraphyin angioplasty,296(ab) highincidenceof nonrespondersto, in pre-liver schizophrenicpatientstreated with 3fl'fl reinjection and improvement of left transplantpatients, 75l(ab) typicalor atypicalneuroleptics,304(ab) ventricularfunctionfollowing myocardialperfusiondefectsize after early and effectsof intravenousethanolon intrasynaptic revascularization,172(ab) delayedÂ°Â°â€œ1@csestamibiSPECF, 187 measuresin humanbasal ganglia,527(ab) transientocclusion,simultaneousassessmentof perfusion scintigraphy, relationship of diagnostic endogenous,sensitivityof PET measurement myocardialperfusionand leftventricular accuracyto hemodynamicresponseon, with â€œCraclopride to changes in, 262(ab) functionduring,1(ab) 380(ab) 6-'8F, comparisonwith 6-'@FFNE, 619 validationof â€˜3Nammoniatracer kineticmodel prognosticimportanceof transientventricular inviva releaseof, displacementof â€˜@!IBF for quantificationof myocardial blood dilationby, 735(ab) equilibriumbindingby D-amphetamineto flowusingPET, 83 testingin cerebrovascularpatients, 1389(k) measure in, 186(ab) invitrotransportersites, imaginginhuman value of dobutamineÂ°@FcsestamibiSPECF thalliumscan variables,genderdifferencesfor usingâ€œCWIN35,428PET,938(ab) and echocardiographyin detection,vs. longtermcardiacevent-freesurvivalin 5-iodo-3-tyramineas potentialmetabolictracer coronaryangiography,889,895 vascular surgerypatients,736(ab) for, 1096(ab) Cr. See Computedtomography arr@@myocardial imaging PET imaging of reuptake sites in Parkinson's Cuello,Jorge L, Du Pont Award, 29N(7) additivevalue of radionudide diseaseby â€œCWIN 35,428and PET, Cydotron, PET, regulation,25N(4) ventriculographyfor risk stratification 115(ab) C@ne, can challengeassay predictin viva prior to vascularsurgery,292(ab) receptordensity,inviva assessmentin pituitary stabilityand biodistributionof @â€˜Fc cerebrovascularaccidentassociatedwith, 128 macroadenomaand correlationwith in labeledto antibodies?,231(ab) transientleftventricularcavitydilatation vitro assay, 530(ab) inducedby, significanceas assessedby reproducibilityof repeatedmeasuresof â€œC 99'@Tcsestamibi SPEC!', 297(ab) raclopride binding in human brain, 609 D Disintegrias,labeled,preliminaryevaluationfor transporters Daisy,Luke, Du Pont Award,29N(7) thrombusimaging,258(ab) MIBOuptakeby, 1140 Davison,Alan, PaulC. AebersoldAward,26N(5) Dhiresls,renography,1029(le) selectivelabelingin vitro and in viva in rat Demeatia,diagnosticaccuracyof FDO-PETin, false-positive,methodfor minimization, brain using1-125RTI-55combinedwith 6(ab) normalizedclearance-to-uptakeslope clomiprammne,952(ab) 2-Deoxy-D-@se, intra-tumoraldistributionin ratio, 762 striatal, SPECF imagingdemonstratesloss in xenograftsof humanovarian validation of renal output efficiency as objective Parkinson'sdisease, 116(ab) adenocarcinoma,autoradiographic quantitativeparameterinevaluationof Doxoruiddu.See also Adriamycin evaluationof, 75 upper urinarytract obstruction,845 antimyosinpositivityin cardiotoxicity,earlier 12-Deoxyphorbol13-lsobotyrate-2041â€•CJbutyrate, DMIPPA.See 15-(p-Iodophenyl)-3,3- thanconventionalevidence,1507 potential ligand for PET, 431 Dimethylpentadecanoic acid bolusadministrationvs. continuousinfusion, DepartmentofEner@ (DOE@ DNAflowcytometly,proliferativeactivityof cardiotoxicityassessmentby â€œIn fundingof neutron capture therapyresearch, human cancer cells, FDG uptake vs., 414 antimyosinstudies,43(ab) 29N(4) cardiomyopathy,MIBOevaluationas potential isotopesupply, 34N(7) increasesdetectionofviability by Â°Â°â€œTc tracer for monitoring,1282 labs billwouldenhancetechnologytransfer, sestanubiin canineisChemiamodel, cardiotoxicityduringadministrationof, â€˜@I 52N(6) 384(ab) MIBOvs. â€œInantimyosinstudiesfor â€˜molecularnuclear medicine'grants,fundingfor 99mTcsestamibi imaging, beta blocker therapy assessmentof, 44(ab) medicalapplicationsprograms,15N(2) does not affect,747(ab) detectionof cardiotoxicityin patientswith Â°9Moplan, 20N(4) oonrFc sestamibi SPECF and echocardiography sarcomasby â€œInantimyosin newresearchdirector,34N(7) incoronaryarterydiseasedetection,vs. monoclonalantibodystudies, 1503 proposestwo isotopeinitiatives,47N(6) coronaryangiography,889 Dual-energyx-rayabeorptiometry,of forearm, report hints at restructuringof isotopeprogram, DOE. See Department of Energy 441(ab) 49N(6) Duodenum stop-gapisotopeplan, 13N(4),24N(4) dopaminergic-cholinergicinteractionmeasured chroniculcer,gastricemptyingafter @0 with PET and â€œCraclopridein normal laparoscopic anterior seromyotomy and Alzheimer's disease vs., regional cerebral blood humansubjects,263(ab) posterior trance! vagotoiny in, 30(ab) @ flowin, 1090,1101 Dl receptor, @23!TISCH SPECr, ilealduplication, @Â°â€œTcpertechnetate unipolarand bipolar,patternsof regional 208 scintigraphyin, 294 cerebralglucosemetabolismin, 183(ab) D2receptors Do PontAward,Jorge L Coelloand Luke Daley, Dinbetas effect of nitrous oxide and methohexital 29N(7) gastricantral motilitydisturbancesin, anesthesiaon bindingof 3HNMSP, Dyspepila,idiopathic,characterizationof gastric characterizationusingscintigraphic 939(ab) emptying pathophysiology in, using technique,576 estimation of binding potential in striatum scintigraphy,31(ab) long-termefficacyof cisaprideuse intreatment withâ€˜@IIBZMSPECT,2076 ofgastropathy in, 819(ab) firstexperiencewith new ligandâ€˜@IIBF E non-insulin-dependent,detectionof glomerular compared with â€˜@!!BZM, 934(ab) hyperfiltrationusingtwo plasmasample imagingwith â€˜@I!BThfSPECTin patients Edgedetection,varyingthresholdSPECF methodof 51CrEDTAin Koreanswith, with parkinsoman syndrome, 980(ab) technique for spleen volume, vs. CF withoutovert proteinuria,518(ab) multipleradiotracerstudiesof invitroin volumes,963 type 2, heart and Skeletalmuscleglucose controland dopamine-depletedmice, dis@ by PET in, 2064 190(ab) alcoholandits effectson brain,798 Dl@ii, and myocardialuptakeof â€˜@IMIBOin occupancyas functionof intravenousrising antimyosinpositivityin dcxorubicin leftventricularhypertrophysecondaryto dose of RWJ-37796in normalliving cardiotoxicity,earlierthan conventional valvularaorticstenosis,57 human brain, 434(ab) evidence, 1507

2306 TheJournalofNuclearMedicine Fluorlne.18-BPA

atherosclerosisimaging,1321 absence, different kinetics of â€œCdiprenorphine myocardialperfusiondefectsize after early and @ clinicalPET, 1132 with and without provocation of seizures, delayed @@@IrFc 187 dedicatedSPECF camerascomeof age, 1789 224(ab) radionuclidecineangiographyduring,and exercise-dipyridamolemyocardialperfusion complexpartial, PET-FDOand post-surgical therapeuticimplicationsin stablepatients imaging,2061 seizureoutcomein, 79(ab) with three-vesselcoronarydisease, FDO accumulationin tumortissue, 419 focal,medicallyintractable,â€˜@Ilomazenil 129(ab) FDO-PET in oncology, 6 SPEC!' in presurgicalwork-up of radionudlideventriculography,prognostic functionalbrain imagingin elderly, 1101 patientswith, 80(ab) efficacyin patientswith and without functionalstagingofcancer patientsin ictal SPEC!' using @FcHMPAO,methodsfor priormyocardialinfarction,127(ab) predictionof therapeuticresponseand rapidpreparationand optimal renography,reproducibilityof results,554(ab) survival,1087 deploymentduringspontaneousseizures, in renovascularhypertension,48 hepatic handling of radiopharmaceuticals, 666 â€¢smTcMIBImyocardialtomography, usefulnessof in vitro model,2030 partial,clinicalevaluationof interictalâ€˜8FFDG comparisonbetweenadenosineand, hightechnologysquared,889 PET in, 1892 752(ab) immunoadsorption,enhancementstrategyfor temporallobe treadmillscore in medicallytreated patients radroÃ¼nmunotherapy,1020 glucosemetabolismresponseto OABA-A with coronaryartery disease,comparison @ isnuclearmedicineviableandcan measure stimulationstudiedwith PET in, 78(ab) of prognosticvalueof SPECF imagingin, 294(ab) viability?,924 localizingpowerof iota!regionalcerebral Extra@ Immunoad@, is the whole really the sum of the parts?, 2198 bloodflowrelativeto surgicaloutcome, tumor-to-normaltissue ratio, 448 measurementof myocardialbloodflowby 82(ab) Eye,movements,examinationof neuralcontrol radiolabeledtracers, 1518 refractory,regionalalterationof with PET, 932(ab), 963(ab) optimizationof radioiodinetherapyof benzodiazepinereceptordistributionin, thyrotoxicosis,1638 81(ab) PET in patient evaluation before and after heart -in F transplantation,834 effectson gastricemptying,alcoholabsorption, Fab fragments,CEA monoclonalantibodyF(ab')2 pheochromocytomalocalization,180 andsmallintestinaltransit,582 andFab',â€˜@!labeled,incolorectal practicalproceduresand pharmacological interaction with CCK in viva, on gallbladder cancerimaging,61 applications of quantitative PET, 1006 contractionin prairiedogmodel,298(ab) Fatty adds secondgenerationhypoxiaimagingagents,411 intravenous,effectson gastricemptying â€˜8Flabeled, for quantitative PET studies of simultaneous @Â°â€˜TlflÂ°â€•Tcdual-isotopecardiac followingesophagogastrectomy,32(ab) myocardialmetabolism,425(ab) SPECF, 2006 E-selectln,labeledmonoclonalantibodyagainst, @23I,uptake, oxidation, and lipid distribution in SPECFHMPAOandballoontestocclusion, imaging inflammation and vascular normalcaninemyocardium,649 1243 activation with, 243(ab) metabolism,myocardialuptakeof â€˜@Ibranched thallium reinjection imaging, search for optimal E@ fatty acid analogueas markerof, 726(ab) protocol,743 intravenous erythromycin effects on gastric uptake, and left ventricular function and therapy in nuclearmedicine,1037 emptyingfollowing perfusion,serialcourse in arI.fl SPEC!' in evaluation of gliomas, 2089 esophagogastrectoiny,32(ab) cardiomyopathichamster, 1309 whatshouldwe expectfromcardiacPET?,978 is a semi-solidswallowa better test of transit FDA.See Food and DrugAdministration Effectivedoseequivalent,applicationto nuclear thanmultipleliquidswallows?,818(ab) Fertility medicinepatients,714 roleof esophagealfunCtiOnalScintigraphyand radionuclidehystemsalpingography,appropriate Ejectionfraction barium studies in management of fornewassistedreproductiontechniques, estimationusingfilteredfirstpassstudies, endoscopicvaricealsclerotherapy, 797(ab) 386(ab) 817(ab) sperm cell dynamics in female rabbit genital leftventricular scintigraphic studies of oropharyngo-esophageal tract after inseminationmonitoredby assessedfromgated @Â°â€œTcsestamibiSPEC!', functionin stroke and other neurologic radiolabeledspermatozoa,1134 1871 disorders, 34(ab) Fever,of unimownorigin,scintigraphywith â€œIn development of ambulatory recorder for scintigraphyvs. pH probe for quantificationof po@ydlonalIgGin, 242(ab) measurementwith miniatureCs! pediatricgastroesophagealreflux,1228 FThroblasts,Chinesehamsterovary, hypoxiaeffect photodiodedetector, 842(ab) sequentialten-secondacquisitionsfor detection on accumulationof Â°Â°â€œFcglucarateand first-passradionucide anglographywith of gastroesophagealreflux,658 9OnTFcgluconate, 242 O9TwFc,394 Fluorlne-18 MIBOevaluationas potentialtracer for bonedensityand,comparisonof tamoxifenand cardiacPET, 978 monitoringdoxorubicincardiomyopathy, hypoestrogenemia,803(ab) cryogenicsolidtargetfor productionfrom 1-125IVME2vs. â€˜@IIBHPE, distributionin enriched 0-18 @2'269(ab) 1282 immaturefemalerat, 272 electrophilic,new methodfor production validationof peak diastolicfillingrates and, receptor-bindingradiopharmaceuticalsfor startingfromaqueous â€˜8F,27C@ab) determined from gated Â°@Fcsestamibi imagingof estrogenreceptor-positive humanstriatalsignal,recovery, sliceoriented myocardialperfusionimageinversion, humanbreast tumors, 1056(ab) PET, 481 520(ab) Europe,perspectiveon futureof nuclearmedicine, identificationof metallicsilvercrystalsin water Elderly.See aLsoAging 169 targetused for routineproduction, functionalbrain imagingin, 1101 EuropeanAssociationOfNuclearMedicine, 273(ab) risk stratificationafter coronaryartery bypass scientifichighlightsof EANMCongress nocarrieraddedâ€˜8F4-fluorophenylsulfonyl grafting,prognosticvalue of radionuclide 1992,17N(2) compounds,one-steplabelingof cineangiographyin, 126(ab) Exercbe antiepileptic drug fluoresone and Embolism,pulmonary.See Pulmonaryembolism captoprilscintirenography,1l58(ab) interleukinenhancerCL 259,763,271(ab) Encephalopathy diagnosticvalue of myocardialSPECF using Fluorine-iSaromatics,synthesisvia polymer hepatic, situs inversusdiagnosedby per rectal oomTc tetrofosmin in study of coronary boundtin reagents, 1105(ab) portal Scintigraphy,surgicalresultsfor artery disease,480(ab) fluorlne-18BMY14802,synthesisand PET portacavalshunt in, 301 ECO, comparisonof factorsinfluencing studies of, 246 H!V, SPECF, 185(ab) cost-effectivenessof diagnosisand Th,odne-18-BPA, uptake depending on DNA EnvironmentalProtectionAgency(EPA) managementof coronarydisease, 136(ab) synthesisand melaninincorporationin aean AirAct,24N(4),34N(7) effect on equivalence between adenosine and B16 melanomas in viva studied by emissionstandards, 29N(10) exercise2o@11myocardialtomographyin double-tracer microautoradiography, Epilepsy.See also Seizures coronaryartery disease,379(ab) 1118(ab)

Subject index â€¢1993 2307

â€” c1@aractciizationof pathophysioiogym Fluorine-18-fallypride

Fluorine-18-fallypride, as improved PET regional cerebral glucose utilization in lymphoma vs. nonmalignant CNS lesions in radiotracer for dopamine D2 receptors, heterogeneous tissues, 360 AIDS and, 567 1129(ab) regional uptake vs. blood flow in untreated myocardial perfusion and myocardial cell death, Fluorine-18-FBT, molecular dÃ©composition- primary breast cancers, 290(ab) 866(le) reconstitution approach to novel rotating PET scanner using BOO block PET vesamicol receptor radioligands, 21(ab) detectors, 1367 in assessment of hepatocellular carcinoma, 6-FIuorlne-18-FDA, heart uptake, metabolism, and SPECT, in detection of viable myocardium comparison with histological findings, effect of desipramine, 619 during hyperinsulinemic glucose 12(ab) FluorÃne-18-FDG clamping, 727(ab) in dementia, diagnostic accuracy, 6(ab) accumulation in inflammation tissue, 412(ab) standardized uptake values corrected for body in differentiation of benign and malignant assessment of myocardial viability early during surface area, less dependent on body size pulmonary opacities, 73(ab) post-ischÃ©miereperfusion in pigs with, than values corrected for body weight, evaluation of vertebral compression fractures 179(ab) 287(ab) in cancer, 17(ab) bacterial endotoxin test, PET, 469 uptake and cancer cell proliferative activity, 414 initial evaluation of imaging of metastatic uptake in head and neck cancer, 77(ab) "C methionine vs., in head and neck cancer, testicular neoplasms, 15(ab) Fluorine- 18-FDGal, high accumulation by in oncology, 6 1711 well-differentiated hepatomas of mice and effects of hypoxia on cultured human tumor cell in patients with malignant lymphoma, rats, 780 uptake of, 288(ab) 6-nuorine-18-FDOPA 1022(ab) improving purity of preparations, 1114(ab) frame-to-frame registration for movement predictive importance in patients with influence of plasma glucose levels on uptake in temporal lobe seizures, 83(ab) correction of dynamic studies, 275(ab) bronchial carcinoma, 355 metabolism is enhanced in patients with residual/recurrent ovarian cancer detection initial estimation of unidirectional clearance of, Parkinson's disease, 114(ab) using, 16(ab) results of clinical ROC study comparing 954(ab) putamen uptake constant in PET studies, maintained uptake, glycogen accumulation in methods for improving quantitation of, filtered backprojection and maximum chronically hypoperfused myocardium, 679 likelihood estimator images in, 1198 5(ab) Kluorine-18-FDOPA uptake, in vitro assessment of, 2278(le) for monitoring early response of human and analogs, efficiency removal of tin uptake and proliferative activity of human adenocarcinoma cell line to radiotherapy, contaminants from preparations of, cancer cells, 414 uptake into normal bone marrow is markedly 773 1110(ab) in myocardial viability assessment, 89(ab) NCA asymmetric, preparation from I8F florid increased by recombinant G-CSF and GM-CSF, 1137(ab) PET ion, 1106(ab) accuracy in distinguishing cerebral infections Fluorine-18-FEOBV, vesicular tracer for mapping Food and Drug Administration (FDA) approves new bone metastasis therapy, 30N(8) from lymphoma in patients with AIDS, central cholinergic neurons in vivo, 142(ab) preclinical studies of, 490(ab) NDA sought for cancer imaging radiolabeled attenuation scans, cardiac, three-dimensional Huiirine- 18-KKS,radiotoxicity in cell culture, peptide, 24N(1) NRC regulations on departures from registration of, 311 783(ab) manufacturer's instructions, 523(le) comparability in probable Alzheimer's Fluorine-18-2-F-L-FMPT, synthesis of potential overhauls adverse event reporting system, disease, 1460 PET tracer for tyrosine hydroxylase 30N(10) in differentiation of recurrent or residual activity, 22(ab) PET plan panned by physicians, 26N(4) musculoskeletal sarcomas from Fluorine-18-fluoxetine, as potential marker for radiopharmaceuticals, 24N(4) posttherapy changes, 124(ab) serotonin uptake sites, 1112(ab) seeking advisors for medical devices committee, dynamic studies for assessment of ovarian Fluorine-18-FMFMT, specific central dopamine 32N(5) cancer, 14(ab) probe, 959(ab) versatile cancer imaging peptide nears approval, effects of tissue heterogeneity on parameter Fluorine-I8-FMISO, imaging of hypoxia and 32N(7) estimates, 153(ab) reoxygenation in human tumors with, Fracture fusion with CT or MRI to localize foci of 76(ab) scintimetric evaluation of remodeling after, 1403 increased activity, 1190 h-Himrini'-lK-FNK. heart uptake, metabolism, and vertebral compression, in cancer patients, FDG hypermetabolic cerebral fungal infection with, effect of desipramine, 619 PET evaluation of, 17(ab) 143(ab) Fluorine-18-5-F-6-NQP, PET radioligand for initial assessment in imaging of malignant serotonin uptake sites, synthesis and melanoma, 1420 biological evaluation of, 19(ab) interjetai, clinical evaluation in partial Fluorine-18-MDL11939, synthesis and in vivo epilepsy, 1892 evaluation of, 20(ab) lung tumor metastasis to breast detected by, Fluorine-18-MIBG, novel synthesis for PET Gallbladder. .sVralso Hepatobiliary tract 1571 studies, 1107(ab) contraction, interaction in vivo between CCK in lymphoma differentiation from Fluorine-18-N-aHyl-S-fliioropropylepidepride, very and erythromycin in prairie dog model, nonmalignant CNS lesions, in AIDS, 567 potent and specific dopamine D2 PET 298(ab) pediatrie tumor studies, 199(ab) radioligand, 958(ab) ejection fraction, nondiagnostic for sphincter of pheochromocytoma studies, 41(ab) Fluorine-18-PFBG, potential tracer for imaging Oddi dysfunction in patients with intact prognostic and diagnostic usefulness in heart and tumor using PET, 312(ab) gallbladder, 815(ab) primary brain tumor management, 6-Fluorine-18-TP-3 monoclonal antibody, fragment, emptying, fatty meal superior to continuous 141(ab) imaging osteosarcoma in dogs using PET sincalide infusion in normal healthy quantitative analysis of glucose utilization by, and, 1017(ab) volunteers, 301(ab) in detecting myocardial viability, 3(ab) Fluorine-18-iiracil, PET studies after systemic perforation, bile leak mimicking bowel activity residual/recurrent ovarian cancer detection administration of, in patients with liver and false-negative result in using, Hn.il'i mÃ©tastasesfrom colorectal carcinoma, morphine-augmented cholescintigraphy, in ""Te HMDP negative bone tumors, 288 1075 131 thyroid cancer imaging with, 38(ab) Fluorodeoxyglucose with rim sign, prompt visualization of, 1169 planar imaging, influence of high and low insulin blood glucose concentration influence on uptake Gallium-67 levels during eugylcemic clamping, in cancer, PET study of, 1 avid mediastinal mass following therapy for 757(ab) fit-constrained parametric images of cancer Hodgkin's disease, 2t"TI scintigraphy for planar scintigraphy, early treatment response in using, 155(ab) assessment of, 1326 malignant lymphoma as determined by, in head and neck cancer, advanced, imaging benign mediastinal and parahilar uptake of, in 1706 after chemotherapy, 12 treated lymphoma, 1330

2308 The Journal of Nuclear Medicine Harris, C. Craig

distributionin normalandhypotransferrinemic Gastroeso@ reflux changes in local utilization in awake rat during tumor-bearingmice,2135 pediatric,scintigraphyvs. pHprobefor acuteandchronicethanoladministration, elevated uptake in rheumatoid lung patient, quantification of, 1228 793 cellular basis for, 351(le) sequentialten-secondacquisitionsfor detection, changesof metabolismand cell proliferationin gonadaluptakeandlocalizationin rodent 658 treatedosteosarcomacells, 1035(ab) model,770(ab) GastrOintestInal tract concordantly increased OLUT 1 gene lung uptake, computer quantitation of, 1076(ab) can liquids be used to predict abnormal solid expressionand FDO-uptakein human scintigraphy phase gastric emptying?, 33(ab) pancreaticcarcinoma,1044(ab) early detectionof lymphomarecurrencewith, characterizationof gastricemptying consumptionof intracranialmeningiomain 2101 pathophysiology in idiopathic dyspepsia relationto histologicalgrading, intuberculousandnontuberculousinfectious using scintigraphy, 31(ab) proliferation rate and cellular density, spondylitis,853 effectof misoprostolon postprandialintestinal 1043(ab) skeletalscintigraphyindeterminingprognosis transitand motilityin patientswith decreased left frontal metabolism is noted in forchildrenwithstageIV intestinaldysmotility,813(ab) youngnormalmales,874(ab) neuroblastoma,1082,1087 ilealduplicationof stomachandduodenum, heart and skeletalmuscledisposalin type 2 successfulimagingof North American 99mTc pertechnetate scintigraphy in, 294 diabeticpatientsas determinedby PET, pulmonaryblastomycosis,958 localizationof gastroenteropancreatictumors 2064 transferrin-dependentandindependentuptake with â€œInsomatostatin analogue, 156(ab) insulin and non-insulin mediated myocardial of, in transformedanduntransformed scintigraphyvs. pH probe for quantificationof utilization during hyperglycemic clamp in cells, 1032(ab) pediatricgastroesophagealreflux,1228 type-i diabetesevaluatedwith PET and unsuspectedcomplicationsof bacterial sequential ten-second acquisitions for detection FDO, 758(ab) endocarditisimagedby, 955 of gastroesophagealreflux,658 mapping of utilization in brain, improved @ GalIlum-67-cttrate Gated blood li@ng. See also Blood pool method with fixed vascular volume, disseminatedNorthAmericanblastomycosis, imaging 950(ab) 458 application and interpretation of principal myocardial metabolism, resting, maintenance in in liquidgastricemptyingscintigraphy,1619Qe) componentanalysisof, 843(ab) dysfunctionalmyocardiumwith @Â°â€˜11 postradiotherapy, unilateral sialadenitis on, 953 loadindependenceof earlydiastolicfilling redistribution,171(ab) 99m@Fccitrate vs. , for imaging inflammatory parameters in anesthetized canine model, paradoxical increase of human brain metabolism lesions,332(ab) 1520 inducedby OABA-Aagonist, usefulnessin patientswith acute disseminated SPEC!' demonstratedby PET,411(ab) tuberculosis,and comparisonwith chest firstharmonicanalysisprovidesrefined patterns of regional cerebral metabolism in x-rays, 1918 assessment of site of initial activation of umpolar and bipolar depressive Coll@68 accessorypathwaysin patientswith disorders,183(ab) clinicalPET, 1132 Wolff-Parkinson-Whitesyndrome, quantitativeanalysisof utilizationby â€˜8FFDO potential tracers for imaging heart with PET, 744(ab) PET in detecting myocardial viability, 228 fully automatic identification of cardiac blood 3(ab) Gammacamera poolin, 891(ab) regionalcerebralmetabolicratefor,modeling dualdetector,measurementof glomerular quantitative,enhancedsensitivityfor plasmaactivitycurveforPET filtrationrateusing,351(ab) non-invasiveassessmentof coronary measurement of, 152(ab) energy spectrum analysis for each section of artery disease, 131(ab) regionalcerebralmetabolismin Alzheimer's imageusingradionuclidespectroscopy 99m'Fcsestamibi vs. @Â°â€œfl,inhomogeneity of disease, effect of age of onset on, 7(ab) sytemformulti-isotopestudy,865(ab) bull's-eyes, 281 regionalcerebralmetabolismin coma, â€˜@â€˜iimages,scattercorrectionin, 236(ab) Gaucher's disease, â€œInleukocyte imaging, 818 vegetative and persistent vegetative miniature,clinical,448(ab) Generators, Isotope state, 369(ab) planar Ho-166 imaging, 864(ab) clinicalPET, 1132 regionalcerebralutilizationwith â€˜8FFDOand slat collimation for high sensitivity 2D and 3D eluateeffectson labelingefficiencyof @â€œFc PET in heterogeneous tissues, 360 emission imaging, 28(ab) sestamibikits, 730(ab) regionalmetabolicactivityin Alzheimer's Gastricemptying @Oaradiopharmaceutical that is retained in disease, quantitation of, after correction antral motility disturbance characterization, in myocardium,1127 foreffectsof atrophy,8(ab) diabetes,usingscintigraphictechnique, improvedW-188fRe-188and @â€˜MoP@â€•Tcgel spectrum of regional cerebral consumption in 576 chemistry,144(ab) choreaticdisorders, 118(ab) characterization of pathophysiology in invivo Dy-166/Ho.166,developmentfor value of quantitativeanalysisof utilizationin idiopathicdyspepsiausingscintigraphy, radionuclideradiotherapy,1080(ab) detectionof myocardialviabilityby PET, 31(ab) Genital tract, female rabbit, sperm cell dynamics after inseminationmonitoredby 2068 delayed,postprandialgastricmotilityin infants Glycogen,accumulationin chronically radiolabeled spermatozoa, 1134 with gastroesophageal reflux and, 2120 hypoperfused myocardium with Glomenilar filtration rate (GFR). See also Kidney eiythromycineffectson, 582 ambulatoryrenalmonitor,199 maintained FDG uptake, 5(ab) 67Gainliquidscintigraphy,1619(le) easy procedurefor determinationin children Granulocytes â€œIn intravenous erythromycin effects on, following using @â€œTcDTPA, one plasma sample esophagogastrectomy, 32(ab) and externalcountingwith thyroidprobe, 99m'FcWBCs vs. , for examination of patients after laparoscopic anterior seromyotomy and 470(ab) with inflammatoryboweldisease, 1052 posterior trunca)vagotomy in chronic measurementintermsof extracellularfluid usingFicoll-Hypaquetechniquein diagnosis duodenal ulcer, 30(ab) volume,471(ab) of syntheticvasculargraftinfection, liquidsin predictionof abnormalsolidphase, measurement using dual detector gamma 238(ab) 33(ab) camera and geometric mean and pulmonary,kinetics,165(ab) rates established with dual isotope scintigraphy, comparisonwith referencein vitro Graves' orbitopathy, orbital â€œInDTPA octreotide corrected for tissue attenuation, scatter, method,351(ab) accumulation in, not based on blood-pool and patient movement, 822(ab) Glucose radioactivity, 158(ab) andsmallboweltransit,inportalhypertension, blood, influenceof concentrationon FDO 443(ab) uptake in cancer, PET study of, 1 H solid cerebral metabolism response to GABA-A effectof soupon, 821(ab) stimulationstudiedwith PET in temporal Harris, C. Craig, Hevesy Nuclear Medicine lagphasein, 1701 lobeepilepsy,78(ab) PioneerAward,24N(5)

Subject Indexâ€¢1993 2309 Headandneckcancer

Hendand neckcancer doublelabeled6-FDAto assessfactors myocardialextractionof @FcMB! in isolated advanced,FDG imagingafter chemotherapy,12 responsibleforkineticsof 6-['@F]FDAin rabbitheart, 927 comparisonof â€˜8FFDGand â€œCMETin, 1711 baboon, 310(ab) myocardialkineticsof â€œCHED, retention labelingof monoclonalantibodieswith @seRe earlyassessmentof perfusion,function,viability mechanismsand effectsof usingMAG3chelatefor andprognosisafterfirstmyocardial norepinephrine,1287 radioimmunotherapyof, 1953 infarction,335(ab) myocardialperfusionand necrosisestimates squamous,detectionof lymphnode metastases earlymyocardialclearancekineticsof @â€˜Fc with @Kand PET in experimental with MRIand FDG-PETin, 216(ab) teboroximein differentiationof normal myocardialinfarction,49(ab) uptake of â€˜8FFDG and â€œCMET in, 77(ab) andflow-restrictedcaninemyocardiumat myocardialsubstrateutilizationand left Healthca@iaccess rest, 630 ventricularfunctionin Adriamycin reimbursement,19N(7),28N(10) effect of cardiopulmonary bypass surgery on cardiomyopathy,1529 U.S. effortsfadingto improve,30N(5) pulmonaryvascularpermeability, negativexo@ s@er and positiveRb-82PET Healthcare pulicy,19N(7),28N(10),32N(11) assessmentby transvasculartransportof myocardialperfusionimaging,400 Heart. See aLsoCardiovascularsystem; 67@3a,1077(ab) noninvasivediagnosisof transplantarteriopathy Myocardium effect of motion on SPEC!' imaging, 1355 with dipyridamOkthalliumSCintigraphy, absence of nonneuronal uptake of MIBO in evaluationof â€œCEP! in isolatedworkingrat 2049 denervatedrabbithearts, 176(ab) heart, 174(ab) parametricimagesfor quantitative applicationand interpretationof principal evaluationof pulmonarysystemicbloodflow measurements of regional myocardial component analysis of gated images, using ECO gated acquisition, 1441 bloodflowin humans,862 843(ab) failure,effectsof drugtherapyon oxygen PET assessment of cardiotoxicity by â€œInantimyosin consumptionand cardiacefficiency â€˜3Nammonia,automatedregiondefinition studies,bolusadministrationvs. determinedusingâ€œCacetate PET, for,336 continuousinfusionof doxorubicin, 427(ab) potentialssoa tracers, 228 43(ab) â€˜8FPFBGaspotentialtracer,312(ab) procedurefor patient repositioningand assessmentof endothdlialfunctionwith PET genderdifferencesforlongtermevent-free compensationfor misalignmentbetween cold pressor test in patientswithvarious survivalin vascularsurgerypatients, transmissionand emissiondata in, 137 degreesof atherosclerosis,137(ab) analysisof clinicaland dipyridamOle SNMCardiovascularCouncilpositionpaper atherosclerosisimaging,1321 thalliumscanvariables,736(ab) on clinicaluseof, 1385 oomTclabeledpeptidesfor, 259(ab),260(ab) glycogenaccumulationin chronically SNMpositionpaper, 25N(4) automated analysis program for evaluation of hypoperfusedmyocardiuniwith Tc-94m teboroxime, 1058 PET studies, 968 maintainedFDG uptake, 5(ab) PET attenuation scans, three-dimensional bacterialendocarditis,unsuspected humanpathologiccorrelationwith PET in registrationof, 311 @ complicationsimagedby 67@ iSChemiCand nonischemic phantom evaluation of simultaneously acquired 955 cardiomyopathy,39 dual-isotoperest @â€˜TI/stressÂ°Â°â€œTc biodistributionand imagingof @â€œTcnative hypertrophicmyocardium,approachesto SPECF images, 1998 LDL and oxidizedLDL, 261(ab) identifyand characterize,1013 phantom study ofbreast tissue attenuation in biokinetics of Â°Â°â€œTctetrofosmin, 1254 â€˜@â€˜IIVM as markerfor myocardial hypoxia, 918 m@ unagin&992 blood pool, fully automatic identification in immediate2o@11reinjectionfollowingstress prognosticimportanceof transientventricular , gatedSPECFimages,891(ab) imaging,hi myocardialviability dilationby dipyridamole,735(ab) 76BrMBBG,PETrndiotracerformapping detection,737 prognosticvalue of normalÂ°Â°â€œTcsestamibi sympatheticnervesof, 1739 impactof antianginalmedications myocardialperfusionimaging,211(ab) cardiacevents within 12monthsafter peakheartrate,andlevelof stresson proselytism,retroversionand fiscalnihilismin non-ischemicnon-invasiveimagingtest in prognosticvalue of normalexercise @â€˜11 nuclearcardiology,1823 patientswith prior myocardialinfarction, studies,337(ab) quantitativeperfusionimagingassessing 295(ab) peak heart rate and stress levelon prognostic acquireddiscreteperipheralpulmonary â€œCforskolin as ligand for visualization of value of normalexercisemyocardial artery stenosis, 1995 adenylatecydase-relatedsecond perfusionimagingstudy, 1467 rapidback to back adenosinestress/restÂ°Â°â€œTc messenger system, 1944 infections,detectionwith radiolabeled teboroximemyocardialperfusionSPECF characterizationof reinjection @â€œ11image,879 leakocytes,868Qe) usingtripl@detectorcamera, 1485 @ clinicaldecisions,860 leftventricularmassandinfarctsize estimation reverseredistributionon restingar@11 in comparison of 6-'8F FNE and 6-'8F FDA and, fromâ€˜3NammoniaPETbasedon coronaryartery disease,relationto 619 pathologicalexaminationof explanted coronaryanatomyand ventricular comparisonof true and falseneurotransmitters hearts, 826 function,725(ab) in, 491(ab) leftventricularpeakpowerduringexercise, reversible20!flperfusiondefectsin rightbundle comparisonof uptake,oxidation,and lipid noninvasive approach for assessment of branchblock and normalcoronary distributionof HIDA,pIPPA, and contractilereserve, 1877 angiogram,1218Qe) DMIPPA,649 leftventricularsystolicanddiastolicfunction riboseinfusionreduces MIB!but not @Â°â€œfl concordanceof nutritivemyocardialperfusion measurementsusingambulatory extractionin isOlatedrabbitheart, reserve and flowvelocityreserve in radionudlidemonitor,effectsof different 177(ab) conductancevessels, 717 timeaveragingon accuracyof, 1602 risk stratificationprior to vascularsurgery, detectionof patientmotionduringtomographic load independenceof early diastolicfilling 293(ab) myocardialperfusionimaging,1341 parametersin anesthetizedcaninemodel, serialcourseof leftventricularfunction, detectionofventricular dysfunctionand carditis 1520 perfusionand fatty acid uptake in in children with Kawasaki disease using mechanicaloverloadhypertrophyand failure, cardiomyopathichamster, 1309 equilibriummultigatedblood pooling dynamicanalysisof â€˜@IMIBO simultaneous @â€˜11fl@â€•FcSPECT, experimental ventriculographyand @FcHMPAO scintigramsin, 589 verificationof energyweighteddual WBCheart scan, 1066(ab) MIBOpotentialas tracer for monitoring isotopetechniquefor, 108(ab) distributionof deoxyglucoseand Â°Â°â€œTc doxorubicincardiomyopathy,1282 simultaneous transmission-emission @Â°â€˜11 glucaratein acutelyischemic MIBOuptakeby norepinephrine,dopamineand imaging,280(ab) myocardium,1303 serotonintransporters, 1140 SPECF dobutamine @â€œTcsestamibiSPEC!' and MIBOuptake in patientswith aceticstenosis, correctionfor attenuationand geometricpoint echocardiography,coronaryangiography 1392(k) response distortions in, 111(ab) vs. , in coronary artery disease detection, motiondetectionand correctionin SPEC!', new importance of attenuation compensation and 895 methodologicalapproachto, 358(ab) itsimplementationin, 110(ab)

2310 TheJournalofNuclearMedicine Indium-Il 1-antimyosin

OO@wFc,non-uniformcompensationusing HevesyNuclearMedicinePioneerAward,C. Craig . imaging in human tumors with â€˜8F FM!SO, acquiredtransmissiondata,112(ab) Harris, 24N(5) 76(ab) sympatheticneurons, â€œCEPI vs. â€œCHED for Hip, MR!and SPECFbone scans in renal evaluationof, 42(ab) allograftrecipients,381 characterizationof â€˜@â€˜I!VMas markerfor, synthesisandevaluationof â€œCCGP20712A,a Hl@c add, transportdisturbance,renovascular 918 beta 1-selectiveadrenoceptorligandfor hypertension, 48 â€˜@â€˜IHDA metabolism in, 51(ab) imagingof, 188(ab) 11W.SeeHumanimmunodeficiencyvirus myocardhalkineticsof putativehypoxictissue synthesisand initialevaluationof o.â€•Cpalmitic Hodgkin'sdisease,therapyfor, @â€˜11scintigraphy markerafter regionalischemiaand acid as imagingagent, 311(ab) for assessmentof 67@3@avidmediastinal reperfusion,53(ab) syntheticpeptideimmunogensfor development massfollowing,1326 PDT-induced,in Dunningprostate tumors, â€˜@I of cardiac myosin light chain-i specific Holmlum-166 DOTMP, new agent for bone IAZA,405 radioimmunoassay,2144 marrowablation, 125(ab) synthesisof 4-substitutedmisonidazole systolicpressurealterationeffectson HumanImmunodefidencyvinis (11W).See aLso derivativesfor imaging,314(ab) radionuclidemeasurementsof left Acquiredimmunodeficiencysyndrome 99mTcnitroimidazole complexes localizing, ventricularfillingdynamics,747 (AIDS) separationof isomersof, 64(ab) osmTcin first-passangiographicstudiesof left encephalopathy and depression, SPEC!' in, tumor, and tumorperfusion,885 ventricular function, 394 185(ab) thalliumreverse redistributionin perspective, focalinfectionin, â€œInpolyclonalhumanIgOin identificationof, 1621 1692 ICP. See Institutefor ClinicalPET 2rofl reinjection and improvement of left radioimmunodetectionof Pneumocystiscarinii IIIDA.See 17-Iodoheptadecanoicacid ventricularfunctionfollowing pneumoniain, 239(ab) Immuaoadsorpdon,enhancementstrategyfor revascularization,172(ab) Hydrogeu-3acetate,cerebralmetabolismof dual radioÃ¼nmun@y, 1020 transplantation tracer autoradiographyof, 936(ab) Imm@ evaluationof allograftvasculopathyby Â°@â€˜9'cHydrogen-3AF-DX116,selectiveM2muscarinic linker-,â€œIand Â°Â°Ylabeled,938 teboroximewashout, 734(ab) receptor antagonist, rat in viva binding radiolabeled,synthesis,metalchelatestability PET in patient evaluation before and after, and pharmacokineticprofileof, 1130(ab) studies, and enzymedigestionof 834 Hydroxya@te, ocular implants peptide-linkedDOTAderivativeand its uptake mechanism of neutral myocardial determinationofvascularizationandvascular corresponding,104(ab) imagingagent Â°â€œFcN-NOET,65(ab) ingrowthrate by @Â°9'cMDPbone scan, whatshouldwe expectfromcardiacPET?,978 709(ab) antibodiesin, 2264 Helicobacterpylori, radiation dose estimates for 9omTc MDP evaluation, 467 with anti-PMNmonoclonalantibodyfor C-14 urea breath test, 821 Hype@demia, familyhistoryof coronaryartery diagnosisof septic looseningof hip Hemangloendothelioma,bone, SCintigraphic diseaseand, evaluationof coronaryflow prosthesis, 333(ab) â€˜doughnutsign' on skeletalimaging,297 reserve in asymptomaticmaleswith, of bonemarrow Hemangloma,hepatic 760(ab) in staging oflow, intermediate, and high cavernous,2278Qe) gradenon-Hodgkin'slymphoma, metastatic malignancy masquerading as, on pulmonary 1000(ab) labeledRBCscintigraphy,1172 emphysema vs. , pulmonary perfusion usefulnessusingÂ°Â°â€œFcantigranulocyte 99mTcRBC SPEC!', 375 distributionfollowingsinglelung monoclonalantibodyin patientswith Hemoglobin,liposomeencapsulated,use of Â°@â€œTc transplantationin, 167(ab) suspectedbone metastases, 1002(ab) liposomelabelingprocedureto monitor perfusion lung scintigraphic patterns of of colorectalcancer,with @Â°â€œTcIgG3labeled circulationpropertiesin rat shock model, histologicsubtypes, 1071(ab) wholehumanmonoclonalantibody 542(ab) roleofventilation-perfusionlungscanningin 88BV59, 1007(ab) Hepatohlllaiytract. See aLsoGallbladder,Liver diagnosticevaluationof patientswith, of infection, @â€˜1@cantigranulocyteantibody cholescintigraphyin diagnosisof acute 1075(ab) ftugmen:, 240(ab) cholecystitis,morphineaugmentationis renovascular inmanagementof ovariancancer,clinicalutility superiorto delayedimaging,1866 diagnosiswith captoprilrenalscintigraphyin of, 545(suppl) efficacyof quantitativecholescintigraphyin patient with solitary kidney, 1166 in prostate cancer, current applications of, diagnosisof sphincterof Oddi dynamicrenalimagingwith @Fcsestamibi 549(suppl) dysfunction,302(ab) in assessment of, 552(ab) in surgical management of colorectal cancer, factorsalteringexcretionof @9'cMAG3, MAG3/enalaprilatprotocol for diagnosis in 541(suppl) 515(ab) single visit, 1154(ab) oomTcanti-AFPFabl, in evaluationof treated hot spot scan in focalnodularhyperplaSia,2105 perfusion abnormality in, 48 germcell tumors, 1001(ab) imagingpattern in patientssuspectedof biliary Impotence,penilebloodflow,tumescence,523(le) leak, 303(ab) effecton uptakeof monoclonalantibodyin Indium-ill promptvisualizationof gallbladderwithrim smallcell lungcancerxenografts, biotinderivativeslabeledwith,influenceof sign, 1169 1012(ab) endogenousbiotinon biodistributionin scintigraphy transurethraltreatmentof benignprostate mice, 1091(ab) cavernous hepatic hemangioma, 849 hypertrophy,Xe-prostateclearancestudy chelated derivatives of ANP for in vivo imaging CCK administrationbefore,efficacyin after, 553(ab) of receptors, 226(ab) patientswithsystemicillnesses,299(ab) Hyperthyroidism,quickdiagnosiswith gonadaluptakeand localizationin rodent in evaluation of solitary solid liver masses, semiquantitative30-minute @FcMIBI model,770(ab) 697 thyroiduptake, 71 inimunoscintigraphy morphine-augmented Hyperventilation,effecton cerebralcirculationin clinicalutilityin ovariancancer management, delayedimagingvs., in suspectedacute moyamoyadisease, 246(ab) 545(suppl) cholecystitis,506 Hy@ current applicationsin prostatecancer, false-negative,bile leak fromgallbladder effecton accumulationof @Â°â€œFcglucarateand 549(suppl) perforation mimicking bowel activity 9OlwFcgluconate by Chinese hamster insurgicalmanagementofcolorectalcancer, and,131 ovary cells, 242 541(suppl) pediatric,hepaticextractionfraction effectson culturedhumantumorcell uptakeof Indlum-lll-aitbnyosln, cardiotoxicityassessment determinationby deconvolutionanalysis, thymidine,L-methionineand FDG, by 214 288(ab) bolus administration vs. continuous infusion of quantitative,in childrenwith cystic fibrosis inheart,novelÂ°Â°â€œTclabelednitroheterocycle doxorubicin,43(ab) andliverdisease,1060(ab) capableof identificationof, 722(ab) â€˜@IMIBO vs., 44(ab)

SubjectIndexâ€¢1993 2311 Indium-i11-antimyoslnFab

Indium-lil-antlmyoslnFab, identificationand in patients with paragangliomaor medullary MacroscintDTPA-IgGin rat modelof, characterizationof hypertrophic thyroidcarcinoma,555(ab) 839(ab) myocardium,1013 SPECF,inpatientswithbrainandpituitary fungal, hypermetabolic cerebral, with PET FDG Indlum-lll-antlsenseprobes,noninvasiveimaging tumors, 140(ab) studies, 143(ab) of c-myc oncogene mRNA with, in Indlum-lll-oxlae, biodistribution of labeled imaginginflammationandvascularactivation mammarytumor mouse, 1039(ab) platelets in dog injected with with labeled monoclonal antibody against Indlum-lll-CYr-l03, repeated administration in anti-thrombocytic monoclonal antibody, E-selectin,243(ab) colorectalcarcinomapatients, interim 476(ab) imagingof focalsites of inflammationin reportof safety,efficacyand HAMA Indlum-lll-pentetreotide, biodistribution in non-humanprimateswith @Fclabeled development, 1006(ab) patients with carcinoid tumors, 157(ab) humanpolyclonalIgO,832(ab) Indlum-lll-DTPA imagingof inflammation/abscesswith bispecific monoclonal antibody-mediated autologous,sequestration,correlationwith IMMU-MN3,827(ab) targeting dimer to primary colorectal splenectomyin idiopathic ofjoint replacements,radionuclidediagnosisof, tumors,pharmacokinetics, thrombocytopenic purpura, 182 331(ab) biodistribution,scintigraphyand immune combinedwithB-modeultrasonography,in labelingneutrophilsby hybridizationwith â€œIn response, 1662 functionaland anatomicalevaluationof DTPAAHON, 841(ab) effectof degreeof conjugationper MoABon carotid atherothrombosis, 828(ab) new class of radiopharmaceutical for imaging, metabolismand clearanceof its â€œIn correlationof splenicsequestrationstudiesand @â€œ1'câ€œinfection,â€•474(ab) chelatein mice,228(ab) clinical outcomes in cancer patients, nuclearimagingof acuteinflammatorylesions receptortargetedproteins,intracellular 477(ab) with recombinant human interleukin-8, metabolismof, 1728 Indium-lll@ IgG 416(ab) Indlum-lll-DTPAAHON, labeling neutrophils by evaluationof accuracyfor detectinginfection, pulmonary,â€œInDTPAIgGlungimagingin, hybridization with, 841(ab) 241(ab) 1078(ab) Indlum-lll-DTPA IgG identifyingfocalinfectionin H!V, 1621 softtissue,andosteomyeitis,new lungimagingin patientswithpulmonary to quantitate atherosclerosis in Watanabe antigranulocyteFab' fragmentfor infections, 1078(ab) heritablehyperlipidemicrabbitswith diagnosisof, 830(ab) phase II! safety and efficacy study in patients scintigraphy, effect of age and treatment suspectedinflammationor, phase Ill safety and with suspected inflammationor infection, with antioxidants or ethinylestradiol, efficacystudyof â€œInDTPAIgOin 831(ab) 1316 patientswith, 831(ab) Iadlum-lll-DTPA octreotide scintigraphy, in fever of unknown origin, synthetic vascular graft, â€œInlabeled orbitalaccumulationin Graves' orbitopathynot 242(ab) granulocytesusingFicoll-Hypaque based on blood-poolradioactivity, Iadlam-lll-somatostatln analogee, localization of technique in diagnosis of, 238(ab) 158(ab) gastroenteropancreatic tumors with, Â°@â€œTclabeled chemotactic peptides for imaging, somatostatinreceptor imagingin pituitaryusing, 156(ab) 833(ab) 159(ab) Indlum-lll-transferdn, in imagingand tuberculousand nontuberculousspondylitis, Indinm-1llira@es quantitationof intestinalproteinloss in 67@ @ig@phyin, 853 comparedwith Â°Â°@FcWBCsfor examinationof patientswithstomachcancer,392(ab) viral encephalitis, detection in children by @rc patientswith inflammatorybowel Indlum-ll4m HMPAI brain SPECF, 984(ab) disease, 1052 effect of protein and pH on exchange from IgG Infertility. See Fertility using Ficoll-Hypaque technique in diagnosis of and HSA to lactoferrin, 1138(ab) Inflammatory bowd disease, prospective syntheticvascular graftinfection,238(ab) mutagenic effects in rat, 531(ab) comparativestudy of Â°Â°@cWBCsand Indimn-lll-kuhacytes Infants. See Pediatric patients â€œIngranulocytes for examination of cardiovascularinfectiondetectionwith, 868(le) patientswith, 1052 in Gaucher's disease, 818 myocardial. See Myocardial infarction In memodam, William H. Oldendorf, 871 scintigraphy posterior cerebral artery, and related visual field InsemInatIon, sperm cell dynamics in female rabbit in cutaneous sarcoidosis, 812 defects, 1009 genitaltract after, monitoredby in detection of unsuspected pulmonary,ventilation-perfusion/chestx-ray radiolabeledspermatozoa,1134 pseudomembranouscolitisin criticalcare matchless likelyto representpulmonary Institute for Clinical PET (ICP), management patients, 35(ab) embolismif 0 is â€œdecreasedâ€•rather than merger,32N(7) Indlum-lll-llnker-lmmwiocou@jugstes,evaluationin â€œabsent,â€•58(ab) In@in nudemiceanddogs,938 nOb,pulmonaryinfiltratesand, simultaneous effecton FDG-PETimagingin patientswith Indlum-lll-lymphocytes,SCintigraphy,direct occurrence in sickle cell disease with lymphoma, 1049(ab) assessmentof efficacyof anti-rejection acute chest syndrome, 614 influenceof highandlowlevelson planarâ€˜@F therapy using, 755(ab) FDG imaging during euglycemic Indiwn4ll-monocioaalan@ bacterial clamping,757(ab) A7, novel chemical linker with hydrocarbon localization of â€œInIgG, @â€œTcIgG and â€œIn and non-insulinmediatedmyocardialglucose spacer for, 102(ab) WBC at sites of, 1975 utilizationdaringhyperglycemicclampin BrE-3,radioimmunolocalizationof metastatic Â°Â°â€œTcHYNIC derivatized chemotactic type-i diabetesevaluatedwith PET and breast carcinomausing, 1067 peptideanalogsforimagingfocalsites, FDG, 758(ab) CilO, radioimmunoscintigraphyin 836(ab),1964 Intestine, small, transit, erythromycin effects on, carcinoma, 1656 bone SCintigraphy, 2236 582 can length of hydrocarbon bond in chemical cardiovascular, detection with radiolabeled IodIne-123,high-activity,for diagnosticevaluation spacer alter pharmacokineticsof, 103(ab) leakocytes, 868Qe) of patients with thyroid cancer, 161(ab) effectof transferrinserum levelson deposition dissociation of indium from IgG in foci of, JOdIne-123-BMIPP,identificationand in liver and axial skeleton, 1143(ab) 417(ab) characterization of hypertrophic to eosinophilpercxidase,radioimmunodetection early detection of avascular necrosis, animal myocardium, 1013 of Hodgldn's disease and non-Hodgkin's modelof, 71@ab) lodlne-123-BZA,phase I! SCintigraphicclinicaltrial __s with, 1246 evaluation of accuracy of â€œInpolyclonal IgO of malignantmelanomaandmetastases spatiallocalizationof metastaticprocesses fordetectionof, 241(ab) with, 1260 using,CT and SPEC1@imageregistration focal Iodine-123CPAmonodonalantibodyfragments, and fusion for, 562(suppl) biodistributionand imagingstudiesof @Fc colorectalcancer imaging,61 Indlum-lll-octieotlde labeledliposomesin ratswith,2160 Jodlne-123-donycydlne, detection of scintigraphy comparison of Â°Â°â€œTcSHNH labeled IgG, metalloproteinases in arthritic rat tissues fordetectionof paragangliomas,873 @â€œTcHIG Technescan, and â€œIn by imaging with, 1087(ab)

2312 TheJournalofNudearMedicine @oflura@

Iadlne-123fatty acids cardiac uptake in patients with aortic stenosis, efficacyfor thyroidablation,1927 myocardialuptakeof branchedanalogueas 1392(le) gammacameraimages,scatter correctionin, marker of fatty acid metabolism, dynamic analysis of scintigrams in cardiac 236(ab) comparisonwith kineticsof â€œC mechanical overload hypertrophy and immunoadsorption,enhancementstrategyfor @tate,726(ab) failure,589 radioimmunotherapy,1020 uptake, oxidation, and lipid distribution in factorslimitingprecisionand accuracy,793(ab) long-termresultsfromtwoschedulesof normalcaninemyocardium,649 identification and characterization of treatmentfor toxic multinodulargoiter, Iodlne-123.HDA,assessmentof myocardial hypertrophicmyocardium,1013 795(ab) viabilityearlyduringpost-ischemic â€œInantimyosin vs. , to assess cardiotoxicity no harmto infantsfrommothers'therapy, reperfusionin pigswith, 179(ab) during doxorubicin administration, 44(ab) 32N(7) Iodin@7A mild to moderate degree of uptake in adrenals optimizationof therapyof thyrotoxicosis,1638 PDT-induced hypoxia in Dunning prostate mustbe carefullyinterpretedfor radiationabsorbeddoses, correlationto nodal tumors, 405 diagnosis of pheochromocytoma, 39(ab) metastases, 524Qe) tumor hypoxiaand tumor perfusion,885 myocardial SPECF, cardiomyopathy outcome scintigraphy,paradoxicalchangesin findingsin Iodlne-1234BF predictionusing,46(ab) advancedfollicularthyroidcancer, 1574 biodistnbution and dosimetry of, potent myocardial uptake in left ventricular therapy, in differentiatedthyroidcarcinomain radioligandfor imagingD2dopamine childhood,1061(ab) hypertrophy secondary to valvular aortic receptor, 1910 therapyfor thyroidcancer,detectionof stenosis, 57 displacement of equihbrium binding by chromosomalaberrationinducedby, D-amphetamineto measurein vivo pheochromocytoma evaluation with, improved 784(ab) by SPECF imaging, 4@ab) dopamine release, 186(ab) vitamin C as radioprotector against, 637 scintigraphy, as index of severity in primary first experience with, comparison with â€˜@l halhie-l31-CC-4@,phase II trial in refractorycolon IBZM, 934(ab) hypertrophiccardiomyopathy,45(ab) cancer, 205(ab) Iodlne-l23-IBHPE,1-125IVME2vs., distribution SPECF,inchildren,1062(ab) Iodlne-131-HDA,metabolismin normal,ischemic, in immature female rat, 272 lodlae-123-TISCH,dosimetry,208 and hypoxiccaninemyocardium,51(ab) Iodlne-123-Tyr-3-ocfreotlde, Scintigraphy, role in Iodlne-l3l-hlppurate,renovascularhypertension, in metastatic melanoma, 1028(ab) staging of small-cell lung cancer, 1397 48 new D2 ligand â€˜@IIBF compared with, 934(ab) Iodlne-125 lodlae43l4PPA, potentialfor clinicalevaluation I@altne-l23-IBZMdopamineD2rece@or brain implants, verification with dedicated of pancreaticinsufficiencyby urine estimationof bindingpotentialin striatumwith SPEC!' camera, 892(ab) analysis,946 SPECF, 2076 extracorporealimmunoadsorption, Iodlne-131-IQNP,new selectivemuscarinic striatalimagingin schizophrenicpatientstreated tumor-to-normaltissueratio, 448 antagonist, whole body distribution of, with typical or atypical neuroleptics, Iodlne-125-D(L)norfealluramine,1100(ab) 937(ab) 304(ab) Iodlne-125-ICAR,Ml selectivemuscarinic Iodine-l31-IUDR and @9'cHMPAObrainperfusionSPECFin antagonist,1101(ab) assessmentof brain tumorproliferativeactivity evaluation of patients with and at risk for Iodin@-l25-2'-IDZ,as potentialimagingagentfor using, 139(ab) Huntington'sdisease, 1274 SPECF investigations of benzodiazepine uptake and retention as measure of tumor Iodlne-1234L1S,dopaminergicD2 receptor receptors, 932 growth,1152 SPEC!' imaging in Rett syndrome, Iodlne-125.IgG,mouse,modificationof charge Iodlne-131-IVM,characterizationas markerfor increase of specific binding in striatum, followingradioiodinationwithvarious myocardialhypoxia,918 1717 oxidants, 1145(ab) Iodlne-131-MIBG 1ndine423-BW IodlDe-125.Iomaz4euil,@â€œTcHMPAOand, in imagingof pheochromocytomas,correlation cerebral blood flow and partition coefficient, double tracer autoradiography in with CT, MRand surgery, 791(ab) graphicplot analysis,498 experimental brain ischemia, 935(ab) lesiondetectioninneumblastoma,865(le) functional mapping of flow and back-diffusion Iodlne-125-IQNP,new selectivemuscarinic pheochromocytomalocalization,180 rate in humanbrain, 839 antagonist, whole body distribution of, scintigraphy,preoperativeand postoperative in lobar primarypulmonarylymphoma,1980 937(ab) evaluationof paragangliomas,173 SPEC!', new graphic method for estimation of IOdIIe-125-IUDR trace elementenhancementof therapy exchange distributionvolumein differential diagnostic and therapeutic implications of yields, 148(ab) diagnosisof PSP and Parkinson's uptake in exfoliated cells obtained from Iodlne-131-monodonalantibodies,anti-smallcell disease, 119(ab) patientswith bladdercancer, 1038(ab) lungcancer, radiotherapyin micewith, SPEC!'splitdose method,quantitative in radiotherapyof solid brain tumors in rats, 1013(ab) assessment of cerebrovascular reserve 1123(ab) Iodlne-131-monodonalantibody using,245(ab) tumortargetingin vitroand metabolicfate of, M195, radioimmunotherapytrials in patients transrectally administered, temporal changes of followingIntratumOralinjectionin with myeloidleukemias,207(ab) biodistobutionin chronicliverdisease, patientswith colorectalcancer, 1175 MN-14F9(ab),,phase I radioimmunotherapy 442(ab) Iodlne-125-IVME2,â€˜@IIBHPEvs., distributionin with, 206(ab) uptake and localization, SPEC!' and planar im,nature female rat, 272 lodlne-13l-Na, lowvs. highdose therapy in brain imaging in crack abuse, 899 I@U5@HBG thyrotoxicosis,796(ab) Iadine-l2Momuenll potentialas tracer for monitoringdoxorubicin Iodlae-13l-sodlumIodide,therapeutic formation of â€˜@I1-iodobutane in labeling by cardiomyopathy, 1282 administrationsof, radiationdose to iododestannylation, 356(ab) uptake, by norepinephrine, dopamine and upperspinefrom, 695 SPECF, in presurgicalwork-upof patientswith serotonintransporters, 1140 Iodlne-l3l-th@ne, circulating,in thyroid medically intractable focal epilepsy, lodlae-l25-PAB,malignantmelanomaimaging cancers,36(ab) 80(ab) agent,2169 17-lodoboptadecanoleadd (1HDA),uptake, SPEC!' brain imaging demonstrates significant Iosllne-125-SAP,scintigraphy,amyloidosis oxidation,and lipiddistributionvs. benZodiaZepine receptor reserve in regression demonstrated by, 473(ab) pIPPA and DMIPPA in normal canine humanandnon-humanprimatebrain, Iodlne-l31 myocardium,649 408(ab) absorbeddose calculationsin Haversiancanals, Iodo-@lyilne, biotinylated,for pretargeted Iodine-u3-mDR,uptakeandretentionas measure 1361 radiationdelivery,1147 of tumorgrowth,1152 bronchogenic carcinoma mimicking metastatic Irou-@,transform-dependentand independent Iodlae-123-JVM,nuclearmedicineviability,924 thyroidcarcinoma,809 uptakeof, in transformedand lodine@llBG characteristics,1219(le) untransformedcells, 1032(ab) absence of nonneuronal uptake in denervated dose selectionand absorbeddose profilesin liallarane, changesin Â°Â°â€œ9@cRBCdistnl,utionin rabbithearts,176(ab) treatmentof diffusetoxicgoiters,387 ferret induced by, 829(ab)

SubjectIndexâ€¢1993 2313 Isotretinoin

Isotretinoin, enthesopathy of patellar tendon rapid measurement of total and regional blood Kzypton-Slm insertion,455 flow with PET and â€˜@owater in patients controlled delivery of boll in normal subjects, with differentdegreesof renalfailure, resultsand implicationsof, 1859 349(ab) J inhaledin lungimaging,radiationabsorbeddose real-timemonitoring,ambulatory,199 estimatesfrom, 1382 Jay, Michael,Berson-YalowAward,30N(7) reduceduptakeof @â€œTclabeledFab' fragments underestimation of segmental defect size in lung Joint in animal model using cleavable chelator, scanning, 370 bone SPEC!' in recent meniscal tears, 713(ab) 1147(ab) Kuranz, John, people in nuclear medicine, 29N(6) rheumaticdiseases,imagingwith Â°@â€œTclabeled renaloutputefficiency,validationas objective OKT3,714(ab) quantitativeparameterin evaluationof uptake of Tc-99anti-rat-CD4monoclonal upper urinarytract obstruction,845 L antibody,in rat adjuvantarthritis,92 reproducibilityof exerciserenographyresults, Jones, Alan, Paul C. Aebersold Award, 26N(5) 554(ab) LAMPF. See Los Alamos Meson Physics Facility Journal OlNudear Modidne(JNM) scars, @Â°@1@cDMSA SPET in looking for, Laparoscopy, anterior seromyotomy and posterior appraisal of primacy claim policy, 1616(le) 550(ab) truncal vagotoiny, in chronic duodenal new editor, 25N(4),29N(4) scintigraphy,in acute scleroderma,1163 ulcer,gastricemptyingafter,30(ab) 34th year of publishing, 38N(6) solitary,diagnosisof renovascularhypertension Leukocytes. See also White blood cells with captopril renal scintigraphy in 1â€˜11n patient with, 1166 K cardiovascularinfectiondetectionwith, SPECF imaging with @FcDMSA for 868(k) Kawasakl disease, long-term follow up of detectionof scars in childrenwith in Gaucher's disease, 818 myocardialperfusionabnormalitiesin, vesicouretericreflux,198(ab) 213(ab) 99mTcDTPArenal uptake-plasmavolume scintigraphy, in cutaneous sarcoidosis, 812 @â€œTc,â€˜â€œIngranulocytes vs. , for examination K@ product, as quantitativeestimationof acutetubularnecrosis,radiolabeledlysozymeas glomerularfiltrationrate, 1390(k) of patientswithinflammatorybowel potential imaging agent in, 187(ab) transplantation disease, 1052 ambulatoryrenalmonitor,2276(le) avascularnecrosisin MRIand SPECF bone 99@TFcHMPAO, clinical experience in detection captopriladministrationeffectson ScintigraphiC scans, 381 of inflammatoryandinfectiousdiseases, parameters,517(ab) carcinoma in transplanted kidney detected 837(ab) clinicalevaluationof new renaltracer @â€˜9'c with MAG3 scintigraphy, 2185 U- LLEC, in transplantedpatients,514(ab) tubulointerstitialdisease,poor Â°Â°@FcDMSA biological properties of, temporal lobe findings clinicalvalue of triplehead SPECF imaging renaluptakeand,354(le) in SPED' studies of patients with mood with @FcDMSA as initial diagnostic uptake of TC-99m DTPA, quantification using disordersmaybe influencedby, 184(ab) tool in adultwomenwith recurrentacute planar SCintigraphy,1184 â€œCCOP 20712A, synthesis and evaluation of, pyelonephritis,551(ab) uptakeof @FcDTPA,Â°Â°â€œTcDMSAvs., 188(ab) corticalblood flow,comparisonof â€˜3Nammonia 1217(le) â€œC-labeledphorbolesters, proteinkinaseC andâ€˜@owaterforquantificationwith validationof bloodflowquantthcationby â€˜3N imaging,431 PET, 195(ab) ammoniaand dynamicPET in â€œCMQNB, quantification of myocardial determination of plasma flow using @Fc hypertensive patients, l164(ab) muscarinicreceptors, 981 @ MAG3,1167(ab) KInetic analysis D2, â€˜@IIBF,comparisonwith IBZM, diuretic renography, 1O29Qe) in canine myocardium, surface barrierfi 934(ab) dynamicimagingwith Â°@Fcsestamibiin detectorformeasurement,882(ab) D3, for SPECF imaging, 529 hypertension patients, potential for of â€œCdiprenorphineinpatientswithabsence factorsunderlyingD-amphetaznineinduced assessmentof renovasculardisorders, epilepsywith and withoutprovocationof displacementof dopamineD2 552(ab) seizures, 224(ab) radioligands in rhesus monkeys, 526(ab) estimationof quantitativeimagesusingplanar cellular,of FDGuptakeby tumortissue 5-HT2receptorspecific,â€˜@FMDL11939,20(ab) scintigraphy, 852(ab) components in vivo studied by iodinatedtetralinsas potentialsigmaligandsfor focalrenal parenchymalabnormalitieson microautoradiography,1136(ab) SPECFimaging,353(ab) MAG3 high resolution computer clinical evaluation of model for quantification of novel,formappingcentralcholinergic enhancedimagingand their significance, liverfunctionwith @FcPMTand innervation,357(ab) 549(ab) dynamicscintigraphy,8R@ab) novelnitrogenheterocyclebasedN3S, improvedformulasfor estimationof renaldepth comparisonwith equilibriumSPECT preparationand unexpected labelling in adults, 1766 measurementsof benzodiazepine propertiesof, 539(ab) mappingof localbloodflowwithPETandâ€˜@O receptor binding potential in human N2S2and N2SO,novel @Fccomplexesbased water, 196(ab) su_s, 994(ab) on, 538(ab) measurementof GFRusingdualdetector of â€œCPYRILmetabolitesinplasmaandbrain, gammacameraand geometricmeanand 947(ab) PET, for serotonin uptake sites, synthesis and comparisonwith referencein vitro ofintracellularhybridizationofc-mycmRNA biologicalevaluationof, 19(ab) potential, for mapping dopamine reuptake sites method, 351(ab) oncogenewith â€œInASDONprobes in normalized clearance-to-uptake slope ratio, leukemiccells, 1051(ab) by SPECF, methodto minimizefalse-positive myocardial â€˜â€˜Cacetate, by simultaneously potentialforSPECFstudyof brainMAO, diureticrenograms,762 fitting data from multiple ROIs, 193(ab) 1098(ab) optimumsampletimesfor single-injection, â€˜3Nammonia, for quantification of myocardial potential5-HT,@,354(ab) multisample renal clearance methods, blood flow, using PET, validation of, 83 potentiallyusefulM3-selectivecholinoceptorfor 1761 newapproachto estimateradiationdosimetryof PET imaging, 1120(ab) perfusionabnormalityin renovascular flow-basedradiotracers,762(ab) serotonin reuptake, 90(ab) hypertension,48 newestimationmethodaccountingforPET tripodal tris(salicylaldimine), funCtiOnaliZed,Ga quantitationof parenchymalretentionof @â€œTc accumulated counts of blood-time complexes,228 MAG3 in renal transplants, 1156(ab) activitycurves, 154(ab) vesamicol receptor, novel, molecular quantitativeevaluationof bloodflowin of pulmonary granulocytes, 165(ab) decomposition-reconstitutionapproach renovascular hypertension by â€˜3N putativehypoxictissuemarker after regional to, 21(ab) ammoniaand dynamicPET, 1166(ab) ischemia and reperfusion, 53(ab) linear accelerator, â€œStarWars,â€•put to medical quantitative measurement of blood flow and quantification by, unified approach to, 706 use, 30N(8) oxidative metabolism with â€œCacetate of relationshipbetweencerebralmetabolismand Llpoproteins, biodistribution and imaging of @Fc PET, 347(ab) lactateconcentration,956(ab) nativeLDL and oxidizedLDL, 261(ab)

2314 TheJournalofNudearMedicine Lymphoma

lAyer.See aLsoHepatobiiary tract subtraction for tumor imaging using @Â°â€˜Tl,@â€œTc radioaerosolventilationimaging,completenose alcoholiccirrhosis,prognosticvalueof colloid and three head SPEC!', 390(ab) closureand, 1835Qe) aminopyrinebreath test vs. uptake creates artifactualdefects in @Fc radioimmunodetectionof Pneumocystlscarinii Child-Turcotte-Pughscore, 809(ab) myocardialSPECTimages,quantitative pneumoniain HI\' patients,239(ab) cavernoushepatichemangiotna,849,2278(k) phantomanalysis,902(ab) revisedscintigraphiccriteriafor interpretation comparisonof hepaticmetabolismof LosAlamosMesonPbyulcsFacility(LAMP@),early ofventilation-perfusionscans for 16a-['@F]FESand l6@-('8FJFMOX dosing of accelerator,effecton nuclear pulmonaryembolism,59(ab) utilizingisolatedhepatocytesfrom medicineresearch,51N(6) rheumatoiddisease,cellularbasis for elevated differentspecies, 189(ab) 67Gauptakein,351Qe) comparison of methods for identifying early bronchogeniccarcinomamimickingmetastatic roleof â€˜@ITyr-3.octreotidescintigraphyin methotrexate-inducedhepatotoxicityin thyroidcarcinoma,809 stagingof small-cellcancer, 1397 patients with rheumatoid arthritis, 1905 carcinoma,PET followup studiesfor evaluation scans, intermediateprobability,prevalenceof effectiveportalvenous flowevaluationusing of treatmentresponsein, 75(ab) thromboembolicdiseasein patientswith, echo-Dopplerflowmetiycombinedwith clinicalevaluationof mucociliarytransport 55(ab) perjejunal portal SCintigraphyin chronic systemin diffusepanbronchiolitisusing scintigraphy,in acute chest syndromein diseaseof, 1103 aerosolinhalationcinescintigraphy, childrenwith sicklecell disease, 1059(ab) evaluationof experimentaltumorsusing @aF 1070(ab) singletransplants FDO PET, 2124 controlleddeliveryof Kr-81mboli in normal pulmonaryperfusiondistributionfollowing, handlingof radiopharmaceuticals,usefulnessof subjects,results and implicationsof, 1859 differencebetweenemphysemagroup in vitro model, 2030 detailedanalysisof patientswith matched and primarypulmonaryhypertension hemangioma ventilation-perfusiondefectsand chest group, 167(ab) metastaticmalignancymasqueradingas, on radiographicopacities,1851 quantitativeventilation-perfusionScintigraphy labeledRBCscintigrapl@y,1172 detectionof primarycancerwith @Â°â€œTc in, 166(ab) Â°Â°@â€˜TcRBC SPECF, 375 sestamr@bi,558(ab) suspectedmalignantsolitarynodulesof, hepaticarterialflowstudy and SPECF using different features of pulmonary metastases in pre-surgicalevaluationusingPET-FDO 9omTcMAAin embolizedand differentiatedthyroidcancer, natural imaging,72(ab) nonembolizedhepatocellularcarcinoma, history and multivariate statistical 9omTcaerosolcolloidformulationwith improved 811(ab) analysisof prognosticvariables, 1626 deliveryefficiencyfor ventilation hepaticextractionfraction,determinationby differentiationof benignand malignantopacities imaging,268 deconvolutionanalysis,in pediatric with FDG-PET, somTcDTPAaerosolclearance,inhaled population,214 does detoxificationreverseacute alveolitisof furosemideeffecton, 163(ab) hepatocellular carcinoma, FDG-PET vs. crack smokers?, 164(ab) oomTcm first-passangiographicstudiesof left histologicalfindingsin assessmentof, effect of cardiopulmonary bypass surgery on ventricularfunction,394 12(ab) pulmonaryvascularpermeability, two-steptargetingofexperisnentalmetastases highaccumulationof â€˜8FFDGaIby assessmentby transvasculartransportof withbiotinylatedantibodyand well-differentiated hepatomas of mice and 67c@a,1077(ab) radiolabeledstreptavidin,1011(ab) rats, 780 evaluationof suspectedmalignantpulmonary underestimationof segmentaldefectsize, 370 @ histologicaland functionalevaluationin chronic lesionswith SPECF,556(ab) uniformityof scan interpretation,diagnostic diseaseby @â€œTcGSASCintigraphy, evaluationof systemicbloodflowusingECG algorithmsand, 661 824(ab) gatedacquisition,1441 uptake of Â°@â€œFclaminin peptide PA22-2 is intracellularmetabolismof â€œInDTPAlabeled 67Gauptake,computerquantitationof, 1076(ab) decreasedin emphysemaand increased receptortargetedproteins,1728 hypertrophicpulmonaryosteoarthropathyin in tumored lung, 1133(ab) investigationof lobar distributionof inferior nasopharyngealcarcinoma,as early sign ventilation-perfusion/chest x-ray match less mesentericbloodflowby â€˜@IIMP, of pulmonary metastasis, 719(ab) likelyto representpulmonaryembolism 825(ab) â€œInDTPAIgOimaging,in patientswith ifQisâ€•decreasedâ€•ratherthan isolatedperfusedrat,hepatobiliaryhandlingof @naryinfections,1078(ab) â€œabsent,â€•58(ab) 1-1251@yr3octreotideand â€œInDTPA â€œInpOIyC1Onalhuman IgG,identifyingfocal ventilation-perfusionscans, 353(le) D-Phel-octreotideby, 2025 infectionin HI\', 1621 abnormalitiesinducedby bronchoalveolar metastases interobseivervariabilityin SCintigraphy lavage,1854 accuratedetectionusingPET-FDG,13(ab) interpretation, 1834(k) in PIOPEDstudy, 1109,1119 clinicalutilityof taggedRBCliverbloodpool lobarprimarylymphoma,1980 probabilitycategorydistributionin university imagingstudy in distinguishing localizationof â€œInlabeledIgO, PMNand and communityhospitals,57(ab) hemangiomasfrom,816(ab) anti-ICAM1in rat modelfor ARDS, roleindiagnosticevaluationof patientswith fromcolorectalcarcinoma, 1135(ab) pulmonaryhypertension,1075(ab) radioimmunoscintigraphyusingâ€˜@â€˜I North Americanblastomycosis Lymphnodes monoclonalantibodyF19, 327(ab) disseminated,670a-citrateand bone false-positive,by radiohnmunoguidedsurgery, misleadingfigureof focalactivityin, 2276(k) scintigraphy,458 804 @ newtechniqueto evaluatetransplantpatients, successful67@ of, 958 â€œInkukocyte im*ging in Gaucher's disease, 447(ab) observationof fullerenesin Technegas 818 orthotopictransplantation,quantificationof liver ventilation unit, 1082(ab) metastases,detectionin squamoushead-neck functionusingC-14aminopyrinebreath open bronchialstumppost-pneumonectomy, cancerwith MR.Iand FDG-PET,216(ab) test, 446(ab) â€˜â€œXeventilationimaging,462 reactive,comparisonof FDG, L-methionineand perfused,handlingof somatostatinanalogues PET imaging of non-small-cell carcinoma with thymidineaccumulationinto by, â€œCMET, relationship between experimentalinfectionsand, 413(ab) physiopathologicalsignificanceof @Â°â€˜@flper radioactivityuptakeand flow-cytometric sentinal,locationin high-riskmelanomaof rectumscintigraphyin Cirrhosis,1642 parameters, 1886 trunk, 1435 portacavalshunt, surgicalresults in sites pretargetedradiationdeliveryto, 8W for, 1147 smallmetastases,gammaprobe assistedcx viva inversusdiagnosedby per rectalportal primarypulmonaryhypertension,perfusionlung detectionfollowingadministrationof scintigraphy,301 scintigraphicpatterns of histologic â€œInmonoclonalantibodiesto colorectal pretargetedradiationdeliveryto, BIP for, 1147 subtypes, 1071(ab) cancers, 1818 quantitative evaluation of severity of disease by pulmonarygranulocytekinetics, 165(ab) Lympboma Â°Â°@@FcDTPA GSA, 823(ab) pulmonarysegmentalprojectioncharts for use assessmentofbrain tumorproliferativeactivity solitarysolidmasses, hepaticscintigraphyin in identification of segmental anatomy on usingâ€˜@â€˜IIUDR, 139(ab) evaluationof, 697 lungscan images,486(ab) B-cell

SubjectIndexâ€¢1993 2315 â€˜@â€˜IQSPECT dosimetry of patients treated Malignant melanoma. See Melanoma in vitro assessment of uptake, 2278Qe) with monoclonal antibodies, 509(ab) Mansfield,RobertK., Berson-YalowAward, formonitoringearlyresponseof human newantibodyfor,30N(10) 30N(7) adenocarcinoma cell line to radiotherapy, early detection of recurrence with 67(@ Mathematical modeling â€˜8FFDG and thymidine vs. , 773 scintigraphy,2101 compartmentalmodelfor simultaneous PET FDG-PET in differentiation from nonmalignant measurement of myocardial blood flow in differentiationof recurrentor residual CNS lesions, in AIDS, 567 and oxygenconsumption,â€œCacetate, musculoskeletalsarcomasfrom malignant,FDG-PETin, 1022(ab) 4(ab) posttherapychanges, 124(ab) pilottherapywithfractionatedCu-67BAT quantificationof myocardialmuscarinic in differentiationof recurrent or residual LYM-1,370(ab) receptorswith PET in humans,981 tumorfromposttreatmentchanges, primaryCNS, in non-AIDSpatients, radiolabeledantibodiesas cancer therapeutics, 214(ab) comparison of @Â°â€˜TlSPECT and â€˜8F 1028(k) Metbetrexate,neurotoxicityinducedby, FDO PET with MRI in evaluation of, MedicalInternalRadiationDose(MIRD) appearanceon â€˜â€œInWBC,67Ga-citrate 219(ab) Comm@ee and 2@@11chloride scintigraphy, 1377 treated, benign mediastinal and parahilaruptake applicationof effectivedose equivalentto M@m@ of 67@3@@,1330 nuclearmedicinepatients,714 circulatingâ€˜@â€˜ithyroxinein thyroidcancers, Lymphoscintigraphy, in high-risk melanoma of report on radiation absorbed dose estimates 36(ab) trunk, predicting draining node groups, frominhaledKr-81mgasin lungimaging, radiolabeled antibodies as cancer therapeutics, defininglymphaticchannelsand locating 1382 1028(k) sentinal node, 1435 Medicare,fee schedule,22N(4) MIRD Committee. See Medical Internal Radiation MedI-PbySIcSAward,CarolynJ. Anderson,22N(7) Dose Committee M Melanoma Molecularmedicine,new, 165 MagneticresonaneeImaglag(MW) high-risk of trunk, lymphoscintigraphy in, 1435 Molecularreca@on units,monoclonalantibodies bone scans in renal allograft recipients, 381 imaging agent, 1-125PAB, 2169 and,533(suppl) comparedwith bone Scintigraphyin diagnosisof initialassessmentof PET usingFDG in imaging Molybdenum.99 skeletal metastases in prostate cancer at of, 1420 DOE plan, 20N(4) initial presentation, 12t@ab) phase II scintigraphicclinicaltrialwith â€˜@I high purity fission, production in South Africa, comparisonto SCintigraphy,in volume BZA, 1260 1828(le) estimationoflarge multinodulargoiters, Meningloma Monitoringresponse,benignmediastinaland 794(ab) intraosseous,appearanceon bone scintigraphy parahilar uptake of 67Ga in treated comparisonwith @Â°â€˜11SPECF and â€˜@FFDG over five years, 961 lymphoma, 1330 PET in evaluation of primaryCNS 20',nSPECFforpredictinghistologicaltypesof, Monoaminetransporters,MIBOuptakeby, 1144) lyinphomain non-AIDSpatients,219(ab) 2091 Monoclosialantibodies detection of lymph node metastases in Metastasis. See aLso Cancer anti-CEA squamoushead-neckcancerwith axillaiy lymph node, comparison of detection conjugatedto bifunctionaltransitionmetal FDG-PET and, 216(ab) on attenuationcorrectedanduncorrected carboratecomplex,pharmacokineticsin evidence for coupling of carboxyl group wholebodyPETimagesinpatientswith tumor-bearingmice, 1294 coordinationto aminedeprotonation, breastcancer,547(ab) successfulhumanizationof highaffinity ReO(EC) complexes derived from bone murinemonoclonalantibodyMN-14, cysteine, 147(ab) in breast cancer, 291(ab) 1020(ab) FDG PET fusion with, to localize foci of EXAFSstructuralcharacterizationof anti-EGFR, comparison of phase I trials of, increasedactivity, 1190 solutionsof @asRe}I@p therapeutic 1005(ab) high-resolution, of brain, error bounds for five agentfor, 146(ab) antiferritin,evaluationof â€œInand @Â°Ylabeled registrationtechniquesbasedon, 948(ab) FDA approves new therapy for, 30N(8) linker-immunoconjugatesin nude mice integrateddisplay,manipulationandanalysisof Circulating â€˜@â€˜Ithyroxine in thyroid cancers, and dogs,938 images,497(ab) 36(ab) anti-ICAM-1,myocardialuptakein detecting lumbar, in back pain with emphasis on marrow intraoperativeassessmentof brain malignancies acutemyocardialinfarctionof rat, changesin endplatesinassociationwith using @Â°â€˜11,138(ab) 257(ab) disc degeneration, 711(ab) liver anti-TAG-fl,clinicalcomparisonof multislicecerebralbloodvolumemappingof accurate detection using PET-FDG, 13(ab) radiolocalizationof two, 1009(ab) braintumors,comparisonwithPET masqueradingas hepatichemangiomaon CC49, @â€œTclabelingof trisuccinconjugatedto, studies using FDG and CO. 985(ab) labeled RBC scintigraphy, 1172 107(ab) @ and PET with â€˜8FFDGfor detectionof lung CEA fragments, in colorectal cancer pancreatic cancer, 877(ab) different features in differentiated thyroid imaging,61 in posterior cerebral artery infarction and cancer, 1626 chemical modification to afforddiscriminated related visual field defects, 1009 experimental,two-steptargetingwith releaseof hippurate-likechelate in quantitativeanalysisof datainnormalagingand biotinylatedantibodyand radiolabeled non-targetfor target-selective Alzheimer'sdisease, 1681 radionuclidebonescansvs., indetectingspinal streptavidin, 1011(ab) radioactivitydelivery,106(ab) metastases,2191,2198 nodal,correlationof radiationabsorbeddoses colorectal cancer, current imaging strategies, three-dimensionalcoordinatematchingbetween to, 524(le) 537(suppl) PET and, using maximum gradient prostate,â€˜53SmEDTMPbiodistributionand direct labeling with @â€œTcby novel method, 278(ab) dosimetryestimation,1031 photoactivationprocess, 397(ab) 305-member stereotactic atlas for activation spatiallocalizationof metastaticprocesses,CF directly and indirectly @â€˜1@clabeled, 109 studies,277(ab) and SPECF image registration and fusion effectof degreeof DTPAconjugationper, on used for anatomic information, registration and using radiolabeled monoclonals, metabolism and clearance of its â€œIn relativequantitationof SPECTandPET 562(suppl) chelateinmice,228(ab) data in neuroimagingwith, testicular, initial evaluation of FDG PET enhancedquantitativeradioimmunotherapy Ma@ @o@anee ca@ (MW) imagingof, 15(ab) imagingwith MIRDOSEdosimetry fluorinatedmacromolecularprobes as thyroid carcinoma, bronchogenic carcinoma software, 510(ab) biosensors for non-invasive pH mimicking,809 againstE-selectin,imaginginflammationand assessmentwith, 495(ab) MetIIIOnInC vascular activation with, 243(ab) P-31, estimation of concentrations of effects of hypoxia on cultured human tumor cell hyperthermiaeffecton uptakeof, in smallcell phosphorousmetabolitesusing,861(ab) uptake of, 288(ab) lungcancerxenografts,1012(ab)

2316 TheJournalof NuclearMedicine Myocardlum

imagingagentsin nuclearmedicine,531(suppl) MRI.See Magneticresonanceimaging diagnosisby usingexerciseand rest myocardial IMMU-MN3, imaging of inflammation/abscess MRS.See Magneticresonancespectroscopy scintigraphyusing @Tctetrofosmin, with, 827(ab) MU1tIdIIIgresistance, enhancement of @Tc 479(ab) â€˜â€˜â€˜In,spatial localization of metastatic processes sestamibiaccumulationin MDRcellsby earlymyocardialclearancekineticsof @â€œTc using, CI' and SPECI' image registration cytotoxicdrugsand MDRreversing teboroxime, 630 andfusionfor,562(suppl) agents,560(ab) human pathologic correlation with PET in intact and F(ab')2fragmentsof MX-35, Muscasinicreceptors ischemicand nonischemic comparative study in xenograft model, IQNP high affinity antagonist, in vitro and in cardiomyopathy,39 1015(ab) vivo evaluationof, 1128(ab) hypertrophiccardiomyopathycomplicatedwith intra-tumoraldistributioninxenograftsof myocardial,quantificationwith PET in humans, ventricularaneurysmand myocardial humanovarianadenocarcinoma, 981 necrosis,2227 autoradiographicevaluationof, 75 newselectiveantagonist,wholebody â€˜@â€˜IHDA metabolism in, 51(ab) â€˜3'I-YBI-450-2106, distributionof, 937(ab) â€˜@â€˜IIVMas markerformyocardialhypoxia,918 radioimmunopharmacokineticsof, PET images of phosphoinositide response in leftventricularmassandinfarctsize estimation 1139(ab) primatebrain, 94(ab) from â€˜3NammoniaPET, based on kit-formulatedconjugationof NHS.BATester preparationof threeâ€œC-labelednovelfunctional pathologicalexaminationof explanted to, @Tclabeling and Ml selective agonists, 18(ab) hearts, 826 radioimmunoscintigraphy,1019(ab) quantification in vivo with â€œCNMPB and PET, nitratesimprovedetectionof ischemicby viable labelingwith 2â€•AtusingSAPC,396(ab) distinction of ligand delivery and binding, myocardiumby20'll reinjectionSPECF, lackof HAMAresponseinpatientsimagedwith 430(ab) ImmuRAID-CEAand ImmuRAID-MN3, MuscIIIOSkeIetaIsystem,recurrentor residual 1472 planarandSPECFimagingusingnovel @â€œTc l008(ab) sarcomas,FDG and methioninePET in M195,in acute myelogenousleukemia,422 differentiationfromposttherapychanges, rntroimidazole,50(ab) Mu-9,clinicalevaluationfortargeting 124(ab) rightventricular @Â°â€˜11kineticsin pulmonary gastrointestinal carcinoma, 375(ab) MyocardlalInfarction hypertension,relationto rightventricular murine,Re-188,209(ab) acute sizeand function,1695 newstrategyforlabelingwithâ€œIn,394(ab) does myocardialdenervationcontributeto silent peptidesandmolecularrecognitionunitsand, silentischemiaearlyafter,47(ab) does myocardialdenervationcontribute,early 533(suppl) modelsfor predictinglong-termoutcomeby after acute myocardialinfarction,47(ab) planarimaging,attenuationcorrectionof quantitativeadenosinetomography, spontaneous,assessedby @â€œTcsestamibi geometric mean images, 237(ab) 212(ab) imaging,134 in radioimmunoscintigraphy,2264 myocardialuptakeof radiolabeled Tc-94m teboroxime synthesis, dosimetry and radiolabeled anti-ICAM-1 monoclonal antibody in initialPET imagingstudies, 1058 acceptanceby medicalinsurers,32N(3) detectionin rat, 257(ab) thalliumreverseredistributionin perspective, integratedapproachto estimating myocardialviabilityassessmentby sequential 1692 biodistribution and radiation absorbed PET scan following, 89(ab) uptake mechanism of neutral myocardial dose from,511(ab) rest-redistributionon SPECF @â€˜Tl imagingagent @FcN-NOET,65(ab) radiolabeledstabilizedF(ab')2fragmentsof scintigraphyafter, predictsnormalwall Myocardium.See aLsoMyocardialinfarction; antifemtin in nude mouse model, 2152 motionon lowdose dobutamine Myocardialischemia â€˜@Re echocardiography,170(ab) accuracyof 3@TlSPECF at rest for evaluation dosimetry, 908 totally occluded infarct-related artery and, ofviability, in comparison to â€˜8FFDG radioimmunotherapy, preparationand roleof quantitativeplanar @â€œflimaging PET, 729(ab) evaluation,260 forviabilitydetermination,728 assessmentof cardiotoxicityby â€˜â€œInantimyosin synthesis,metalchelatestabilitystudies,and deoxyglucoseand @Fcglucaratedistribution studies, bolus administration vs. enzymedigestionof peptide-linked in, 1303 continuousinfusionof doxorubicin, DOTA derivative and its corresponding experimental 43(ab) radiolabeledimmunoconjugates,104(ab) myocardialperfusionand necrosisestimates assessmentof coronaryreserve in man, synthesisand characterizationof new tiipeptide with 38Kand PET in, comparisonof PET with â€˜@Owaterand bifunctional chelating agent for SPECI' and planar imagingwith instant @Fc intracoronaryDopplertechnique,1899 radiolabelingof, 398(ab) antimyosin kit, 191(ab) assessmentof residualviabilitywith @Fc 99mTc 170H.82, for imaging breast cancer, leftventricularmassandinfarctsize estimation MIBI,749(ab) 1003(ab) fromâ€˜3NammoniaPET, based on assessmentof viabilityearly during @â€œTc-labeledanti-ratCD4,joint uptakeand pathological examination of explanted post-ischemicreperfusionin pigswith bodydistributionof, in rat adjuvant hearts, 826 â€˜5FFDO and â€˜@IHDA, 179(ab) arthritis,92 prior automated analysis program for evaluation of @Fc-bbeled01(13, imaging rheumaticjoint cardiaceventswithin 12monthsafter PET studies, 968 diseaseswith, 714(ab) non-ischemic non-invasive imaging test in blood flow vascularthrombusdetection,scintigraphic patients with, 295(ab) methods for, 554(suppl) prognostic efficacy of exercise radionucide assessment of endotheial function with PET Morphine-augmentedChOIeScIntIgIapliy ventriculographyand coronary coldpressortestin patientswithvarious delayedimaginghasunacceptablylowpositive angiographyin patientswith andwithout, degreesof atherosclerosis,137(ab) predictivevalue for acute cholecystitis 127(ab) quantificationusing PET, validation of â€˜3N whencomparedto, 300(ab) rapidimagingwith @Fc-labeledantimyosin ammoniatracer kineticmodelfor, 83 delayedimagingvs., in suspectedacute recombinantsingle-chainFv, 234 quantificationusing PET and â€˜3Nammonia in cholecystitis,506 teborox,meis markerof bloodflowfollowing patients with angiographically false-negative,bile leak fromgallbladder reperfusionof, 48(ab) documented coronary artery disease, perforation mimicking bowel activity Myocardlal 133(ab) and, 131 acute,deoxyglucoseand @â€œTcglucarate resting,maintenancein dysfunctional Motion.See Patientmotion distributionin, 1303 myocardiumwith @Â°â€˜11redistribution, Motorlisaction,mirrormovementsduring assessmentof myocardialviabilityearlyduring 171(ab) recoveryfromstroke, 225(ab) reperfusionafter, in pigswith â€˜8FFDG simultaneousmeasurementof oxygen @ Movementdisorders and HDA, 179(ab) consumptionand, â€œCacetate, choreatic, spectrum of regional cerebral glucose assessment of perfusion defect size after compartmentalmodelfor, 4(ab) consumptionin, 118(ab) SPECT imaging with @Fcsestamibi blood flow measurement by radiolabeled Parkinson's disease. See Parkinson's disease after stress, 187 tracers, 1518

SubjectIndexâ€¢1993 2317 Myocardlum

catheterablationinducednecrosis,antimyosin glucose metabolism, simple method to estimationwith PET and â€˜@Owater antibodyimagingfor identificationof, quantitatefromMB ratio in myocardial administeredby constantintravenous 256(ab) â€˜FFDG study, 875(ab) infusion,340(ab) celldeath,FDGand,myocardialperfusionand, glucoseutilizationduringhyperglycemicclamp FIXI and, myocardialcelldeath and, 866Qe) 866(k) in type-i diabetes evaluated with PET glycogenaccumulationin chronically characteristicsof glucosemetabolismin and FDG, insulinand non-insulin hypoperfusedmyocardiumwith hypertrophiccardiomyopathy,PET study mediated,758(ab) maintainedFDG uptake, 5(ab) usingâ€˜FFDG,426(ab) glucoseutilizationenhancementby Acipimox, human pathologic correlation with PET in comparisonof differenttechniquesfor 429(ab) ischemicand nonischemic @ calculatingbloodflow,343(ab) hibernating,detectionby gatedbloodpool cardiomyopathy,39 comparisonof factorsinfluencing scintigraphyunder lowdose dobutamine imagingwith 99'@Tctetrofosinin,222 cost-effectivenessof diagnosisand and isosorbide dinitrate infusion, 378(ab) inhomogeneityof gatedand ungatedSPECF management of coronary disease, 136(ab) hypertrophic,approachesto identificationand S9IwFcsestamibi bull's-eyes, comparison comparisonof â€˜3Nammoniabloodflow characterization,1013 with @Â°â€˜11,281 measurementtechniques,192(ab) â€˜@I-MIBGSPECT,cardiomyopathyoutcome nutritivereserve, flowvelocityreserve and, comparisonof uptake,oxidation,and lipid predictionusing,46(ab) in conductance vessels, 717 distributionof IHDA, pIPPA, and â€˜@I-MIBGuptake in leftventricular prognosticimplicationsof dipyridamole @â€˜9'c sestamibiSPECF imaging,336(ab) DMIPPA, 649 hypertrophysecondaryto valvularaortic scintigraphy,personnelradiationdosimetry compartment model for measurement of stenosis,57 from @â€œTcsestamibivs. 2Â°'Tl,1210 regionalbloodflowwith â€œCMTPand influenceof patientheight/weightand type of simultaneousassessmentof leftventricular PET, 342(ab) stress on count rates with @â€œfland functionand, duringtransientcoronary decreasedcoronaryreserve in idiopathicdilated sSmTcsestamibi,731(ab) occlusion,1(ab) cardiomyopathyassessedusingPET with kineticsof putativehypoxictissuemarkerafter SPECFimages,patientmotioneffectson, 303 â€˜@owater,134(ab) regionalischemiaand reperfusion,53(ab) 99@@Fctetrofosmin, human biodistribution, detectionand correctionof patientmotionin long-termfollowup of perfusionabnormalities dosimetry,and safetyof use in imaging, dynamicand static SPECF using in patientswith Kawasakidisease, 30 multi-detectorcamera, 1349 213(ab) 3fl@fl SPECF, left ventricular differentiationofperfusion abnormalitiesfrom modelingof â€œCacetate kineticsby cavity-to-myocardialcount ratio, resting attenuationeffectson combined simultaneouslyfittingdata frommultiple leftventriculardysfunction,193 xflhlpsnvFcsestamibistudiesusing ROle,193(ab) perfusionabnormalities,gated SPECFwith relativeregionalactivityprofiles,255(ab) multicenter evaluation of new automated 99uwFcsestamibi for assessment of, 601 dipyridamolestress @â€˜Fcsestamibi analysisprogramfor PET flowstudies, perfusionand necrosisestimateswith @Kand tomography,independentpredictorof 759(ab) PET in experimental myocardial adverse outcome following acute necrosis,hypertrophiccardiomyopathy infarction,49(ab) ischemicevents, 338(ab) complicatedwithventricularaneurysm perfusiondefectreversibility,independenceof dipyridamokarFflimaging,cerebrovascular and, 2227 re@ asynergyand, 86(ab) accident associated with, 128 normal,ischemic,and hypo,dc, â€˜i'!HDA perfusionimagingand dynamicanalysiswith dobutamine @9'csestamibiSPECF and metabolismin, 51(ab) 99@'Fctetrofosinin, 1478 echocardiography,coronaryangiography normalvs. flowrestricted,earlymyocardial PET measurement of regional blood flow vs., in coronary artery disease detection, clearancekineticsof @â€˜Fcteboroximein permitsrecognitionofviable and 889 differentiation,630 non-viablemyocardiumin chronic does denervationcontributeto silentischemia novelapproachto quantifyingextent and m@al infarction,87@b) early after acute myocardialinfarction?, severity of canine perfusion defects by prognosticrelevanceof â€œInantimyosinFab 47(ab) PET polar mapping, 756(ab) accumulationin patientswith dilated does perfusibletissue indexreflecttissue that optimalidentificationofviabilitywith SPECF, cardiomyopathy,753(ab) can exchangewater or flow 85(ab) prognosticvalueof normal @â€œ9@csestainibi heterogeneity?,344(ab) oxygenconsumption,refinedmethodfor perfusionimaging,211(ab) dynamicand gated PET â€˜3Nammoniaimaging quantificationusingmeantransittime quantificationof muscarinicreceptorswith PET confirmsinhomogeneoustracer retention with â€œCacetate and dynamic PET, in humans,981 buthomogeneousperfusionin normal 878(ab),2038 quantitativeSPECF, feasibilityof multicenter subjects, 132(ab) oxygenconsumptionrate,effectof plasmatime trial assessedby meansof cardiac dynamicPET studiesusingimage-derivedinput activitycurve shape on estimateswith phantom,723(ab) recoveryof functionfollowingcoronary functions,440 â€œCacetate studies, 194(ab) revascularization,84(ab) dysfunctional, resting myocardial blood flow oxygenmetabolisminuntreatedGraves'disease and glucosemetabolismmaintenance assessedby PETwith â€œCacetate, regional glucose utilization rate and flow metabolism ratio under fasting, oral with @â€˜11redistribution in, 171(ab) 428(ab) glucoseloadingand hyperinsulinemic effect of motion on @Â°â€˜11SPECF studies, 1845 parametricimagesfor quantitative euglycemicclampingand comparison effect of â€˜rTCstaining on distribution of measurementsof regionalbloodflowin with flow in normal su1@ects,870(ab) radiolabeledpharmaceuticals,178(ab), humans,862 rest and hyperemicbloodflowduringestradiol 1722 perfusion therapy in post-menopausal women by effectsof changesin wallthickeningon ECG absolute,quantificationwith @Kand PET, â€˜3Nammonia and PET, 802(ab) gated SPECF @â€œ1'csestamibiimages, 341(ab) reverse redistributionin resting @@ll 382(ab) assessmentof defectsize after SPECF scintigraphy in patients with coronary exercise-dlipyridamole perfusion imaging, 2061 imagingwith @Fcsestamibiafter stress, artery disease, relationto coronary falseperfusiondefects,computersimulation 187 anatomyandventricularfunction,1688 study of, 109(ab) biokineticsof @â€œTctetrofosminand, 1254 reversible 2rofl perf@ defects in rightbundle â€˜8FFDG in viabilityassessment,89(ab) detectionof patient motionduring branchblockand normalcoronary functionafter coronaryrevascularization, tomographicimaging,1341 angiogram,1218Qe) perfusabletissue indexparallelsoxidative dobutamine @TcsestamibiSPECFand rightventricular @â€˜11kineticsin pulmonary metabolismin predictingrecoveryof, echocardiography,coronaryangiography hypertension,relationto rightventricular 135(ab) vs.,895 size and function,1695 68Garadiopharmaceuticalthat is retainedin, dynamicSPECF using @Fcteboroximefor roleof quantitativeplanar @Â°â€˜11for determining 1127 quantificationof, 733(ab) viability,in acutemyocardialinfarction

2318 TheJournalofNuclearMedicine Oncology

andtotallyoccludedinfarct-related stage IV, 67Gaand @â€œTcMDPskeletal Nuclearblasttestveterans,U.S fundsstudy, artery, 728 scintigraphyin determiningprognosisfor 24N(1) sensitivityof dual isotopeperfusionimagingfor childrenwith,1082,1087 Nuclearmedicine detection of specific atherosclerotic Neurons cultivatingsubspecialistsfor, 1826(le) lesions, comparison to angiography, absence of nonneuronal uptake of MIBO in desktopcomputing,18N(1) 254(ab) denervatedrabbithearts,176(ab) digital,highlyintegrateddepartment,854(ab) simultaneousrest @Â°â€˜TVstress@â€œTcperfusion brain uptakeof @Â°â€œflfromCSF compartment, earlyclosingof acceleratorcouldimpede SPECF, spill correction technique for, 99 research,51N(6) 903(ab) cholinergic futureof, autonomyor integration?,27N(9) structure-activityrelationshipsfor cationicGa in vivo mapping in human brain using SPECF graphicuser interface-basedreportingsystem, radiopharmaceuticals,313(ab) and(-)-5-'@'IIBVM,93(ab) 515 substrateutilizationandleftventricularfunction synthesis and in vitro evaluation of @â€œTc and healthcare reform,32N(11) in Adriamycin cardiomyopathy, DADT-BVM as potential marker for, human element integral to future of, 1825(le) 1529 541(ab) in Israel, 1826(le) @â€œTcteboroxime uptake in cultured cells, vs. sympathetic, MIBG uptake by, 1140 â€œmolecularnuclearmedicineâ€•grants,15N(2) Neurotoxicity 2o@11and @Fcsestamibi, 255 morethanjust medicalimaging,1617(le) thicknessby gated PET and SPECF,variability of acute mercury poisoning, PET FDG brain networkforremoteviewinganddistributed studiesin 10patients,988(ab) andbias,856(ab) processing,859(ab) methotrexate-induced,appearanceon â€œIn newdirectionsfor medicalimagingin the 2o@1@Iperfusion tomography one to five years WBC,67Ga-citrateand @Â°â€˜11chloride nineties,157 after successful coronary angioplasty, scintigraphy,1377 296(ab) Neutroncapturetherapy,DOE fundingof new molecularmedicine,167 20!nSPECFinBland-White-Garland research,29N(4) no moreEdselmechanicsneededin, 1826(le) syndrome,2182 Newsline,Commentary payment schedule threatens future of specialty, up-regulationof beta-adrenergicreceptorsearly Asiaand OceaniaCongressin NuclearMedicine 1827(le) after sympathetic chemical denervation and Biology,17N(5) peoplein nuclearmedicine,20N(6) in dogs assessed with PET and â€œC futureof nuclearmedicine,27N(9) perspective from Europe on future of, 169 CGP12177, 175(ab) Linesfromthe President,34N(3),50N(6), practicalalgorithmfor assessingfloodfield uptake mechanism of neutral imaging agent 32N(9) uniformityin, 847(ab) @â€œTcN-NOET,65(ab) SNMJACNPgovernmentrelations,22N(4), prognosisby, 1087 uptakeof â€˜@Ibranchedfatty acid analogueas 19N(7) quantificationby kineticanalysisin, unffied markerof fatty acid metabolism, SNM annual meeting highlights, 13N(8) approachto, 706 comparisonwith kineticsof â€œC Nitricoxidesynthase,probe for, in viva rat researchopportunities,52N(6) palmitate,726(ab) biodistributionof no-carrier-added1-125 trainingfor future, 167 uptake of radiolabeled anti-ICAM-1 monoclonal DPI, 355(ab) validity ofvoxel based Monte Carlo simulations antibodyin detectingacute myocardial NItrOgen-13,parametricimagesfor quantitative in, energy spectrum analysis, 232(ab) infarctionof rat, 257(ab) measurements of regional myocardial NuclearRegulate.,'Commission(NRC) vectorizedMonteCarlocode for modeling blood flow in humans, 862 ACMUI, 20N(7) photontransportin non-uniformmedia Nltrogen-13.ammonla agreementstates, 20N(7) forSPEC!',895(ab) bacterialendotoxintest, PET, 469 budgetappropriations,29N(10) viabilitydetectionby PET,valueofquantitative cardiacPET, 978 budgetsecurity,20N(7) analysisof glucoseutilizationin, 2068 automatedregiondefinitionfor,336 changing rules on radioactive waste storage, viable comparison of myocardial blood flow 28N(5) detectionby FDGSECTduring measurement techniques, 192(ab) confusionabout radiationsafetyin medicine, hyperinsulinemicglucoseclamping, comparisonwith â€˜@Owater for quantificationof 34N(3) 727(ab) renal cortical blood flow with PET, congressionalhearings,29N(10) identification in patients with chronic 195(ab) congressional inquiries, 20N(7) coronaryartery diseaseusingâ€˜@owater coronary artery disease detection and Curtissleaves,30N(8) and PET, 88(ab) localizationusing,initialresultswith enforcementactions,20N(7) nitroglycerinenhanced @Â°â€˜11reinjectionfor automatedanalysisprogramforPET fees threatenresearchreactors,30N(10) detectionof, 173(ab) studyevaluation,968 licensing fees, 22N(4) dynamicand gated PET imagingconfirms newboss toutsself-regulation,23N(10) inhomogeneous myocardial tracer patientâ€œfollow-up,â€•chairman'smandate, retentionbut homogeneousperfusionin N 30N(3) normalsubjects, 132(ab) patientreleasecriteria,20N(7) NationalBiomedicalTracer Facility,DOE's in situ production,post irradiationâ€˜3Cand 2H pregnancyrule, 20N(7) stop-gap isotope plan and, 13N(4), NMR analysis of aqueous ethanol and proposedamendments,25N(9) 24N(4) aceticacidsolutionsfor, 1115(ab) Neip,WilB., peoplein nuclearmedicine,32N(6) in-targetpreparationof, 1113(ab) radiationprotection,22N(4) radiopharmacyregulations,22N(4),20N(7), Neuroblastoma kinetic model for quantification of myocardial comparisonof biodistributiondata withTLD bloodflowusingPET, validationof, 83 29N(10) absorbeddose measurementsusing myocardialbloodflowquantification,488 regulationson departuresfrommanufacturer's instructions,523(le) @ monoclonalantibody3F8 conjugates PET, left ventricular mass and infarct size towarda balancedperspective,17N(10) in xenografted athymic nude mice, estimationfrom,based on pathological user fees, 29N(10) 423(ab) examination of explanted hearts, 826 determination of GD2 antigen concentration in, Nitrolmidazoles,viability,924 using monoclonal antibody 3F8 by Nontumor-promotingactivity,â€œClabeledphorbol 0 quantitative autoradiography, 457(ab) esters,proteinkinaseC imaging,431 lesiondetectionwithâ€˜@â€˜IMIBG,865Qe) NOrepineplirIne OcularImplants,hydroxyapatite, @FcMDP optimizeddiagnosticstrategyfor, in 6-'F, comparisonwith 6-'8F FDA, 619 evaluation,467 opsoclonus-myoclonus, 1922 transporters,MIBGuptakeby, 1140 Officeofllealth Care Policy(OHCP),availability SIMS microscopy imaging of intratumor NorthAmericanblastomycosis of bulletin,29N(4) biodistribution of MIBG in human 67Ga-citrate and bone scintigraphy, 458 oldendorf;WIfthamH., In Memopiam,871 SK-N-SH cell line xenografted into nude successful67Gaimagingof, 958 OncoIoiy.See aLsoCancer mice, 1565 NRC.See NuclearRegulatoryCommission newengineforPET/SPEC!',13N(8)

Subject Indexâ€¢1993 2319 O@ft

Othlt, â€œInDTPAoctreotideaccumulationin tasks is abnormalin patientswith detectionand correctionin cardiacPET Graves' orbitopathynot based on schizophrenia,1068(ab) imaging, using automated registration blood-pool radioactivity, 158(ab) PET comparedwith, in assessmentof coronary algorithm,883(ab) Oropba,ynx,scintigraphicstudiesof reserve in man, 1899 detection and correction in dynamic and static oropharyngo-esophagealfunctionin practicalproceduresand pharmacological myocardial SPECF using multi-detector stroke and other neurologic disorders, applicationsof quantitativePET,1006 camera, 1349 34(ab) quantitativebloodflowstudies, noninvasive detectionduringtomographicmyocardial Osteonecrosis,dysbaric,animalmodelof, 710(ab) arterialmonitorfor, 1000 perfusionimaging,1341 @ Ova@an Oxygen-18, new supplier breaks isotope effecton cardiac SPEC!' imaging,1355 adenocarcinoma,xenograftsof, intra-tumoral monopoly,52N(6) effect on anTI SPECF, 1845 dism@butionof 2-DOand monoclonal Oxygen-18 CO2, enriched, cryogenic solid target head antibodiesin, autoradiographic forproductionof â€˜@Ffrom,269(ab) correctionstrategyduringbrain imaging, evaluationof, 75 276(ab) clinicalimmunoscintigraphyof ovarian P SPECF and PET reconstruction methods carcinomausingâ€˜@â€˜I145-9monoclonal accounting for, 360(ab) Pagot'sdisease,in patientwithbreast cancer, 1214 antibody,1651 during tomographic myocardial perfusion Palladlm-109, complex,synthesisand dynamicâ€˜8FFDG PET studiesfor assessment imaging, effectiveness of detection characterizationof phosphorous of, 14(ab) methods,740(ab) hydrazide steroid conjugate and, 145(ab) FDG uptake and proliferativeactivity,414 Paul C. Aebersold Award, Alan Jones and Alan Psecreas immunoscintigraphyin managementof, clinical Davison,26N(5) agent for potential clinical evaluation of utilityof, 545(suppl) pancreaticinsufficiencyby urine analysis, Pediatric patients influenceof anti-idiotypicHAMAon three 946 autismin, abnormalregionalcerebralbloodflow differenttumormarkerassays in ovarian cancer response to auditory stimulation in, cancer patients,503(ab) diagnosis with PET and FDG, 1055(ab) 307(ab) quantitation of CA-M0v18 antigen in sections experimentalradioimmunotherapyemploying hepatobiliary scintigraphy, determination of of ovariancarcinoma,1004(ab) â€˜@â€˜Imonoclonal antibody PAM4, hepaticextractionfractionby residual/recurrentcancer, detectionusingFDG 1010(ab) deconvolutionanalysis,214 PET, 16(ab) localizationof gastroenteropancreatictumors high-resolutionSPECFimagingof spine in, supra-additiveeffectof x@Pchromicphosphate with â€œInsomatostatin analogue, 156(ab) 202(ab) and CDDPin, 217(ab) Pancreatic 11pase,site specific/stable normalizedclearance-to-uptakesloperatio for targeting with MOv-18 monoclonal antibody radioiodination,â€˜@â€˜I1,2-Pal.MPPA, minimization of false-positive diuretic labeled with S9mTc,323(ab) urine analysis, 946 renograms, 762 tissuedistributionof radiOlabekdcMOV18IgG, PET FDG studies of tumors in, 199(ab) F(ab')2, and Fab' in, 326(ab) adenoma postprandial gastric motility in infants with Ovary,cells, Chinesehamster, hypoxiaeffecton comparative study of @â€œTcsestamibi/@â€•fl gastroesophageal reflux and delayed accumulationof @9'cglucarateand with @Fcpertechnetatesubtraction gastric emptying, 2120 @â€œFcgluconate,242 scintigraphy and ultrasonography in 99mTcHMPAOin brain death determination, Oxygen localizationof, 804(ab) 203(ab) @ consumption,simultaneousmeasurementof relative 9srn@ MIBI uptake in, 2o'@nscintigraphy,in solidtumors, 200(ab) myocardialblood flowand, â€œCacetate, 807(ab) 20111 SCintigraphy for assessment of 67Ox avid compartmentalmodelfor, 4(ab) hyperfunctioning tissue, intraoperative mediastinalmassfollowingtherapy for metabolicrate of, modelingapproachto validationof @â€œ1@csestamibiand â€˜@I Hodgkin'sdisease, 1326 eliminateneed to separatearterialplasma subtractiontechniqueforpreoperative in â€˜@OinhalationPET, 1333 localizationof, 805(ab) blood flow, tumescence, 523(le) @ myocardialconsumptionrate, effectof plasma scintigraphy, @Fcpertechnetate, and hemodynamics, design and implementation of time activitycurve shapeon estimates 99mTcsestami@bi,808(ab) circumferentialnon-imagingprobewith with â€œCacetate studies, 194(ab) subtraction scintigraphy, ai1TIP@@@Tc, superiortemporalresolutionfor Oxygen-iS,PET, study of regionalcerebralblood ultrastructuralhistologycorrelationwith, measurement of, 1160(ab) flowmeasuredduringbehavioral 24 15-(p-Iodophenyl)pentadecanok acid (pIPPA), challenge in obsessive compulsive 99mTcsestami@bias imagingagent,806(ab) uptake, oxidation, and lipid distribution disorder, 180(ab) Parkismen'sdiomse vs. IHDA and DMIPPA in normal canine Ozygea-15gas, PET and autoradiographicmethod dysphagia in parkinsonism, assessment by solid myocardium, 649 with continuous inhalation of, 1672 phase radionudide SCintigraphy, 812(ab) Oxygen-iSRBC,andâ€˜@owaterrequireseparate functional receptor testing in patients with ANP, â€œInchelated derivatives for in viva external dispersion corrections, 197(ab) idiopathicParkinson'ssyndromevs. imagingof receptors,226(ab) Oxygen-iSwater Parkinsonplus syndrome,117(ab) ApoBsynthetic, @â€œTclabeled,for comparisonwith â€˜3Nammoniafor quantification metabolismof 6-['8flFDOPAis enhancedin atherosclerosis imaging in hyperlipidemic of renalcorticalbloodflowwithPET, patientswith, 114(ab) rabbits, 260(ab) 195(ab) newgraphicmethodforestimationof cancer imaging, 32N(7) concordanceof nutritivemyocardialperfusion distribution volume on â€˜@IIMP SPECF chemotactic reserve and flow velocity reserve in in differential diagnosis of PSP and, high affinity Tc-labeled, 62(ab) conductancevessels, 717 119(ab) in viva bioactivity and biodistribution of decreasedcoronaryreserve in idiopathicdilated PET imaging of dopamine reuptake sites by â€œC analogs in nonhuman primates, 2130 cardiomyopathyassessedusingPET WIN 35,428 and PET, 115(ab) 99mTclabeled, for infection imaging, 833(ab) with, 134(ab) SPECFimagingdemonstratesloss of striatal 99mTclabeledfor localizingacute bacterial in identification ofviable myocardium in dopamine transporters in, 116(ab) infectionin rabbit, 2176 patientswithchroniccoronaryartery Patientmotion a9nrFclabeled HYNIC derivatized analogs for disease,88(ab) automatic correction for artifacts in dynamic imagingfocalsitesof bacterialinfection, â€˜3Nammonia vs. , for quantificationof radionucidestudiesusing 836(ab), 1964 myocardialbloodflowusingPET, 83 cross-correlationmethod,501(ab) cyclic, @Fclabeled,for thrombusimaging, and â€˜@olabeledred bloodcellsrequireseparate correctionalgorithmfor studiesacquiredfrom 60(ab) externaldispersioncorrections,197(ab) multipleheadcameras,500(ab) monoclonalantibodiesand,533(suppl) PET, suggests that regional brain activation correctionsystemfor tomographicimaging radiolabekd,cancer imaging,NDAsoughtfor, during performance of specific memory based on CCD video cameras, 359(ab) 24N(1)

2320 TheJournalofNudearMedicine Positronem@&on tomo@y (PEt)

radiopharmaceuticals,2253 PKC.SeeProteinkinaseC automated iterative three-dimensional receptortargetedradiolabeledpolypeptides, Planar Imaging registration of images, 2009 intracellularmetabolism, 229(ab) activityquantitationusinglowresolution andautoradiographicmethodwithcontinuous snakevenom,preliminaryevaluationfor measuredattenuationscans,858(ab) inhalationof â€˜@ogas, 16'72 thrombusimaging,258(ab) attenuationcorrectionof geometricmean bacterialendotoxintest, 469 synthesis,metalchelatestabilitystudies, and images,accuracyof quantitation,237(ab) blockdetectors,effectof indexof refractionon enzymedigestionof peptide-linked brain, in crack abuse, 899 detectorelementidentificationin, 866(ab) DOTA derivative and its corresponding correlation of sestamibi defect size with flow in bloodglucoseconcentrationinfluenceon FDG radiolabeledimmunoconjugates,104(ab) chronicinfarctmodel,385(ab) uptake in cancer, I synthetic, 15N(11) early and late, and SPECF thaffium imaging in 76BrMBBGas radiotracerformapping syntheticimmunogensfor developmentof evaluatingactivityof soft tissueand bone sympatheticnervesof heart, 1739 cardiacmyosinlightchain-i specific tumors, 123(ab) can zooming be used in EM reconstruction of radioimmunoassay,2144 estimationof quantitativerenalimagesusing, images?, 887(ab) @â€œFclabeled 852(ab) cardiac, SNMCardiovascularCouncilposition evaluationfor imagingatheroscleroticlesions â€˜FFDG, influence of high and low insulin paper on clinicaluse of, 1385 in vitro, 259(ab) levels during eugylcemic clamping, cerebralglucosemetabolismresponseto evaluationfor imaginginfectionin rabbit 757(ab) GABA-Astimulationstudiedwith,in model,414(ab) gammacamera,Ho-166,864(ab) temporallobeepilepsy,78(ab) imagingof focalsites of inflammationin pheochromocytomaevaluationwith â€˜@IMI@G â€œC-labeledphorbolestersas potentialligands, non-humanprimateswith, 415(ab) is improved by use of SPECF imaging, protein kinase C imaging, 431 Pericarditis, unsuspected complications of 40(ab) clinical,1132,2269 bacterialendocarditisimagedby G-67 quantification of renal uptake of @â€œTcDTPA practicaliterativereconstructiontechnique scanning, 955 using,1184 Pe@ vascular disease, funCtiOnalimaging, SPECF and, of ischemic canine myocardium for,873(ab) 865(le) using novel @â€œFcnitroimidazole, 50(ab) â€œC-McN-5652Zradiotracerfor studying PET. See Positronemissiontomography andSPECFof experimentalmyocardial serotonin uptake sites, 120 Phantom infarctionwith instant @Fcantimyosin comparedwith â€˜@Owater and intracoronary Alderson,quantitativeSPECF imagingwith kit, 191(ab) Doppler technique, in assessment of 67Cain,901(ab) @â€œTcDMSASPETvs., in lookingfor renal coronaryreserve in man, 1899 comparisonwith humangray/whitematter scars, 550(ab) comparisonof apparentvascularvolumeimages ratios, 933(ab) 20111 forwater,oxygenandCOin, 944(ab) pinhole collimation for ultra-highresolution, quantitative, for determining viability in acute comparisonof highspecificactivity6-'F FNE small-field-of-view SPECF studies, 29(ab) myocardial infarction and totally and6-'@FFDA,heartuptake, quantitativeanalysisof hepaticuptakecreating occludedinfarct-relatedartery, 728 metabolism,andeffectof desipramine, artifactual defects in @fcmyocardial stress, quantitativereproducibilityof, 168(ab) 619 SPECFimages,902(ab) Phama concordanceof nutritivemyocardialperfusion spill correction technique for simultaneous rest activitycurve for PET measurementof regional reserveand flowvelocityreserve in ar@11/stress @Fcmyocardial perfusion cerebralmetabolicrate for glucose, conductance vessels, 717 SPECF,903(ab) 152(ab) of â€œCPlC11195bindingto peripheral arterial, modeling approach to eliminate need to benzodiazepinereceptorsin Alzheimer's evaluation with â€˜@IMIBO improvement by separate,in â€˜@OinhalationPET, 1333 disease,465(ab) SPED' imaging, 40(ab) D-dimerin evaluationof suspectedpulmonary â€˜â€˜Craclopride, sensitivity of measurements to histopathologicallyproven, 24-hrurinary embolus,896 changesin endogenousdopamine, catecholarninesare normalin some protein binding of renal agents, 1162(ab) 262(ab) patientswith positiveMIBGscans and, @FcDTPA renal uptake-plasma volume â€œCTBZ and, in viva human imaging of 792@ab) product,as quantitativeestimationof monoaminergicnerve terminalsusing, â€˜@â€˜IMIBO imaging of, correlation with CT, MR glomerularfiltrationrate, 1390(le) 92(ab) andsurgery,791(ab) time activity curve 64Cutested as radioimmunotherapyagent, â€˜@IMIBG in, factors limiting precision and constructionfromcontaminatedleft 22N(7) accuracy,793(ab) ventricular measurements in dynamic â€œCWIN 35,428, in vitro dopamine transporter localization,180 cardiac PET FDG studies and improving sites imagingin humanusing,938(ab) mildto moderatedegreeof â€˜@IMIBOuptakein estimation of MMRGIc, 885(ab) cyclotrons,regulation,25N(4) adrenals must be carefully interpreted for effectof shape on estimatesof myocardial determinationof skeletalmuscleviabilitywith, diagnosis of, 39(ab) oxygenconsumptionrate with â€œC 436(ab) PET FDG studies of, 41(ab) acetatestudies,194(ab) differentiationof residualor recurrentchest Phorbol esters, â€œC-labeled,protein kinase C Platelets tumorsfromposttherapychanges, imaging,431 effectof SC.47643and heparinon deposition, 162(ab) Phos@nositlde, PET images of response in and fibrin accretion in canine dopaminergic-cholinergicinteractionmeasured primatebrain, 94(ab) arteriovenousshunt model,838(ab) with â€œCraclopride and, in normal Phospholipid ethers, radioiodinated analog, immunoadsorption,enhancementstrategyfor humansubjects,263(ab) selectivelocalizationin humantumor radioimmunotherapy,1020 dynamic @ xenografts,787 I autologous, sequestration, correlation myocardial blood flow quantification, 488 withsplenectomyin idiopathic totalgraphicalanalysisof data with MRS.estimationof concentrationsof thrombocytopenicpurpura, 182 identificationof up to four parameters, phosphorous metabolites using, 861(ab) vascularthrombus,ScintigraphiCmethodsfor 886(ab) MRS changes in tumor Pi/NTP ratios in detectionof, 554(suppl) dynamicand gated â€˜3Nammoniaimaging response to radioimmunotherapy, 421(ab) Podts@momission tomogmpby @fl confirmsinhomogeneousmyocardial Phospborus-32 chromlc phosphate alcoholandits effectson brain,798 tracer retention but homogeneous radiosynovectomyfor treatmentof hemarthrosis assessmentof agentsto monitorearly response perfusionin normalsubjects, 132(ab) andsynovitisassociatedwithhemophilia, of human adenocarcinoma cell line to dynamiccardiacstudiesusingimage-derived 715(ab) radiotherapy,773 inputfunctions,440 supra-additiveeffectwithCDDPinovarian attenuation correction using count-limited empiricalobservationof resolutiondegradation carcinoma,217(ab) transmissiondata in, 143 utilizing block detectors, 404(ab) pH probe, scintigraphy vs., for quantificationof attenuationscans, cardiac, three-dimensional endothelialfunctionassessmentwith cold pediatric gastroesophageal reflux, 1228 registration of, 311 pressortest in patientswithvarious

Subject Indexâ€¢1993 2321 Positronemlulon tomography(PET)

degreesof coronaryatherosclerosis, lungtumor metastasisto breast detectedby, high-speedautomateddiscretebloodsampling 137(ab) 1571 for, 1357 to estimateRi therapyoutcomeinpatients in lymphoma differentiationfrom identificationand characterizationof with liver metastases, 1023(ab) nonmalignant CNS lesions, in AIDS, 567 hypertrophicmyocardium,1013 evaluationof â€œCMDL72,978Aas MAO-B in oncology, 6 in identification ofviable myocardium in inhibitorfor, 1116(ab) inpatientswithmalignantlymphoma, patientswithchroniccoronaryartery evaluation of coronary flow reserve in 1022(ab) disease,88(ab) asymptomatic males with hyperlipidemia pediatrictumor studies, 199(ab) imagesof phosphoinositideresponsein primate andfamilyhistoryof coronaryartery pheochmmocytomastudies,41(ab) brainby, 94(ab) disease, 760(ab) andpost-surgicalseizureoutcomeincomplex imagingof dopaminereuptakesites in evaluation of emission-transmission partialepilepsy,79(ab) Parkinson's disease by â€œCWIN 35,428 misregistrationin thorax, 872(ab) predictiveimportancein patientswith and, 115(ab) evidenceof viabilityidentifieshighrisk patients temporallobeseizures,83(ab) imagingof non-small-celllungcarcinomawith with reverse redistributionon planar in pre-surgical evaluation of patients with â€œCMET, relationship between thalliumimaging,334(ab) suspectedmalignantsolitarypulmonary radioactivityuptakeand flow-cytometric examinationof neuralcontrolof eye movements nodules,72(ab) parameters, 1886 with, 932(ab), prognostic and diagnostic usefulness in integrated display, manipulation and analysis of â€˜8FBMY 14802, potential antipsychotic drug, primarybrain tumormanagement, images,497(ab) 246 141(ab) investigation of fUnctiOnalneuroanatomy of â€˜F dynamicstudiesfor assessmentof ovarian in prostatic cancer, 1021(ab) syntacticprocessingand sentence cancer, 14(ab) quantitativeanalysisof glucoseutilizationby, comprehension using, 222(ab) recoveryof myocardialfunctionfollowing in detecting myocardial viability, 3(ab) inischemicandnonischemiccardiomyopathy, coronary revascularization,84(ab) residual/recurrentovariancancerdetection human pathologic correlation with, 39 in @â€œTcHMDP negative bone tumors, 288 using,16(ab) IUDRuptakeandretentionas measureof FDA plan pannedby physicians,26N(4) resultsof clinicalROCstudycomparing tumor growth, 1152 FDG filteredbackprojectionand maximum @Kand, myocardial perfusion estimates with, accuracy in distinguishingcerebralinfections likelihoodestimatorimagesin, 1198 inexperimentalmyocardialinfarction, from lymphomain patientswith AIDS, thyroidcancer imagingwith, 38(ab) 49(ab) 142(ab) FDGuptakeand cancer cellproliferative mappingof localrenalbloodflowwith â€˜@O advanced head and neck cancer after activity,414 water and, 196(ab) chemotherapy,12 FDOPA in measurementof cerebralmetabolismfollowing assessmentof breast lesionswith, 218(ab) performanceevaluationof different noradrenergic challenge in patients with in assessment of hepatocellular carcinoma, optimization methods for intra-subject posttraumatic stress disorder and in comparison with histological findings, registrationof images,879(ab) healthysubjects,972(ab) 12(ab) quantitationof putamenuptakeconstantof, measurementof regionalcerebralmetabolicrate inbronchogeniccarcinomastaging,74(ab) 679 forglucose,modelingplasmaactivity comparabilityin probableAlzheimer's simplifiedquantitativestudiesusingestimated curve for, 152(ab) disease, 1460 inputfunctionderivedfrompopulation measurementof regionalmyocardialbloodflow comparativeefficacyof CT in detectionof blood curve, 867(ab) permitsrecognitionofviable and tumorsites inpatientswithabdominal FES, assessmentof breast lesionswith, 218(ab) non-viablemyocardiumin chronic andpelvicmalignancies,215(ab) â€˜8F2FDMFas potentialimagingagentfor brain myocardialinfarction,87(ab) comparison with MRI in evaluation of glycosidases, biodistribution and tissue methionine primaryCNS lymphomain non-AIDS assays, 1124(ab) in differentiationof recurrentor residual patients, 219(ab) â€˜8Ffluoroacylatedoctreotidefor quantitative musculoskeletalsarcomasfrom in dementia, diagnostic accuracy, 6(ab) somatostatinreceptor imagingwith, posttherapy changes, 124(ab) fordetectionof pancreaticcancer,391(ab) 315(ab) indifferentiationof recurrentor residual in differentiation of benign and malignant followupstudiesforevaluationof treatment tumorfromposttreatmentchanges, pulmonary opacities, 73(ab) responsein patientswith lungcarcinoma, 214(ab) in differentiation of recurrentor residual 75(ab) andMRIwithâ€˜FFDGfordetectionof musculoskeletal sarcomas from â€˜8FPFBGaspotentialtracer,312(ab) pancreaticcancer, 877(ab) posttherapychanges,124(ab) functional brain mapping, comparison and multicenterevaluationof newautomated in early delayed radiationnecrosis following optimizationof data acquisition analysisprogramfor flowstudies, 759(ab) cerebral stereotactic radiosurgery, strategies,150(ab) myocardialkineticsof â€œCHED, retention 976(ab) ssGa radiopharmaceutical that is retained in mechanismsand effectsof effectsof tissueheterogeneityon parameter myocardium,1127 norepinephrine, 1287 estimates, 153(ab) gated, myocardialthicknessby, 856(ab) myocardial muscarinic receptor quantification effectson quantitationof comparisonof genderdifferencesincerebralbloodflowwith, with, 981 anatomically defined vs. physiologically 264(ab) â€˜3Nammonia based regionallocalization,2201 heart, 978 cardiac, automatedregiondefinitionfor, 336 evaluationof experimentallivertumors using, cardiovascular research fellowships awarded leftventricularmassandinfarctsize 2124 to investigators of diagnosis, 29N(7) estimationfrom,826 evaluation of vertebral compression fractures potential @Gatracers, 228 tracer kinetic model for quantification of in cancer, 17(ab) procedurefor patient repositioningand myocardialbloodflowusing,validation fusionwith CT or MRIto localizefociof compensationfor misalignmentbetween of, 83 increasedactivity, 1190 transmissionand emissiondata, 137 newestimationmethodaccountingfor hypermetaboliccerebralfungalinfectionwith, SNMpositionpaper, 25N(4) accumulatedcountsof blood-time 143(ab) heart and skeletalmuscleglucosedisposalin activitycurves in tracer kineticmodeling, imagingin abdomenand pelvis, 1027(ab) type 2 diabeticpatientsas determined 154(ab) initialassessmentinimagingof malignant by, 2064 noisereductionin attenuationcorrectionby melanoma,1420 highaccumulationof â€˜FFDGalby maximumlikelihoodhistogram initialassessmentof detectionof skeletal well-differentiated hepatomas of mice and sharpening of attenuation images, 101(ab) metastaticprostate carcinoma,1045(ab) rats,780 â€˜so,studyofregionalcerebralbloodflow initialevaluationof imagingof metastatic high resolution, with solid state scintillation measuredduringbehavioralchallengein testicular neoplasms, 15(ab) detectors,403(ab) obsessivecompulsivedisorder, 180(ab)

2322 TheJournalofNudearMedicine Rathatlondo@

â€˜@oinhalation,modelingapproachtoeliminate stereotactictransformationof scansby Prostate,benignhypertrophy,prostatic need to separate arterialplasmain, 1333 deformation of standard brain atlas, hemodynamicchangeafter transurethral inoncology,13N(8) 279(ab) hyperthermictreatmentof, 553(ab) @ â€˜@owater,decreasedcoronaryreservein studiesof functionof dopaminetransporterin Proda& idiopathic dilated cardiomyopathy cocaineabusers,406(ab) correlation of bone scans and serum PSA levels assessedusing, 134(ab) studiesof neuroblastomawith â€œCHED, in treatmentof prostatecancer, 121(ab) in patient evaluation before and after heart 1034(ab) immunoscintigraphyin, current applicationsof, transplantation, 834 studiesof reversibleandirreversibleMAOB 549(suppl) performancecharacteristicsof new generation inhibitors,525(ab) â€œIn7-E11-C53 anti prostate antibody, utility scanner,401(ab) studiesofworkingmemoryin humans,221(ab) in preoperative workup of patients with performanceevaluationof highresolution study of remote effects of stroke on 5HT2 carcinomaof prostate,458(ab) scannerECATEXACTHR.,402(ab) serotonergicspecificbinding,clinical metastaticcancer, â€˜53SmEDTMP phosphoinositideturnoverimaginglinkedto correlations,971(ab) biodistributionand dosimetryestimation, muscarinic cholinergic receptor in central superiorityover MRIfor earlydiagnosisof 1031 nervoussystemby, 1543 dementia of Alzheimer's type, 464(ab) PET with â€˜8FFDG in cancer, 1021(ab) @ plasmaglucoselevelsand18@p@ in after systemicadministrationof â€˜8Furacilin PSAlevelsin patientswith newlydiagnosed bronchialcarcinomas,355 patients with liver metastases from cancer, associationwith occurrenceand polarmapping,novelapproachto quantifying colorectalcarcinoma,1075 pattern of metastaseson stagingbone extent and severity of perfusion defects Tc-94m teboroxime, 1058 scintigraphy,1025(ab) on caninemyocardiumby, 756(ab) testsfees vs. qualityof careforSPEC!'vs., and rateof changein serumPSAvs PSAlevelas potentialtracerfortyrosinehydroxylase cost-effectivenessof diagnosisand screeningtest for prostatecancer, activity,22(ab) managementof coronarydisease, 136(ab) 504(ab) power spectra estimationfor adaptiveWiener theoretical decoding resolution limits of detector ProteinWnaseC (PKC),â€œC-labeledphorbolesters filterreconstruction,881(ab) des@nusingquadrantsharing as potentialligandsfor PET, 431 private center opens in New York, 53N(6) photomultipliers and cross-coupled BOO, Ps@ embo&m quantification of myocardial flow and coronary 405(ab) applicationof neuralnetworksto flowreserve usingâ€˜3Nammoniain fortherapymanagementin treatedmalignant ventilation-perfusionimagingfor patientswith angiographically lymphomas,1033(ab) diagnosisof, 850(ab) documentedcoronaryartery disease, three-dimensional chest radiographfindingsin, 1074(ab) 133(ab) correctionandcharacterizationof scattered comparisonof clinicalpresentationand outcome quantitative,practicalproceduresand events in, using scanners with retractable inyoungervs.olderpatients,1073(ab) pharmacologicalapplicationsof, 1006 septa, 671 detailed analysis of patients with matched quantitativeanalysisof data in normalagingand forimprovedpatientthroughput,880(ab) ventilation-perfusiondefectsandchest Alzheimer'sdisease, 1681 integration display of emission and radiographicopacities, 1851 quantitativeâ€˜@Owater bloodflowstudies, transmissionimages,888(ab) diagnosticalgorithmsand lungscan noninvasivearterialmonitorfor, 1000 three-dimensionalbrain imageregistrationand interpretation,uniformityof, 661 radiationdose to technOlOgistsduring enhancement of signal/noise ratio in less likelyrepresentedby ventilation-pcrfusion/ quantitativevs. qualitativestudies,769 functionalpatterns, motortask and, chestx-raymatchif 0 is â€œdecreasedâ€• radio@ for serotoninuptake sites, synthesis 151(ab) ratherthan â€œabsent,â€•58(ab) andbiologicalevaluationof, 19(ab) three-dimensionalcoordinatematchingbetween prevalenceof thromboembolicdiseasein Rb-82 MRIand, usingmaximumgradient patientswith intermediateprobability essentialor not?, 1834(k) method,278(ab) lungscans, 55(ab) myocardialperfusionimaging,400 as toolin insanitydefense,13N(1) ratmodelof,removalofearlynon-specific recoveryof resolutionby finiteelements total bodyimagingof recurrentrecto-sigmoid blood pool activity from antifibrin images method,97(ab) cancerwith â€˜8FFDG, 1041(ab) applied to, 855(ab) re-evaluationof aminoacid studies, 1936 tumorlocalizationand systemicdistributionof regionaldistri1@ution,observationfromPIOPED regionalcerebralglucoseutilizationwithâ€˜8F effector cells monitored by, 289(ab) study,56(ab) FDG in heterogeneoustissues, 360 validationof tissuedensitymeasurementsfrom revisedscintigraphiccriteriafor interpretation relationship of blood flow and functional transmissionimages,548(ab) ofventilation-perfusionscansfor, 59(ab) outcome after coronary valueof quantitativeanalysisof glucose simplemodelof, in rat, 1072(ab) revascularization,761(ab) utilizationin detectionof myocardial suspected reproducibilityof repeatedmeasuresof â€œC viabilhyby, 2068 plasmaD-dimerin evaluationof, 896 raclopride binding in human brain, 609 Potaasiam-38,and PET, myocardialperfusionand ventilationimagingwith â€œPertechnegasâ€•in, rotatingscannerusingBOOblock detectors, necrosisestimateswith, in experimental 488(ab) 1367 myocardialinfarction,49(ab) underestimationof segmentaldefectsize, 370 semi-quantitativeassessmentof recurrentbrain P@panq ventilation-perfusionscintigraphyin PIOPED tumorsusingâ€œCmethionineand â€˜@F andbirthhistories,afterâ€˜@â€˜Itherapyin study, 54(ab),1109,1119 FDG, 973(ab) differentiatedthyroidcancer, 787(ab) sequentialmyocardialscanfollowingmyocardial NRC rule, 20N(7) infarction,89(ab) placentaltransferand fetalbiodistributionof Q serialmeasurementsof renalcorticalbloodflow radioiodinein guineapig, 767(ab) Qualityassurance,WBClabelingwith test based in kidney transplants in swine model, placentaltransferof technetiumlabeled on adherence,345 348(ab) radiopharmaceuticalsin guineapig, simultaneousemissionCT and x-ray 778(ab) automateddailyOC program,853(ab) transmissionCT usingcompositex- and Progestin,technetiumand, improvedcomplexas expert system,objectorientedapproachto, gamma-raydetectors,400(ab) potential imaging agent for steroid 862(ab) skeletal fluoride kinetics and bone mineral receptors,61(ab) Qualitymanagement,Pennsylvaniamedicalcenter densitywithDXAinbeagleswith Progressivesupranudear palsy,new graphic finedfor allegedviolations,32N(8) nutritional osteoporosis, 700(ab) methodfor estimationof distribution sliceoriented, recoveryof humanstriatalsignal, volumeon â€˜@IIMPSPEC!' in 481 differentialdiagnosisof Parkinson's R spatialdependenceof scatter energyspectrum, diseaseand, 119(ab) Radiationdosimet,y 851(ab) Prolylendopeptidase,inhibitors,â€œC-labeled, absorbeddose calculationsin Haversiancanals spectralanalysisof scatter distributionsin dual synthesisand mousebrain uptakeof, for severalbeta-emittingradionucides, energyacquisitionmodeon, 889(ab) 23(ab) 1361

Su*ct Indexâ€¢1993 2323 RadiOaCtiVe waste

automating large-scale processing of data, Red@ve wade phase I trialsof refractorytesticularcarcinoma 780(ab) BRC exemptions, 20N(1) with â€˜@â€˜I5F9.3monoclonalantibody, bone marrow,for radioimmunotherapy,689 danger in too many waste sites, 52N(6) 208(ab) correlationof radiationabsorbeddosesto nodal dis@ of smallquantitiesin locallandfills,349 preclinicalcomparisonof toxicityand, for Mu-9 metastases,524(le) low-level,24N(4),34N(7),17N(9),32N(l0) anti-@SApIgOlabeledwithâ€˜@â€˜I,@â€˜Â°Yor effectivedose equivalentapplicationto nuclear publicopinionpoll,30N(5) Re-188, 1014(ab) medicinepatients,714 storage, NRC changing rules, 28N(5) radiolabeledantibodiesas cancer therapeutics, estimatesfor C-14urea breath test, 821 unregulated,waste handlersand hospitalsat 1028(k) estimatesfor â€˜8F4-FDG,779(ab) odds, 25N(2) radondosimetryand,implicationsof RBE-LET estimatesfor @â€œrcP215,peptidefor imagingof Radi@ relationshipforalpha-emittersinviva atheroscleroticplaques,764(ab) cardiacmyosinlightchain-l specific,synthetic for,536(ab) estimation of maximum possible organ radiation peptideimmunogensfordevelopmentof, â€˜@Remonoclonalantibodies doses from â€œClabeled compounds, 2144 dosimetry,908 763(ab) immunoadsorption, enhancement strategy for preparationand evaluation,260 estimation of upper limits on human radiation radioimmunotherapy,1020 time-dosefractionationin, implicationsfor absorbeddosesfrom â€œClabeled one-step,porouspolymericmembranesfor, selectingradionucides, 1801 compounds,2208 502(ab) time-dose-fractionation in, implications to exposureto surgicalpersonnelduring syntheticmembranesused to simplify,30N(7) selectionof radionuclides,419(ab) intraoperativeimmunoscintimetryafter RMiehomanndate@on Radlojodinatlon,estrogens,comparative applicationof â€œInor @â€œFclabeled colorectalcancer, with â€˜@IlabeledCPA distribution,272 monoclonalantibodies,773(ab) monoclonalantibodyfragments,61 Radlolsotopes.See aLsospec4ficradioLrotopes HanfordEnvironmentalDose Reconstruction medullarythyroidcancer, usingbispecific BrookhavenLinac isotopeproducer, 16N(2), Project, 25N(1) anti-CEA/anti-In-DTPA antibody and 1828(Ie) heterogeneity of microscopic dose distribution â€œInDTPAdimer,1267 DOE isotopeprogram,report hintsat in radioimmunotherapy, theoretical of Pneumocystiscariniipneumonia,in14W restructuring,49N(6) analysisof, 1016(ab) patients, 239(ab) DOE proposestwo initiatives,47N(6) humanstudiesof â€œInlabeledpolydonalIgG, preoperative, with @Fcmonoclonal antibodies dual,brainSPECTimagingformonitoring 769(ab) in colorectal and gynecological surgery, cognitive activation, 267(ab) of â€˜@IEpidepride, 772(ab) 325(ab) Radiofigands.See Ligands;specific4gands of â€˜@IIBF, 1910 of smalltumors,MonteCarloStudyof, 857(ab) Radlonudides.See also specificrudiotmcer imagingligandof D2dopaminereceptor, of thrombi, in presence of circulating antigen ambulatorymonitor,leftventricularsystolicand 774(ab) D-dimer,754(ab) diastolicfunctionmeasurementsusing, immunoadsorption,enhancementstrategyfor Radloimmunoguldedsurgesy,false-positivelymph 1602 radioimmunotherapy,1020 nodesby, 804 comparisonof bone scans and magnetic internal, using data derived from Radloimmunotherapy.See aLsoRadiotherapy resonance imaging in detecting spinal autoradiographs, 1811 breastcancer,with @Â°YIâ€•NBRE-3,204(ab) metastases,2191,2198 â€˜@ITISCH, 208 of cancer,labelingof monoclonalantibodies dual â€˜@â€˜itreatment of diffuse toxic goiters, 387 with @arReusing MAG3 chelate for, 1953 comparison of diagnostic accuracy with same IUDR uptake and retention as measure of ChL-6,biologicenhancementshownby day @â€œTcisonitrile stress/@Â°'Tlrest tumor growth, 1152 correlationof effectorcell, complement perfusionscintigraphy,251(ab) monoclonalantibodyM195in acute and lymphokineactivationwith diagnosticaccuracyof stress perfusion myelogenous leukemia, 422 therapeutic effects, 372(ab) scintigraphyusing20111at rest and @â€œTc optimizeddose planningof radioiodinetherapy clinicalimplementationof combined3-Dand isonitnilewith stress, 253(ab) ofbenignthyroidaldiseases,1632 MIRD-based dosimetry with â€˜@â€˜ICC49 experimentalvalidationof magnetically personnel monoclonalantibody,508(ab) enhancedtherapy, 371(ab) comparisonfor quantitativevs. qualitative clinicalimplementationof modeling-based high resolution slit aperture for imaging small PET studies, 775(ab) treatmentplanning,â€˜@â€˜IM195antibody animalswith SPECT,26(ab) from @â€œTcsestamibivs. 20111myocardial againstchronicmyelogenousleukemia, hystemsalpingography, appropriate for new perfusionscintigraphy,1210 418(ab) assistedreproductiontechniques,797(ab) quantitativevs. qualitativePET, radiationdose 64Cutested as agent,22N(7) imagequantitation,channelratiomethodof to technologists during, 769 designof SPECTbased 3-Dtreatmentplanning scatter correctionfor, 330 radiation absorbed dose estimates from inhaled programfor, 507(ab) inexpensive conversion of dual Gantry Kr-81mgas in lungimaging,1382 enhancementstrategyfor, immunoadsorption, multidetectorbodyscannerto determine distributionfor dosimetry,785(ab) radiolabeledantibodiesas cancer therapeutics, 1020 metallic,novelbiologicalmethodto evaluate 1028(k) experimental,of pancreaticcanceremploying rates from patientsundergoing20111study, chelating agents for labeling antibodies â€˜@â€˜Imonoclonal antibody PAM4, 776(ab) with, @arRemonoclonalantibodies,908 1010(ab) nonlinearestimationof scatteredphotons using revised,for FDOPAwith carbidopa heterogeneity of microscopic radiation dose neuralnetworks,848(ab) pretreatment,768(ab) distribution in, theoretical analysis of, parameterevaluationof dynamicstudies structuralchangesin dosimetermatrixand 1016(ab) compressedby principalcomponent parametersaffectingaccuracyfor â€˜@â€˜IM195 trials in patients with myeloid analysisand JPEG technique,849(ab) mini-TLDs,781(ab) leukemias,207(ab) rare earth, chemistryof novelmacrocyclic of @FcATCinvisualizationof internal isotopeselectioncalculatiOnsbasedon antibody aminophosphonic acids chelates and their mammarylymphnodes, 766(ab) uptake from 3-D reconstructions of serial in vivo biodistribution, @â€œTctetrofosmin, 30 autoradiographs,420(ab) â€˜@Re,monoclonalantibodiesfor therapeutic administrations of â€˜@â€˜Isodium monoclonalantibodyM195in acute immunotherapy,260 iodide, radiation dose to upper spine myelogenousleukemia,422 spectroscopysystemfor multi-isotopestudy, from, 695 parallel and cone beam, study of resolution and gamma-rayenergyspectrumanalysisfor three-dimensional,for radioimmunotherapy sensitivityfor, 316(ab) each section of image using, 865(ab) treatmentplanning,790(ab),1595 phase I utility of Ommayograms in patients with time-dosefractionationin radioimmunotherapy, with â€˜@â€˜IMN-14F(ab)2,206(ab) leptomeningealcarcinomatosis,966(ab) implicationsfor selectingradionucides, using Re-188 labeled murine monoclonal wholebodycylindricaldetectorforsmallanimal 1801 antibody,209(ab) imaging,25(ab)

2324 TheJournalof NuclearMedicine Rhenlum-188

continuous,evaluationoflesion detectability â€˜@Ilabeled CPA monoclonal antibody cardiologydominatingU.S. sales, 28N(4) with cone beam, fan beam and parallel fragmentsin imaging,61 effectof TFC stainingon distributionof, beamcollimationin SPECTby, 321(ab) inununoscintigraphyin surgicalmanagement, 178(ab),1722 diagnosticalgorithmsand lungscan 541(suppl) effectsof ban on enricheduraniumexports, interpretation,uniformityof, 661 perrectalportalScintigraphy,situsinversus 19N(3) resultsof study comparingfiltered diagnosedby, surgicalresults for EXAFS structuralcharacterizationof solutions backpr@ectionand maximumlikelihood portacavalshunt in, 301 of Rh-186 HEDP, therapeutic agent for estimatorimagesin FDG PET studies, Reflux,gastroesophageal,sequentialten-second metastatic bone cancer, 146(ab) 1198 acquisitionsfor detection,658 â€˜8FBMY14802,potentialantipsychoticdrug, -n R@ wailmotion 246 affinitylabelingof neuroreceptorsusinggamma first-passradionuclideangiographicstudiesof â€˜8FFBT, molecular decomposition rays, 95(ab) left ventricular function with @â€˜Tc,394 reconstitution approach to novel benzodiazepine MIBOevaluationas potentialtracer for vesamicolreceptorradioligands,21(ab) cerebraldistributionin anxietydisorders, monitoringdoxorubicincardiomyopathy, FDA regulation,24N(4) 181(ab) 1282 highresolutionsit aperturefor imagingsmall regionalalterationof distributionin refractory resting,relationshipof segmentaluptakeof animalswith SPECT, 26(ab) temporallobeepilepsyrevealedby group @â€˜1'csestamibito, 728(ab) manufacturer's instructions, NRC regulations averagingtechniques,81(ab) 20@11reinjection and improvement of left on departures, 523(le) beta-adrenergic, myocardial, up-regulationearly ventricularfunctionfollowing peptide,2253 aftersympatheticchemicaldenervation revascularization,172(ab) preparation of three â€œClabeled novel functional in dogsassessedwith PET and â€œC Renalfhoctiosr.See also Kidney Ml selective muscarinic agonists, 18(ab) ReO(EC) complexes derived from cysteine, CGP12177, 175(ab) non-invasivereal-timemeasurementof, 1616(le) 147(ab) dopamine D2, multiple radiotracerstudies of in in acute care of patients at risk of acute renal studiesof cyclosporin-Atoxicityinrats,and viva in controland doparnine-depleted failure,1161(ab) correlationwith histologicalfindings, mice, 19@ab) prognosticvalue of assessmentin childrenwith 1086(ab) EGF primaryvesicoureteralreflux,468(ab) synthesisand characterizationof andblockageon humantumortissueby MAb quantificationof renaluptakeof @FcDTPA phosphorous-hydrazide steroid conjugate 425 and its fragments, 1029(ab) usingplanarscintigraphy,1184 andits Pd-109complex,145(ab) monoclonal antibodies against, 1005(ab) relative,effectof differentROISfor background @â€œ1@ctetrofosmin, myocardial perfusion functionaltestingin patientswith idiopathic correctionin patientswith unilateral imaging,222 Parkinson's syndrome vs. Parkinson plus nephrectomy,346(ab) toughchoicesandcomfortlevel, 1829Qe) syndrome,117(ab) ReO(EC)complexesderivedfromcysteine, Radlophannacy,NRC regulations,22N(4),20N(7) 5-HT2, â€˜8FMDL11939 as potent specific ligand, NMRand structuralevidencefor 2@ab) couplingof carboxylgroupcoordination against â€˜@â€˜I,vitaminC in, 637 â€œInchelated derivatives of ANP for in vivo to amine deprotonation, 147(ab) NRC, 22N(4) imagingof, 226(ab) Radiotherapy.See aLsoRadioimmunotherapy mu-opioid,ethanolincreasesbindingin man captopril,with @TcMAG3,1157(ab) BIP for pretargeted delivery of, 1147 measuredby â€œCcarfentaniland PET, diuretic, 1029(k) comparisonof 67Caand â€œCuas potential 1069(ab) false-positive,methodfor minimization, radionuclidesfor,535(ab) muscarinic normalizedclearance-to-uptakeslope early responseof humanadenocarcinomacell myocardial,quantificationwith PET in ratio, 762 lineto, assessmentof agentsfor humans,981 validationof renaloutput efficiencyas monitoring,773 PET images of phosphoinositide response in objectivequantitativeparameterin formetastaticbonecancer,EXAFSstructural primatebrain, 94(ab) evaluationof upper urinarytract characterization of solutions of Rh-186 nicotine,radioiodinated(S)-5-iodonicotineas obstruction,845 HEDP, 146(ab) newradiopharmaceuticalforSPECT exercise, reproducibility of results, 554(ab) in mice,with â€˜@â€˜Ilabeledanti-smallcelllung studiesinbrain,1093(ab) MAG3,artificialneuralnetworkclassifierfor cancer monoclonalantibody, 1013(ab) nicotiniccholinergic,in viva labelingin brain analysis,844(ab) unilateral sialadenitis after, 67Ga-citrate imaging, using 3H CYT, s9mTcMAG3,automateddetectionof 953 octreotidescintigraphyfor detectionof parenchymalpixelsin, 845(ab) Radiotracers.See also specificradiotmcer paragangliomas,873 Renovascularhypedenslca.See Hypertension, antisenseoligonucleotidesas, for diagnostic opioid,delta, imagingin man,410(ab) renovascular nuclearmedicine,1084(ab) P-glycoprotein,quantitationof expressionin Reperfhslon,of myocardialinfarction,teboroxime dual,autoradiographyof cerebralacetate vivowith 1-125MRK-16monoclonal is markerof bloodflowfollowing,48(ab) metabolism,936(ab) antibody,454(ab) Reportgeneration,graphicuser interface-based high resolution slit aperture for imaging small somatostatin system,515 animalswith SPECT,26(ab) imagingin endocrineophthalmopathywith Rhenlum-186-HEDP kineticmodeling,new estimationmethod â€œInDTPA-PHE-octreotideandhigh chemistry and biological behavior of particles, accountingfor PET accumulatedcounts resolutionSPEC!', 798(ab) potentialradiopharmaceuticalfor of blood-timeactivitycurves,154(ab) imagingin pituitaryusingâ€œInDTPA radiationsynovectomy,1536 MonteCarlosimulationsof cross-talk octreotideand highresolutionbrain multipleinjectionsof, biodistributioneffectsin componentindualisotopeimaging, SPECT, 159(ab) ratsof, 1085(ab) 234(ab) scintrgraphyin malignantlymphoma,800(ab) therapeutic agent for metastatic bone cancer, multiple,studiesof dopamineD2receptorsin scintigraphyof endocrinetumors,799(ab) EXAFSstructuralcharacterizationof vivo in controland dopamine-depleted steroid, improved progestin-technetium complex solutionsof, 146(ab) mice, 190(ab) as potentialimagingagentfor,61(ab) Rbeninm-186inoiiodoaalantibodies potential, for mapping PEP in CNS, 1099(ab) targetedradiolabeledpolypeptides,intracellular chimenc NR-Lu-13,2111 Receiveroperatingcharacteristic(ROC)analysis metabolism,229(ab) dosimetry,908 comparability of FDG PET studies in probable vesamicol,novelradioligands,molecular radioimmunotherapy,preparationand Alzheimer'sdisease, 1460 decomposition-reconstitutionapproach evaluation,260 comparisonof simultaneoustransmission to,21(ab) usingMAG3chelatefor radioimmunotherapyof emissiontomographyto routineSPECT cancer, 1953 fordiagnosisof coronaryarterydisease colorectalcancer Rhenium-188,generatorreadiedfor clinicalcancer on 20@11imaging,281(ab) current imagingstrategies,537(suppl) treatment,33N(7)

Subject Indexâ€¢1993 2325 Rhenlum-188 monoclonal antibody

Rheaium-1@monodonalantibody,phase I newmethodforquantitativeSPECT,modified as indexof severityinprimaryhypertrophic radioimmunotherapyusing,209(ab) convolutionsubtractionwith dualenergy cardiomyopathy,45(ab) Rhes,matolddisease windowfor â€˜@â€˜i,909(ab) â€˜@â€˜IMIBG, preoperative and postoperative joint,imagingwith @TclabeledOKT3,714(ab) nonlinearestimationof scatteredphotonsin evaluationof paragangliomas,173 lung,cellularbasisfor elevated67@3@uptakein, radionudlideimagingusingneural â€œInleukocyte 351(le) networks, 848(ab) in cutaneous sarcoidosis, 812 Ribose,infusionreducesMIBIbut not 20111 . post-reconstruction artificial neural network for, in detection of unsuspected extractionin isolatedrabbit heart, in SPECT, 67(ab) pseudomembranouscolitisin criticalcare 177(ab) quantitativecomparisonof extendeddual patients,35(ab) ROCanalysis.See Receiveroperating photon window and iterative â€œInoctreotide, in patients with paraganglioma characteristicanalysis reconstructionbased, 285(ab) ormedullarythyroidcarcinoma,555(ab) Rotatingscanner,PET, usingBOOblock simple,non-uniform,for SPECF, 896(ab) â€œInpolyclonal IgG, in fever of unknown detectors, 1367 spatialdependenceof scatter energyspectrum, origin,242(ab) Rubidlum-82,PET 851(ab) myocardialperfusion,personnelradiation assessmentof regionalskeletalmuscleperfusion three-dimensionalPET dosimetryfrom @Fcsestamibivs. 20111 with, 345(ab) with plane integrals,890(ab) in, 1210 cardiac,978 usingscannerswith retractablesepta, 671 oropharyngo-esophagealfunctionin stroke and essentialor not?, 1834{le) validationof spectral-imageacquisitionsystem, other neurologicdisorders,34(ab) myocardialperfusionimaging,400 451(ab) of pancreatic transplants, comparison of Sc@hy radionucide angiogram and blood pool appearanceof pathophysiologiclociin central imagingwith 20111,826(ab) S type tinnitus, @FcHMPAOstudy of, parathyroid, @Fcpertechnetate,201'fl,and Salivary @ls,postradiotherapyunilateral 992(ab) @â€œTcsestamibi, 808(ab) sialadenitis, 6@Ga-citrateimaging, 953 blue-noiseditheringfor printingscintigramson perjejunal portal, evaluationof effectiveportal Ssmarhim-153-EIYrMP highresolutionb/w printers,860(ab) venous flowin chronicliverdiseases administeredfor bone pain, pharmacokinetics bone usingecho-Dopplerflowmetrycombined andtoxicityof, 534(ab) comparedwith MRIin diagnosisof skeletal with, 1103 biodistributionand dosimetryestimation,1031, metastasesin prostatecancer at initial pH probe vs., for quantificationof pediatric 2280Qe) presentation,120(ab) gastroesophagealreflux,1228 in bone metastases of hormone refractory differencein intervertthralfusionrate of portal, per rectal, surgicalresultsfor portacaval prostate carcinoma,1839 cervicaland lumbarspineassessmentby, shunt in sift,sinversusdiagnosedby, 301 comparisons of chelate structures on lesion to 712(ab) revisedcriteriafor interpretationof normalboneuptakeratiosby QARG,in disseminatedNorth Americanblastomycosis, ventilation-perfusionscans for pulmonary ratlesionmodel,1083(ab) 458 embolism,59(ab) multidose,forpainfulbonemetastasis,1047(ab) â€œdoughnutsignâ€•due to subtraction, parathyroid, 20111P@â€•Tc, Samarhun-153HEDP,chemistryand biological hemangioendothelioma,297 ultrastructuralhistologycorrelationwith, behaviorof particles,potential intraosseousmeningiomaappearanceover 24 radiopharmaceuticalfor radiation fiveyears, 961 @â€œTcpertechnetate, in ileal duplication of synovectomy,1536 in metabolic bone disease, 2247 stomachand duodenum,294 oncologyand infection,2236 Sarcoidosis,cutaneous, â€œInleukocyte thyroid,unusualfindingsin adenoma,465 orthopedicscanning,2241 20111 scintigraphyin, 812 SPECT in recent meniscal tears, 713(ab) forassessmentof 67Gaavidmediastinalmass Sarmma yield for identifying occult malignancy in followingtherapyfor Hodgkin'sdisease, hemangioendothelial,scintigraphicâ€œdoughnut patientswith musculoskeletalpain, 1326 signâ€•on skeletalimaging,297 122(ab) complementary role with mammography in musculoskeletal,recurrentor residual,FDG and CCK administrationbefore, efficacyfor diagnosisofbreastcancer,2095 methioninePET in differentiationfrom hepatobiliary scans in patients with leftventricularcavity-to-myocardialcount posttherapychanges,124(ab) systemicillnesses,299(ab) ratio, restingleftventriculardysfunction, osteosarcoma,imagingin dogsusingâ€˜8FTP-3 in characterizationofgastric antral motility 193 monoclonalantibodyfragmentand PET, disturbances,in diabetes,576 mass abnormalitiesof breast, 18 1017(ab) characterizationof gastricemptying in pediatric solid tumors, 200(ab) Scatter,correction pathophysimogyin idiopathicdyspepsia ventilation-perfusion assessmentof scatter componentsin very high using,31(ab) in PIOPED study, 54(ab) resolutionPETscanner,545(ab) dynamicMAG3,role in diagnosisof acute quantitative,in singlelungtransplants, channelratio methodfor radionuclideimage pyelonephritis,469(ab) 166(ab) quantitation, 330 evaluationof bile dynamicsfollowing vesicoureteral,direct, 466(ab) Compton endoscopicsphincterotomy,820(ab) WBC,routineapplicationof fractionated compensation using triple-energy window exercise,in renovascularhypertensiOn,48 FIMPAOstored at â€”71Y'Cfor, 151 methodforsingle-anddual-isotope 67@a,early detection of lymphoma recurrence Sdadllationcamera SPECT,2216 with, 2101 channelratiomethodof scattercorrectionfor by curve fitting photopeak region of energy heart and skeletalmuscle,in radionucide image quantitation, 330 spectraacquiredat every imagepoint, dermat@polymyositis,707(ab) highresolutionpinholeSPECF for smallanimal 235(ab) hepatobiliaiy imaging,27(ab) dual photopeakwindow,investigationusing morphine-augmented,false-negative,bileleak Sditillator, smallfiberopticallycoupledplastic extendedwindows,284(ab) fromgallbladderperforationmimicking positronprobe, 450(ab) in â€˜@â€˜Igammacameraimages, bowelactivityand, 131 Sderoderma,acute, renalscintigraphyin, 1163 subtraction-windowsvs. spectral-fitting morphine-augmentedvs. delayedimaging, Seizures.SeeaLsoEpilepsy in, 236(ab) suspectedacute cholecystitis,506 frontallobe,focuslocalizationwithictal@â€œTc iterativeestimationof patientouter contour pediatric,hepaticextractionfraction HMPAO SPECT, 978(ab) fromemissiontomographicprojection determination by deconvolution analysis, localizingfocuswith FDG-PETimagingin images,904(ab) 214 temporal lobe epilepsy@using modified limitationsof dualenergytechnique,resultsin @23IMIBG lateralization criteria, 979(ab) 2D and 3D acquisitionsfromtwo dynamicanalysisof, in cardiacmechanical post-surgicaloutcomeand PET-FDGimaging, commercialPET systems,544(ab) overloadhypertrophyand failure,589 in complex partialepilepsy, 79(ab)

2326 TheJournalofNuclearMedicine Singlephotonemissioncomputedtomography(SPEC!)

spontaneous,rapidpreparationand optimal correctionfor attenuationand geometricpoint heart, cardiovascularresearchfellowships deployment of @TcHMPAO during, responsedistortionsin,111(ab) awardedto investigatorsof diagnosis, 666 importanceof attenuationcompensationand 29N(7) temporallobe, predictiveimportanceof its implementationin, 110(ab) high-resolution brain imager FDG-PETin, 83(ab) cardiacimaging,effectof motionon, 1355 feasibilityof, 99(ab) Self-referral,bans on, 22N(4) cerebral activation oflexical decision in somatostatinreceptorimagingin pituitary Serotonin psychopathsusing,306(ab) using, 159(ab) potentreceptorspecificligand,â€˜8FMDL11939, clinicalevaluationof highspatialresolution high-resolution imaging of spine, in children and 20(ab) reconstructiontechniqueusingfan-beam adolescents, 202(ab) reuptakeligands,90(ab) collimator,921(ab) highresolutionslit aperturefor imagingsmall transporters,M!BGuptakeby, 1140 clinicalvalidationof CT/MRIregistrationand, animalswith, 26(ab) uptake sites in radiolabeled monoclonal antibody highresolutiontriplehead, in infectious highlypotent indanamine5-HTuptake studies of colorectal carcinoma, 374(ab) spondylitis,330(ab) blockersas radiotracersforimagingof, comparisonof manualand automated in HIV encephalopathy and depression, 185(ab) 1092(ab) coregistrationof brain imageswithout @23IIMP, functional mapping of flow and imagingwith â€œCMcN, 91(ab) use of externalfiducialmarkers,919(ab) back-diffusionrate in humanbrain, 839 comparisonof 3-Dsurfaceand transparency PET radiotracerfor studying, 120 â€˜@ITIScH, dosimetry, 208 renderingsto tomographicsliceimages synthesis and biological evaluation of PET ictal, @FcHMPAO,rapidpreparationand fordetectionof coronaryarterydisease, radioligand for, 19(ab) optimaldeploymentduringspontaneous 931(ab) Shunt converging-beam,methodfor modelingphoton seizures, 666 arteriovenous,effectof SC-47643and heparmn scatter in, 917(ab) identificationand characterizationof on plateletdepositionandfibrinaccretion correction,iterativereconstructionmethodsfor hypertrophicmyocardium,1013 in canine model, 838(ab) nonuniform attenuation distribution, 1204 â€˜@IIMP portacaval,surgicalresults in situs inversus in crack abuse, 899 newgraphicmethodfor estimationof diagnosedby per rectalportal demonstratesloss of striataldopamine distnbutionvolumeindifferential scintigraphy,301 transportersin Parkinson'sdisease, diagnosisof PSP and Parkinson's right-to-left, scintigraphic sign for detection of, 116(ab) disease,119(ab) 1607 determinationof attenuationmap from quantitativeassessmentof cerebrovascular Sialadenitis,unilateral,postradiotherapy,67@3@. projectiondata alone,918(ab) reserveusingsplitdose method,245(ab) citrate imaging,953 Diamox,cerebrovascularvasodilatorytests, â€˜@Ilomazenil, in presurgical work-up of Sicklecelldisease,with acute chest syndrome, 244(ab) patients with medically intractablefocal simultaneous occurrence of rib infarction dopaminergicD2receptorimagingin Rett epilepsy, 80(ab) andpulmonaryinfiltratesin, 614 syndrome,increaseof specfficbindingin â€˜@â€˜IIUDR, assessment of brain tumor Siegel,BarryA., peoplein nudear medicine, stratum, 1717 proliferativeactivityusing,139(ab) 42N(6) dualisotopebrain imagingfor monitoring imageregistrationand fusionfor spatial Singlephotonemissioncomputedtomography cognitiveactivation,initialstudiesin localizationof metastasesusing (SPECI') humans,267(ab) radiolabeledmonoclonals,562(suppl) adenosine, quantitative, models for predicting dualisotopemyocardialperfusionimaging, imagingofhypoxicbrain,365(ab) long-termoutcomeafteracute sensitivityfor detectionof specific imagingof sigmareceptorsin viva in primates, myocardialinfarctionby, 212(ab) atherosclerotic lesions, 254(ab) 1097(ab) adenosine20111,comparisonof resultsusing dynamic,using @9@cteboroximefor @23IMIBG, myocardial, cardiomyopathy four-vs. six-minuteinfusionprotocol, quantificationof myocardialperfusion, outcomepredictionusing,46(ab) 737(ab) 733(ab) in improvement of pheochromocytoma application of massively parallel computer for dynamicquantitativeâ€˜33Xeregionalcerebral evaluationwithâ€˜@!MIBG,40(ab) three-dimensionalmaximuma posteriori bloodflowon PRISM3-headed inactive enantiomer of @-ClT,tracer of reconstructionin SPECT,71(ab) tomograph,266(ab) nonspecificbrainuptake,1131(ab) in back pain, with emphasis on marrow changes dynamicvalidationstudies,graphicplot analysis independenceof regionalasynergyand in end plates in association with disc forcerebralbloodflowandpartition myocardialperfusiondefectreversibility, degeneration,711(ab) coefficient, 498 86(ab) and biodistributionstudieswith @FcCBPAO, EEO-leadattenuationin, 923(ab) â€œInoctreotide, in patients with brain and newbrainperfusionimagingagent, evaluationoflesion detectabilitywithcone pituitarytumors, 140(ab) 970(ab) beam,fanbeamandparallelbeam investigationof effectsand designof source biplane gated, and gated equilibrium and collimationin, by continuousROC collimationfor transmissionimagingin, first-pass radionucide angiographic analysis,321(ab) 899(ab) quantitative measures of left ventricular evaluationof quantificationusingin vivo dog systolicand diastolicperformance, studiesand @FcMAA,96(ab) in viva mapping of cholinergic neurons in 130(ab) fastandstableweightedleastsquares-conjugate humanbrain using(-)-5-'@IIBVMand, bone gradientalgorithmfor, 98(ab) 93(ab) diagnosisof partialand total physealarrest fast transmissionCT for determiningattenuation iterativeestimationof patientoutercontour by, 1410 mapsusingcollimatedlinesource, fromemissiontomographicprojection in recent meniscaltears, 713(ab) rotatableair-copper-leadattenuatorsand images,904(ab) bone scans in renalallograftrecipients,381 fan-beamcollimation,1577 iterativereconstructionalgorithmwith natural bonescintigraphyof spineinpatientswith FDG, in detectionofviable myocardiumduring pixelbasis, 66(ab) malignanttumors,utilityof, 717(ab) hyperinsulinemicglucoseclamping, IUDRuptakeand retentionas measureof brain, neuralnetworkclassifierfor, 100(ab) 727(ab) tumorgrowth,1152 brain activationimages,propagationof 67Ga,unsuspectedcomplicationsof bacterial less than 2mmhighresolution,with pinhole registration errors in, 900(ab) endocarditisimagedby, 955 collimatorfor smallanimals,925(ab) brain bloodflow,in temporaryballoon 67Ga-citrate,disseminatedNorth American localizingpowerof ictalregionalcerebralblood occlusion of carotid and intracerebral blastomycosis, 458 flowin temporallobeepilepsyrelativeto arteries, 1239 gated,myocardialthicknessby,856(ab) surgicaloutcome,82(ab) braindopamineD2 receptorimagingin humans gated @â€œFcsestamil,i,leftventricularejection MCSPECF II, design and construction of@24(ab) with â€˜@IIBZM administered as constant fractionassessedfrom,1871 measurementof benzodiazepinereceptor infusion,435(ab) generalized dual energy window scatter number and affinity in primate brain, card@ compensationfor, 283(ab) comparisonwith in vitro values,431(ab)

Subject Indexâ€¢1993 2327

A Single @onemissioncomputedtomography(SPEC!)

metastatic malignancy masquerading as hepatic segmentationof body, lungs,and patienttable test-retestvariabilityof brainperfusion hemangiomaon labeledRBC fromscatter and primarywindowimages studies in normal human subjects, scintigraphy,1172 in, 248(ab) methodfor estimatingparametersof a fan-beam simplenon-uniformscatter correctionfor, @â€œTcRBC, liver hemangioma, 375 and cone-beamsystem,usingfivepoint 896(ab) @Tcsestamibi sources,912(ab) simultaneousimagingof 20111and @Fcusing gated,forassessmentof myocardialperfusion modelingeffectsof compositionand fourenergywindows,897(ab) abnormalities,601 inhomogeneityof scatteringmediaon simultaneous 20'TlP@â€•Fccardiac imaging, gated and ungatedbull's-eyes,inhomogeneity, scatter responsefunctionin, 282(ab) experimentalverificationof energy comparisonwith 20111,281 multi-radionudlide,eliminationof scattered weighted dual isotope technique for, myocardialperfusiondefectsize after stress, photonsin simultaneousdata acquisition 108(ab) 187 for,914(ab) single-and dual-isotope,Comptonscatter quantitative programfor assessment of compensation using triple-energy window perfusiondefectseverityin stress detectionand correctionof patientmotion methodfor,2216 imaging with, 732(ab) usingmulti-detectorcamera, 1349 slat collimationfor highsensitivity2D and 3D significanceof transientdipyridamole-induced emissionbased techniquefor obtaining imaging,28(ab) leftventricularcavitydilatationas attenuationcorrectiondatafor,898(ab) stationaryhemisphericalimagerfor assessedby,297(ab) myocardialperfusionimages,patientmotion three-dimensionalbrain imaging,474 @Fcsestamibi perfusion images, abnormal effectson, 303 study of abnormalregionalcerebralbloodflow segmentalcontractioncreates defects myocardialperfusionimaging,detectionof responseto auditorystimulationin despitenormalmyocardialbloodflow, patient motion during, 1341 childhoodautism,307(ab) noiseand spatialresolutionpropertiesof symmetrycomputedanalysisof perfusion 724(ab) ML-EM reconstructed images, 69(ab) reconstructedslices, 922(ab) temporal lobe findings in mood disorders may in oncology, 13N(8) systemwithtwo opposingdetectors, cone-beam be influenced by biological properties of optimalidentificationof myocardialviability tomographyusingorbits satisfyingdata radioligand,184(ab) with, 85(ab) sufficiencyconditionfor, 318(ab) tests fees vs. qualityof care for PET vs., and phantomstudyofbreasttissueattenuationin Tanaka's ifiterediterativereconstruction cost-effectivenessof diagnosisand â€” imaging,992 methodcan make EM algorithmpractical managementof coronarydisease, 136(ab) physicalperformanceevaluationof Toshiba forclinicaluse in, 68(ab) thalliumimagingin evaluatingactivityof soft GCA-9300A @e-beadedsystem, 1778 @TcDMSA tissue and bone tumors, 123(ab) pinhole,highresolution,for smallanimal clinicalvalueof triplehead imagingas initial three-dimensionalBayesianreconstructionfor, imaging,27(ab) diagnostictool in adultwomenwith 70(ab) pinholecollimationfor ultra-highresolution, recurrentacute pyelonephritis,551(ab) 3-Dregistrationof brain images,893(ab) small-field-of-viewstudies, 29(ab) fordetectionof renalscarsinchildrenwith 20111 planarimagingand, of ischemiccanine vesicouretericreflux,198(ab) accuracyat rest for evaluationof myocardial myocardiumusingnovel @â€œTc renal scans, 1065(ab) viabilityin comparisonto â€˜8FFDG PET, nitroimidazok,50(ab) @â€œTcEGD vs. 133Xe,in mild to moderate 729(ab) andplanarimagingof experimentalmyocardial regional cerebral blood flow in childhood brain tumors, 201(ab) infarctionwith instant @Fcantimyosin abnormalities, 754 clinicalevaluationin supratentorialgliomas, kit, 191(ab) @TcHMPAO 2085,2089 post-reconstructionartificialneuralnetworkfor in assessment of collateral cerebral perfusion comparisonof prognosticvalue in treadmill compensationof collimator,attenuation during temporary internal carotid artery exercisescoreinmedicallytreated and scatter effectsin, 67(ab) occlusion,1235 patientswith coronaryartery disease, proselytism, retroversion and fiscal nihilism in brain perfusion,â€˜@IIBZMdopamineD2 294(ab) nuclearcardiology,1823 receptor and, Huntington's disease and, comparisonwith MR.!in evaluationof quantitativeeffectsof count rate dependent 1274 primaryCNS lymphomain non-AIDS Wienerfilteron imagequality,basal brain scan in schizophrenia, 309(ab) patients,219(ab) gangliaphantomstudy simulatingâ€˜@I brain scans, segmental analysis of, 9(ab) effectof motionon, 1845 dynamicSPEC!' imaging,905(ab) indetectionofposturalcerebral leftventricularcavity-to-myocardialcount quantitativegatedbloodpoolimaging,enhanced hypoperfusionin patientswith ratio, restingleftventriculardysfunction, sensitivityfor non-invasiveassessmentof cerebrovascular disease, 1931 193 coronary artery disease, 131(ab) in diagnosis of chronic fatigue syndrome, lowlikelihoodof coronaryeventsinyoung @ quantitativeimagingwith67@ Alderson 182(ab) patientswith normalresults, 210(ab) Diamox,in identificationof diaschisisin phantom,901(ab) myocardialimagingin Bland-White-Garland quantitativesame-dayrest-stress @â€œTc stroke, 249(ab) syndrome,2182 evaluationof brain in autisticdisorder, sestamibi,definitionandvalidationof myocardialperfusionimaging,400 stress normallimitsand criteriafor 308(ab) forpredictinghistologicaltypesof abnormality,1494 high resolution, in probable Alzheimer's rapidback to back adenosinestress/rest @Fc disease,vs. FDG PET, 10(ab) meninglomas,2091 teboroximemyocardialperfusion,using methodologicalfeaturesfor neurostimulation 20â€•flSCintigraphy,rest-redistributionafteracute triple-detectorcamera, 1485 studieswith, 1217(le) myocardialinfarctionpredictsnormal rapidly converging iterative reconstruction in patients with cortical visual loss, 1447 wall motionon lowdose dobutammne algorithmsin, 1793 pee-,intra-,and postoperativemonitoringin echocardiography,170(ab) regularizediterativereconstructionmethod patients with severe carotid stenosis, two-and three-dimensional,fast reconstruction whichpreservessharp edges, 924(ab) 247(ab) methodfor, 915(ab) reversible an11 perfusion defects in right bundle in prediction of cerebral palsy in high-risk vectorizedMonteCarlocode for modeling branchblockand normalcoronary neonates, 1223 photontransportin non-uniformmedia angiogram,1218Qe) regionalcerebralbloodflowimprovement for,895(ab) routine, ROC comparison to simultaneous with treatmentin cocaineusers, 723 verificationofvarying thresholdedgedetection transmissionemissiontomographyfor regional cerebral blood flow in chronic techniquefor spleenvolume,vs. CT diagnosisof coronaryartery diseaseon alcoholism,relationto volumes,963 20@11imaging, 281(ab) neuropsychologicaltesting, 1452 view fromthe top, 907(ab) scanninglinesourcefor simultaneousemission restingand activationpatterns of prefrontal wholebodycylindricaldetectorforsmallanimal andtransmissionmeasurementsin,1752 bloodflowin schizophrenia,305(ab) imaging,25(ab)

2328 TheJournalofNudearMedicine Surgery

Skeleton.See also Bone difference in intervertebralfusion rate of quantitativeprogramfor assessmentof 67Gaand @FcMDPscintigraphyin cervicaland lumbarspine, assessmentby perfusion defect severity in, 732(ab) determining prognosis for children with bonescintigraphy,712(ab) 20111 stageIV neuroblastoma,1082 high-resolution SPECT imaging, in children and cost-effectiveselectionof patientsfor metastases,MRIvs. bone scintigraphyin adolescents,202(ab) reinjection prior to redistribution imaging diagnosisin prostatecancerat initial lumbar,bone mineraldensityheterogeneity, usingcriteriabasedon quantitative presentation, 120(ab) 705(ab) analysisof, 169(ab) scintigraphic â€œdoughnutsignâ€•due to SPECT and lumbar MRI in back pain, with quantitativereproducibilityof, 168(ab) hemangioendotheiomaof bone,297 emphasison marrowchangesinend resting myocardial blood flow and glucose Skin, â€œInleukocytescintigraphyin cutaneous platesin associationwithdisc metabolism maintenance in dysfunctional sarcoidosis,812 degeneration, 711(ab) myocardiumwith redistribution,171(ab) Smallintestine,transit, eiythromycineffectson, tuberculousand nontuberculousspondylitis, Striatum 582 67@ scintigraphy in, 853 â€œCraclopride binding, reproducibilityof Snakevenom,Russian,radioactive,28N(5) vertebral compression fractures in cancer repeatedmeasures,609 Society of Nuclear Medicine (SNM) patients,FDGPETevaluationof, 17(ab) does FDOPAuptakedecreasewith age?, actionsof Boardof Trustees, 25N(4) 5â€” 989(ab) estimation of dopamine D2 receptor binding annual meeting highlights, 13N(8) idiopathicthrombocytopenicpurpura, annualmeetingpreview,22N(5) splenectomycorrelationwith potential with @23IIBZM SPECT, 2076 sequestrationof autologousâ€œInlabeled in viva visualization of transplants in primate CardiovascularCouncilpositionpaper, on platelets,182 modelof Huntington'sdisease,960(ab) clinicaluse of cardiacPET, 1385 pretargetedradiationdeliveryto, BIPfor, 1147 recoveryof signalin sliceorientedPET, 481 coordinatorto staffnew office,24N(1) volume,verificationofvarying thresholdedge SPECT imaging demonstrates loss of dopamine electionresults,32N(7) detection SPECT technique for, vs. CT transportersin Parkinson'sdisease, government relations update, 22N(4), 19N(7), volumes,963 116(ab) 28N(10) Stenosis Stroke medical imaging in the nineties, 157 aortic, cardiac uptake of MIBG in patients with, associated with dipyridamole 20111myocardial Mid-WinterMeeting,desktopcomputing, 1392(le) imaging, 128 18N(1) valvularaortic, leftventricularhypertrophy characterizingpenumbrawith NMR nominees for offices, 25N(4) secondaryto, myocardialuptakeof â€˜@I spectroscopy and SPECF, 364(ab) relocationto Washington,25N(4) MIBG in, 57 dementiaand, intrasubjectcomparisonof restructuring, 25N(4) Ster@ Neurolite to Ceretec in, 945(ab) planpassesBoardof Trustees,26N(10) automated,detectionof intercommissuralline diaschisisin, identificationusingDiamox @Fc Soft tissue forlocalizationof functionalbrain HMPAO SPEC@ measures of infections,new antigranulocyteFab' fragment images,322 cerebrovascularreactivity,249(ab) fordiagnosisof, 830(ab) 305-memberMRI-basedatlas for activation dipyridamole testing in, 1389(le) localizationof bone seeking studies,277(ab) mirrormovementsduringrecoveryfrom, radiopharmaceuticals,1612 transformationof PETscansby deformationof 225(ab) sarcomas,detectionand gradingwith PET and standardbrain atlas, 279(ab) scintigraphicstudiesof oropharyngo-esophageal FDG, 1030(ab) Sternberg Fellowship, establishment, 33N(7) functionin, 34(ab) tumors, use of early, late and SPECF thallium Stomach Stronfium-89 chloride, therapy in nuclear imagingin evaluatingactivityof, 123(ab) antralmotilitydisturbancecharacterization,in medicine, 1037 Software. See Computers, software diabetes, using SCintigraphiCtechnique, Soketunee abuse Somatostatin 576 does detoxificationreverseacute alveolitisof handlingof analoguesby perfusedrat liver, erythromycin effects on, 582 crack smokers?, 164(ab) 801(ab) ilealduplication, @â€œTcpertechnetate evaluationof chronictolueneabuse patients localizationof gastroenteropancreatictumors scintigraphyin, 294 usingcerebralperfusionSPECT,997(ab) with â€œInsomatostatin analogue, 156(ab) lagphase in solidgastricemptying,comparison mappingâ€œCmethamphetamineandâ€œCEcstasy receptor imagingin endocrineophthalmopathy, of quantificationby physiologicaland binding sites in monkey brain with PET, with â€œInDTPA-PHE-octreotide and mathematical definitions, 1701 1109(ab) high resolution SPECT, 798(ab) postprandialgastricmotilityin infantswith regional cerebral blood flow improvement with receptorimaginginpituitaryusingâ€œInDTPA gastroesophagealrefluxand delayed treatment in chronic cocaine polydrug octreotideand highresolutionbrain gastricemptying,2120 users, 723 SPECT, 159(ab) regional motility in healthy volunteers, cisapride Subtraction scintigraphy, parathyroid, 20111P@Fc, receptorpositivetumors, humanin vivo effect on, 393(ab) ultrastructuralhistologycorrelationwith, detectionby â€œInoctreotide, 1031(ab) 24 receptorscintigraphyinmalignantlymphoma, conjugated CilO IgG antibody, evaluation for Sorgssy tumordetection, 1119(ab) coronary artery bypass grafting, prognostic 800(ab) conjugatedmonoclonalantibodiesand valueof radionucide cineangiographyfor receptorscintigraphyof endocrinetumors, radiolabeledbiotin,distributed riskstratificationin elderlyafter, 126(ab) 799(ab) pharmacokineticmodelof two-step effectof cardiopulmonarybypass surgeryon receptor scintigraphy with â€œInoctreotide, in imagingand treatmentprotocols,1552 pulmonaryvascularpermeability, localization of gastrinomas and preparation of immunoconjugates of monoclonal assessmentby transvasculartransportof metastasesin Zollinger-Ellison antibody CC49 for 2-step targeting of 67@a, syndrome,389(ab) colon cancer with â€œInand @â€œTcbiotin, intraoperativeassessmentof brain malignancies scintigraphy, in granulomatous diseases, 395(ab) using20111,138(ab) SjOgren's syndrome and rheumatoid pretargeted,BIPforlocalizationto, 1147 monitoringwith @FcHMPAOSPECt in arthritis,472(ab) StressImagfng patientswith severe carotidstenosis, SPECT. See Single photon emission computed immediate20111reinjectionfollowing,in 247(ab) tomography myocardial viability detection, 737 PET differentiationof residual or recurrent Spermcelllabeling,in monitoringspermcell @â€˜Fcsestamibi, rest 20111and, quantitative chest tumors from changes after, 162(ab) dynamics in female rabbit genital tract assessmentof reversibilityfor separate PET-FDG evaluation before, in patients with after insemination, 1134 acquisitiondualisotopemyocardial suspectedmalignantsolitarypulmonary Spine perfusionSPECT,250(ab) nodules,72(ab) continuingloss ofvertebral mineraldensityin @Fcsestamibi SPECT radioinununoguided,false-positivelymphnodes renal transplants, 440(ab) myocardialperfusiondefectsize, 187 by, 804

Subject Indexâ€¢1993 2329 Sym@ ne@ous @m

results,for portacavalshuntin sites inversus, atherosclerosisimagingin hyperlipidemic in urinarytract infection in children, 467(ab) 301 rabbits, 260(ab) use in detection of renal scarring in children @ value of lomazenil SPECF in presurgical evaluation for imaging atherosclerotic lesions with repeatedurinarytract infections, work-upof patientswithmedically in viva, 259(ab) 1165(ab) intractable focal epilepsy, 80(ab) preparationand unexpectedlabellingproperties SPECT, for detection of renal scars in children vascular of novel nitrogen heterocycle based N3S with vesicoureteric reflux, 198(ab) cardiac riskstratificationprior to, 293(ab) ligands, 539(ab) SPET,lookingforrenalscarswith,550(ab) genderdifferencesforlongtermcardiac progestin and, improved complex as potential triplehead SPECTimagingas initialdiagnostic event-freesurvivalin, 736(ab) imagingagentfor steroidreceptors, tool in adultwomenwith recurrentacute Sympathetic nervous system 61(ab) pyelonephritis,551(ab) leftventricularinnervationinarrhythmogenic promptvisualizationof gallbladderwith rim Technetiuni-99m-DTPA rightventriculardisease,2(ab) sign, 1169 aerosol deposition and clearance in MIBO uptake by norepinephrine, dopamine and renalScintigraphyinacutescleroderma,1163 e@mentaI acute pulmonaryembolism, serotonintransporters,1140 scintigraphicevaluationof livermasses, 489(ab) up-regulation of myocardial beta-adrenergic cavernoushepatichemangioma,849 aerosollungclearance,inhaledfurosemide receptorsearly after sympathetic scintigraphy vs. pH probe for quantification of effecton, 163(ab) chemicaldenervationin dogsassessed pediatricgastroesophagealreflux,1228 captoprilrenogram,quantitativeanalysisof, with PET and â€œCCGP12177, single-pass cerebral extraction and capillary 1416 permeability-surface area product, 641 diagnosisof renovascularhypertensionwith SPECT captoprilrenalscintigraphyinpatient T and MRI, in posteriorcerebralartery with solitarykidney, 1166 TCT. See Transmission computed tomography infarction and related visual field defects, false-positivediureticrenograms,methodfor Ã§rc@ 1009 minimization,normalized Teboroxhne simultaneousimagingof 20111and, 897(ab) clearance-to-uptakesloperatio, 762 kineticsas indicatorof myocardialbloodflow, systolicpressurealterationeffectson improvedpost-perfusionaerosolinhalation 363(ab) radionucide measurementsof left imagingfor rapiddiagnosisof pulmonary marker of blood flow following reperfusion of ventricular filling dynamics, 747 embolism, 487(ab) myocardialinfarction,48(ab) 20111 and quantificationof renaluptakeusingplanar Technetium-94m, production from isotopically experimentalverificationof energyweighted scintigraphy,1184 enrichedMo-94MoO3,1151(ab) dual isotope technique for simultaneous real-timemonitoringof renalfunction, Technetium-94in teboroxime, synthesis, dosimetry SPECT cardiac imaging with, 108(ab) ambulatory,199 andinitialPETimagingstudies,1058 parathyroidsubtractionscintigraphy, renal uptake-plasma volume product, as Technetlum-99m ultrastructural histology correlation with quantitativeestimationof glomerular alternatesynthesisof thiolactoneforlabeling resultsof, 24 filtrationrate, 1390(le) biopeptides with, 1152(ab) uptake mechanism of neutral myocardial @â€œTcDMSA and, differential renal uptake of, analysisof DNA singlestrand breaks in patients imaging agent @FcN-NOET, 65(ab) 1217(le) and in vitro caused by, 788(ab) uptake of cationic complexes in cultured human Technetium-99m-ECD, SPECT bone imagingwith energy-weightedacquisition, colon carcinoma cells, 1127(ab) brain, in stroke, 967(ab) 997 use of polylysine as linker for chelate and usefulness in diseases of central nervous cardiacSPECT, non-uniformcompensation biotin, 1088(ab) system, specialreferenceto comparison usingacquiredtransmissiondata,112(ab) TedInetIUID-99manti-AFPFabi, to â€˜@IIMP and @â€œTcHMPAO SPECT, compared with Am-241 as transmission source radioimmunoscintigraphy, in evaluation 983(ab) forattenuationcorrectionof 20,'flcardiac of treated germ cell tumors, 1001(ab) â€˜@â€˜Xevs., inmildto moderateregionalcerebral SPECT, 113(ab) TechnetiUm.99mantibodies,can cysteine-challenge bloodflowabnormalities,747 development of synthetic polymer based blood assay predictin vivo stabilityand Tedine*IWD-99mglucarate pool imagingagentlabeledwith, 149(ab) biodistributionof?, 231(ab) accumulationby Chinesehamsterovary cells, directly and indirectly labeled antibodies, 109 Technetium-99m antigranulocyte antibody hypoxia effect on, 242 duallabelingof humanIgwith @â€˜Â°Yand,using fr@zginent,immunoscintigraphyof distributionin acutelyischemicmyocardium, EDTB, 1140(ab) infection,240(ab) 1303 evidenceforcouplingof carboxylgroup TechnetiUin-99m antimyosin, recombinant Technetluni-99m gluconate, accumulation by coordination to amine deprotonation single-chain Fv, rapid infarct imaging, Chinese hamster ovary cells, hypoxia relevanceto, RCO(EC)complexes 234 effecton, 242 derived from cysteine, 147(ab) Teclinetlum-99manti.r*t-CDRmosodonal Technedum.99m-HMDP first-passangiographicstudiesof leftventricular antibody, joint uptake and body negativebone tumors, â€˜@FFDG PET in, 288 function,394 distributionof, in rat adjuvantarthritis, scintimetric evaluation of remodeling after bone highaffinitychemotacticpeptideslabeledwith, 92 fractures in man, 1403 62(ab) Technetlum-99in-dtrate, 67Ga-citrate vs. , for Techaetlum-99m-HMPAO highresolutionslit aperturefor imagingsmall imaginginflammatorylesions,332(ab) brain SPECT animals with SPECT, 26(ab) TechneIIUm-99mcolloid,aerosol,formulationwith in detection of postural cerebral independenceof regionalasynergyand improved delivery efficiency for lung hypoperfusionin patientswith myocardial perfusion defect reversibility, ventilation imaging, 268 cerebrovasculardisease, 1931 86(ab) Technetiuin.99M cyclic peptides, for thrombus increasedcerebralperfusionafter detachable labelingof antibodieswith, 1617(le) imaging,60(ab) balloon embolization of carotid load independence of early diastolic filling Teckaetiua,-99m-DADT-BVM, potential marker for cavernous fistula on, 1987 parametersin anesthetizedcaninemodel, cholinergic neurons, synthesis and in in Rett's syndrome, 1058(ab) 1520 vivo evaluation of, 541(ab) brain SPECFwith memoryactivationin lungscan,uniformityof interpretation, Technedum-99m-dlpbosphonate, diagnosis of Alzheimer'sdisease,462(ab) diagnosticalgorithmsand, 661 partial and total physeal arrest by bone in determination of brain death in children, metastaticmalignancymasqueradingas hepatic SPECT, 1410 uncoupling of flow and function, 203(ab) hemangiomaon labeledRBC TeCIInetIUm-99m.DMSA fractionated, stored at â€”70Â°C,routine scintigraphy, 1172 renal uptake applicationforWBCscintigraphy,151 novelbifunctionalchelatingsystemfor, 540(ab) poor, and tubulointerstitialdiseaseof kidney, gonadaluptakeand localizationin rodent novelcomplexesbased on newN2S2and N2SO 354(k) model,770(ab) ligands,538(ab) @â€œI'c-DTPAvs., 1217(le) high resolution SPEC!' in probable Alzheimer's peptideslabeledwith scintigraphy disease, vs. FDG PET, 10(ab)

2330 TheJournalofNuclearMedicine ictal SPECT using, methods for rapid imaging of focal sites of inflammation in uptake and biodistributionduring rat tibial bone preparationandoptimaldeployment non-humanprimateswith, 832(ab) repair, 104 duringspontaneousseizures,666 Technedum-99m-1L2, labeling and purification for uptake in primaryamyloidosis, with review of I-125-Iomazenil and, in double tracer in vivo detection of chronic lymphocytic mechanismsof soft tissue localizationof autoradiography in experimental brain infiltration, 1141(ab) bone seeking radiopharmaceuticals, 1612 ischemia,935(ab) Technetlum-99m.LDL, biodistribution and imaging utilitywith SPECTin hydroxyapatiteocular regional cerebral blood flow improvement with of oxidized LDL and, 261(ab) implants,438(ab) treatmentinchroniccocainepolydrug Technetium-99m leukocytes, compared with â€œIn Technetium-99m-MIBI users, 723 granulocytesfor examinationof patients in evaluation of patients with primary response to visual cognitive stimulation with inflammatorybowel disease, 1052 carcinomaof breast, comparisonwith assessed by, in Alzheimer type dementia, Technetium-99m Uposome 20111, 557(ab) 11(ab) biodistributionand imagingstudiesin rats with separate-daySPECT,fast stress and rest SPECT focalinfection,2160 acquisitionsfor, 524(ab) in assessment of collateral cerebral perfusion evaluation as tumor imaging and drug delivery SPECT duringtemporaryinternalcarotidartery agent, 1148(ab) discrepancies in perfusion defect estimates occlusion, 1235 labelingwith long-chainalkyl between â€˜3NammoniaPET and, not and balloontest occlusion,predicting monohydroxamamides,1149(ab) explained by differences in tracer tolerance prior to permanent cerebral use oflabeling procedure to monitor circulation behavior,483(ab) artery occlusion, 1243 @ properties of liposome encapsulated vs. zll'fl evaluation of childhood brain brain scan in schizophrenia, 309(ab) and CT and MRIin evaluationof patients hemoglobinin rat shockmodel,542(ab) tumors, 1045 withchronicbrain injury,965(ab) Technetlum-99m LLEC, clearance, estimation by thyroiduptake, semiquantitative30-minute, in diagnosis of chronic fatigue syndrome, simplifiedmethod,516(ab) quickdiagnosisof hyperthyroidismwith, 182(ab) Technetlum-99m lymphocytes, new approach to 71 Diamox, in identification of diaschisis in labelinginvitro,evaluationof Technetiuin-99mmonodonalantibodies stroke, 249(ab) radiolabeled cell immune functions, determinationof specificand nonspecific evaluation of brain in autistic disorder, 1126(ab) binding and its significance on tissue 308(ab) Technedum-99m-MAA distribution,1144(ab) indicates that some posterior cerebral evaluationof SPECTquantificationusingin directly and indirectly labeled, 109 perfusion abnormalities may resolve in vivo dog studies and, 96(ab) kit-formulatedconjugation of NHS-BAT ester selected patients with extrinsic vertebral prevalenceof thromboembolicdiseasein to, 1019(ab) artery compression after surgery, 368(ab) patientswithintermediateprobability lackof HAMAresponsein patientsimagedwith methodological features for neurostimulation lung scans, 55(ab) ImmuRAID-CEA and ImmuRAID-MN3, studies with, 1217(le) scintigraphic sign for detection of right-to-left 1008(ab) in patients with cortical visual loss, 1447 shunts,1607 OK'F3,imagingrheumaticjoint diseaseswith, pre-,intra-,andpostoperativemonitoringin ventilation-pethrsion scintigraphy in PIOPED 714(ab) patientswithseverecarotidstenosis, study,1109,1119 in prediction of dosimetry of 1ssRemonoclonal 247(ab) Technetium-99m MAG3 antibodies,908 in prediction of cerebral palsy in high-risk clearanceof, preliminaryresultsof multicenter Technetlum-99m N neonates,1223 trial to determine by single sample and multiplebond,synthesisof newclassof brain regionalcerebralbloodflowin chronic camera based techniques, 1163(ab) imaging agents containing, 537(ab) alcoholism,relationto diuretic renography, 1029(le) synthesisof neutraldithiocarbamatecomplex neuropsychological testing, 1452 high resolution computer enhanced renal with, bearing ester groups, 63(ab) restingandactivationpatternsof prefrontal parenchymalimaging,clinical TechnetlUm-99Mnaaocollold blood flow in schizophrenia, 305(ab) significanceof renalparenchymal changes marrowlocalizationas resultof test-retest variability of brain perfusion abnormalities on, 549(ab) treatmentwithrecombinanthuman studiesin normalhumansubjects, identificationof factorsoptimizing granulocytecolonystimulatingfactorin 248(ab) radiochemicalpurityof, 1159(ab) canine model, 840(ab) value for predictionof cerebralpalsyin renography, automated detection of scintigraphyin orthopedicinfections, high-riskneonates, 1057(ab) parenchymalpixelsin, 845(ab) comparisonwith â€œInlabeled SPECT brain scans, segmental analysis of, high scintigraphy,carcinomain transplantedkidney leukocytes,1646 correlationbetweentemporaldefectsand detected with, 2185 Technetium-99m nitrolmidazole memory loss in, 9(ab) validationof renaloutput efficiencyas objective complexes, separation of isomers of, 64(ab) spermatozoaradiolabeledwith, in monitoring quantitativeparameterin evaluationof novel,planarand SPECTimagingof ischemic spermcell dynamicsinfemalerabbit upper urinarytract obstruction,845 caninemyocardiumusing,50(ab) genitaltract after insemination,1134 validityof determinationof clearancefrom Technetlum-99m-pertechnetate Technetlum-99m-HMPAO leukocytes cardiactime-activitycurve obtained postradiotherapy unilateral sialadenitis, 953 clinical experience in detection of inflammatory duringroutinerenalimaging,350(ab) scintigraphy,in ilealduplicationof stomachand and infectiousdiseases,837(ab) Technetlum-99m-MBI, myocardial extraction, in duodenum,294 in diagnosis of focal purulent disease, 1428 isolatedrabbitheart,927 Technetlum-99m Q3, new myocardial imaging Technetlum-99m-HMPAOWBC Technetlum-99m-MDP agent cardiovascularinfectiondetectionwith, 868(le) biomatrix hydroxyapatite ocular implants, 467 organ uptake and biodistribution studies of, in patients presenting with abdominal pain, boneScintigraphy 765(ab) 444(ab) in determining prognosis for children with preparationfor clinicalstudies, 1153(ab) Technetlum-99m-HSA,new methodsfor labeling, stage IV neuroblastoma, 1082, 1087 Technetium-99m RBC, distribution in ferret, 387(ab) effect of clodronate treatment in metastatic isoflurane induced changes in, 829(ab) Technetium-99m-IgG breast cancer, 1039 Technetlum-99m-aestamlbl comparison with @FcHIG Technescan and enthesopathyof patellartendoninsertion, clinical decisions, 860 â€œInMacroscintDTPA-IgGinratmodel isotretinointherapy, 455 combinedwith20@11studies,differentiationof of focalinfection,839(ab) intraosseousmeningiomaappearanceon bone myocardial perfusion abnormalities from andMIBGevaluationas potentialtracerfor scintigraphy over five years, 961 attenuation effects using relative regional monitoringdoxorubicincardiomyopathy, MR.!and SPECF bone scans in renal allograft activityprofiles,255(ab) 1282 recipients,381 detectionof primarylungcancerwith, 558(ab) polyclonal,human Paget'sdiseaseinpatientwithbreastcancer, dynamic renal imaging with, in hypertensive in diagnosis of focal purulent disease, 1428 1214 patients,552(ab)

Subject Indexâ€¢1993 2331

A Technetlumâ€”99msulphur collold

enhancementof accumulationin multidrug rapid back to back adenosine stress/rest dipyridamolescintigraphy,noninvasive resistant cells by cytotoxic drugs and myocardial perfusion SPECT using diagnosis of cardiac transplant MDRreversingagents,560(ab) triple-detectorcamera, 1485 arteriopathy with, 2049 gated SPECF, left ventricular ejection fraction tomographicimaging,comparisonwith 20,11 identificationand characterizationof assessed from, 1871 imaging following intravenous hypertrophic myocardium, 1013 generatoreluateeffectson labelingefficiencyof dipyridamole infusion, 522(ab) immediate reinjection following stress imaging, kits, 73(@ab) uptake in cultured myocardial cells, v@20111 in myocardial viability detection, 737 increasedJunguptakein diagnosisof coronary and Â°Â°â€œTcsestamibi,255 influenceof patientheight/weightand type of artery disease, 482(ab) TeCIInetIUm-99m-tetiOIOSmIn stress on count rates in myocardium influenceof patientheight/weightandtypeof biokineticsof, 1254 with, 731(ab) stress on count rates in myocardium humanbiodistribution,dosimetry,andsafetyof, intraoperative assessment of brain malignancies with, 30 using,138(ab) intraoperative validation of subtraction myocardial perfusion imaging, 222 as markerof myocardialhypoperfusion,1510 techniquefor preoperativelocalizationof myocardial perfusion imaging and dynamic myocardlial imaging, dipyridamole and hyperfunctioning parathyroid tissue, analysiswith, 1478 additive value of radionudide TeCIInetIUm-99U.TMPAO,evaluation of isomers 805(ab) ventriculography for risk stratification as markerof myocardialhypoperfusion,1510 of, evidencethatGSHis notsignificantly prior to vascularsurgery,292(ab) involvedin cerebralretention, 1150(ab) miniaturized and rapid paper chromatographic cerebrovascularaccidentassociatedwith, 128 Technetium-99m-trlsuccln, conjugated to technique for radiochemical quality monoclonalantibodyCC49, myocardial perfusion tomography, one to five control of, 1090(ab) years after successfulcoronary biodistribution in athymic mice bearing myocardial multiple-gated SPECT simulation for coloncancerxenografts,107(ab) angioplasty,296(ab) determiningaccuracyof count-based Tecbnetium-99ni(V)-DMSA myocardial SPECT in Bland-White-Garland systolicwall-thickeningmeasurement, imaging of differentiated thyroid tumors with, syndrome,2182 383(ab) 37(ab) normalexercisemyocardialperfusionimaging normalmyocardialperfusionimaging, pituitary adenoma imaging using, 160(ab) study, impactof antianginalmedications, prognostic value of, 211(ab) scintigraphicevaluationof tenosynovial peak heart rate and stress level on as parathyroid imaging agent, 806(ab) giant-celltumor using,1745 prognosticvalue of, 1467 personnelradiationdosimetryfrommyocardial uptake in intra-abdominalmassive deposit of perfusion imaging with pharmacologic perfusion scintigraphy, 20111compared amyloid protein, 815 intervention,comparisonbetween with, 1210 Technologists, PET, radiation dose during dipyridamole and dobutamine for pronebreastimagingin patientswithsuspicion quantitativevs. qualitativestudies, 769 detection of coronary artery disease, of breastcancer,559(ab) Technology,transfer, DOE labsbillwould 381(ab) relationship of segmental uptake to resting enhance,52N(6) perrectumscintigraphy,physiopathological regionalwall motion,728(ab) Temporallobeepilepsy significancein livercirrhosis, 1642 SPECT predictiveimportanceof FDG-PETin, 83(ab) personnel radiation dosimetry from myocardial gated, for assessmentof myocardialperfusion refractory,regionalalterationof benzodiazepine perfusion scintigraphy, @Fcsestamibi abnormalities, 601 receptordistributionin, 81(ab) comparedwith, 1210 gatedand ungatedbull's-eyes,inhomogeneity, Temporalsam@, dynamiccardiacPET studies planar,quantitative,rolefordetermining comparisonwith 20r11,281 usingimage-derivedinputfimctions,440 viabilityin acute myocardialinfarction myocardial perfusion defect size after stress, Ten-secanda@sitioss, sequential,for detection andtotallyoccludedinfarct-related 187 of gastroesophagealreflux,658 artery, 728 quantitativesame-dayrest-stress, 1494 Testes redistribution, resting myocardial blood flow significance of transient dipyridamole-induced metastaticneoplasms,initialevaluationof and glucosemetabolismmaintenancein leftventricularcavitydilatationas FDG/PETimagingof, 15(ab) dysfunctional myocardium with, 171(ab) assessed by, 297(ab) mouse, vitamin C as radioprotector against â€˜@â€˜i, reinjection SPECT and echocardiography, dobutamine, 637 andimprovementofleft ventricularfunction value in coronary artery disease refractorycarcinomaof, phase I followingrevascularization,172(ab) detection,vs. coronaryangiography,889, radioimmunotherapy trials with â€˜@â€˜i nitroglycerinenhanced,for detectionof viable 895 SF9.3 monoclonal antibody, 208(ab) myocardium,173(ab) spontaneoussilentmyocardialischemia uptake of â€œInin patients from â€œInlabeled repeatedplanarstress imaging,quantitative assessedby,134 platelets, 777(ab) reproducibilityof, 168(ab) stress, rest 20@11and, quantitativeassessmentof Thalllum-201 rest, and stress @Fcsestamil,i,quantitative adenosine SPECT, comparison of results using assessmentof reversibilityfor separate reversibility for separate acquisition dual four-vs. six-minuteinfusionprotocol, acquisition dual isotope myocardial isotope myocardial perfusion SPECT, 737(ab) perfusionSPECT, 250(ab) 250(ab) brain SPECT, in childhoodbrain tumors, rest/delayed SPEC!', adjunctive value to stressSPECT,quantitativeprogramfor 201(ab) demonstrate reversibility of fixed Â°Â°â€œTc assessment of perfusion defect severity brain uptakefrom @SFcompartment,99 sestamibi perfusion defects, 252(ab) in, 732(ab) cardiac SPECT, comparison of Am-241 and resting cardiac imaging, reverse redistribution in uptakein culturedmyocardialcells, vs. Â°Â°â€˜9@cas transmission sources for coronary artery disease, 725(ab) teboroxime,255 attenuationcorrectionof, 113(ab) restingmyocardialscintigraphy,reverse Tecbnetlum.99msulphurcolloid,erythromycin characterizationof reinjectionimage,879 redistribution in patients with coronary effects on gastric emptying, alcohol clinicaldecisions,860 artery disease, 1688 absorption,and smallintestinaltransit, clinicalevaluationof SPECTin supratentorial reverse redistobution in perspective, 1692 582 gliomas, 2085, 2089 reversible perfusion defects in right bundle TechnetiUm-99m4ebOrOXIme combinedwith @Fcsestamibistudies, branch block and normal coronary dynamicSPECF using,for quantificationof differentiationof myocardial perfusion angiogram, 1218Qe) myocardial perfusion, 733(ab) abnormalities from attenuation effects ril,ose infusion reduces MIBI but not 20@11 early myocardial clearance kinetics in usingrelativeregionalactivityprofiles, extractionin isolatedrabbitheart, differentiationof normaland 255(ab) 177(ab) flow-restricted canine myocardium at cost-effectiveselectionof patientsfor rightventricularkineticsin pulmonary rest,630 reinjection prior to redistribution imaging hypertension,relationto rightventricular in vitro uptake in carcinoma cell lines and usingcriteriabasedon quantitative size and function,1695 normal cells, 1949 analysis of stress image, 169(ab) scintigraphy

2332 TheJournalofNudearMedicine Treatment planning

forassessmentof 67Gaavidmediastinalmass bonemarrowdosimetryfor Graves' orbitopathy,orbital â€œInDTPA followingtherapyfor Hodgkin'sdisease, radioimmunotherapy, 689 octreotideaccumulationnot basedon 1326 bronchogemccarcinomamimickingmetastatic blood-poolradioactivityin, 158(ab) complementaryrolewith mammographyin thyroidcarcinoma,809 long-termresultsof two schedulesof diagnosisof breast cancer, 2095 correlation of radiation absorbed doses to nodal radioiodinetreatmentfor toxic improves life expectancy in heart attack metastases,524Qe) multinodulargoiter,795(ab) survivors,35N(10) dosimetry of â€˜@Remonoclonal antibodies, 908 lowoccurrenceof clinicallysignificance mass abnormalitiesof breast, 18 immunoadsorption,enhancementstrategyfor ophthalmopathy after ablative treatment paradoxicalchangesin findingsin advanced radioimmunotherapy,1020 with radioactive iodine for Graves' follicularthyroidcancer, 1574 monoclonalant,1,odyM195in acute hype@, 182@le) in pediatric solid tumors, 200(ab) myelogenous leukemia, 422 medullarycancer search for optimalprotocolfor reinjection optimizationof radioiodinetherapyof â€œInoctreotidescintigraphyin patientswith, imaging,743 thyrotoxicosis,1638 555(ab) simultaneous transmission-emission cardiac â€˜53Sm-EDTMPbiodistributionand dosimetry radioimmunodetectionusingbispecific imaging,280(ab) estimation,1031 anti-CEA/anti-In-DTPAantibodyand SPECT time-dosefractionationin radioimmunotherapy, â€œInDTPAdimer,1267 accuracyat rest for evaluationof myocardial implications for selecting radionuclides, metastaticcarcinoma,bronchogeniccarcinoma viabilityin comparisonto â€˜8FFDG PET, 1801 mimicking,809 729(ab) trace elementenhancementof â€˜@â€˜IMIBG optimizationof radioiodinetherapyof adenosine,quantitative,modelsfor predicting therapy exchange yields, 148(ab) thyrotoxicosis,1638 long-termoutcomeafteracute ThermolumInescentdosimeters,radiationdose to papillarycarcinoma,false-positivescans in, myocardialinfarctionby, 212(ab) PET technologists during quantitative vs. 2280(k) comparisonof prognosticvalue in treadmill qualitative studies, 769 radioiodinetherapyin thyrotcrcicosis,lowvs. exercisescore in medicallytreated Th highdose â€˜@â€˜INa therapy, 796(ab) patientswithcoronaryarterydisease, â€œInlabeled platelet sequestration, 182 semiquantitative30-minUteÂ°Â°â€œTcMifil uptake, 294(ab) predictionin patientstreatedwith IsoReHEDP, in quick diagnosis of hyperthyrOidism,71 comparisonwith MRI in evaluationof 1046(ab) volumeestimationoflarge multinodulargoiters, primaryCNS lymphomain non-AIDS Thrombosis comparisonof MRI and Scintigraphy, patients,219(ab) functionaland anatomicalevaluationof carotid 794(ab) @ detectionof thymicabnormalityin atherothrombosis, 828(ab) Thyroid myastheniagraviswith, 1048(ab) â€œInFBD as new imaging agent, 475(ab) circulatingâ€˜@â€˜ith@ne in, 36(ab) in evaluationoflung and mediastinaldisease, novelmonoclonalantibodyFab' kit with dual differentiated,imagingwith Â°Â°@Fc(V)DMSA, 1037(ab) @Â°â€œ1@clabeling sites for thrombus 37(ab) evaluationof suspectedmalignantpulmonary imaging,399(ab) imagingwith PET FDG, 38(ab) lesionswith,556(ab) preliminaryevaluationoflabeled disintegrinsfor nodalmetastases,correlationwith radiation in follow-up of patients with lung cancer thrombusimaging,258(ab) absorbeddoses, 524Qe) duringradiotherapy,1042(ab) scintigraphicmethodsfor detectionof, unusual scintigraphic findings in adenoma, 465 gated and ungated bull's-eyes, inhomogeneity, 554(suppl) Thyroxine,â€˜@â€˜i,circulating,in thyroidcancers, comparison with Â°Â°â€œTcsestamibi, 281 99mTc labeled cyclic peptides for thrombus 36(ab) leftventricularcavity-to-myocardialcount imaging,60(ab) Tracan ratio, restingleftventriculardysfunction, 1@ 68Ga,potentialforimagingheartwithPET,228 193 effectsof hypoxiaon culturedhumantumorcell PET,potential,fortyrosinehydrcxylase lowlikelihoodof coronaryeventsinyoung uptake of, 288(ab) activity,22(ab) @ patientswithnormalresults,210(ab) formonitoringearlyresponseof human Tranamiesios tomographyti@i), fast myocardialperfusionimaging,400 adenocarcinomacelllineto radiotherapy, fordeterminingattenuationmapsusing forpredictinghistologicaltypesof 18Fj@w@ and methionine vs. , 773 collimatedlinesource, rotatable meningiomas,2091 uptake, in vitro assessment of, 2278(le) air-copper-lead attenuators and lan-beam vs. Â°Â°â€œâ€˜TcMIBI in evaluation of childhood uptake and proliferative activity of human collimation,1577 brain tumors, 1045 cancer cells, FDGuptakevs., 414 SPECT Scintigraphy, mt-redistribution after lliymldlnekinase,HSV-specifled,NCA IVaraU cardiac acute myocardial infarction predicts probesfor detectionof, 1095(ab) evaluationof allograftvasculopathyby @â€œTc normalwallmotionon lowdose Thyroglobulin,circulatingâ€˜@â€˜Ithyroxinein thyroid teboroximewashout, 734(ab) dobutamineechocardiography,170(ab) cancers, 36(ab) PET in patient evaluation before and after, osmTcand 834. experimentalverificationof energyweighted ablation,assessmentof â€˜@â€˜Iefficacyfor, 1927 liver, new techniqueto evaluatepatients, dual isotopetechniquefor simultaneous adenoma,unusualscintigraphicfindings,465 447(ab) SPECT cardiac imaging with, 108(ab) benigndiseasesof, optimizeddose planningof renal parathyroidsubtractionscintigraphy, radioiodine therapy of, 1632 avascularnecrosisin MRI and SPECFbone ultrastructuralhistologycorrelationwith cancer scans, 381 resultsof, 24 advancedfollicular,paradoxicalchangesin carcinomain transplantedkidneydetected oomTcMIBIvs., in evaluationof patientswith â€˜@â€˜Iscintigraphic findings in, 1574 with MAG3 scintigraphy, 2185 primarycarcinomaof breast, 557(ab) differentiated,differentfeaturesof pulmonary singlelung thyroidadenoma,465 metastasesin, 1626 pulmonaryperfusiondistributionfollowing, 24-hour redistribution scintigraphy, superior to high-activity â€˜@Ifor diagnostic evaluation of differencebetweenemphysemagroup rest sestamibiimagingin identificationof patientswith, 161(ab) and primarypulmonaryhypertension myocardialviabilitywith SPECT,85(ab) correlationof radiationabsorbeddoses to nodal group, 167(ab) uptake in cultured myocardial cells, vs. metastases, 524(le) quantitativeventilation-perfusionScintigraphy teboroxime,255 differentiatedcarcinoma,chromatographic 111, 166(ab) Thallium-201-chlo.ida identification in serum of endogenously in lobar primary pulmonary lymphoma, 1980 radioiodinatedthyroidhormonesafter dopamine,invivo sites imagingin humanusing reversible perfusion defects in right bundle â€˜@â€˜iwhole-body scintigraphy in follow-up â€œCWIN 35,428 PET, 938(ab) branchblock and normalcoronary of patientswith,2032 norepinephrine,dopamineand serotonin,MIBG angiogram,1218(le) dose selectionand absorbeddose profilesin uptakeby, 1140 sequential, 67Ga-citrate and, in AIDS, 834(ab) radioiodinetreatmentof diffusetoxic Treatmeuti@'I.g, monoclonalantibodyM195in â€˜I'herapeuticnuclearmedicine,1037 goiters,387 acute myelogenousleukemia,422

SubjectIndexâ€¢1993 2333 Trlphenyl tetrazollum chloride (fl'C)

Thpb@ tetrazoiluai chloride (T1'C), effect of sarcomas from posttherapy changes, plasmaglucoselevelsand â€˜8FFDG uptakein stainingon distributionof radiolabeled 124(ab) bronchialcarcinomas,355 pharmaceuticals, 178(ab), 1722 FDG uptake and proliferative activity of human predlinicalcomparisonof therapyand toxicity TrC.SeeTriphenyltetrazoliumchloride cancercells, 414 forMu-9anti-@SApIgOlabeledwith Tubuloluteritltlal disease, poor @â€˜9@cDMSA renal fit-constrainedparametricimagesusingFDG, â€˜@â€˜I,@Â°Yor Re-188, 1014(ab) uptake in, 354(le) 155(ab) prostate, current applications of Tumescence, evaluation of penile blood flow, â€˜8FPFBG as potential tracer, 312(ab) immunoscintigraphy in, 549(suppl) 523(k) functional staging of cancer patients in quantitativeevaluationof uptakein laboratory Tumors. See aLso Cancer, specific location prediction of therapeutic response and animals using in @PM)and cx viva â€”ope survival, 1087 imaging,1040(ab) adenocarcinoma, early response of cell line to Â°7Gadistributioninnormaland radioinrmunodetection of Hodgkin's disease and radiotherapy, agents for monitoring, 773 hypotransferrinemictumor-bearingmice, non-Hodgkin's lymphomas with â€œanatometabolicâ€•imaging, 1190 2135 monoclonal antibody to eosinophil assessment of efficacy of â€˜@â€˜Ifor thyroid gastroenteropancreatic,localizationwith â€œIn percxidase, 1246 ablation, 1927 somatostatinanalogue,156(ab) radiolabeled antibodies as cancer therapeutics, benignmediastinaland parahilaruptakeof 67Ga glioma, functional imaging correlates of 1028(k) in treated lymphoma, 1330 prognosis,975(ab) recurrentcarcinoidand occultdistant bispecificmonoclonalantibody-mediated growth of@!UDR uptake and retention as metastasis,visualizationby @â€œTc targetingof â€œInDTPAdimerto primary measure of, 1152 colorectaltumors, 1662 hepatomas,well-differentiated,high sestamibi, 1748 residualor recurrent,methioninePET in bloodglucoseconcentrationinfluenceon FDG accumulation of â€˜8FFDGaI by, 780 uptake in cancer, PET study of, 1 Ho-166 DOTMP for bone marrow ablation, differentiation from posttreatment bone 125(ab) changes,214(ab) hemangioendothelioma, SCintigraphiC hypervascular brown, detection on three-phase role of â€˜@ITyr-3octreotide scintigraphy in â€œdoughnutsignâ€•on skeletal imaging, 297 bonescan,2188 stagingof small-celllungcancer, 1397 â€¢9m'FcHMDPnegative,â€˜@FFDG PET in, 288 hypoxia and perfusion, 885 roleof P-glycoproteininaccumulationof 20111 brain hy@a and reoxygenation in, imaging with â€˜@F andÂ°Â°@Fcsestamibiincells, 1125(ab) assessmentof proliferativeactivityusingâ€˜@â€˜I FMISO, 76(ab) scintigraphicevaluationof tenosynovial IUDR, 139(ab) â€˜@ILAZA,PDT-induced hypoxia in Dunning giant-cell tumor using @Fc(V)-DMSA, intraoperativeassessmentusing20111,138(ab) prostate tumors, 405 1745 prognosticand diagnosticusefulnessof I-125-1VME2vs. â€˜@IIBHPE in estrogen small FDG-PET in management, 141(ab) receptor-positive cancers, 272 detectabilityin MonteCarlostudyof 20111 vs. Â°Â°@fc MIBI SPECF in evaluation of immunoadsorption, enhancement strategy for radioimmunodiagnosis, 857(ab) childrenwith, 1045 radioimmuno@, 1020 treatmentwith magneticallyenhanced breast immunoscintigraphy in surgical management of radionuclide therapy, 422(ab) effectof clodronatetreatmenton bone colorectal cancer, 541(suppl) softtissueandbone,useof early,lateand scintigraphy in, 1039 improvedlocalizationand radioÃ£nagingwith SPECT thallium imaging in evaluating radioimmunolocalization of metastatic chemically modified monoclonal activityof, 123(ab) carcinoma using â€œInmethyl benzyl antibodies,455(ab) solid,solitary,liver, hepaticscintigraphyin DTPA BrE-3 monoclonal antibody, 1067 initial assessment of PET using FDG in imaging evaluationof, 697 bronchogeniccarcinomamimickingmetastatic of malignant melanoma, 1420 targetingin viva and metabolicfate of 1-125 thyroidcarcinoma,809 in vitro cytotoxicity of MABO, 1024(ab) IUDRfollowingintratumoralinjectionin carcinoid,â€œInpentetreotidebiodistributionin in vitro uptake of @â€˜I'ctebororcimein patients with colorectal cancer, 1175 patients with, 157(ab) carcinoma cell lines and normal cells, thyroid,high-activityâ€˜@Ifor diagnostic chemotherapy resistance of, use of anti-sense 1949 evaluationof patientswith, 161(ab) forpredictionof, 23N(5) liver,evaluationusingâ€˜8FThU PET, 2124 tissue heterogeneityeffectson FDG parameter chest,residualor recurrent,PETdifferentiation localization and systemic distribution of effect estimates, 153(ab) from posttherapy changes, 162(ab) cells monitored by PET, 289(ab) 20111 Scintigraphy for assessment of 67Ga avid clinical immunoscintigraphy of ovarian lung, metastasis to breast detected â€˜@FFDG mediastinalmassfollowingtherapyfor carcinomausing â€˜@â€˜I145-9monoclonal PET, 1571 Hodgkin'sdisease, 1326 antibody, 1651 malignant,â€œInlamininpeptidefragmentsfor urinoma, study of frequency of rejection colorectalcancer detectionof, 1081(ab) mimicking on @FcDIM imaging of current imagingstrategies,537(suppl) metastatic malignancy masquerading as hepatic renaltransplants, 1155(ab) PET studies after systemic administrationof hemangioma on labeled RBC xenografts, human, selective localization of â€˜8Furacil in patients with liver scintigraphy, 1172 radioiodinatedphospholipidether analog metastasesfrom, 1075 metastatic processes, spatial localization of, CT in, 787 comparativeefficacyof PET-FDGand CT in and SPECT image registration and fusion Tumor-seeking agents detectionof tumorsites in patientswith using radiolabeled monoclonals, autoradiographicevaluationof intra-tumoral abdominal and pelvic malignancies, 562(suppl) distributionof 2-DOand monoclonal 215(ab) mice with, pharmacokinetics of anti-CPA antibodiesin ovarianadenocarcinoma correlationof radiationabsorbeddoses to nodal monoclonal antibody conjugated to xenografts, 75 metastases, 524(k) bifunctional transition metal carborane clinical immunoscintigraphy of ovarian early treatment response in malignant complex in, 1294 carcinoma using â€˜@â€˜I145-9 monoclonal lymphoma as determined by planar â€˜@F neuroendocrine, of gastrointestinal tract, antibody,1651 FDG scintigraphy, 1706 detection somatostatinreceptor clinicalutilityof immunoscintigraphyin ovarian effectsof hypoxiaon culturedhumantumorcell scintigraphy, 388(ab) cancer management,545(suppl) uptake of thyinidine, L-methinoine and non-small-celllungcarcinoma,PET imaging early response of human adenocarcinoma cell FIX;, 288(ab) with â€œCMET, 1886 lineto radiotherapy,773 evaluationof Cu(FFSM)as tracer of perfusion, para@as extracorporeal immunoadsorption to increase comparisonwith labeledmicrospheresin â€˜@â€˜IMIBO scintigraphy in preoperative and tumor-to-normal tissue ratio, 448 spontaneous canine neoplasms, 492(ab) postoperative evaluation, 173 FDG uptake and proliferative activity of human evaluationof recurrencein irradiatedtumorbed octreotide scintigraphy for detection of, 873 cancercells, 414 with PEI'-FDO, 1050(ab) PET follow-up studies for evaluation of functional staging of cancer patients in FDG and methionine PET in differentiation of treatmentresponsein patientswith lung predictionof therapeuticresponseand recurrentor residualmusculoskeletal carcinoma, 75(ab) survival, 1087

2334 The Journal of Nudear Medicine Xsnon-133

immunoadsorption,enhancementstrategyfor X-133 imaging, open bronchial stump 20,11 SPECT, left ventricular radioimmunotherapy, 1020 post-pneumonectomy,462 cavity-to-myocardialcount ratio, 193 immunoscintigraphy in surgical management of Veudladon-perlmiou, right, arrhythmogenic right ventricular disease, colorectalcancer, 541(suppl) applicationof neuralnetworksto imagingfor sympatheticleftventricularinnervation initial assessment of PET using FDG in imaging diagnosingpulmonaryembolism, in, 2(ab) of malignantmelanoma,1420 850(ab) Ventriculography,radlonudide monoclonal antibody M195 in acute detailed analysis of patients with matched additivevalue to dipyridamole20111imagingfor myelogenous leukemia, 422 ventilation-perfusion defects and chest risk stratificationpriorto vascular octreotide scintigraphy for detection of radiographicopacities, 1851 surgery,292(ab) paragangliomas,873 lungscanning,353(le) dobutamine,in assessmentof myocardial phase II scintigraphicclinicaltrialof malignant melanomaand metastaseswith â€˜@IBZA, andhighresolutionMRItechniquesin viabilityafter thrombolytictherapyfor 1260 patientswithpulmonaryembolism, acute myocardialinfarction,746(ab) radioimmunodetection of Hodgkin's disease and 484(ab) exercise,prognosticefficacyin patientswith non-Hodgltin'slymphomaswith influenceof resultson pulmonary and withoutprior myocardmiinfarction, monoclonal antibody to eosinophil angiographyprocedure,485(ab) 127(ab) peroxidase,1246 probabilitycategorydistributionin university firstpass, comparingfivesecondhalf-life radioimmunolocalization of metastatic breast and communityhospitals,57(ab) Ir-191mand @Â°â€œTcDTPA using high carcinoma using â€œInmethyl benzyl roleindiagnosticevaluationof patientswith count rate â€œmulticrystalâ€•camera, DTPA BrE-3 monoclonal antibody, 1067 pulmonary hypertension, 1075(ab) 742(ab) radiolabeledantibodiesas cancer therapeutics, matchwithchestx-rayless likelyto represent Vesamicolreceptors,radioligands,molecular 1028(k) pulmonaryembolismif 0 is â€œdecreasedâ€• decomposition-reconstitutionapproach scintigraphic evaluation of tenosynovial rather than â€œabsent,â€•58(ab) to,21(ab) giant-cell tumor using Â°@Fc(V)-DMSA, revisedscintigraphiccriteriafor interpretation VitaminA, radioprotectionagainstincorporated 1745 of scans for pulmonaryembolism,59(ab) radionudlidesin viva, 533(ab) selectivelocalizationof radioiodinated scintigraphy VitaminMi, malabsorption,new radiofarmacon phospholipidether analogin human in PIOPED study, 54(ab), 1109, 1119 in diagnosisof@445(ab) tumorxenografts,787 quantitative,in singlelungtransplants, VitaminC, as radioprotectoragainstâ€˜@â€˜I,637 Â°Â°â€œ1@c(V)DMSAuptakein intro-abdominal 166(ab) massive deposit of arnyloid protein, 815 Ventricularunction tumor targetingin viva and metabolicfate of w 1-125IUDRfollowingintratumoral left injectionin patientswith colorectal in Mriamycin cardiomyopathy, 52(ab) Wels,ArThurM, peoplein nuclearmedicine, cancer, 1175 biplanegatedSPECT,gatedequilibrium,and 30N(6) Tyrosinehydrozylase,activity,potentialPET first-passradionudlideangiographic Welch, Mldiad 1., people in nuclear medicine, tracer for, 22(ab) quantitativemeasuresof systolicand 40N(6) diastolic performance, 130(ab) Whitebloodcells.See aLsoLeukocytes U developmentof ambulatoryrecorderfor qualityassuranceoflabelingwith test basedon measuringejectionfracturewith adherence,345 Ulcer,duodenal,chronic,gastricemptyingafter miniatureCsI photodiodedetector, scintigraphy,fractionatedHMPAOstoredat laparoscopic anterior seromyotomy and 842(ab) â€”70Â°C,routineapplication,151 posterior truncal vagotomy in, 30(ab) diagnosticreliabilityof evaluatingdilatation Urea, C-14,breath test, radiationdose estimates and hypertrOphywith radionudlide for,821 ventriculography,echocardiographyand x Urinarytract @rocorrelationwithautopsy,743(ab) 24-hrurinarycatecholaminesare normalin effectsof beta-blockadetherapywith ACEI in somepatientswithpositiveMIBOscans patientswith dilatedcardiomyopathy, comparativestudyof intact and F(ab')2 andhistopathologicallyproven 128(ab) fragmentsof monodonal antibodyMX-35 pheochromocytomas,792(ab) first-passradionuclideangiographywith in, 1015(ab) upper,obstruction,validationof renaloutput â€¢SlwFc,394 humanovarianadenocarcinoma,intra-tumoral efficiencyas objectivequantitative globaland regionalmeasurementby cardiac distributionof 2-DOand monoclonal parameterin evaluationof, 845 PET, 424(ab) antibodiesin, autoradiographic measurementsusingambulatoryradionuclide evaluationof, 75 V monitor,1602 humantumor, selectivelocalizationof non-deterministicknowledge-basedboundary radioiodinatedphospholipidether analog Vagotomy,truncal, posterior,laparoscopic anteriorseromyotomyand,inchronic detector, 745(ab) in, 787 and perfusionand fatty aciduptake, serial Xenou-W duodenal ulcer, gastric emptying after, 3@ab) coursein cardiomyopathichamster, 1309 dynamic quantitative regional cerebral blood Vanadlimr-48,as transmissionsource for perfusiondefectsize after early and late flowSPECTon PRISM3-headed attenuationcorrectionof PETimages, S9IwFcsestamibi SPECF after stress, 187 tomograph,simulationand phantom 871(ab) prognosticimportanceof transientdilationby studiesof, 362(ab) Vasculardisease,peripheral,functiOnalimaging, dipyridamole,735(ab) prostate clearancestudy, and prostatic 865(le) rest-redistributionSPECF thallium imaging to hemodynamicchangeafter transurethral Ventilation assessviabilityin leftventricular hyperthermictreatmentof benign controlled delivery of Kr-81m boli in normal dysfunction,339(ab) prostatehypertiophy,553(ab) subjects, results and implications of, 1859 simultaneousassessmentof myocardial regionalcerebralbloodflowhn*ghigwith diagnostic algorithms and lung scan perfusionand, duringtransientcoronary CERASPECFstationaryringcamera, interpretation, uniformity of, 661 occlusion,1(ab) 361(ab) plasmaD-dimerinevaluationof suspected sympatheticinnervationin arrhythmogenic regionalcerebralbloodflowsystemusing pulmonaryembolus,896 rightventriculardisease,2(ab) triple-headedSPECTcamera, radiationabsorbeddose estimatesfrominhaled systolicand diastolic,effectsof adenosineon developmentof and initialresultsfrom, Kr-81m gas in lung imaging, 1382 perfusionand, 377(ab) 906(ab) 9omTcaerosol colloid formulation for imaging, zrr11 reinjection and improvement following SPEC1' 268 revascularization,172(ab) dynamicquantitativeregionalcerebralblood

Subject Indexâ€¢1993 2335 Xenon-@133m

flow: PRISM3-headedtomograph, Xeuon-133m,â€˜@â€˜idecay and, 1219(k) new bifunctional chelates for labeling of monoclonalantibodies,comparative 99nrr@6@:E@vs.,inmildtomoderateregional Y cerebralbloodflowabnormalities,754 biodistributionin non-tumorbearingnude ventilationimaging Ytt,ium-90 mice, 1122(ab) open bronchialstumppost-pneumonectomy, analogousradiotherapeutics,measurementof Yttrlum-90collold,synovectomyof knee, 462 Soypharmacokineticswith PETand therapeuticvalueof, 718(ab) prevalence of thromboembolic disease in radiationdosecalculationof, 2222 patientswith intermediateprobability duallabelingof humanIgwith Â°Â°@â€˜Tcand, using evaluationin lungscans,55(ab) EDTB, 1140(ab) nudemiceanddogs,938

2336 The Journal of NuclearMedicine I. EDITORIAL POLICY licationwithoutfirstundergoinga processofrevision. Revisedmanuscripts arejudged on the adequacy of responsesto suggestionsand criticisms made TheJournalofNuclear Medicinepublishesmaterialofinterestto theprac duringtheinitialreview.Twocopiesofthe revisedmanuscriptsshouldbesent titionersand scientistsin the broadfieldofnuclearmedicine. Profferedarticles with a diskette (3.5 or 5.25) containingthe word processingfileofthe manu describingoriginallaboratoryorclinical investigations,casereports,technical script.Thediskshouldbe labeledwiththenameofthe file,wordprocessing notes and letters to the editor will be considered for publication. From time software, operating environment (i.e., DOS, Windows) and platform (i.e., to time,invitedarticles,editorials,andreviewsofselected topicswill be pub IBM,MacIntosh).A disketteneednotbe sentbeforea revisionis requested. lished. Manuscripts, including illustrations and tables, must be original and ReviewersfortheJournal may seekassistancefromsourceswithintheir insti notunderconsiderationby anotherpublication. tution when reviewingmanuscripts,but the data reportedin submittedmanu The Journal ofNuclear Medicine has agreed to receive manuscripts in scripts must be kept confidential at all times. accordance with the Uniform Requirementsfor Manuscripts Submitted to All accepted manuscripts are subject to editing for scientific accuracy, BiomedicalJournals, as cited in the following sources: Ann Intern Med(1988; clarity and style. 108:258â€”265)and BrMedJ(1988; 296:401â€”405).In preparing manuscripts, authors should follow the Un@for,nRequirementsfor Manuscripts Submitted to Biomedical Journals and the specific author instructions detailed below. IV. FORMAT REQUIREMENTS Also, helpful guidance in conforming to the â€œUniformRequirementsâ€• may be foundin MedicalStyle& Format:AnInternationalManualforAuthors, A. GeneralRequirements Editors, and Publishers by Edward J. Huth, MD (Philadelphia: IS! Press; Manuscriptsmust be written in English.When necessary,authors should 1987). seek the assistance ofexpenenced, English-speaking medical editors. A mcd ical editor should review the final draft of the original and any revisions of II. MANUSCRIPT SUBMISSION themanuscript. Type the manuscripton white bond paper, 8@X 11in. (21.6 X 27.9cm), Submit one original and three copies of the manuscript and four copies withmarginsofat least l@in. (4 cm).Type on one sideofthe paperonly,dou ofthefiguresto: ble spacing every page. Begin each of the following sections on separate StanleyJ. Goldsmith, MD pagesandinthefollowingorder:titlepage,abstract,text,acknowledgments, TheJournalofNuclearMedicine references,tables(eachon a separatepage),andlegends.Numberpagescon 136MadisonAve. secutively,beginningwiththetitlepage.Typethenameof theseniorauthor New York, NY 10016-6760 andpagenumberintheupperright-handcornerofeach page. (212)889-1905 B.TitlePage FAX: (212) 889-6582. Original manuscriptswill not be acceptedby facsimile. Thetitlepageofthe manuscriptshouldinclude:(I) conciseandinforma All manuscripts should be accompanied by a covering letter from the tivetitle(fewerthan200 characters);(2) shortrunninghead-orfootlineof no authorresponsibleforcorrespondenceregardingthemanuscript.Thecover more than 40 characters (letters and spaces) placed at the bottom ofthe title ing letter should contain the following copyright disclosure statement in corn pageandidentified;(3) completebyline,withfirstname,middleinitial,and pliancewiththeCopyrightRevisionActof 1976,effectiveJanuary1, 1978. lastnameofeach authorandhighestacademicdegree(s),upto tenauthors Upon acceptance by The Journal ofNuclear Medicine, allcopyright own may be cited; (4)complete affiliation foreach author, with the name of depart ershipfor the article ______is transftrred ment(s) and institution(s) to which the work should be attributed; (5) dis to The Society ofNuclear Medicine. We, the undersigned co-authors of this claimer, if any; (6) name, address, and telephone number of one author article, have contributed sign@ficantIy to andshare in the responsibiityfor the responsible for correspondence about the manuscript; and (7) name and release ofany part or all ofthe material contained within the article noted address of author to whom reprint requests should be directed, or statement above. The undersignedstipulate that the materialsubmitted to The Journal of thatreprintsarenotavailablefromtheauthor.Financialsupportforthework NuclearMedicineis new,originalandhasnotbeensubmittedtoanotherpub should be noted in a statement on this page. licationfor concurrent consideration. C. Abstract We also attest that any human and/or animal studies undertaken as part A structured abstract must be included with each original scientific man ofthe researchfrom which this manuscript was derived are in compliance uscriptsubmittedto theJournal.Theabstractshouldcontaina maximumof with regulations ofour institution(s) and with generally accepted guidelines 350wordsandincludefourclearlyidentifiableelementsofcontent:rationale governing such work (goals ofthe investigation), methods (description ofstudy subjects or experi Wefurther attest that we have herein disclosed any and allfinancial or ments,animalsandobservationalandanalyticaltechniques),results(major other relationships which could be construed as a conflict ofinterest, and findings), and principle conclusions. Except for the rationale which should that all sources offinancialsupportfor this study have been disclosed and are state the goals ofthe investigation, these sections should be preceded by head indicated in the acknowledgement. ings (i.e., Methods, Results and Conclusions). Three to five key words This statement must be signed by all oldie listed co-authors. Copyrightrequirementdoesnotapplyto workpreparedby UnitedStates should also be submitted with the abstract. governmentemployeesas part oftheir officialduties. D.Text Thecoveringlettershouldalsocontaina statementthatthemanuscripthas 1.Presentation beenseen andapprovedby all authorsandshouldgive anyadditionalinfor mation which may be helpfi.il to the Editor. Ifthere has been any prior publi Genericnamesshouldbe usedthroughoutthetext. Identifyinstruments cation ofany part ofthe work, this should be acknowledged and appropriate and radiopharmaceuticals by manufacturer name and address in parentheses writtenpennission included.Ifcolor illustrationsare included,a statementthat anddescribeproceduresin sufficientdetailto allow otherinvestigatorsto theauthor(s)is (are)willingto assumethecostofcolor separationandrepro reproducetheresults. ductionis requested. Thetextoforiginal scientificandmethodologyarticlesis usuallydivid Youmaysuggestindividualswhocouldserveasreviewersforyourman ed intothefollowingsections:Introduction,MaterialsandMethods,Results, uscript. Discussion, and Summaryor Conclusion. The text of original, scientific papers,exclusive of theabstract,legends,tablesandreferences,shouldnot exceed5000 words. III. REVIEW PROCEDURE CaseReportsshouldcontainaconcisedescriptionofno morethan1250 Submitted manuscripts are reviewed for originality, significance, ade words,exclusive ofthe abstract,legends,tablesandreferences,illustrated quacy ofdocumentation, reader interest, and composition. withno morethanthreefigures,emphasizingthe nuclearmedicineaspectsand Manuscripts not submitted instructions in accordance with these instruc including methodology, data, and correlative studies. tions will be returned to the author for correction prior to beginning the peer Letters should concern previouslypublished material or matters of gen review process. cml interestandshouldbe briefandto thepoint.A diskette(3.5 or 5.25 disk All manuscriptsconsideredsuitableforreviewareevaluatedby a mini only)containinga copyofthe workprocessingfi@eofthe lettershouldaccom mum oftwo reviewers.It is unusual for a manuscriptto be accepted for pub panya hardcopy versionof the manuscript.The disk shouldbe labeledas

InformationforAuthors 55A A describedabovein ReviewProcedure.Lettersshouldalso be accompaniedby datafromanunpublishedsourceareused,obtainpermissionfromtheprin a copyright disclosure statement as specified above in Manuscript cipal investigator and acknowledge filly. Submission.All materialis subjectto editing.Letterscommentingon previ 6. Illustrations ouslypublishedarticlesshouldbereceivedwithinoneyearofthedateofthe Illustrationsshouldclarifyandaugmentthetext. Because imagingis a referencedarticle'spublication.Lettersshouldcontainno morethan10ref. majoraspectofnuclear medicine,the selectionofsharp, high-qualityillus erences. trationsis of paramountimportance.Figuresof inferiorquality will be Journal policy prohibits the use ofhyperbolic terms or phrases in the returnedto the author for correctionor replacement. title,abstract,orbodyofthe textofsubmittedmanuscripts.Qualitativeclaims Submit four complete sets ofglossy illustrations, no smaller than 3@X 5 as to the superiority(superior,best...), primacy (first, novel, unique) or per in. nor largerthan8 X 10 in. Do not send originalartwork.Glossy pho formance ofan idea or instnsment should be omitted. tographs ofline drawingsrenderedprofessionallyon white drawing paper in 2. References blackIndiaink,withtemplateortypesetlettering,shouldbesubmitted.No References should be cited in consecutive numerical order at first men hand-drawnortypewritten artwillbe accepted.Letters,numbers,and symbols tion in the text anddesignatedby the referencenumberunderlinedandin (typeset or template) must be clear and of sufficient size to retain legibility parentheses.Referencesappearinginatableorfigureshouldbenumbered after reduction. sequentiallywiththoseinthetext. Eachillustrationmustbe numberedandcitedin consecutiveorderin the Thereferencelistmustbetypeddouble-spacedandnumberedconsecu text.Illustrationsshouldbe identifiedon a gummedlabelaffixedto theback tively,as in thetext.TheJournalfollowsIndexMedicusstyle forreferences ofeach illustrationandcontainthefollowinginformation:figurenumber,part andabbreviatesjournalnamesaccordingtotheListofJournalsIndexedin offigure (ifmore thanone),seniorauthor'sname,anddesignationof â€œtop.â€• Index Medicus. â€œUnpublishedobservationsâ€•and â€œpersonalcommunicationsâ€• Colorillustrationswill be consideredforpublication,butthe authoris shouldnotbeusedasreferences,althoughwrittenâ€”notverbalâ€”communicaresponsible for all charges relating to separations and printing. An estimate tions may be notedas such in thetext. Referencescited as â€œinpressâ€•must ofthese chargeswill be sentto the authoratthetimeofproduction.Author havebeen acceptedandnotmerelyin preparationor submitted.The author approvalofcharges is requiredbeforeproductionwill continue.Fourcom is responsiblefortheaccuracyofall referencesandmustverifythemagainst pletesetsofglossycolorphotographs(nottransparencies)mustbesubmitted theoriginaldocument. for review. Polaroidprintsarenot acceptable. All submittedillustrations Forjournalarticles,list all authorswhen six or less; forseven or more become the propertyofThe Society ofNuclear Medicineandwill not be authors,listthefirstthreefollowedbyetal.: returned unlessthe manuscriptis rejected. BaumierPL, Krohn KA, CarrasquilloJA, et al. Melanoma local 7. Legendsfor Illustrations izationin nudemice with monoclonalFabagainstp97. J Nuci Med 1985;26:1172â€”1179. Legendsfor illustrationsshouldbe concise and shouldnot repeatthe text. Legends should be typed double-spacedon a separatepage. Eachfigure WeissmannHS,BadiaJ, SugarmanLA, KlugerL, RosenblattR, shouldbe citedin consecutivenumericalorderin the text.Numberthefig Freeman LM. Spectrumofâ€•Tc-IDAcholescintigraphicpatterns ureswith an arabicnumberfollowingthe word â€œFIGUREâ€•.Use lettersto des in acutecholecystitis.Radiology1981;138:167â€”175. ignate parts ofillustrations (e.g., A, B, C) and describe each part clearly in Forbooksandbookchapters,follow theexamplesbelow: thelegend.Anyletterdesignationsorarrowsappearingontheillustration DeGroot U. Evaluation ofthyroid function and thyroid disease. shouldbe identifiedanddescribedfully. In:DeGrootU, StanbuiyJB,eds. Thethyroidanditsdiseases,4th Original (not previously published) illustrations are preferred for publi cationin theJournal;however,if illustrationshave been publishedprevi edition. New York: Wiley; 1975:196â€”248. ously,authorsareresponsibleforobtainingwrittenpermissionfromthepub Dupont B. Bone marrow transplantation in severe combined usherto reprint.The sourceofthe originalmaterialmustbe cited in theref. immunodeficiency with an unrelated MLC compatible donor. erencesandthe following creditline in parenthesesincludedin the legend: ln:White RI, SmithR, eds. Proceedings ofthe third annual meet â€œReprintedwith permissionofRef. X.â€•All permissionreleases must be sub ing ofihe International Society ofExperimental Hematology. miftedto the Editor at the time ofmanuscript submission. Houston:InternationalSocietyforExperimentalHematology; 1974:44-46. F. Acknowledgments 3. Units of Measurement Acknowledgepersonsoragenciescontributingsubstantiallytothework, including any grant support. All measurements should be listed in SI units. Older conventions may be used after the SI units but shouldbe placed in parentheses. 4. AbbreviationsandSymbols V. MANUSCRIPT CHECKLIST Withtheexceptionofunits ofmeasurement,theJournaldiscouragesthe Original double-spacedtyped manuscriptand three copies. use ofabbreviations. For additionalinformationon proper medical abbrevia tions, consult the CBESty1e Manual, Fifth Edition (Bethesda, MD: Council of ______3.5or5.25diskette Biology Editors, 1983).When an abbreviationis used, it should be preceded ______Foursetsofunmountedglossyfigures(nosmallerthan3@4X5 by thefullwordornameofthe itembeingabbreviated. in. nor larger than 8 x 10 in.). 5. Tables Copyright transfer. Type each tabledouble-spacedon a separatepage. Do not submittables as ______Titlepagewithtitle,authors'namesandcompleteaffiliations; photographs. completeaddress,telephonenumberandfaxnumberforcon-c- Tablesshouldbe self-explanatoryandshouldsupplement,notduplicate, spondingauthor,complete addressofauthor for reprint requests. thetext.Eachtablemustbe citedin consecutivenumericalorderin thetext. Number the tables consecutively with an arabic number following the word _____Structured abstract (maximum350 words) and key words.. â€œTABLE.â€•Thetitlesshouldbedescriptive,brief,andtypedcenteredinupper ______Referencesinconsecutivenumericalorder.Referencelisttyped andlower-caseletters.Placehorizontalrulesbelowthetitle,columnheadings, double-spaced. andattheendof thetable.Donotuseverticallines.Giveeachcolumna Figuresand tables in consecutivenumericalorder. shortorabbreviatedheading. Place @xplanatorymatterinfootnotes,notintheheading.Usethefollow Legendsforallfigures,typeddouble-spaced. ing symbols, in this sequence: , t, @,Â§,Â¶, @.Expand in the footnote all ______Consentformsforpatientphotographs. nonstandard abbreviations used in each table. For footnotes, identify statisti ______Writtenpermissionfromthepublishertoreprintpreviouslypub cal measures ofvariatior.s, such as standarddeviation and standarderrorof the lishedfiguresandtables. mean If datafromanotherpublishedsourceareused, obtainwrittenper missien fromthepublisherofthe originalsourceandacknowledgefully. If

56A The Journalof NuclearMedicineâ€¢Vol.34 â€¢No. 12 â€¢December 1993 The Journal is testing a new method to enable you to get information on a more timely basis from our advertisers. Listed below are the companies that have advertised in this issue, as well as those that have been mentioned in the New Products section. simply circle the JNM numbers of those companies you are interested in, fill out the form, and mail or FAX it to TheSocietyof NuclearMedicine,MarketingDept., 136MadisonAve., DiRECT RESPONSE New York, NY 10016. FAX: (2 12) 545-022 1. We will send it to the advertiser. Deadline: February 15, 1994 Advertisers for December 1993

ADAC Laboratories 34 DuPontCompany I 51 PickerInternational217 WillardIndustries,Inc Milpitas,CA No. Billerica,MA Bedford,OH Charlotte, NC (800) 538-8531 (800) 343-7851 (216)475-1111 (800)476-1230 Following8A, 30A Following8A, InsideBackCover Page39A Following44A 23 Capintec,Inc. 126 Medi-Physics,Inc. 175 Scinta,Inc. A SNMMeetings Ramsey,NJ Arlington Heights, IL SilverSpring,MD Pages 6A, 37A (800) 631-3826 (708)593-6300 (301)593-9478 Page2A Pages23A-26A Page39A B SNMMembership Information 32 DiversifiedDiagnostic I 32 NuclearFields 181 SiemensMedicalSystems,C SNMBookOrder Products, Inc. Des Plaines,IL Inc. Information Houston,TX (800) 932-5840 Hoffman Estates, IL (713)955-5323 Pagel6A (708) 304-7252 BackCover InsideFrontCoverâ€”iA

From:

YourName:, ______Title:______

Institution: Dept:

Address:

City: ______State:______zin@

Phone: FAX:

Primary Specialty:. SecondarySpecialty:

CIrcleOneAnswerIn EachCategory Employer Purchase Authority SNM Member 1. Hospital I. Recommend 1. Yes a. 500patientsplus 2. Specify 2. No b. 300-499 patients 3. Purchase C. 200-299 patients SNMSubscriber d. 100-199 patients 1. Yes 2. PrivateClinic Reason for Inquiry 2. No 3. R&DCommercial 1. ImmediatePurchase 4. University 2. GeneralInformation 5. Government 3. BudgetingInformation @ 6. Other ______. . i@ â€”

Indexto Advertisers ;@7A